{
  "captured_at": "2025-11-11T23:00:56.550222+00:00",
  "search_term": "porphyria",
  "search_resolution": {
    "normalized_condition": "porphyria",
    "mesh_terms": [
      "Porphyria, Variegate",
      "Variegate Porphyria",
      "Porphyria Variegata",
      "Protoporphyrinogen Oxidase Deficiency",
      "Ppox Deficiency"
    ],
    "reused_cached": false,
    "search_term_id": 1,
    "query_payload": {
      "normalized_query": "porphyria",
      "esearch": {
        "ids": [
          "68046350",
          "68017121",
          "68017119",
          "68017118",
          "68017094"
        ],
        "translation": "\"porphyrias\"[MeSH Terms] OR porphyria[Text Word]",
        "primary_id": "68046350",
        "query": "((\"Porphyria, Variegate\"[mesh] OR \"Variegate Porphyria\"[mesh] OR \"Porphyria Variegata\"[mesh] OR \"Protoporphyrinogen Oxidase Deficiency\"[mesh] OR \"Ppox Deficiency\"[mesh]) OR (\"Porphyria Variegata\"[tiab] OR \"Porphyria, Variegate\"[tiab] OR \"Ppox Deficiency\"[tiab] OR \"Protoporphyrinogen Oxidase Deficiency\"[tiab] OR \"Variegate Porphyria\"[tiab])) AND (((\"Anesthesia\"[mesh] OR \"Anesthesia, General\"[mesh] OR \"Anesthesia, Conduction\"[mesh] OR \"Anesthetics\"[mesh] OR \"Anesthesiology\"[mesh] OR \"Analgesia\"[mesh] OR \"Analgesia, Epidural\"[mesh] OR \"Conscious Sedation\"[mesh] OR \"Monitoring, Intraoperative\"[mesh] OR \"Pain, Postoperative\"[mesh]) OR (\"anesthesia\"[tiab] OR \"anaesthesia\"[tiab] OR \"anesthetic\"[tiab] OR \"anesthetics\"[tiab] OR \"sedation\"[tiab] OR \"conscious sedation\"[tiab] OR \"regional anesthesia\"[tiab] OR \"nerve block\"[tiab] OR \"perioperative\"[tiab] OR \"induction of anesthesia\"[tiab] OR \"general anesthesia\"[tiab] OR \"postoperative pain\"[tiab])) OR ((\"Anesthetics, Intravenous\"[mesh] OR \"Anesthetics, Local\"[mesh] OR \"Anesthetics, Inhalation\"[mesh] OR \"Analgesics, Opioid\"[mesh] OR \"Analgesics, Non-Narcotic\"[mesh] OR \"Neuromuscular Blocking Agents\"[mesh] OR \"Hypnotics and Sedatives\"[mesh] OR \"Cholinesterase Inhibitors\"[mesh] OR \"Cyclodextrins\"[mesh] OR \"Parasympatholytics\"[mesh] OR \"Adrenergic Agonists\"[mesh] OR \"Adrenergic beta-Antagonists\"[mesh] OR \"Vasodilator Agents\"[mesh] OR \"Cephalosporins\"[mesh] OR \"Cyclooxygenase 2 Inhibitors\"[mesh] OR \"Antiemetics\"[mesh] OR \"Serotonin Antagonists\"[mesh] OR \"Adrenal Cortex Hormones\"[mesh] OR \"Glucagon\"[mesh] OR \"Calcium Compounds\"[mesh] OR \"Ringer's Lactate\"[mesh] OR \"Anticonvulsants\"[mesh] OR \"Anti-Arrhythmia Agents\"[mesh] OR \"Nitrates\"[mesh] OR \"Adenosine\"[mesh] OR \"Muscle Relaxants, Central\"[mesh] OR \"Sodium Chloride\"[mesh]) OR (\"analgesic opioid\"[tiab] OR \"opioid\"[tiab] OR \"opioids\"[tiab] OR \"benzodiazepine\"[tiab] OR \"benzodiazepines\"[tiab] OR \"volatile anaesthetic\"[tiab] OR \"volatile anesthetic\"[tiab] OR \"volatile anaesthetics\"[tiab] OR \"volatile anesthetics\"[tiab] OR \"volatile agent\"[tiab] OR \"volatile agents\"[tiab] OR \"inhalational anaesthetic\"[tiab] OR \"inhalational anesthetic\"[tiab] OR \"nitrous oxide\"[tiab] OR \"neuromuscular blockade\"[tiab] OR \"neuromuscular blocker\"[tiab] OR \"neuromuscular blockers\"[tiab] OR \"neuromuscular blocking agent\"[tiab] OR \"neuromuscular blocking agents\"[tiab] OR \"muscle relaxant\"[tiab] OR \"muscle relaxants\"[tiab] OR \"neuromuscular reversal agent\"[tiab] OR \"hartmann's solution\"[tiab] OR \"hartmanns solution\"[tiab] OR \"sodium chloride\"[tiab])) OR ((\"Critical Care\"[mesh] OR \"Critical Care Outcomes\"[mesh] OR \"Emergency Medicine\"[mesh] OR \"Emergency Treatment\"[mesh] OR \"Intensive Care Units\"[mesh] OR \"Perioperative Care\"[mesh] OR \"Perioperative Period\"[mesh] OR \"Resuscitation\"[mesh]) OR (\"critical care\"[tiab] OR \"intensive care\"[tiab] OR \"icu\"[tiab] OR \"anaesthetic emergency\"[tiab] OR \"emergency department\"[tiab] OR \"emergency medicine\"[tiab] OR \"perioperative\"[tiab] OR \"rapid sequence induction\"[tiab] OR \"resuscitation\"[tiab]))) AND \"Humans\"[mesh] AND (\"Review\"[pt] OR \"Systematic Review\"[pt] OR \"Meta-Analysis\"[pt] OR \"Case Reports\"[pt] OR \"Clinical Study\"[pt] OR \"Observational Study\"[pt])"
      },
      "esummary": {
        "primary_id": "68046350",
        "mesh_terms": [
          "Porphyria, Variegate",
          "Variegate Porphyria",
          "Porphyria Variegate",
          "Protoporphyrinogen Oxidase Deficiency",
          "Porphyria Variegata",
          "Porphyria, South African Type",
          "Ppox Deficiency",
          "Deficiency, Ppox",
          "Ppox Deficiencies"
        ],
        "raw_xml": "<?xml version=\"1.0\" encoding=\"UTF-8\" ?>\n<!DOCTYPE eSummaryResult PUBLIC \"-//NLM//DTD esummary v1 20041029//EN\" \"https://eutils.ncbi.nlm.nih.gov/eutils/dtd/20041029/esummary-v1.dtd\">\n<eSummaryResult>\n<DocSum>\n\t<Id>68046350</Id>\n\t<Item Name=\"DS_YearIntroduced\" Type=\"String\">2005</Item>\n\t<Item Name=\"DS_ScopeNote\" Type=\"String\">An autosomal dominant porphyria that is due to a deficiency of protoporphyrinogen oxidase (EC 1.3.3.4) in the LIVER, the seventh enzyme in the 8-enzyme biosynthetic pathway of HEME. Clinical features include both neurological symptoms and cutaneous lesions. Patients excrete increased levels of porphyrin precursors, COPROPORPHYRINS and protoporphyrinogen.</Item>\n\t<Item Name=\"DS_RegistryNumber\" Type=\"String\"></Item>\n\t<Item Name=\"DS_HeadingMappedTo\" Type=\"String\"></Item>\n\t<Item Name=\"DS_MeshTerms\" Type=\"List\">\n\t\t<Item Name=\"string\" Type=\"String\">Porphyria, Variegate</Item>\n\t\t<Item Name=\"string\" Type=\"String\">Variegate Porphyria</Item>\n\t\t<Item Name=\"string\" Type=\"String\">Porphyria Variegate</Item>\n\t\t<Item Name=\"string\" Type=\"String\">Protoporphyrinogen Oxidase Deficiency</Item>\n\t\t<Item Name=\"string\" Type=\"String\">Porphyria Variegata</Item>\n\t\t<Item Name=\"string\" Type=\"String\">Porphyria, South African Type</Item>\n\t\t<Item Name=\"string\" Type=\"String\">Ppox Deficiency</Item>\n\t\t<Item Name=\"string\" Type=\"String\">Deficiency, Ppox</Item>\n\t\t<Item Name=\"string\" Type=\"String\">Ppox Deficiencies</Item>\n\t</Item>\n\t<Item Name=\"DS_Subheading\" Type=\"List\">\n\t\t<Item Name=\"string\" Type=\"String\">blood</Item>\n\t\t<Item Name=\"string\" Type=\"String\">cerebrospinal fluid</Item>\n\t\t<Item Name=\"string\" Type=\"String\">chemically induced</Item>\n\t\t<Item Name=\"string\" Type=\"String\">classification</Item>\n\t\t<Item Name=\"string\" Type=\"String\">complications</Item>\n\t\t<Item Name=\"string\" Type=\"String\">congenital</Item>\n\t\t<Item Name=\"string\" Type=\"String\">diagnosis</Item>\n\t\t<Item Name=\"string\" Type=\"String\">diagnostic imaging</Item>\n\t\t<Item Name=\"string\" Type=\"String\">diet therapy</Item>\n\t\t<Item Name=\"string\" Type=\"String\">drug therapy</Item>\n\t\t<Item Name=\"string\" Type=\"String\">economics</Item>\n\t\t<Item Name=\"string\" Type=\"String\">embryology</Item>\n\t\t<Item Name=\"string\" Type=\"String\">enzymology</Item>\n\t\t<Item Name=\"string\" Type=\"String\">epidemiology</Item>\n\t\t<Item Name=\"string\" Type=\"String\">ethnology</Item>\n\t\t<Item Name=\"string\" Type=\"String\">etiology</Item>\n\t\t<Item Name=\"string\" Type=\"String\">genetics</Item>\n\t\t<Item Name=\"string\" Type=\"String\">history</Item>\n\t\t<Item Name=\"string\" Type=\"String\">immunology</Item>\n\t\t<Item Name=\"string\" Type=\"String\">metabolism</Item>\n\t\t<Item Name=\"string\" Type=\"String\">microbiology</Item>\n\t\t<Item Name=\"string\" Type=\"String\">mortality</Item>\n\t\t<Item Name=\"string\" Type=\"String\">nursing</Item>\n\t\t<Item Name=\"string\" Type=\"String\">parasitology</Item>\n\t\t<Item Name=\"string\" Type=\"String\">pathology</Item>\n\t\t<Item Name=\"string\" Type=\"String\">physiopathology</Item>\n\t\t<Item Name=\"string\" Type=\"String\">prevention and control</Item>\n\t\t<Item Name=\"string\" Type=\"String\">psychology</Item>\n\t\t<Item Name=\"string\" Type=\"String\">radiotherapy</Item>\n\t\t<Item Name=\"string\" Type=\"String\">rehabilitation</Item>\n\t\t<Item Name=\"string\" Type=\"String\">surgery</Item>\n\t\t<Item Name=\"string\" Type=\"String\">therapy</Item>\n\t\t<Item Name=\"string\" Type=\"String\">urine</Item>\n\t\t<Item Name=\"string\" Type=\"String\">veterinary</Item>\n\t\t<Item Name=\"string\" Type=\"String\">virology</Item>\n\t</Item>\n\t<Item Name=\"DS_PaPx\" Type=\"List\"></Item>\n\t<Item Name=\"DS_PreviousIndexing\" Type=\"List\">\n\t\t<Item Name=\"string\" Type=\"String\">Porphyria (1964-2004)</Item>\n\t\t<Item Name=\"string\" Type=\"String\">Porphyria, Hepatic (1993-2004)</Item>\n\t</Item>\n\t<Item Name=\"DS_SeeRelated\" Type=\"List\"></Item>\n\t<Item Name=\"DS_PaList\" Type=\"List\"></Item>\n\t<Item Name=\"DS_IdxLinks\" Type=\"List\">\n\t\t<Item Name=\"LinksType\" Type=\"Structure\">\n\t\t\t<Item Name=\"Parent\" Type=\"Integer\">68017094</Item>\n\t\t\t<Item Name=\"TreeNum\" Type=\"String\">C06.552.830.625</Item>\n\t\t\t<Item Name=\"Children\" Type=\"List\"></Item>\n\t\t</Item>\n\t\t<Item Name=\"LinksType\" Type=\"Structure\">\n\t\t\t<Item Name=\"Parent\" Type=\"Integer\">68017094</Item>\n\t\t\t<Item Name=\"TreeNum\" Type=\"String\">C16.320.850.742.625</Item>\n\t\t\t<Item Name=\"Children\" Type=\"List\"></Item>\n\t\t</Item>\n\t\t<Item Name=\"LinksType\" Type=\"Structure\">\n\t\t\t<Item Name=\"Parent\" Type=\"Integer\">68017094</Item>\n\t\t\t<Item Name=\"TreeNum\" Type=\"String\">C17.800.827.742.625</Item>\n\t\t\t<Item Name=\"Children\" Type=\"List\"></Item>\n\t\t</Item>\n\t\t<Item Name=\"LinksType\" Type=\"Structure\">\n\t\t\t<Item Name=\"Parent\" Type=\"Integer\">68017094</Item>\n\t\t\t<Item Name=\"TreeNum\" Type=\"String\">C18.452.811.400.625</Item>\n\t\t\t<Item Name=\"Children\" Type=\"List\"></Item>\n\t\t</Item>\n\t</Item>\n\t<Item Name=\"DS_EntryDate\" Type=\"Date\">2004/07/15 00:00</Item>\n\t<Item Name=\"DS_RevisionDate\" Type=\"Date\">2020/02/28 00:00</Item>\n\t<Item Name=\"DS_HeadingMappedToList\" Type=\"List\"></Item>\n</DocSum>\n\n</eSummaryResult>\n"
      },
      "ranked_mesh_terms": [
        {
          "term": "Porphyria, Variegate",
          "normalized": "porphyria, variegate",
          "overlap": 1,
          "jaccard": 0.7,
          "similarity": 0.6429,
          "score": 0.6829,
          "alias_overlap": 2,
          "has_primary_token": true,
          "rank": 0,
          "extra_tokens": [
            "variegate"
          ],
          "token_sequence": [
            "porphyria",
            "variegate"
          ]
        },
        {
          "term": "Variegate Porphyria",
          "normalized": "variegate porphyria",
          "overlap": 1,
          "jaccard": 0.7,
          "similarity": 0.6429,
          "score": 0.6829,
          "alias_overlap": 2,
          "has_primary_token": true,
          "rank": 1,
          "extra_tokens": [
            "variegate"
          ],
          "token_sequence": [
            "variegate",
            "porphyria"
          ]
        },
        {
          "term": "Porphyria Variegate",
          "normalized": "porphyria variegate",
          "overlap": 1,
          "jaccard": 0.7,
          "similarity": 0.6429,
          "score": 0.6829,
          "alias_overlap": 2,
          "has_primary_token": true,
          "rank": 2,
          "extra_tokens": [
            "variegate"
          ],
          "token_sequence": [
            "porphyria",
            "variegate"
          ]
        },
        {
          "term": "Porphyria Variegata",
          "normalized": "porphyria variegata",
          "overlap": 1,
          "jaccard": 0.7,
          "similarity": 0.6429,
          "score": 0.6829,
          "alias_overlap": 2,
          "has_primary_token": true,
          "rank": 4,
          "extra_tokens": [
            "variegata"
          ],
          "token_sequence": [
            "porphyria",
            "variegata"
          ]
        },
        {
          "term": "Porphyria, South African Type",
          "normalized": "porphyria, south african type",
          "overlap": 1,
          "jaccard": 0.45,
          "similarity": 0.4865,
          "score": 0.4609,
          "alias_overlap": 3,
          "has_primary_token": true,
          "rank": 5,
          "extra_tokens": [
            "african",
            "south",
            "type"
          ],
          "token_sequence": [
            "porphyria",
            "south",
            "african",
            "type"
          ]
        },
        {
          "term": "Protoporphyrinogen Oxidase Deficiency",
          "normalized": "protoporphyrinogen oxidase deficiency",
          "overlap": 3,
          "jaccard": 0.3,
          "similarity": 0.3913,
          "score": 0.3274,
          "alias_overlap": 3,
          "has_primary_token": false,
          "rank": 3,
          "extra_tokens": [
            "deficiency",
            "oxidase",
            "protoporphyrinogen"
          ],
          "token_sequence": [
            "protoporphyrinogen",
            "oxidase",
            "deficiency"
          ]
        },
        {
          "term": "Ppox Deficiency",
          "normalized": "ppox deficiency",
          "overlap": 2,
          "jaccard": 0.2,
          "similarity": 0.25,
          "score": 0.215,
          "alias_overlap": 2,
          "has_primary_token": false,
          "rank": 6,
          "extra_tokens": [
            "deficiency",
            "ppox"
          ],
          "token_sequence": [
            "ppox",
            "deficiency"
          ]
        },
        {
          "term": "Ppox Deficiencies",
          "normalized": "ppox deficiencies",
          "overlap": 2,
          "jaccard": 0.2,
          "similarity": 0.2308,
          "score": 0.2092,
          "alias_overlap": 2,
          "has_primary_token": false,
          "rank": 8,
          "extra_tokens": [
            "deficiencies",
            "ppox"
          ],
          "token_sequence": [
            "ppox",
            "deficiencies"
          ]
        },
        {
          "term": "Deficiency, Ppox",
          "normalized": "deficiency, ppox",
          "overlap": 2,
          "jaccard": 0.2,
          "similarity": 0.1667,
          "score": 0.19,
          "alias_overlap": 2,
          "has_primary_token": false,
          "rank": 7,
          "extra_tokens": [
            "deficiency",
            "ppox"
          ],
          "token_sequence": [
            "deficiency",
            "ppox"
          ]
        }
      ]
    },
    "mesh_terms_used": [
      "Porphyria, Variegate",
      "Variegate Porphyria",
      "Porphyria Variegata",
      "Protoporphyrinogen Oxidase Deficiency",
      "Ppox Deficiency"
    ]
  },
  "pubmed_search": {
    "query": "(\"Porphyria, Variegate\"[mesh] OR (\"Porphyria Variegata\"[tiab] OR \"Porphyria Variegate\"[tiab] OR \"Porphyria, South African Type\"[tiab] OR \"Porphyria, Variegate\"[tiab] OR \"Ppox Deficiency\"[tiab] OR \"Protoporphyrinogen Oxidase Deficiency\"[tiab] OR \"Variegate Porphyria\"[tiab] OR \"porphyria\"[tiab])) AND (((\"Anesthesia\"[mesh] OR \"Anesthesia, General\"[mesh] OR \"Anesthesia, Conduction\"[mesh] OR \"Anesthetics\"[mesh] OR \"Anesthesiology\"[mesh] OR \"Analgesia\"[mesh] OR \"Analgesia, Epidural\"[mesh] OR \"Conscious Sedation\"[mesh] OR \"Monitoring, Intraoperative\"[mesh] OR \"Pain, Postoperative\"[mesh]) OR (\"anesthesia\"[tiab] OR \"anaesthesia\"[tiab] OR \"anesthetic\"[tiab] OR \"anesthetics\"[tiab] OR \"sedation\"[tiab] OR \"conscious sedation\"[tiab] OR \"regional anesthesia\"[tiab] OR \"nerve block\"[tiab] OR \"perioperative\"[tiab] OR \"induction of anesthesia\"[tiab] OR \"general anesthesia\"[tiab] OR \"postoperative pain\"[tiab])) OR ((\"Anesthetics, Intravenous\"[mesh] OR \"Anesthetics, Local\"[mesh] OR \"Anesthetics, Inhalation\"[mesh] OR \"Analgesics, Opioid\"[mesh] OR \"Analgesics, Non-Narcotic\"[mesh] OR \"Neuromuscular Blocking Agents\"[mesh] OR \"Hypnotics and Sedatives\"[mesh] OR \"Cholinesterase Inhibitors\"[mesh] OR \"Cyclodextrins\"[mesh] OR \"Parasympatholytics\"[mesh] OR \"Adrenergic Agonists\"[mesh] OR \"Adrenergic beta-Antagonists\"[mesh] OR \"Vasodilator Agents\"[mesh] OR \"Cephalosporins\"[mesh] OR \"Cyclooxygenase 2 Inhibitors\"[mesh] OR \"Antiemetics\"[mesh] OR \"Serotonin Antagonists\"[mesh] OR \"Adrenal Cortex Hormones\"[mesh] OR \"Glucagon\"[mesh] OR \"Calcium Compounds\"[mesh] OR \"Ringer's Lactate\"[mesh] OR \"Anticonvulsants\"[mesh] OR \"Anti-Arrhythmia Agents\"[mesh] OR \"Nitrates\"[mesh] OR \"Adenosine\"[mesh] OR \"Muscle Relaxants, Central\"[mesh] OR \"Sodium Chloride\"[mesh]) OR (\"analgesic opioid\"[tiab] OR \"opioid\"[tiab] OR \"opioids\"[tiab] OR \"benzodiazepine\"[tiab] OR \"benzodiazepines\"[tiab] OR \"volatile anaesthetic\"[tiab] OR \"volatile anesthetic\"[tiab] OR \"volatile anaesthetics\"[tiab] OR \"volatile anesthetics\"[tiab] OR \"volatile agent\"[tiab] OR \"volatile agents\"[tiab] OR \"inhalational anaesthetic\"[tiab] OR \"inhalational anesthetic\"[tiab] OR \"nitrous oxide\"[tiab] OR \"neuromuscular blockade\"[tiab] OR \"neuromuscular blocker\"[tiab] OR \"neuromuscular blockers\"[tiab] OR \"neuromuscular blocking agent\"[tiab] OR \"neuromuscular blocking agents\"[tiab] OR \"muscle relaxant\"[tiab] OR \"muscle relaxants\"[tiab] OR \"neuromuscular reversal agent\"[tiab] OR \"hartmann's solution\"[tiab] OR \"hartmanns solution\"[tiab] OR \"sodium chloride\"[tiab])) OR ((\"Critical Care\"[mesh] OR \"Critical Care Outcomes\"[mesh] OR \"Emergency Medicine\"[mesh] OR \"Emergency Treatment\"[mesh] OR \"Intensive Care Units\"[mesh] OR \"Perioperative Care\"[mesh] OR \"Perioperative Period\"[mesh] OR \"Resuscitation\"[mesh]) OR (\"critical care\"[tiab] OR \"intensive care\"[tiab] OR \"icu\"[tiab] OR \"anaesthetic emergency\"[tiab] OR \"emergency department\"[tiab] OR \"emergency medicine\"[tiab] OR \"perioperative\"[tiab] OR \"rapid sequence induction\"[tiab] OR \"resuscitation\"[tiab])) OR \"porphyria\"[tiab]) AND \"Humans\"[mesh] AND (\"Review\"[pt] OR \"Systematic Review\"[pt] OR \"Meta-Analysis\"[pt] OR \"Case Reports\"[pt] OR \"Clinical Study\"[pt] OR \"Observational Study\"[pt])",
    "pmids": [
      "26132003",
      "31326287",
      "34661997",
      "38772406",
      "36642627",
      "30737139",
      "30594473",
      "9120442",
      "24700519",
      "18762710",
      "32220159",
      "36028858",
      "40114189",
      "27052088",
      "35164799",
      "31919062",
      "1061096",
      "36575494",
      "31570358",
      "25016127",
      "8290408",
      "27746433",
      "24131077",
      "13831266",
      "31085196",
      "29097018",
      "35304965",
      "26159905",
      "36598516",
      "24891059",
      "30709634",
      "27220836",
      "26743053",
      "30328490",
      "8224350",
      "31402774",
      "10604794",
      "21104216",
      "35665475",
      "16296947",
      "25294203",
      "15965664",
      "8316998",
      "35531651",
      "2203445",
      "24365356",
      "27982422",
      "38902527",
      "29392446",
      "9516676",
      "29383964",
      "9540990",
      "27796941",
      "28922972",
      "22049218",
      "1418699",
      "9540991",
      "2697245",
      "15880959",
      "2186782",
      "28321838",
      "398301",
      "39313028",
      "8831012",
      "16215360",
      "11480131",
      "26817125",
      "10327477",
      "38618923",
      "16934166",
      "28730628",
      "2673325",
      "25387219",
      "3298037",
      "9254745",
      "10343202",
      "11422163",
      "17009615",
      "39438413",
      "24809927",
      "9516677",
      "9211196",
      "6390167",
      "20554455",
      "2663971",
      "6120576",
      "25301776",
      "2660638",
      "23605133",
      "1530913",
      "12809070",
      "17190918",
      "25154161",
      "9638727",
      "15868463",
      "10599375",
      "7616661",
      "15239394",
      "10787385",
      "17763398",
      "7864431",
      "12367763",
      "40464666",
      "7616667",
      "8342401",
      "23515149",
      "10418219",
      "24261722",
      "2518297",
      "16222352",
      "11117426",
      "28815861",
      "2092571",
      "117341",
      "10223097",
      "20955962",
      "10599349",
      "88665",
      "8616881",
      "814414",
      "329249",
      "10082597",
      "8571113",
      "11021563",
      "7616668",
      "9516679",
      "10504904",
      "8993961",
      "1494724",
      "8344",
      "15187315",
      "15021955",
      "31706631",
      "23601071",
      "29516370",
      "7354149",
      "27624508",
      "36883342",
      "40694238",
      "7586575",
      "15660919",
      "36178265",
      "7451141",
      "39016183",
      "29557620",
      "25445397",
      "20417053",
      "24635077",
      "19883519",
      "3561676",
      "24073655",
      "18040123",
      "1997060",
      "26872826",
      "27871506",
      "15826795",
      "15180190",
      "3319294",
      "9738863",
      "26596031",
      "7939407",
      "11298551",
      "21146060",
      "22428497",
      "15175780",
      "11422339",
      "2222353",
      "15726012",
      "17037005",
      "34009428",
      "10401000",
      "31745600",
      "11507366",
      "3986654",
      "371027",
      "23473551",
      "10870850",
      "603745",
      "21734717",
      "25137868",
      "23993340",
      "2317449",
      "14156579",
      "12029239",
      "14066107",
      "14626138",
      "24439243",
      "4873642",
      "9645026",
      "497083",
      "13289451",
      "13419051",
      "7293816",
      "6143163",
      "32247286",
      "6028689",
      "6152284",
      "37926131",
      "24438652",
      "13428299"
    ],
    "article_count": 200,
    "fallback_used": false
  },
  "articles": [
    {
      "pmid": "26132003",
      "rank": 1,
      "score": 6.95,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 259,
      "preferred_url": "https://doi.org/10.1002/0471142905.hg1720s86",
      "title": "Porphyria Diagnostics-Part 1: A Brief Overview of the Porphyrias."
    },
    {
      "pmid": "31326287",
      "rank": 2,
      "score": 6.86,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 261,
      "preferred_url": "https://doi.org/10.1016/j.ymgme.2019.04.008",
      "title": "Heme biosynthesis and the porphyrias."
    },
    {
      "pmid": "34661997",
      "rank": 3,
      "score": 5.48,
      "content_source": "pmc-full-text",
      "has_content": true,
      "token_estimate": 8670,
      "preferred_url": "https://doi.org/10.1002/brb3.2389",
      "title": "Acute porphyrias - A neurological perspective."
    },
    {
      "pmid": "38772406",
      "rank": 4,
      "score": 4.66,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 128,
      "preferred_url": "https://doi.org/10.1055/s-0044-1787076",
      "title": "Understanding Hepatic Porphyrias: Symptoms, Treatments, and Unmet Needs."
    },
    {
      "pmid": "36642627",
      "rank": 5,
      "score": 4.510000000000001,
      "content_source": "pmc-full-text",
      "has_content": true,
      "token_estimate": 3922,
      "preferred_url": "https://doi.org/10.1053/j.gastro.2022.11.034",
      "title": "AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review."
    },
    {
      "pmid": "30737139",
      "rank": 6,
      "score": 4.0600000000000005,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 275,
      "preferred_url": "https://doi.org/10.1016/j.ymgme.2019.01.007",
      "title": "Murine models of the human porphyrias: Contributions toward understanding disease pathogenesis and the development of new therapies."
    },
    {
      "pmid": "30594473",
      "rank": 7,
      "score": 3.88,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 234,
      "preferred_url": "https://doi.org/10.1016/j.ymgme.2018.11.012",
      "title": "Recent advances on porphyria genetics: Inheritance, penetrance & molecular heterogeneity, including new modifying/causative genes."
    },
    {
      "pmid": "9120442",
      "rank": 8,
      "score": 3.46,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 146,
      "preferred_url": "https://doi.org/10.1136/jnnp.62.4.319",
      "title": "The little imitator--porphyria: a neuropsychiatric disorder."
    },
    {
      "pmid": "24700519",
      "rank": 9,
      "score": 3.38,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 177,
      "preferred_url": "https://doi.org/10.1002/hep.27086",
      "title": "Liver transplantation in the management of porphyria."
    },
    {
      "pmid": "18762710",
      "rank": 10,
      "score": 3.08,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 207,
      "preferred_url": "https://doi.org/10.2133/dmpk.23.236",
      "title": "Role and relevance of PEPT2 in drug disposition, dynamics, and toxicity."
    },
    {
      "pmid": "32220159",
      "rank": 11,
      "score": 3.01,
      "content_source": "pmc-full-text",
      "has_content": true,
      "token_estimate": 1844,
      "preferred_url": "https://doi.org/10.7705/biomedica.4767",
      "title": "Acute intermittent porphyria: A case report."
    },
    {
      "pmid": "36028858",
      "rank": 12,
      "score": 2.86,
      "content_source": "pmc-full-text",
      "has_content": true,
      "token_estimate": 4199,
      "preferred_url": "https://doi.org/10.1186/s13023-022-02463-x",
      "title": "Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION study."
    },
    {
      "pmid": "40114189",
      "rank": 13,
      "score": 2.8400000000000003,
      "content_source": "pmc-full-text",
      "has_content": true,
      "token_estimate": 3632,
      "preferred_url": "https://doi.org/10.1186/s13023-025-03606-6",
      "title": "Neurodevelopmental retardation and neurological symptoms in homozygous variegate porphyria: two new cases and a literature review."
    },
    {
      "pmid": "27052088",
      "rank": 14,
      "score": 2.76,
      "content_source": "pmc-full-text",
      "has_content": true,
      "token_estimate": 1969,
      "preferred_url": "https://doi.org/10.4103/0971-9784.179623",
      "title": "Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria."
    },
    {
      "pmid": "35164799",
      "rank": 15,
      "score": 2.6,
      "content_source": "pmc-full-text",
      "has_content": true,
      "token_estimate": 2235,
      "preferred_url": "https://doi.org/10.1186/s13052-022-01215-8",
      "title": "A boy with blistering of sun-exposed skin and finger shortening: the first case of Variegate Porphyria with a novel mutation in protoporphyrinogen oxidase (PPOX) gene in Iran: a case report and literature review."
    },
    {
      "pmid": "31919062",
      "rank": 16,
      "score": 2.56,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 160,
      "preferred_url": "https://doi.org/10.1136/bcr-2019-232236",
      "title": "Paediatric porphyria and human hemin: a treatment challenge in a lower middle income country."
    },
    {
      "pmid": "1061096",
      "rank": 17,
      "score": 2.5,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 144,
      "preferred_url": "https://doi.org/10.1073/pnas.72.12.5126",
      "title": "Porphyria variegata and porphyria cutanea tarda in siblings: chemical and genetic aspects."
    },
    {
      "pmid": "36575494",
      "rank": 18,
      "score": 2.46,
      "content_source": "pmc-full-text",
      "has_content": true,
      "token_estimate": 2103,
      "preferred_url": "https://doi.org/10.1186/s13256-022-03708-w",
      "title": "Porphyria: a case report."
    },
    {
      "pmid": "31570358",
      "rank": 19,
      "score": 2.46,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 138,
      "preferred_url": "https://doi.org/10.1136/bcr-2019-231133",
      "title": "Acute intermittent porphyria: analgesia can be dangerous."
    },
    {
      "pmid": "25016127",
      "rank": 20,
      "score": 2.42,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 260,
      "preferred_url": "https://doi.org/10.1016/j.amjmed.2014.06.036",
      "title": "Acute porphyrias in the USA: features of 108 subjects from porphyrias consortium."
    },
    {
      "pmid": "8290408",
      "rank": 21,
      "score": 2.3800000000000003,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 132,
      "preferred_url": "https://doi.org/10.1136/pgmj.69.816.781",
      "title": "Homozygous variegate porphyria: an evolving clinical syndrome."
    },
    {
      "pmid": "27746433",
      "rank": 22,
      "score": 2.38,
      "content_source": "pmc-full-text",
      "has_content": true,
      "token_estimate": 2126,
      "preferred_url": "https://doi.org/10.2169/internalmedicine.55.7108",
      "title": "Transient Worsening of Photosensitivity due to Cholelithiasis in a Variegate Porphyria Patient."
    },
    {
      "pmid": "24131077",
      "rank": 23,
      "score": 2.22,
      "content_source": "pmc-full-text",
      "has_content": true,
      "token_estimate": 1351,
      "preferred_url": "https://doi.org/10.3109/13506129.2013.837390",
      "title": "Variegate porphyria complicated by systemic AA amyloidosis: a case report."
    },
    {
      "pmid": "13831266",
      "rank": 24,
      "score": 2.06,
      "content_source": null,
      "has_content": false,
      "token_estimate": null,
      "preferred_url": "https://doi.org/10.1177/003591576005301118",
      "title": "Porphyria cutanea tarda."
    },
    {
      "pmid": "31085196",
      "rank": 25,
      "score": 1.45,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 288,
      "preferred_url": "https://doi.org/10.1053/j.gastro.2019.04.050",
      "title": "Clinical Guide and Update on Porphyrias."
    },
    {
      "pmid": "29097018",
      "rank": 26,
      "score": 1.4000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 243,
      "preferred_url": "https://doi.org/10.1016/j.pediatrneurol.2017.09.013",
      "title": "Antiepileptic Drugs and Liver Disease."
    },
    {
      "pmid": "35304965",
      "rank": 27,
      "score": 1.3,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 77,
      "preferred_url": "https://doi.org/10.1111/ddg.14743",
      "title": "The Porphyrias."
    },
    {
      "pmid": "26159905",
      "rank": 28,
      "score": 1.2,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 226,
      "preferred_url": "https://doi.org/10.1016/j.jemermed.2015.04.034",
      "title": "Acute Porphyrias."
    },
    {
      "pmid": "36598516",
      "rank": 29,
      "score": 1.1,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 460,
      "preferred_url": "https://doi.org/10.1007/s00063-022-00978-6",
      "title": "[Acute hepatic porphyrias]."
    },
    {
      "pmid": "24891059",
      "rank": 30,
      "score": 1.05,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 104,
      "preferred_url": "https://doi.org/10.1016/j.det.2014.03.001",
      "title": "The cutaneous porphyrias."
    },
    {
      "pmid": "30709634",
      "rank": 31,
      "score": 1.0,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 139,
      "preferred_url": "https://doi.org/10.1016/j.annder.2018.12.005",
      "title": "[The cutaneous porphyrias]."
    },
    {
      "pmid": "27220836",
      "rank": 32,
      "score": 0.9500000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 140,
      "preferred_url": "https://doi.org/10.1016/j.redar.2016.03.011",
      "title": "Femoral and sciatic nerve block for knee arthroscopy in a patient with acute intermittent porphyria."
    },
    {
      "pmid": "26743053",
      "rank": 33,
      "score": 0.95,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 78,
      "preferred_url": "https://doi.org/10.1007/s00105-015-3745-3",
      "title": "[Neurocutaneous porphyrias]."
    },
    {
      "pmid": "30328490",
      "rank": 34,
      "score": 0.8999999999999999,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 249,
      "preferred_url": "https://doi.org/10.1007/s00108-018-0509-z",
      "title": "[Porphyrias-what is verified?]."
    },
    {
      "pmid": "8224350",
      "rank": 35,
      "score": 0.8500000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 208,
      "preferred_url": "https://doi.org/10.1016/0020-711x(93)90683-6",
      "title": "Biochemistry of porphyria."
    },
    {
      "pmid": "31402774",
      "rank": 36,
      "score": 0.8,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 143,
      "preferred_url": "https://doi.org/10.1080/00207454.2019.1655014",
      "title": "Neurological and neuropsychiatric manifestations of porphyria."
    },
    {
      "pmid": "10604794",
      "rank": 37,
      "score": 0.75,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 109,
      "preferred_url": "https://doi.org/10.1016/s1085-5629(99)80027-3",
      "title": "The cutaneous porphyrias."
    },
    {
      "pmid": "21104216",
      "rank": 38,
      "score": 0.7,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 198,
      "preferred_url": "https://doi.org/10.1007/s00108-010-2751-x",
      "title": "[Porphyrias]."
    },
    {
      "pmid": "35665475",
      "rank": 39,
      "score": 0.6499999999999999,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 187,
      "preferred_url": "https://doi.org/10.1007/s11910-022-01205-7",
      "title": "Neurological Manifestations of Acute Porphyrias."
    },
    {
      "pmid": "16296947",
      "rank": 40,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 137,
      "preferred_url": "https://doi.org/10.2217/14622416.6.8.849",
      "title": "Pharmacogenetics and anesthesiologists."
    },
    {
      "pmid": "25294203",
      "rank": 41,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 89,
      "preferred_url": "https://pubmed.ncbi.nlm.nih.gov/25294203/",
      "title": "[Anaesthetics and porphyria]."
    },
    {
      "pmid": "15965664",
      "rank": 42,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 139,
      "preferred_url": "https://doi.org/10.1007/s00108-005-1455-0",
      "title": "[Acute abdomen]."
    },
    {
      "pmid": "8316998",
      "rank": 43,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 145,
      "preferred_url": "https://pubmed.ncbi.nlm.nih.gov/8316998/",
      "title": "[Anesthesia and porphyria]."
    },
    {
      "pmid": "35531651",
      "rank": 44,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 195,
      "preferred_url": "https://doi.org/10.1080/17512433.2022.2075848",
      "title": "Givosiran for the treatment of acute hepatic porphyria."
    },
    {
      "pmid": "2203445",
      "rank": 45,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 213,
      "preferred_url": "https://pubmed.ncbi.nlm.nih.gov/2203445/",
      "title": "The cutaneous porphyrias."
    },
    {
      "pmid": "24365356",
      "rank": 46,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 121,
      "preferred_url": "https://doi.org/10.1016/B978-0-7020-4087-0.00056-5",
      "title": "Porphyria and its neurologic manifestations."
    },
    {
      "pmid": "27982422",
      "rank": 47,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 158,
      "preferred_url": "https://doi.org/10.1111/bjh.14459",
      "title": "Update review of the acute porphyrias."
    },
    {
      "pmid": "38902527",
      "rank": 48,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 219,
      "preferred_url": "https://doi.org/10.1007/s00105-024-05370-3",
      "title": "[An overview of porphyrias]."
    },
    {
      "pmid": "29392446",
      "rank": 49,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 128,
      "preferred_url": "https://doi.org/10.1007/s11920-018-0867-1",
      "title": "Psychiatric Aspects of Acute Porphyria: a Comprehensive Review."
    },
    {
      "pmid": "9516676",
      "rank": 50,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 115,
      "preferred_url": "https://doi.org/10.1055/s-2007-1007138",
      "title": "Variegate porphyria."
    },
    {
      "pmid": "29383964",
      "rank": 51,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 214,
      "preferred_url": "https://doi.org/10.1080/03007995.2018.1435521",
      "title": "Acute intermittent porphyria: general aspects with focus on pain."
    },
    {
      "pmid": "9540990",
      "rank": 52,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 109,
      "preferred_url": "https://doi.org/10.1046/j.1523-1747.1998.00147.x",
      "title": "Variegate porphyria: identification of a nonsense mutation in the protoporphyrinogen oxidase gene."
    },
    {
      "pmid": "27796941",
      "rank": 53,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 296,
      "preferred_url": "https://doi.org/10.1007/s12664-016-0698-0",
      "title": "Hepatic porphyria: A narrative review."
    },
    {
      "pmid": "28922972",
      "rank": 54,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 125,
      "preferred_url": "https://doi.org/10.1177/1089253217732129",
      "title": "Perioperative Anesthetic Management of Patients Having Liver Transplantation for Uncommon Conditions."
    },
    {
      "pmid": "22049218",
      "rank": 55,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 266,
      "preferred_url": "https://doi.org/10.1136/jclinpath-2011-200276",
      "title": "A review of the clinical presentation, natural history and inheritance of variegate porphyria: its implausibility as the source of the 'Royal Malady'."
    },
    {
      "pmid": "1418699",
      "rank": 56,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 261,
      "preferred_url": "https://doi.org/10.2165/00002018-199207060-00005",
      "title": "Adverse effects of general anaesthetics."
    },
    {
      "pmid": "9540991",
      "rank": 57,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 136,
      "preferred_url": "https://doi.org/10.1046/j.1523-1747.1998.00148.x",
      "title": "Homozygous variegate porphyria: identification of mutations on both alleles of the protoporphyrinogen oxidase gene in a severely affected proband."
    },
    {
      "pmid": "2697245",
      "rank": 58,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 244,
      "preferred_url": "https://doi.org/10.1016/0952-8180(89)90080-9",
      "title": "The pharmacology of propofol."
    },
    {
      "pmid": "15880959",
      "rank": 59,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 65,
      "preferred_url": "https://doi.org/10.1111/j.1875-595x.2005.tb00035.x",
      "title": "Oral aspects of porphyria."
    },
    {
      "pmid": "2186782",
      "rank": 60,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 250,
      "preferred_url": "https://doi.org/10.1111/j.1365-2133.1990.tb16122.x",
      "title": "Photosensitivity in the elderly."
    },
    {
      "pmid": "28321838",
      "rank": 61,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 165,
      "preferred_url": "https://doi.org/10.1111/ijd.13580",
      "title": "Porphyria cutanea tarda: an intriguing genetic disease and marker."
    },
    {
      "pmid": "398301",
      "rank": 62,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 288,
      "preferred_url": "https://pubmed.ncbi.nlm.nih.gov/398301/",
      "title": "The porphyrias."
    },
    {
      "pmid": "39313028",
      "rank": 63,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 147,
      "preferred_url": "https://doi.org/10.1016/j.rceng.2024.09.004",
      "title": "Therapeutic approach to acute crises of hepatic porphyrias."
    },
    {
      "pmid": "8831012",
      "rank": 64,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 46,
      "preferred_url": "https://pubmed.ncbi.nlm.nih.gov/8831012/",
      "title": "Anaesthesia for porphyria."
    },
    {
      "pmid": "16215360",
      "rank": 65,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 262,
      "preferred_url": "https://doi.org/10.1097/01.ccm.0000182790.35728.f7",
      "title": "Neurologic disorders in pregnancy."
    },
    {
      "pmid": "11480131",
      "rank": 66,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 29,
      "preferred_url": "https://doi.org/10.12968/hosp.2001.62.7.1613",
      "title": "Treatment of acute porphyria."
    },
    {
      "pmid": "26817125",
      "rank": 67,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 203,
      "preferred_url": "https://pubmed.ncbi.nlm.nih.gov/26817125/",
      "title": "THINK PORPHYRIA: CASE REPORT AND REVIEW OF LITERATURE."
    },
    {
      "pmid": "10327477",
      "rank": 68,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 179,
      "preferred_url": "https://doi.org/10.1016/s0248-8663(99)83073-2",
      "title": "[Hepatic porphyria]."
    },
    {
      "pmid": "38618923",
      "rank": 69,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 227,
      "preferred_url": "https://doi.org/10.1111/liv.15924",
      "title": "Case-based discussion of the acute hepatic porphyrias: Updates on pathogenesis, diagnosis and management."
    },
    {
      "pmid": "16934166",
      "rank": 70,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 334,
      "preferred_url": "https://pubmed.ncbi.nlm.nih.gov/16934166/",
      "title": "Clinical approach to the weak patient in the intensive care unit."
    },
    {
      "pmid": "28730628",
      "rank": 71,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 266,
      "preferred_url": "https://doi.org/10.1111/joim.12646",
      "title": "Acute hepatic porphyria and cancer risk: a nationwide cohort study."
    },
    {
      "pmid": "2673325",
      "rank": 72,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 123,
      "preferred_url": "https://doi.org/10.1111/j.1365-2133.1989.tb01808.x",
      "title": "Late onset erythropoietic porphyria."
    },
    {
      "pmid": "25387219",
      "rank": 73,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 242,
      "preferred_url": "https://doi.org/10.3810/pgm.2014.11.2839",
      "title": "Drugs and acute porphyrias: reasons for a hazardous relationship."
    },
    {
      "pmid": "3298037",
      "rank": 74,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 228,
      "preferred_url": "https://pubmed.ncbi.nlm.nih.gov/3298037/",
      "title": "Porphyria: genetic and acquired."
    },
    {
      "pmid": "9254745",
      "rank": 75,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 236,
      "preferred_url": "https://pubmed.ncbi.nlm.nih.gov/9254745/",
      "title": "Variegate porphyria in South Africa, 1688-1996--new developments in an old disease."
    },
    {
      "pmid": "10343202",
      "rank": 76,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 91,
      "preferred_url": "https://doi.org/10.1159/000029854",
      "title": "Variegate porphyria: past, present and future."
    },
    {
      "pmid": "11422163",
      "rank": 77,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 196,
      "preferred_url": "https://doi.org/10.1046/j.1365-2230.2001.00825.x",
      "title": "The management of porphyria cutanea tarda."
    },
    {
      "pmid": "17009615",
      "rank": 78,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 193,
      "preferred_url": "https://doi.org/10.2298/sarh0608331k",
      "title": "[Postoperative cognitive deficits]."
    },
    {
      "pmid": "39438413",
      "rank": 79,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 257,
      "preferred_url": "https://doi.org/10.1007/s10620-024-08661-w",
      "title": "Hepatocellular Carcinoma in Acute Hepatic Porphyria: A Meta-Analysis of Observational Studies."
    },
    {
      "pmid": "24809927",
      "rank": 80,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 198,
      "preferred_url": "https://doi.org/10.1016/j.ejim.2014.03.011",
      "title": "A challenging diagnosis for potential fatal diseases: recommendations for diagnosing acute porphyrias."
    },
    {
      "pmid": "9516677",
      "rank": 81,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 157,
      "preferred_url": "https://doi.org/10.1055/s-2007-1007139",
      "title": "Acute porphyrias: pathogenesis of neurological manifestations."
    },
    {
      "pmid": "9211196",
      "rank": 82,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 182,
      "preferred_url": "https://doi.org/10.1023/a:1005313024076",
      "title": "Hepatic porphyrias in children."
    },
    {
      "pmid": "6390167",
      "rank": 83,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 225,
      "preferred_url": "https://doi.org/10.1007/BF00224769",
      "title": "Ferrochelatase and N-alkylated porphyrins."
    },
    {
      "pmid": "20554455",
      "rank": 84,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 206,
      "preferred_url": "https://doi.org/10.1016/j.seizure.2010.05.008",
      "title": "Antiepileptic treatment in patients with epilepsy and other comorbidities."
    },
    {
      "pmid": "2663971",
      "rank": 85,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 49,
      "preferred_url": "https://doi.org/10.1016/0736-4679(89)90361-2",
      "title": "Acute porphyria in the emergency department."
    },
    {
      "pmid": "6120576",
      "rank": 86,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 84,
      "preferred_url": "https://pubmed.ncbi.nlm.nih.gov/6120576/",
      "title": "The acute attack of porphyria."
    },
    {
      "pmid": "25301776",
      "rank": 87,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 185,
      "preferred_url": "https://doi.org/10.1177/0004563214557568",
      "title": "Hepatocellular carcinoma in variegate porphyria: a case report and literature review."
    },
    {
      "pmid": "2660638",
      "rank": 88,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 241,
      "preferred_url": "https://doi.org/10.1016/s0750-7658(89)80162-5",
      "title": "[Anesthesia and hepatic porphyria]."
    },
    {
      "pmid": "23605133",
      "rank": 89,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 226,
      "preferred_url": "https://doi.org/10.1177/0004563212473278",
      "title": "Role of genetic testing in the management of patients with inherited porphyria and their families."
    },
    {
      "pmid": "1530913",
      "rank": 90,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 355,
      "preferred_url": "https://pubmed.ncbi.nlm.nih.gov/1530913/",
      "title": "New histopathologic findings in drug eruptions."
    },
    {
      "pmid": "12809070",
      "rank": 91,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 305,
      "preferred_url": "https://pubmed.ncbi.nlm.nih.gov/12809070/",
      "title": "[Treatment of acute porphyrias. The importance of follow-up of patients and carriers]."
    },
    {
      "pmid": "17190918",
      "rank": 92,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 208,
      "preferred_url": "https://doi.org/10.1212/wnl.67.12_suppl_4.s28",
      "title": "Optimizing therapy of seizures in patients with renal or hepatic dysfunction."
    },
    {
      "pmid": "25154161",
      "rank": 93,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 146,
      "preferred_url": "https://pubmed.ncbi.nlm.nih.gov/25154161/",
      "title": "Acute intermittent porphyria in pregnancy: a case report and review of literature."
    },
    {
      "pmid": "9638727",
      "rank": 94,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 181,
      "preferred_url": "https://doi.org/10.1111/j.1600-0781.1998.tb00014.x",
      "title": "Update on enzyme and molecular defects in porphyria."
    },
    {
      "pmid": "15868463",
      "rank": 95,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 258,
      "preferred_url": "https://doi.org/10.1007/s10545-005-8050-3",
      "title": "Molecular mechanisms of dominant expression in porphyria."
    },
    {
      "pmid": "10599375",
      "rank": 96,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 263,
      "preferred_url": "https://doi.org/10.1007/978-1-4615-4857-7_60",
      "title": "Newer concepts in antimicrobial therapy."
    },
    {
      "pmid": "7616661",
      "rank": 97,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 18,
      "preferred_url": "https://pubmed.ncbi.nlm.nih.gov/7616661/",
      "title": "[Variegate porphyria]."
    },
    {
      "pmid": "15239394",
      "rank": 98,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 292,
      "preferred_url": "https://doi.org/10.1532/ijh97.03127",
      "title": "Porphyrias in Japan: compilation of all cases reported through 2002."
    },
    {
      "pmid": "10787385",
      "rank": 99,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 334,
      "preferred_url": "https://doi.org/10.1093/alcalc/35.2.109",
      "title": "Alcohol and porphyrin metabolism."
    },
    {
      "pmid": "17763398",
      "rank": 100,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 255,
      "preferred_url": "https://doi.org/10.1002/lt.21261",
      "title": "Liver transplantation for porphyria: who, when, and how?"
    },
    {
      "pmid": "7864431",
      "rank": 101,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 135,
      "preferred_url": "https://doi.org/10.1097/00000539-199503000-00028",
      "title": "Anesthetic considerations in porphyrias."
    },
    {
      "pmid": "12367763",
      "rank": 102,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 123,
      "preferred_url": "https://doi.org/10.1016/s0009-8981(02)00276-0",
      "title": "Human hereditary hepatic porphyrias."
    },
    {
      "pmid": "40464666",
      "rank": 103,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 264,
      "preferred_url": "https://doi.org/10.1097/ANA.0000000000000941",
      "title": "5-Aminolevulonic Acid, a New Tumor Contrast Agent: Anesthesia Considerations in Patients Undergoing Craniotomy."
    },
    {
      "pmid": "7616667",
      "rank": 104,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 110,
      "preferred_url": "https://pubmed.ncbi.nlm.nih.gov/7616667/",
      "title": "[Porphyrias and drugs]."
    },
    {
      "pmid": "8342401",
      "rank": 105,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 100,
      "preferred_url": "https://pubmed.ncbi.nlm.nih.gov/8342401/",
      "title": "Total intravenous anesthesia in South-African genetic porphyria (variegate porphyria)."
    },
    {
      "pmid": "23515149",
      "rank": 106,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 116,
      "preferred_url": "https://doi.org/10.4103/2319-4170.107155",
      "title": "Ketogenic diet: an early option for epilepsy treatment, instead of a last choice only."
    },
    {
      "pmid": "10418219",
      "rank": 107,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 144,
      "preferred_url": "https://pubmed.ncbi.nlm.nih.gov/10418219/",
      "title": "Hepatocellular carcinoma presenting with acquired porphyria: a case report and review of the literature."
    },
    {
      "pmid": "24261722",
      "rank": 108,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 104,
      "preferred_url": "https://doi.org/10.1111/ijd.12305",
      "title": "Cutaneous porphyrias part I: epidemiology, pathogenesis, presentation, diagnosis, and histopathology."
    },
    {
      "pmid": "2518297",
      "rank": 109,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 110,
      "preferred_url": "https://pubmed.ncbi.nlm.nih.gov/2518297/",
      "title": "[Acute intermittent porphyria: a clinical case]."
    },
    {
      "pmid": "16222352",
      "rank": 110,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 136,
      "preferred_url": "https://pubmed.ncbi.nlm.nih.gov/16222352/",
      "title": "Clinical indications for the investigation of porphyria: case examples and evolving laboratory approaches to its diagnosis in New Zealand."
    },
    {
      "pmid": "11117426",
      "rank": 111,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 315,
      "preferred_url": "https://doi.org/10.1023/a:1005645624262",
      "title": "Erythropoietic and hepatic porphyrias."
    },
    {
      "pmid": "28815861",
      "rank": 112,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 139,
      "preferred_url": "https://doi.org/10.1002/hed.24771",
      "title": "Radiation and chemotherapy with no excessive toxicity in a patient with human papillomavirus-related tonsillar cancer and porphyria cutanea tarda: Case report and literature review."
    },
    {
      "pmid": "2092571",
      "rank": 113,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 219,
      "preferred_url": "https://pubmed.ncbi.nlm.nih.gov/2092571/",
      "title": "[Diagnosis and therapy of hepatic porphyria]."
    },
    {
      "pmid": "117341",
      "rank": 114,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 104,
      "preferred_url": "https://pubmed.ncbi.nlm.nih.gov/117341/",
      "title": "[Diagnosis and differential diagnosis of acute hepatic prophyrias (author's transl)]."
    },
    {
      "pmid": "10223097",
      "rank": 115,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 185,
      "preferred_url": "https://doi.org/10.3810/pgm.1999.04.691",
      "title": "Porphyria cutanea tarda. Don't forget to look at the urine."
    },
    {
      "pmid": "20955962",
      "rank": 116,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 187,
      "preferred_url": "https://doi.org/10.1016/j.bpg.2010.08.010",
      "title": "The acute hepatic porphyrias: current status and future challenges."
    },
    {
      "pmid": "10599349",
      "rank": 117,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 268,
      "preferred_url": "https://pubmed.ncbi.nlm.nih.gov/10599349/",
      "title": "Porphyria. From Sir Walter Raleigh to molecular biology."
    },
    {
      "pmid": "88665",
      "rank": 118,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 210,
      "preferred_url": "https://doi.org/10.1007/BF00228992",
      "title": "Hormonal effects on the regulation of hepatic heme biosynthesis."
    },
    {
      "pmid": "8616881",
      "rank": 119,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 168,
      "preferred_url": "https://pubmed.ncbi.nlm.nih.gov/8616881/",
      "title": "[The molecular basis and genetics of diseases associated with disorders of heme biosynthesis]."
    },
    {
      "pmid": "814414",
      "rank": 120,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 44,
      "preferred_url": "https://pubmed.ncbi.nlm.nih.gov/814414/",
      "title": "[Porphyria variegata (author's transl)]."
    },
    {
      "pmid": "329249",
      "rank": 121,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 102,
      "preferred_url": "https://doi.org/10.1080/00325481.1977.11714578",
      "title": "Hepatic porphyrias. Current concepts."
    },
    {
      "pmid": "10082597",
      "rank": 122,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 245,
      "preferred_url": "https://doi.org/10.1177/120347549900300314",
      "title": "Pseudoporphyria induced by propionic acid derivatives."
    },
    {
      "pmid": "8571113",
      "rank": 123,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 229,
      "preferred_url": "https://pubmed.ncbi.nlm.nih.gov/8571113/",
      "title": "[Acute hepatic porphyria and its neurological syndrome]."
    },
    {
      "pmid": "11021563",
      "rank": 124,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 98,
      "preferred_url": "https://doi.org/10.1046/j.1442-9071.2000.00330.x",
      "title": "Congenital porphyria with necrotizing scleritis in a 9-year-old child."
    },
    {
      "pmid": "7616668",
      "rank": 125,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 163,
      "preferred_url": "https://pubmed.ncbi.nlm.nih.gov/7616668/",
      "title": "[Surgical and anesthetic managements of patients with porphyria]."
    },
    {
      "pmid": "9516679",
      "rank": 126,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 119,
      "preferred_url": "https://doi.org/10.1055/s-2007-1007141",
      "title": "Diagnosis of porphyric syndromes: a practical approach in the era of molecular biology."
    },
    {
      "pmid": "10504904",
      "rank": 127,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 92,
      "preferred_url": "https://pubmed.ncbi.nlm.nih.gov/10504904/",
      "title": "Anesthetic considerations in hepatic porphyrias."
    },
    {
      "pmid": "8993961",
      "rank": 128,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 92,
      "preferred_url": "https://doi.org/10.1159/000246284",
      "title": "Hepatoerythropoietic porphyria: relationship with familial porphyria cutanea tarda."
    },
    {
      "pmid": "1494724",
      "rank": 129,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 276,
      "preferred_url": "https://pubmed.ncbi.nlm.nih.gov/1494724/",
      "title": "[Neurological, dermatological and biological manifestations of porphyria variegata. A study of 3 families of Italian origin in Marseilles area]."
    },
    {
      "pmid": "8344",
      "rank": 130,
      "score": 0.6000000000000001,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 117,
      "preferred_url": "https://pubmed.ncbi.nlm.nih.gov/8344/",
      "title": "[Cutaneous side effects of systemic drugs. Part 4 of a synopsis. 6/7. Drugs affecting the central nervous system. C. Drug-induced photosensitivity. D. Drug-induced changes of skin color]."
    },
    {
      "pmid": "15187315",
      "rank": 131,
      "score": 0.4,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 57,
      "preferred_url": "https://doi.org/10.1111/j.1346-8138.2004.tb00699.x",
      "title": "Variegate porphyria."
    },
    {
      "pmid": "15021955",
      "rank": 132,
      "score": 0.4,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 279,
      "preferred_url": "https://doi.org/10.1007/s00101-003-0615-7",
      "title": "[Desflurane in acute intermittent porphyria]."
    },
    {
      "pmid": "31706631",
      "rank": 133,
      "score": 0.4,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 231,
      "preferred_url": "https://doi.org/10.1016/j.ymgme.2019.10.011",
      "title": "Porphyria-induced posterior reversible encephalopathy syndrome and central nervous system dysfunction."
    },
    {
      "pmid": "23601071",
      "rank": 134,
      "score": 0.4,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 229,
      "preferred_url": "https://doi.org/10.1111/eci.12091",
      "title": "Antioxidants restore protoporphyrinogen oxidase in variegate porphyria patients."
    },
    {
      "pmid": "29516370",
      "rank": 135,
      "score": 0.4,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 263,
      "preferred_url": "https://doi.org/10.1007/s12020-018-1569-5",
      "title": "Novel mutation of PPOX gene in a patient with abdominal pain and syndrome of inappropriate antidiuresis."
    },
    {
      "pmid": "7354149",
      "rank": 136,
      "score": 0.4,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 98,
      "preferred_url": "https://pubmed.ncbi.nlm.nih.gov/7354149/",
      "title": "Variegate porphyria. Clinical and laboratory features."
    },
    {
      "pmid": "27624508",
      "rank": 137,
      "score": 0.4,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 277,
      "preferred_url": "https://doi.org/10.1016/j.jemermed.2016.06.058",
      "title": "Acute Porphyria Presenting as Major Trauma: Case Report and Literature Review."
    },
    {
      "pmid": "36883342",
      "rank": 138,
      "score": 0.4,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 81,
      "preferred_url": "https://doi.org/10.1177/14782715231161499",
      "title": "Acute intermittent porphyria: A rare cause of syndrome of inappropriate antidiuretic hormone secretion."
    },
    {
      "pmid": "40694238",
      "rank": 139,
      "score": 0.4,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 258,
      "preferred_url": "https://doi.org/10.1007/s40211-025-00534-6",
      "title": "Acute psychosis in variegate porphyria: a\u00a0case report."
    },
    {
      "pmid": "7586575",
      "rank": 140,
      "score": 0.4,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 139,
      "preferred_url": "https://doi.org/10.1016/0009-8981(95)06085-r",
      "title": "Variegate porphyria: diagnostic value of fluorometric scanning of plasma porphyrins."
    },
    {
      "pmid": "15660919",
      "rank": 141,
      "score": 0.4,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 240,
      "preferred_url": "https://doi.org/10.1111/j.0906-6705.2005.00228.x",
      "title": "Overrepresentation of the founder PPOX gene mutation R59W in a South African patient with severe clinical manifestation of porphyria."
    },
    {
      "pmid": "36178265",
      "rank": 142,
      "score": 0.4,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 92,
      "preferred_url": "https://doi.org/10.1111/pde.15150",
      "title": "A 9-year-old girl with blisters on the hands and face: An early presentation of variegate porphyria."
    },
    {
      "pmid": "7451141",
      "rank": 143,
      "score": 0.4,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 75,
      "preferred_url": "https://pubmed.ncbi.nlm.nih.gov/7451141/",
      "title": "[Porphyria variegata]."
    },
    {
      "pmid": "39016183",
      "rank": 144,
      "score": 0.4,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 289,
      "preferred_url": "https://doi.org/10.1111/liv.16037",
      "title": "High disease burden and healthcare resource usage in patients with acute porphyria-A population-based analysis."
    },
    {
      "pmid": "29557620",
      "rank": 145,
      "score": 0.4,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 246,
      "preferred_url": "https://doi.org/10.5546/aap.2018.e300",
      "title": "[Congenital erythropoietic porphyria: case report and management recommendations]."
    },
    {
      "pmid": "25445397",
      "rank": 146,
      "score": 0.4,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 210,
      "preferred_url": "https://doi.org/10.1016/j.jhep.2014.11.029",
      "title": "Biallelic inactivation of protoporphyrinogen oxidase and hydroxymethylbilane synthase is associated with liver cancer in acute porphyrias."
    },
    {
      "pmid": "20417053",
      "rank": 147,
      "score": 0.4,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 139,
      "preferred_url": "https://doi.org/10.1016/j.jemermed.2010.02.028",
      "title": "A case report of porphyria variegata management in the emergency department."
    },
    {
      "pmid": "24635077",
      "rank": 148,
      "score": 0.4,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 88,
      "preferred_url": "https://doi.org/10.1111/ced.12313",
      "title": "Diclofenac-induced pseudoporphyria; an under-recognized condition?"
    },
    {
      "pmid": "19883519",
      "rank": 149,
      "score": 0.4,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 259,
      "preferred_url": "https://doi.org/10.1017/S0007114509991413",
      "title": "Variegate porphyria induces plasma and neutrophil oxidative stress: effects of dietary supplementation with vitamins E and C."
    },
    {
      "pmid": "3561676",
      "rank": 150,
      "score": 0.4,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 95,
      "preferred_url": "https://pubmed.ncbi.nlm.nih.gov/3561676/",
      "title": "[Porphyria variegata--a case report]."
    },
    {
      "pmid": "24073655",
      "rank": 151,
      "score": 0.4,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 152,
      "preferred_url": "https://doi.org/10.1111/ced.12071",
      "title": "Homozygous variegate porphyria presenting with developmental and language delay in childhood."
    },
    {
      "pmid": "18040123",
      "rank": 152,
      "score": 0.4,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 111,
      "preferred_url": "https://doi.org/10.4103/0028-3886.33303",
      "title": "Acute intermittent porphyria presenting with neurological emergency: review of six cases."
    },
    {
      "pmid": "1997060",
      "rank": 153,
      "score": 0.4,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 161,
      "preferred_url": "https://doi.org/10.1093/bja/66.1.60",
      "title": "Propofol as an i.v. anaesthetic induction agent in variegate porphyria."
    },
    {
      "pmid": "26872826",
      "rank": 154,
      "score": 0.4,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 63,
      "preferred_url": "https://doi.org/10.1177/0956462416633981",
      "title": "Acute intermittent porphyria precipitated by atazanavir/ritonavir."
    },
    {
      "pmid": "27871506",
      "rank": 155,
      "score": 0.4,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 114,
      "preferred_url": "https://doi.org/10.1016/j.jclinane.2016.06.014",
      "title": "Elective cholecystectomy performed on patient with variegate porphyria-Propofol-based total intravenous anesthesia with target-controlled infusion."
    },
    {
      "pmid": "15826795",
      "rank": 156,
      "score": 0.4,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 149,
      "preferred_url": "https://doi.org/10.1016/j.annfar.2005.01.012",
      "title": "[Obstetrical anaesthesia and porphyrias]."
    },
    {
      "pmid": "15180190",
      "rank": 157,
      "score": 0.4,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 193,
      "preferred_url": "https://doi.org/10.1080/00365520410008395",
      "title": "Variegate porphyria presenting with acute autonomic dysfunction, intussusception and renal infarction."
    },
    {
      "pmid": "3319294",
      "rank": 158,
      "score": 0.4,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 122,
      "preferred_url": "https://doi.org/10.1111/j.1399-0004.1987.tb03294.x",
      "title": "Homozygous variegate porphyria. A severe skin disease of infancy."
    },
    {
      "pmid": "9738863",
      "rank": 159,
      "score": 0.4,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 202,
      "preferred_url": "https://pubmed.ncbi.nlm.nih.gov/9738863/",
      "title": "Recurrent missense mutation in the protoporphyrinogen oxidase gene underlies variegate porphyria."
    },
    {
      "pmid": "26596031",
      "rank": 160,
      "score": 0.4,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 103,
      "preferred_url": "https://pubmed.ncbi.nlm.nih.gov/26596031/",
      "title": "[INTENSIVE CARE OF COMPLICATED ACUTE PORPHYRIA]."
    },
    {
      "pmid": "7939407",
      "rank": 161,
      "score": 0.4,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 139,
      "preferred_url": "https://doi.org/10.3109/00365529409092491",
      "title": "A case of association between hepatocellular carcinoma and porphyria variegata."
    },
    {
      "pmid": "11298551",
      "rank": 162,
      "score": 0.4,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 142,
      "preferred_url": "https://doi.org/10.1046/j.1365-2133.2001.04147.x",
      "title": "Homozygous variegate porphyria: a compound heterozygote with novel mutations in the protoporphyrinogen oxidase gene."
    },
    {
      "pmid": "21146060",
      "rank": 163,
      "score": 0.4,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 285,
      "preferred_url": "https://doi.org/10.1016/S0034-7094(10)70079-9",
      "title": "Neuropathic pain in a patient with porphyria. Case report."
    },
    {
      "pmid": "22428497",
      "rank": 164,
      "score": 0.4,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 107,
      "preferred_url": "https://pubmed.ncbi.nlm.nih.gov/22428497/",
      "title": "Anesthesia for cesarian section in pregnant woman with acute intermittent porphyria and hypothyroidism--case report."
    },
    {
      "pmid": "15175780",
      "rank": 165,
      "score": 0.4,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 129,
      "preferred_url": "https://pubmed.ncbi.nlm.nih.gov/15175780/",
      "title": "A rare case of porphyria."
    },
    {
      "pmid": "11422339",
      "rank": 166,
      "score": 0.4,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 245,
      "preferred_url": "https://doi.org/10.1046/j.1528-1157.2001.44200.x",
      "title": "Oxcarbazepine in focal epilepsy and hepatic porphyria: a case report."
    },
    {
      "pmid": "2222353",
      "rank": 167,
      "score": 0.4,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 110,
      "preferred_url": "https://doi.org/10.1111/j.1445-5994.1990.tb01320.x",
      "title": "An unusual case of variegate porphyria with possible homozygous inheritance."
    },
    {
      "pmid": "15726012",
      "rank": 168,
      "score": 0.4,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 229,
      "preferred_url": "https://pubmed.ncbi.nlm.nih.gov/15726012/",
      "title": "Familial occurrence of myoclonic epilepsy syndrome and acute intermittent porphyria."
    },
    {
      "pmid": "17037005",
      "rank": 169,
      "score": 0.4,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 113,
      "preferred_url": "https://pubmed.ncbi.nlm.nih.gov/17037005/",
      "title": "The use of rocuronium and sevoflurane in acute intermittent porphyria--a case report."
    },
    {
      "pmid": "34009428",
      "rank": 170,
      "score": 0.4,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 174,
      "preferred_url": "https://doi.org/10.1007/s00108-021-01029-6",
      "title": "[Abdominal pain and seizure in a\u00a026-year-old student from England]."
    },
    {
      "pmid": "10401000",
      "rank": 171,
      "score": 0.4,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 234,
      "preferred_url": "https://doi.org/10.1093/hmg/8.8.1517",
      "title": "Spectrum of mutations in the HFE gene implicated in haemochromatosis and porphyria."
    },
    {
      "pmid": "31745600",
      "rank": 172,
      "score": 0.4,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 252,
      "preferred_url": "https://doi.org/10.1007/s00277-019-03831-7",
      "title": "Acute porphyrias: a German monocentric study of the biochemical, molecular genetic, and clinical data of 62 families."
    },
    {
      "pmid": "11507366",
      "rank": 173,
      "score": 0.4,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 123,
      "preferred_url": "https://doi.org/10.1097/00042737-200108000-00018",
      "title": "Non-alcoholic steatohepatitis induced by carbamazepine and variegate porphyria."
    },
    {
      "pmid": "3986654",
      "rank": 174,
      "score": 0.4,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 176,
      "preferred_url": "https://doi.org/10.1007/BF03010045",
      "title": "Induction of anaesthesia with etomidate in a patient with acute intermittent porphyria."
    },
    {
      "pmid": "371027",
      "rank": 175,
      "score": 0.4,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 78,
      "preferred_url": "https://pubmed.ncbi.nlm.nih.gov/371027/",
      "title": "The effects of canthaxanthin on the photocutaneous manifestations of porphyria."
    },
    {
      "pmid": "23473551",
      "rank": 176,
      "score": 0.4,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 94,
      "preferred_url": "https://doi.org/10.1016/j.ijoa.2013.01.005",
      "title": "Anaesthetic management of an obstetric patient with variegate porphyria."
    },
    {
      "pmid": "10870850",
      "rank": 177,
      "score": 0.4,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 110,
      "preferred_url": "https://doi.org/10.1006/mgme.2000.2975",
      "title": "Homozygous variegate porphyria in South Africa: genotypic analysis in two cases."
    },
    {
      "pmid": "603745",
      "rank": 178,
      "score": 0.4,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 130,
      "preferred_url": "https://doi.org/10.1111/j.1365-2133.1977.tb14268.x",
      "title": "Inheritance of porphyria cutanea tarda. Analysis of 14 cases in 5 families."
    },
    {
      "pmid": "21734717",
      "rank": 179,
      "score": 0.4,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 181,
      "preferred_url": "https://doi.org/10.1038/jid.2011.186",
      "title": "Digenic inheritance of mutations in the coproporphyrinogen oxidase and protoporphyrinogen oxidase genes in a unique type of porphyria."
    },
    {
      "pmid": "25137868",
      "rank": 180,
      "score": 0.4,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 105,
      "preferred_url": "https://pubmed.ncbi.nlm.nih.gov/25137868/",
      "title": "Ultrasound-guided regional anesthesia in a pediatric patient with acute intermittent porphyria: literature review and case report."
    },
    {
      "pmid": "23993340",
      "rank": 181,
      "score": 0.4,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 359,
      "preferred_url": "https://doi.org/10.1016/j.encep.2012.09.003",
      "title": "[State of dementia due to intermittent acute porphyria: a case report]."
    },
    {
      "pmid": "2317449",
      "rank": 182,
      "score": 0.4,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 74,
      "preferred_url": "https://doi.org/10.1111/j.1365-2133.1990.tb08272.x",
      "title": "Homozygous variegate porphyria: a case report."
    },
    {
      "pmid": "14156579",
      "rank": 183,
      "score": 0.2,
      "content_source": null,
      "has_content": false,
      "token_estimate": null,
      "preferred_url": "https://doi.org/10.1097/00000542-196405000-00017",
      "title": "PHARMACOGENETICS AND ANESTHESIA."
    },
    {
      "pmid": "12029239",
      "rank": 184,
      "score": 0.2,
      "content_source": null,
      "has_content": false,
      "token_estimate": null,
      "preferred_url": "https://pubmed.ncbi.nlm.nih.gov/12029239/",
      "title": "Anaesthesia and porphyria."
    },
    {
      "pmid": "14066107",
      "rank": 185,
      "score": 0.2,
      "content_source": null,
      "has_content": false,
      "token_estimate": null,
      "preferred_url": "https://doi.org/10.1093/bja/35.9.558",
      "title": "MUSCLE DISORDERS AND THE RELAXANTS."
    },
    {
      "pmid": "14626138",
      "rank": 186,
      "score": 0.2,
      "content_source": null,
      "has_content": false,
      "token_estimate": null,
      "preferred_url": "https://pubmed.ncbi.nlm.nih.gov/14626138/",
      "title": "[Porphyria]."
    },
    {
      "pmid": "24439243",
      "rank": 187,
      "score": 0.2,
      "content_source": null,
      "has_content": false,
      "token_estimate": null,
      "preferred_url": "https://doi.org/10.1016/j.jen.2013.11.014",
      "title": "Treatment of acute intermittent porphyria in the emergency department."
    },
    {
      "pmid": "4873642",
      "rank": 188,
      "score": 0.2,
      "content_source": null,
      "has_content": false,
      "token_estimate": null,
      "preferred_url": "https://pubmed.ncbi.nlm.nih.gov/4873642/",
      "title": "Porphyria and pregnancy."
    },
    {
      "pmid": "9645026",
      "rank": 189,
      "score": 0.2,
      "content_source": null,
      "has_content": false,
      "token_estimate": null,
      "preferred_url": "https://pubmed.ncbi.nlm.nih.gov/9645026/",
      "title": "[Variegate porphyria (VP)]."
    },
    {
      "pmid": "497083",
      "rank": 190,
      "score": 0.0,
      "content_source": null,
      "has_content": false,
      "token_estimate": null,
      "preferred_url": "https://doi.org/10.1093/bja/51.8.809",
      "title": "Anaesthetics and porphyria."
    },
    {
      "pmid": "13289451",
      "rank": 191,
      "score": 0.0,
      "content_source": null,
      "has_content": false,
      "token_estimate": null,
      "preferred_url": "https://pubmed.ncbi.nlm.nih.gov/13289451/",
      "title": "[Case of porphyria]."
    },
    {
      "pmid": "13419051",
      "rank": 192,
      "score": 0.0,
      "content_source": null,
      "has_content": false,
      "token_estimate": null,
      "preferred_url": "https://pubmed.ncbi.nlm.nih.gov/13419051/",
      "title": "Porphyria."
    },
    {
      "pmid": "7293816",
      "rank": 193,
      "score": 0.0,
      "content_source": null,
      "has_content": false,
      "token_estimate": null,
      "preferred_url": "https://pubmed.ncbi.nlm.nih.gov/7293816/",
      "title": "[Porphyria variegata]."
    },
    {
      "pmid": "6143163",
      "rank": 194,
      "score": 0.0,
      "content_source": null,
      "has_content": false,
      "token_estimate": null,
      "preferred_url": "https://doi.org/10.1016/s0140-6736(84)92298-0",
      "title": "Homozygous variegate porphyria."
    },
    {
      "pmid": "32247286",
      "rank": 195,
      "score": 0.0,
      "content_source": null,
      "has_content": false,
      "token_estimate": null,
      "preferred_url": "https://doi.org/10.1111/ddg.14079",
      "title": "Two new mutations in the PPOX gene in a patient with variegate porphyria."
    },
    {
      "pmid": "6028689",
      "rank": 196,
      "score": 0.0,
      "content_source": null,
      "has_content": false,
      "token_estimate": null,
      "preferred_url": "https://doi.org/10.1001/archderm.96.1.98",
      "title": "Variegate porphyria (mixed porphyria)."
    },
    {
      "pmid": "6152284",
      "rank": 197,
      "score": 0.0,
      "content_source": null,
      "has_content": false,
      "token_estimate": null,
      "preferred_url": "https://pubmed.ncbi.nlm.nih.gov/6152284/",
      "title": "Porphyria and pain management."
    },
    {
      "pmid": "37926131",
      "rank": 198,
      "score": 0.0,
      "content_source": null,
      "has_content": false,
      "token_estimate": null,
      "preferred_url": "https://doi.org/10.1053/j.gastro.2023.10.031",
      "title": "Sunlight's Dark Side: A Case of Subtle Skin Lesions and Hyperpigmentation."
    },
    {
      "pmid": "24438652",
      "rank": 199,
      "score": 0.0,
      "content_source": null,
      "has_content": false,
      "token_estimate": null,
      "preferred_url": "https://doi.org/10.1016/j.annemergmed.2013.06.013",
      "title": "Images in emergency medicine. Acute intermittent porphyria."
    },
    {
      "pmid": "13428299",
      "rank": 200,
      "score": 0.0,
      "content_source": null,
      "has_content": false,
      "token_estimate": null,
      "preferred_url": "https://pubmed.ncbi.nlm.nih.gov/13428299/",
      "title": "Acute porphyria."
    }
  ],
  "snippets": [
    {
      "snippet_id": 1,
      "pmid": "34661997",
      "drug": "atropine",
      "classification": "risk",
      "snippet_text": "xifloxacin Nitrofurantoin Doxycycline Rifampicin Gentamicin Sulfonamides , Trimethoprim Penicillins a Vancomycin Aciclovir, Ganciclovir, Valaciclovir Antiepileptic therapy Barbiturates (Phenobarbital) Gabapentin Carbamazepin Lacosamide (Valproic acid) Lamotrigine Phenytoin Levetiracetam Primidone Lorazepam, Midazolam (Oxcarbazepine) Magnesium Topiramate Pregabalin Propofol Neuroleptics Melperone Chlorpromazine Haloperidol Levomepromazin Antidepressants (Imipramin) Amitriptyline Duloxetine Mirtazapine SSRIs Steroids (Dexamethasone) Prednisolone (Methylprednisolon) Triamcinolone Others Hormones Atropine Progesterone Betablockers Catecholamines Note : All drugs are classified after their safety in systemic use in a patient. The list is not comprehensive and the authors advise to check in the following databases for updated information on a drug before prescription to a patient with porphyria: http://www.drugs\u2010porphyria.org or http://www.porphyriafoundation.com/drug\u2010database or http://porphyriadrugs.com Drugs in bold are regarded as unsafe and have reportedly triggered attacks. Drugs in parenthesis either have conflicting records in the two databases or are regarded as possibly unsafe or only",
      "snippet_score": 9.2383,
      "cues": [
        "trigger",
        "triggered",
        "unsafe",
        "safe",
        "safety"
      ],
      "article_rank": 3,
      "article_score": 5.48,
      "article_title": "Acute porphyrias - A neurological perspective.",
      "citation_url": "https://doi.org/10.1002/brb3.2389",
      "content_source": "pmc-full-text"
    },
    {
      "snippet_id": 2,
      "pmid": "34661997",
      "drug": "dexamethasone",
      "classification": "risk",
      "snippet_text": "mycin) Carbapenems (Flucloxacillin) Cephalosporins Isoniazid Ciprofloxacin, Moxifloxacin Nitrofurantoin Doxycycline Rifampicin Gentamicin Sulfonamides , Trimethoprim Penicillins a Vancomycin Aciclovir, Ganciclovir, Valaciclovir Antiepileptic therapy Barbiturates (Phenobarbital) Gabapentin Carbamazepin Lacosamide (Valproic acid) Lamotrigine Phenytoin Levetiracetam Primidone Lorazepam, Midazolam (Oxcarbazepine) Magnesium Topiramate Pregabalin Propofol Neuroleptics Melperone Chlorpromazine Haloperidol Levomepromazin Antidepressants (Imipramin) Amitriptyline Duloxetine Mirtazapine SSRIs Steroids (Dexamethasone) Prednisolone (Methylprednisolon) Triamcinolone Others Hormones Atropine Progesterone Betablockers Catecholamines Note : All drugs are classified after their safety in systemic use in a patient. The list is not comprehensive and the authors advise to check in the following databases for updated information on a drug before prescription to a patient with porphyria: http://www.drugs\u2010porphyria.org or http://www.porphyriafoundation.com/drug\u2010database or http://porphyriadrugs.com Drugs in bold are regarded as unsafe and have reportedly triggered attacks. Drugs in parenthesis either have conflicting",
      "snippet_score": 9.2383,
      "cues": [
        "trigger",
        "triggered",
        "unsafe",
        "safe",
        "safety"
      ],
      "article_rank": 3,
      "article_score": 5.48,
      "article_title": "Acute porphyrias - A neurological perspective.",
      "citation_url": "https://doi.org/10.1002/brb3.2389",
      "content_source": "pmc-full-text"
    },
    {
      "snippet_id": 3,
      "pmid": "34661997",
      "drug": "morphine",
      "classification": "risk",
      "snippet_text": "base ) (USA). Classification is usually based on few reports and this may lead to contradictory information in some cases. A privately run website displays the information of both databases as an overview for each drug ( http://porphyriadrugs.com ). Table 4 gives an overview of the safety of drugs commonly used in neurology and psychiatry, but is not exhaustive (Albers & Fink, 2004 ; Anderson et al., 2005 ; Crimlisk, 1997 ; Windebank & Bonkovsky, 2005 ). TABLE 4 List of safe and unsafe medications UNSAFE MEDICATIONS SAFE MEDICATIONS Pain killers Metamizole/Dipyrone ASS, Ibuprofen, Paracetamol Morphine, Hydromorphone Antiemetics Dimenhydrinate MCP Ondansetron Antibiotics/antivirals Clindamycin Azithromycin Erythromycin , (Clarithromycin) Carbapenems (Flucloxacillin) Cephalosporins Isoniazid Ciprofloxacin, Moxifloxacin Nitrofurantoin Doxycycline Rifampicin Gentamicin Sulfonamides , Trimethoprim Penicillins a Vancomycin Aciclovir, Ganciclovir, Valaciclovir Antiepileptic therapy Barbiturates (Phenobarbital) Gabapentin Carbamazepin Lacosamide (Valproic acid) Lamotrigine Phenytoin Levetiracetam Primidone Lorazepam, Midazolam (Oxcarbazepine) Magnesium Topiramate Pregabalin Propofol Neuroleptics M",
      "snippet_score": 9.0383,
      "cues": [
        "unsafe",
        "safe",
        "safety"
      ],
      "article_rank": 3,
      "article_score": 5.48,
      "article_title": "Acute porphyrias - A neurological perspective.",
      "citation_url": "https://doi.org/10.1002/brb3.2389",
      "content_source": "pmc-full-text"
    },
    {
      "snippet_id": 4,
      "pmid": "34661997",
      "drug": "ondansetron",
      "classification": "risk",
      "snippet_text": "ports and this may lead to contradictory information in some cases. A privately run website displays the information of both databases as an overview for each drug ( http://porphyriadrugs.com ). Table 4 gives an overview of the safety of drugs commonly used in neurology and psychiatry, but is not exhaustive (Albers & Fink, 2004 ; Anderson et al., 2005 ; Crimlisk, 1997 ; Windebank & Bonkovsky, 2005 ). TABLE 4 List of safe and unsafe medications UNSAFE MEDICATIONS SAFE MEDICATIONS Pain killers Metamizole/Dipyrone ASS, Ibuprofen, Paracetamol Morphine, Hydromorphone Antiemetics Dimenhydrinate MCP Ondansetron Antibiotics/antivirals Clindamycin Azithromycin Erythromycin , (Clarithromycin) Carbapenems (Flucloxacillin) Cephalosporins Isoniazid Ciprofloxacin, Moxifloxacin Nitrofurantoin Doxycycline Rifampicin Gentamicin Sulfonamides , Trimethoprim Penicillins a Vancomycin Aciclovir, Ganciclovir, Valaciclovir Antiepileptic therapy Barbiturates (Phenobarbital) Gabapentin Carbamazepin Lacosamide (Valproic acid) Lamotrigine Phenytoin Levetiracetam Primidone Lorazepam, Midazolam (Oxcarbazepine) Magnesium Topiramate Pregabalin Propofol Neuroleptics Melperone Chlorpromazine Haloperidol Levomepromazin Antidep",
      "snippet_score": 9.0383,
      "cues": [
        "unsafe",
        "safe",
        "safety"
      ],
      "article_rank": 3,
      "article_score": 5.48,
      "article_title": "Acute porphyrias - A neurological perspective.",
      "citation_url": "https://doi.org/10.1002/brb3.2389",
      "content_source": "pmc-full-text"
    },
    {
      "snippet_id": 5,
      "pmid": "34661997",
      "drug": "lorazepam",
      "classification": "safety",
      "snippet_text": "TIONS SAFE MEDICATIONS Pain killers Metamizole/Dipyrone ASS, Ibuprofen, Paracetamol Morphine, Hydromorphone Antiemetics Dimenhydrinate MCP Ondansetron Antibiotics/antivirals Clindamycin Azithromycin Erythromycin , (Clarithromycin) Carbapenems (Flucloxacillin) Cephalosporins Isoniazid Ciprofloxacin, Moxifloxacin Nitrofurantoin Doxycycline Rifampicin Gentamicin Sulfonamides , Trimethoprim Penicillins a Vancomycin Aciclovir, Ganciclovir, Valaciclovir Antiepileptic therapy Barbiturates (Phenobarbital) Gabapentin Carbamazepin Lacosamide (Valproic acid) Lamotrigine Phenytoin Levetiracetam Primidone Lorazepam, Midazolam (Oxcarbazepine) Magnesium Topiramate Pregabalin Propofol Neuroleptics Melperone Chlorpromazine Haloperidol Levomepromazin Antidepressants (Imipramin) Amitriptyline Duloxetine Mirtazapine SSRIs Steroids (Dexamethasone) Prednisolone (Methylprednisolon) Triamcinolone Others Hormones Atropine Progesterone Betablockers Catecholamines Note : All drugs are classified after their safety in systemic use in a patient. The list is not comprehensive and the authors advise to check in the following databases for updated information on a drug before prescription to a patient with porphyria: http",
      "snippet_score": 8.7383,
      "cues": [
        "safe",
        "safety"
      ],
      "article_rank": 3,
      "article_score": 5.48,
      "article_title": "Acute porphyrias - A neurological perspective.",
      "citation_url": "https://doi.org/10.1002/brb3.2389",
      "content_source": "pmc-full-text"
    },
    {
      "snippet_id": 6,
      "pmid": "34661997",
      "drug": "midazolam",
      "classification": "safety",
      "snippet_text": "MEDICATIONS Pain killers Metamizole/Dipyrone ASS, Ibuprofen, Paracetamol Morphine, Hydromorphone Antiemetics Dimenhydrinate MCP Ondansetron Antibiotics/antivirals Clindamycin Azithromycin Erythromycin , (Clarithromycin) Carbapenems (Flucloxacillin) Cephalosporins Isoniazid Ciprofloxacin, Moxifloxacin Nitrofurantoin Doxycycline Rifampicin Gentamicin Sulfonamides , Trimethoprim Penicillins a Vancomycin Aciclovir, Ganciclovir, Valaciclovir Antiepileptic therapy Barbiturates (Phenobarbital) Gabapentin Carbamazepin Lacosamide (Valproic acid) Lamotrigine Phenytoin Levetiracetam Primidone Lorazepam, Midazolam (Oxcarbazepine) Magnesium Topiramate Pregabalin Propofol Neuroleptics Melperone Chlorpromazine Haloperidol Levomepromazin Antidepressants (Imipramin) Amitriptyline Duloxetine Mirtazapine SSRIs Steroids (Dexamethasone) Prednisolone (Methylprednisolon) Triamcinolone Others Hormones Atropine Progesterone Betablockers Catecholamines Note : All drugs are classified after their safety in systemic use in a patient. The list is not comprehensive and the authors advise to check in the following databases for updated information on a drug before prescription to a patient with porphyria: http://www.drug",
      "snippet_score": 8.7383,
      "cues": [
        "safe",
        "safety"
      ],
      "article_rank": 3,
      "article_score": 5.48,
      "article_title": "Acute porphyrias - A neurological perspective.",
      "citation_url": "https://doi.org/10.1002/brb3.2389",
      "content_source": "pmc-full-text"
    },
    {
      "snippet_id": 7,
      "pmid": "34661997",
      "drug": "propofol",
      "classification": "safety",
      "snippet_text": "n, Paracetamol Morphine, Hydromorphone Antiemetics Dimenhydrinate MCP Ondansetron Antibiotics/antivirals Clindamycin Azithromycin Erythromycin , (Clarithromycin) Carbapenems (Flucloxacillin) Cephalosporins Isoniazid Ciprofloxacin, Moxifloxacin Nitrofurantoin Doxycycline Rifampicin Gentamicin Sulfonamides , Trimethoprim Penicillins a Vancomycin Aciclovir, Ganciclovir, Valaciclovir Antiepileptic therapy Barbiturates (Phenobarbital) Gabapentin Carbamazepin Lacosamide (Valproic acid) Lamotrigine Phenytoin Levetiracetam Primidone Lorazepam, Midazolam (Oxcarbazepine) Magnesium Topiramate Pregabalin Propofol Neuroleptics Melperone Chlorpromazine Haloperidol Levomepromazin Antidepressants (Imipramin) Amitriptyline Duloxetine Mirtazapine SSRIs Steroids (Dexamethasone) Prednisolone (Methylprednisolon) Triamcinolone Others Hormones Atropine Progesterone Betablockers Catecholamines Note : All drugs are classified after their safety in systemic use in a patient. The list is not comprehensive and the authors advise to check in the following databases for updated information on a drug before prescription to a patient with porphyria: http://www.drugs\u2010porphyria.org or http://www.porphyriafoundation.com/dru",
      "snippet_score": 8.7383,
      "cues": [
        "safe",
        "safety"
      ],
      "article_rank": 3,
      "article_score": 5.48,
      "article_title": "Acute porphyrias - A neurological perspective.",
      "citation_url": "https://doi.org/10.1002/brb3.2389",
      "content_source": "pmc-full-text"
    },
    {
      "snippet_id": 8,
      "pmid": "34661997",
      "drug": "levetiracetam",
      "classification": "risk",
      "snippet_text": "tein et al., 2017 ). Thrombophlebitis is the most common side\u2010effect and rarely vein obliteration occurs. Hemin acts as a transcription factor that reduces expression of the rate\u2010limiting hepatic enzyme ALAS1. This leads to down\u2010regulation of the entire pathway and reduction of toxic metabolites. For desperate cases with severe recurrent attacks, liver transplant has been performed leading to clinical and biochemical remission (Seth et al., 2007 ; Singal et al., 2014 ; Soonawalla et al., 2004 ; Stolzel et al., 2019 ). Antiepileptic therapy can be done with Gabapentin, Lacosamide, Lamotrigine, Levetiracetam, Lorazepam, Midazolam, and Pregabalin. Addition of magnesium and propofol has been successful (Bhatia et al., 2008 ; Dawit et al., 2019 ; Engelhardt et al., 2004 ; Stolzel et al., 2019 ; Zaatreh, 2005 ). Unsafe antiepileptics that can worsen AHP should be strictly avoided, especially barbiturates, but also valproic acid and carbamazepine. For the full list of safe and unsafe medications, please refer to Table 4 . Neuropathic pain is a common problem during acute attacks, but also during recovery. Pain management can be done with ASS, Ibuprofen, Paracetamol, opioids and with gabapentin or preg",
      "snippet_score": 8.6383,
      "cues": [
        "avoid",
        "avoided",
        "toxic",
        "unsafe",
        "safe"
      ],
      "article_rank": 3,
      "article_score": 5.48,
      "article_title": "Acute porphyrias - A neurological perspective.",
      "citation_url": "https://doi.org/10.1002/brb3.2389",
      "content_source": "pmc-full-text"
    },
    {
      "snippet_id": 9,
      "pmid": "34661997",
      "drug": "lorazepam",
      "classification": "risk",
      "snippet_text": "17 ). Thrombophlebitis is the most common side\u2010effect and rarely vein obliteration occurs. Hemin acts as a transcription factor that reduces expression of the rate\u2010limiting hepatic enzyme ALAS1. This leads to down\u2010regulation of the entire pathway and reduction of toxic metabolites. For desperate cases with severe recurrent attacks, liver transplant has been performed leading to clinical and biochemical remission (Seth et al., 2007 ; Singal et al., 2014 ; Soonawalla et al., 2004 ; Stolzel et al., 2019 ). Antiepileptic therapy can be done with Gabapentin, Lacosamide, Lamotrigine, Levetiracetam, Lorazepam, Midazolam, and Pregabalin. Addition of magnesium and propofol has been successful (Bhatia et al., 2008 ; Dawit et al., 2019 ; Engelhardt et al., 2004 ; Stolzel et al., 2019 ; Zaatreh, 2005 ). Unsafe antiepileptics that can worsen AHP should be strictly avoided, especially barbiturates, but also valproic acid and carbamazepine. For the full list of safe and unsafe medications, please refer to Table 4 . Neuropathic pain is a common problem during acute attacks, but also during recovery. Pain management can be done with ASS, Ibuprofen, Paracetamol, opioids and with gabapentin or pregabalin. In",
      "snippet_score": 8.6383,
      "cues": [
        "avoid",
        "avoided",
        "toxic",
        "unsafe",
        "safe"
      ],
      "article_rank": 3,
      "article_score": 5.48,
      "article_title": "Acute porphyrias - A neurological perspective.",
      "citation_url": "https://doi.org/10.1002/brb3.2389",
      "content_source": "pmc-full-text"
    },
    {
      "snippet_id": 10,
      "pmid": "34661997",
      "drug": "midazolam",
      "classification": "risk",
      "snippet_text": "bophlebitis is the most common side\u2010effect and rarely vein obliteration occurs. Hemin acts as a transcription factor that reduces expression of the rate\u2010limiting hepatic enzyme ALAS1. This leads to down\u2010regulation of the entire pathway and reduction of toxic metabolites. For desperate cases with severe recurrent attacks, liver transplant has been performed leading to clinical and biochemical remission (Seth et al., 2007 ; Singal et al., 2014 ; Soonawalla et al., 2004 ; Stolzel et al., 2019 ). Antiepileptic therapy can be done with Gabapentin, Lacosamide, Lamotrigine, Levetiracetam, Lorazepam, Midazolam, and Pregabalin. Addition of magnesium and propofol has been successful (Bhatia et al., 2008 ; Dawit et al., 2019 ; Engelhardt et al., 2004 ; Stolzel et al., 2019 ; Zaatreh, 2005 ). Unsafe antiepileptics that can worsen AHP should be strictly avoided, especially barbiturates, but also valproic acid and carbamazepine. For the full list of safe and unsafe medications, please refer to Table 4 . Neuropathic pain is a common problem during acute attacks, but also during recovery. Pain management can be done with ASS, Ibuprofen, Paracetamol, opioids and with gabapentin or pregabalin. In November 20",
      "snippet_score": 8.6383,
      "cues": [
        "avoid",
        "avoided",
        "toxic",
        "unsafe",
        "safe"
      ],
      "article_rank": 3,
      "article_score": 5.48,
      "article_title": "Acute porphyrias - A neurological perspective.",
      "citation_url": "https://doi.org/10.1002/brb3.2389",
      "content_source": "pmc-full-text"
    },
    {
      "snippet_id": 11,
      "pmid": "34661997",
      "drug": "propofol",
      "classification": "risk",
      "snippet_text": "vein obliteration occurs. Hemin acts as a transcription factor that reduces expression of the rate\u2010limiting hepatic enzyme ALAS1. This leads to down\u2010regulation of the entire pathway and reduction of toxic metabolites. For desperate cases with severe recurrent attacks, liver transplant has been performed leading to clinical and biochemical remission (Seth et al., 2007 ; Singal et al., 2014 ; Soonawalla et al., 2004 ; Stolzel et al., 2019 ). Antiepileptic therapy can be done with Gabapentin, Lacosamide, Lamotrigine, Levetiracetam, Lorazepam, Midazolam, and Pregabalin. Addition of magnesium and propofol has been successful (Bhatia et al., 2008 ; Dawit et al., 2019 ; Engelhardt et al., 2004 ; Stolzel et al., 2019 ; Zaatreh, 2005 ). Unsafe antiepileptics that can worsen AHP should be strictly avoided, especially barbiturates, but also valproic acid and carbamazepine. For the full list of safe and unsafe medications, please refer to Table 4 . Neuropathic pain is a common problem during acute attacks, but also during recovery. Pain management can be done with ASS, Ibuprofen, Paracetamol, opioids and with gabapentin or pregabalin. In November 2019, the FDA, and in March 2020, the EMA approved a n",
      "snippet_score": 8.6383,
      "cues": [
        "avoid",
        "avoided",
        "toxic",
        "unsafe",
        "safe"
      ],
      "article_rank": 3,
      "article_score": 5.48,
      "article_title": "Acute porphyrias - A neurological perspective.",
      "citation_url": "https://doi.org/10.1002/brb3.2389",
      "content_source": "pmc-full-text"
    },
    {
      "snippet_id": 12,
      "pmid": "34661997",
      "drug": "opioids",
      "classification": "risk",
      "snippet_text": "osamide, Lamotrigine, Levetiracetam, Lorazepam, Midazolam, and Pregabalin. Addition of magnesium and propofol has been successful (Bhatia et al., 2008 ; Dawit et al., 2019 ; Engelhardt et al., 2004 ; Stolzel et al., 2019 ; Zaatreh, 2005 ). Unsafe antiepileptics that can worsen AHP should be strictly avoided, especially barbiturates, but also valproic acid and carbamazepine. For the full list of safe and unsafe medications, please refer to Table 4 . Neuropathic pain is a common problem during acute attacks, but also during recovery. Pain management can be done with ASS, Ibuprofen, Paracetamol, opioids and with gabapentin or pregabalin. In November 2019, the FDA, and in March 2020, the EMA approved a new therapeutic for patients with recurrent attacks: givosiran (Alnylam Pharmaceuticals, Cambridge, MA, USA) is a small interfering RNA (siRNA) that neutralizes excess ALAS1 mRNA in hepatocytes (Sardh et al., 2019 ; Stolzel et al., 2019 ). Recently published results of the ENVISION\u2010trial ( NCT03338816 ), a phase III, multicenter, placebo\u2010controlled, randomized controlled trial, showed reduction of urinary ALA levels and of the number of acute attacks (Balwani et al., 2020 ). The siRNA is inject",
      "snippet_score": 8.5383,
      "cues": [
        "avoid",
        "avoided",
        "unsafe",
        "safe"
      ],
      "article_rank": 3,
      "article_score": 5.48,
      "article_title": "Acute porphyrias - A neurological perspective.",
      "citation_url": "https://doi.org/10.1002/brb3.2389",
      "content_source": "pmc-full-text"
    },
    {
      "snippet_id": 13,
      "pmid": "34661997",
      "drug": "levetiracetam",
      "classification": "risk",
      "snippet_text": "edications UNSAFE MEDICATIONS SAFE MEDICATIONS Pain killers Metamizole/Dipyrone ASS, Ibuprofen, Paracetamol Morphine, Hydromorphone Antiemetics Dimenhydrinate MCP Ondansetron Antibiotics/antivirals Clindamycin Azithromycin Erythromycin , (Clarithromycin) Carbapenems (Flucloxacillin) Cephalosporins Isoniazid Ciprofloxacin, Moxifloxacin Nitrofurantoin Doxycycline Rifampicin Gentamicin Sulfonamides , Trimethoprim Penicillins a Vancomycin Aciclovir, Ganciclovir, Valaciclovir Antiepileptic therapy Barbiturates (Phenobarbital) Gabapentin Carbamazepin Lacosamide (Valproic acid) Lamotrigine Phenytoin Levetiracetam Primidone Lorazepam, Midazolam (Oxcarbazepine) Magnesium Topiramate Pregabalin Propofol Neuroleptics Melperone Chlorpromazine Haloperidol Levomepromazin Antidepressants (Imipramin) Amitriptyline Duloxetine Mirtazapine SSRIs Steroids (Dexamethasone) Prednisolone (Methylprednisolon) Triamcinolone Others Hormones Atropine Progesterone Betablockers Catecholamines Note : All drugs are classified after their safety in systemic use in a patient. The list is not comprehensive and the authors advise to check in the following databases for updated information on a drug before prescription to a patient",
      "snippet_score": 8.4383,
      "cues": [
        "unsafe",
        "safe",
        "safety"
      ],
      "article_rank": 3,
      "article_score": 5.48,
      "article_title": "Acute porphyrias - A neurological perspective.",
      "citation_url": "https://doi.org/10.1002/brb3.2389",
      "content_source": "pmc-full-text"
    },
    {
      "snippet_id": 14,
      "pmid": "34661997",
      "drug": "levetiracetam",
      "classification": "safety",
      "snippet_text": "wed speech. This had progressed within days to aggressive/erratic behavior and a confusional state with incoherent speech. She was brought to an emergency room and admitted neurologically. Initial laboratory investigations, brain CT and MRI and CSF results were unremarkable. Investigations for infectious causes were negative. A second MRI revealed T2\u2010hyperintensities bilaterally in the basal ganglia without contrast enhancement (Figure SI). Autoimmune encephalitis was suspected and high\u2010dose steroids were started. Because of two episodes with loss of consciousness, seizures were suspected and levetiracetam was started to prevent seizures before transfer to our NICU was organized. Upon admission to our ward, the patient was awake, but confused. Neurological examination revealed severe dysarthria, dysphagia, and a bradykinetic syndrome. She was unable to stand or walk, muscle strength was generally slightly reduced, deep tendon reflexes normal. Blood pressure was within the normal range. We continued high\u2010dose steroids (methylprednisolone 1 g intravenously for 5 days) and repeated the lumbar puncture. Again, basic CSF results were unremarkable. EEG showed diffuse slowing of activity. MRI findings",
      "snippet_score": 8.0383,
      "cues": [
        "prevent"
      ],
      "article_rank": 3,
      "article_score": 5.48,
      "article_title": "Acute porphyrias - A neurological perspective.",
      "citation_url": "https://doi.org/10.1002/brb3.2389",
      "content_source": "pmc-full-text"
    },
    {
      "snippet_id": 15,
      "pmid": "34661997",
      "drug": "opioids",
      "classification": "safety",
      "snippet_text": "al., 1984 ), or small demyelinating lesions (Gibson & Goldberg, 1956 ), ischemic lesions, (Hierons, 1957 ; Suarez et al., 1997 ), and selective reduction of hypothalamic neurons (Suarez et al., 1997 ) have been reported. None of these findings are correlated with imaging studies and are therefore difficult to interpret. 8 TREATMENT Treatment of acute attacks consists of four major points (Figure 3 ): First, identification of precipitating factors and their removal if possible. Porphyrinogenic drugs should be stopped. Second, symptomatic supportive therapy, including adequate pain management (opioids are usually indicated), correction of electrolyte imbalances, and intensive care management, if needed. Third, normocaloric nutrition high in carbohydrates and/or glucose infusions. Sodium levels need to be monitored closely. Finally, severely ill patients should receive hemin (3 mg/kg body weight [up to a maximum of 250 mg] daily for four consecutive days) (Stein et al., 2017 ; Stolzel et al., 2019 ). Hemin is indicated in patients with AHP and any neurological symptoms, in those requiring intensive care and in some cases, for pain management. Heme arginate can be reconstituted in 100 ml nor",
      "snippet_score": 8.0383,
      "cues": [
        "indicated"
      ],
      "article_rank": 3,
      "article_score": 5.48,
      "article_title": "Acute porphyrias - A neurological perspective.",
      "citation_url": "https://doi.org/10.1002/brb3.2389",
      "content_source": "pmc-full-text"
    },
    {
      "snippet_id": 16,
      "pmid": "36642627",
      "drug": "benzodiazepines",
      "classification": "risk",
      "snippet_text": "tivated receptor \u03b3 coactivator 1- \u03b1 , which induces expression of ALAS1. 35 Acute attacks can be associated with hyponatremia and hypomagnesemia due to a combination of hypovolemia and syndrome of inappropriate antidiuretic hormone secretion. 36 , 37 Electrolytes should be monitored during acute attacks and hyponatremia corrected slowly if present. In acute attacks that present with seizures, management should be approached with caution because many anticonvulsant medications, such as barbiturates, hydantoins, carbamazepine, and valproic acid, are contraindicated in AHP. 38 Magnesium sulfate, benzodiazepines, and levetiracetam appear to be safe options in the context of AHP. Best Practice Advice 6: Patients should be counseled to avoid identifiable triggers that may precipitate acute attacks, such as alcohol and porphyrinogenic medications. The low penetrance of AHPs indicates the likely presence of additional factors that are required for clinical symptoms, including precipitating factors and other poorly defined modifying genes and/or epigenetic factors. 39 , 40 Sex hormones, in particular progesterone, are known to precipitate attacks. Other common precipitating factors include medications tha",
      "snippet_score": 7.9832,
      "cues": [
        "avoid",
        "contraindicated",
        "caution",
        "precipitate",
        "trigger",
        "safe",
        "safe option",
        "indicated"
      ],
      "article_rank": 5,
      "article_score": 4.510000000000001,
      "article_title": "AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review.",
      "citation_url": "https://doi.org/10.1053/j.gastro.2022.11.034",
      "content_source": "pmc-full-text"
    },
    {
      "snippet_id": 17,
      "pmid": "36642627",
      "drug": "levetiracetam",
      "classification": "risk",
      "snippet_text": "activator 1- \u03b1 , which induces expression of ALAS1. 35 Acute attacks can be associated with hyponatremia and hypomagnesemia due to a combination of hypovolemia and syndrome of inappropriate antidiuretic hormone secretion. 36 , 37 Electrolytes should be monitored during acute attacks and hyponatremia corrected slowly if present. In acute attacks that present with seizures, management should be approached with caution because many anticonvulsant medications, such as barbiturates, hydantoins, carbamazepine, and valproic acid, are contraindicated in AHP. 38 Magnesium sulfate, benzodiazepines, and levetiracetam appear to be safe options in the context of AHP. Best Practice Advice 6: Patients should be counseled to avoid identifiable triggers that may precipitate acute attacks, such as alcohol and porphyrinogenic medications. The low penetrance of AHPs indicates the likely presence of additional factors that are required for clinical symptoms, including precipitating factors and other poorly defined modifying genes and/or epigenetic factors. 39 , 40 Sex hormones, in particular progesterone, are known to precipitate attacks. Other common precipitating factors include medications that induce cytochrome",
      "snippet_score": 7.9832,
      "cues": [
        "avoid",
        "contraindicated",
        "caution",
        "precipitate",
        "trigger",
        "safe",
        "safe option",
        "indicated"
      ],
      "article_rank": 5,
      "article_score": 4.510000000000001,
      "article_title": "AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review.",
      "citation_url": "https://doi.org/10.1053/j.gastro.2022.11.034",
      "content_source": "pmc-full-text"
    },
    {
      "snippet_id": 18,
      "pmid": "36028858",
      "drug": "opioids",
      "classification": "risk",
      "snippet_text": ", 14 ]. Early treatment is important to prevent disease progression [ 5 , 15 ]. There is a need for treatments that not only reduce or eliminate acute attacks, but also improve chronic manifestations of recurrent AHP. Prevention strategies include identifying and avoiding triggers that may precipitate acute attacks [ 16 , 17 ]. However, some triggers, such as stress, may not always be avoidable [ 17 , 18 ]. Furthermore, many patients continue to experience chronic symptoms between attacks [ 6 , 10 , 11 ]. Opioids are used to manage abdominal, limb, and back pain [ 17 ], but patients receiving opioids may develop somnolence, addiction, tolerance, and hyperalgesia [ 19 ]. Intravenous (IV) hemin is the standard of care for confirmed acute attacks [ 2 , 20 , 21 ]. Hemin is thought to work by decreasing levels of ALAS1, thereby reducing the production of toxic heme precursors [ 22 \u2013 24 ]. Although hemin is not indicated for prophylaxis [ 22 , 23 ], it is often used off-label for this purpose [ 11 ]. Some patients have reported recurrent attacks despite weekly prophylactic hemin administration [ 25 ]. Side effects and complications associated with hemin use include headache, infusion-site react",
      "snippet_score": 6.2244,
      "cues": [
        "avoid",
        "complication",
        "complications",
        "precipitate",
        "side effect",
        "side effects",
        "toxic",
        "trigger",
        "prevent",
        "indicated"
      ],
      "article_rank": 12,
      "article_score": 2.86,
      "article_title": "Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION study.",
      "citation_url": "https://doi.org/10.1186/s13023-022-02463-x",
      "content_source": "pmc-full-text"
    },
    {
      "snippet_id": 19,
      "pmid": "36028858",
      "drug": "opioid",
      "classification": "risk",
      "snippet_text": "ical comparisons were undertaken. Results A total of 94 patients with AHP were enrolled in the ENVISION trial, of whom 46 were assigned to receive placebo and 48 to receive givosiran [ 35 ]. The median (range) age was 37.5 (19\u201265) years, and the mean (SD) years since diagnosis was 9.7 (10.0) [ 35 ]. The median (range) AAR in the 6 months prior to study randomization was 8.0 (0\u201346) [ 35 ]. At baseline, 52% of patients were experiencing chronic symptoms of porphyria, defined as symptoms between attacks daily or on most days [ 35 ]. Chronic symptoms included nausea, fatigue, and pain (Table 1 ). Opioid analgesics were used daily or on most days between attacks in 29% of patients [ 35 ]. Mean daily worst fatigue score was above 4, on a numerical rating scale of 0\u201310, in both treatment groups. Table 1 Chronic symptoms in ENVISION trial participants at baseline Characteristic Placebo (n = 46) Givosiran (n = 48) Total (N = 94) Prior chronic symptoms, n (%) 26 (57) 23 (48) 49 (52) Prior chronic opioid use, n (%) 13 (28) 14 (29) 27 (29) Nausea symptoms (medical history), n (%) 10 (22) 7 (15) 17 (18) Fatigue (medical history), n (%) 4 (9) 1 (2) 5 (5) Daily worst nausea score, weekly mean (SD) 1.9",
      "snippet_score": 5.9244,
      "cues": [
        "condition-match"
      ],
      "article_rank": 12,
      "article_score": 2.86,
      "article_title": "Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION study.",
      "citation_url": "https://doi.org/10.1186/s13023-022-02463-x",
      "content_source": "pmc-full-text"
    },
    {
      "snippet_id": 20,
      "pmid": "36028858",
      "drug": "opioids",
      "classification": "safety",
      "snippet_text": "s with or without prior hemin prophylaxis use. a Analgesic use was collected in an electronic diary up to Month 12 Fig. 8 Mean change from baseline in SF-12 PCS scores in patients with or without prior hemin prophylaxis use. Higher scores represent improvement in that summary or domain Discussion This study used data from the ENVISION trial to demonstrate the severe disease burden associated with recurrent AHP. At baseline, more than half of ENVISION trial patients were experiencing chronic symptoms between attacks, including nausea, fatigue, and pain, and more than one quarter had been using opioids daily or on most days [ 35 ]. We also found a positive correlation between time since diagnosis and AHP disease severity, further highlighting the need to treat patients early with effective therapy. These results showed that the RNAi therapeutic givosiran is effective in patients with recurrent AHP regardless of prior hemin use, and that it reduces analgesic use and pain both during and between porphyria attacks. Overall disease burden in the ENVISION trial population was similar to that observed in the recent EXPLORE study, a prospective, multinational, natural history study of patients wit",
      "snippet_score": 5.7244,
      "cues": [
        "effective"
      ],
      "article_rank": 12,
      "article_score": 2.86,
      "article_title": "Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION study.",
      "citation_url": "https://doi.org/10.1186/s13023-022-02463-x",
      "content_source": "pmc-full-text"
    },
    {
      "snippet_id": 21,
      "pmid": "36028858",
      "drug": "opioids",
      "classification": "safety",
      "snippet_text": "orst pain scores above baseline than placebo recipients, and nearly 50% fewer days with severe pain during attack-free periods. Pain is one of the key factors associated with diminished QOL among patients with AHP [ 11 ]. The SF-12 PCS scores increased by 10.0 and 8.9 points in the open-label extension in the placebo crossover and continuous givosiran groups, respectively. The proportion of patients who used opioid analgesics during attacks was 12% lower in the givosiran group compared with the placebo group during attacks, and 13% lower during attack-free periods. Given that long-term use of opioids is associated with tolerance, dependence, and addiction, a reduction in use of these medications is clinically relevant. Furthermore, evidence for the efficacy of opioids in the management of chronic non\u2013cancer-related pain is limited. A 30-month open-label extension phase of ENVISION was completed in May 2021. Results to date support long-term maintenance of benefit with givosiran. A strength of our study is that, unlike the observational EXPLORE study [ 11 ], all potential porphyria attacks occurring in the ENVISION trial were adjudicated by the investigator. A limitation of our study was t",
      "snippet_score": 5.7244,
      "cues": [
        "efficacy"
      ],
      "article_rank": 12,
      "article_score": 2.86,
      "article_title": "Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION study.",
      "citation_url": "https://doi.org/10.1186/s13023-022-02463-x",
      "content_source": "pmc-full-text"
    },
    {
      "snippet_id": 22,
      "pmid": "36028858",
      "drug": "fentanyl",
      "classification": "risk",
      "snippet_text": "ics at baseline Placebo (n = 46) Givosiran (n = 48) Total (N = 94) Antidepressants Benzodiazepine derivatives 10 (22) 10 (21) 20 (21) Benzodiazepine-related drugs 3 (7) 4 (8) 7 (7) Other anti-depressants 4 (9) 9 (19) 13 (14) SSRIs 2 (4) 4 (8) 6 (6) Antihypertensives ACE inhibitors 2 (4) 1 (2) 3 (3) Angiotensin II receptor antagonists 3 (7) 2 (4) 5 (5) Beta blocking agents, non-selective 1 (2) 3 (6) 4 (4) Beta blocking agents, selective 5 (11) 7 (15) 12 (13) Antiemetics 5HT3 antagonists 12 (26) 12 (25) 24 (26) Pain medications Natural opium alkaloids 27 (59) 23 (48) 50 (53) Opioid anesthetics (fentanyl) 2 (4) 0 2 (2) Opioid/non-opioid combinations 2 (4) 5 (10) 7 (7) Opium alkaloid derivatives 2 (4) 0 2 (2) Other opioids 8 (17) 6 (13) 14 (15) Other analgesics and antipyretics 10 (22) 13 (27) 23 (25) SSRI selective serotonin reuptake inhibitor, ACE angiotensin-converting enzyme, 5HT3 5-hydroxytryptamine A high proportion of patients had received prior hemin prophylaxis (40%) [ 11 ], with many experiencing hemin-related complications, as well as ongoing damage caused by AHP (Fig. 2 ). Complications related to central venous access included thrombosis (8%), infection (18%), and catheter occlusi",
      "snippet_score": 5.4244,
      "cues": [
        "complication",
        "complications"
      ],
      "article_rank": 12,
      "article_score": 2.86,
      "article_title": "Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION study.",
      "citation_url": "https://doi.org/10.1186/s13023-022-02463-x",
      "content_source": "pmc-full-text"
    },
    {
      "snippet_id": 23,
      "pmid": "36028858",
      "drug": "opioid",
      "classification": "risk",
      "snippet_text": "emetics, and analgesics at baseline Placebo (n = 46) Givosiran (n = 48) Total (N = 94) Antidepressants Benzodiazepine derivatives 10 (22) 10 (21) 20 (21) Benzodiazepine-related drugs 3 (7) 4 (8) 7 (7) Other anti-depressants 4 (9) 9 (19) 13 (14) SSRIs 2 (4) 4 (8) 6 (6) Antihypertensives ACE inhibitors 2 (4) 1 (2) 3 (3) Angiotensin II receptor antagonists 3 (7) 2 (4) 5 (5) Beta blocking agents, non-selective 1 (2) 3 (6) 4 (4) Beta blocking agents, selective 5 (11) 7 (15) 12 (13) Antiemetics 5HT3 antagonists 12 (26) 12 (25) 24 (26) Pain medications Natural opium alkaloids 27 (59) 23 (48) 50 (53) Opioid anesthetics (fentanyl) 2 (4) 0 2 (2) Opioid/non-opioid combinations 2 (4) 5 (10) 7 (7) Opium alkaloid derivatives 2 (4) 0 2 (2) Other opioids 8 (17) 6 (13) 14 (15) Other analgesics and antipyretics 10 (22) 13 (27) 23 (25) SSRI selective serotonin reuptake inhibitor, ACE angiotensin-converting enzyme, 5HT3 5-hydroxytryptamine A high proportion of patients had received prior hemin prophylaxis (40%) [ 11 ], with many experiencing hemin-related complications, as well as ongoing damage caused by AHP (Fig. 2 ). Complications related to central venous access included thrombosis (8%), infection (18%)",
      "snippet_score": 5.4244,
      "cues": [
        "complication",
        "complications"
      ],
      "article_rank": 12,
      "article_score": 2.86,
      "article_title": "Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION study.",
      "citation_url": "https://doi.org/10.1186/s13023-022-02463-x",
      "content_source": "pmc-full-text"
    },
    {
      "snippet_id": 24,
      "pmid": "36028858",
      "drug": "opioid",
      "classification": "risk",
      "snippet_text": "(n = 46) Givosiran (n = 48) Total (N = 94) Antidepressants Benzodiazepine derivatives 10 (22) 10 (21) 20 (21) Benzodiazepine-related drugs 3 (7) 4 (8) 7 (7) Other anti-depressants 4 (9) 9 (19) 13 (14) SSRIs 2 (4) 4 (8) 6 (6) Antihypertensives ACE inhibitors 2 (4) 1 (2) 3 (3) Angiotensin II receptor antagonists 3 (7) 2 (4) 5 (5) Beta blocking agents, non-selective 1 (2) 3 (6) 4 (4) Beta blocking agents, selective 5 (11) 7 (15) 12 (13) Antiemetics 5HT3 antagonists 12 (26) 12 (25) 24 (26) Pain medications Natural opium alkaloids 27 (59) 23 (48) 50 (53) Opioid anesthetics (fentanyl) 2 (4) 0 2 (2) Opioid/non-opioid combinations 2 (4) 5 (10) 7 (7) Opium alkaloid derivatives 2 (4) 0 2 (2) Other opioids 8 (17) 6 (13) 14 (15) Other analgesics and antipyretics 10 (22) 13 (27) 23 (25) SSRI selective serotonin reuptake inhibitor, ACE angiotensin-converting enzyme, 5HT3 5-hydroxytryptamine A high proportion of patients had received prior hemin prophylaxis (40%) [ 11 ], with many experiencing hemin-related complications, as well as ongoing damage caused by AHP (Fig. 2 ). Complications related to central venous access included thrombosis (8%), infection (18%), and catheter occlusion/malfunction (24%).",
      "snippet_score": 5.4244,
      "cues": [
        "complication",
        "complications"
      ],
      "article_rank": 12,
      "article_score": 2.86,
      "article_title": "Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION study.",
      "citation_url": "https://doi.org/10.1186/s13023-022-02463-x",
      "content_source": "pmc-full-text"
    },
    {
      "snippet_id": 25,
      "pmid": "40114189",
      "drug": "levetiracetam",
      "classification": "risk",
      "snippet_text": "e the question whether homozygosity for R59W variant is lethal. Two new cases of homozygous variegate porphyria We identified two new cases of homozygous variegate porphyria that have so far not been published. Patient 1 is a now 7-year-old girl. She was admitted to our neonatal department because of hepatopathy on her first day of life, showing cutaneous lesions caused by the light of a pulse oximeter (Fig. 1 A). Nystagmus became apparent at the age of 6 weeks. She developed epileptic seizures, mainly bilateral tonic seizures with eye blinking, at the age of 3 months which did not respond to levetiracetam, but to a combination of valproic acid and phenobarbital. Her subsequent development was globally delayed. Currently, she is able to walk without aid on level ground and expresses herself in simple two-word combinations. She attends a school for children with intellectual disability. She has short stature and microcephaly (at the age of 7 years: height 114 cm (P1, SDS: \u2212 2.24), weight 19 kg (P2, SDS:\u2212 2.02), BMI 14.6 kg/m 2 (P25, SDS:\u2212 0.68) and head circumference 44.7 cm (< P1, SDS: \u2212 5.16), at birth: height 46 cm (< P1, SDS:\u2212 3.02), weight 2450 g (< P1, SDS:\u2212 2.99), head circumference 32 cm",
      "snippet_score": 5.14,
      "cues": [
        "condition-match"
      ],
      "article_rank": 13,
      "article_score": 2.8400000000000003,
      "article_title": "Neurodevelopmental retardation and neurological symptoms in homozygous variegate porphyria: two new cases and a literature review.",
      "citation_url": "https://doi.org/10.1186/s13023-025-03606-6",
      "content_source": "pmc-full-text"
    },
    {
      "snippet_id": 26,
      "pmid": "27052088",
      "drug": "sevoflurane",
      "classification": "risk",
      "snippet_text": "nique and also indicate active disease, with increased risk of acute crisis. Classifying drugs as porphyria safe or unsafe is too simplistic; the duration of exposure and the absolute dose dictate whether an acute crisis would be triggered or not and how would the severity be like. Multiple confounding factors in the perioperative period mean that the trigger for a crisis may be unclear. Propofol has been considered as a safe drug for both induction and maintenance of anesthesia in the patients with AIP.[ 17 18 19 ] Modern inhalation agents are generally considered safe in porphyric patients. Sevoflurane has been reported as a safe agent for both induction and maintenance of anesthesia. Safe use of isoflurane has also been reported;[ 20 21 22 ] therefore, it should probably be classified as safe, although further information needs to be obtained. Enflurane has been shown to induce porphyrin synthesis in animal models[ 20 ] but has been used safely in patients. Reports of a possible association of halothane with crises contradict both experimental and clinical experience.[ 23 24 ] Preoperative starvation should be minimized; if a prolonged fast is unavoidable, a dextrose\u2013saline infusion should",
      "snippet_score": 5.6462,
      "cues": [
        "avoid",
        "risk",
        "risk of",
        "trigger",
        "triggered",
        "unsafe",
        "safe",
        "safely"
      ],
      "article_rank": 14,
      "article_score": 2.76,
      "article_title": "Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.",
      "citation_url": "https://doi.org/10.4103/0971-9784.179623",
      "content_source": "pmc-full-text"
    },
    {
      "snippet_id": 27,
      "pmid": "27052088",
      "drug": "propofol",
      "classification": "risk",
      "snippet_text": "that appropriate drug regimens are selected.[ 13 14 15 16 ] Particular attentions should be given to the presence of peripheral neuropathy and autonomic instability, as they will influence the anesthetic technique and also indicate active disease, with increased risk of acute crisis. Classifying drugs as porphyria safe or unsafe is too simplistic; the duration of exposure and the absolute dose dictate whether an acute crisis would be triggered or not and how would the severity be like. Multiple confounding factors in the perioperative period mean that the trigger for a crisis may be unclear. Propofol has been considered as a safe drug for both induction and maintenance of anesthesia in the patients with AIP.[ 17 18 19 ] Modern inhalation agents are generally considered safe in porphyric patients. Sevoflurane has been reported as a safe agent for both induction and maintenance of anesthesia. Safe use of isoflurane has also been reported;[ 20 21 22 ] therefore, it should probably be classified as safe, although further information needs to be obtained. Enflurane has been shown to induce porphyrin synthesis in animal models[ 20 ] but has been used safely in patients. Reports of a possible as",
      "snippet_score": 5.5462,
      "cues": [
        "risk",
        "risk of",
        "trigger",
        "triggered",
        "unsafe",
        "safe",
        "safely"
      ],
      "article_rank": 14,
      "article_score": 2.76,
      "article_title": "Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.",
      "citation_url": "https://doi.org/10.4103/0971-9784.179623",
      "content_source": "pmc-full-text"
    },
    {
      "snippet_id": 28,
      "pmid": "27052088",
      "drug": "succinylcholine",
      "classification": "risk",
      "snippet_text": "phyric crisis had their symptoms worsened following induction of anesthesia with thiopental.[ 27 ] Thus, although thiopental will not always precipitate a crisis, all barbiturates must be considered contraindicated in porphyric patients. Etomidate is potentially porphyrinogenic in animal models[ 17 ] at least one human porphyric crises has been reported after its use.[ 28 ] etomidate should probably be considered unsafe. Although there are some reports showing ketamine's potentiality in triggering AIP crisis,[ 24 ] it might be safe because it has been used safely in quiescent AIP.[ 24 29 30 ] Succinylcholine has been used for many years and has been proven to be safe, as has tubocurarine.[ 31 ] Though both pancuronium and alcuronium have been classified as unsafe by some authors, they have been widely used by many anesthetists without harm. Atracurium[ 21 22 32 ] and vecuronium[ 33 ] have been used safely in small numbers of patients despite some experimental evidence for porphyrinogenicity. We safely used atracurium in the current patient. Morphine and its analogues (including codeine) are of proven safety, and fentanyl has been shown to be safe both in chick embryo culture models and in clinica",
      "snippet_score": 5.2462,
      "cues": [
        "contraindicated",
        "precipitate",
        "trigger",
        "triggering",
        "unsafe",
        "worsened",
        "safe",
        "safely",
        "safety",
        "indicated"
      ],
      "article_rank": 14,
      "article_score": 2.76,
      "article_title": "Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.",
      "citation_url": "https://doi.org/10.4103/0971-9784.179623",
      "content_source": "pmc-full-text"
    },
    {
      "snippet_id": 29,
      "pmid": "27052088",
      "drug": "atracurium",
      "classification": "risk",
      "snippet_text": "tentially porphyrinogenic in animal models[ 17 ] at least one human porphyric crises has been reported after its use.[ 28 ] etomidate should probably be considered unsafe. Although there are some reports showing ketamine's potentiality in triggering AIP crisis,[ 24 ] it might be safe because it has been used safely in quiescent AIP.[ 24 29 30 ] Succinylcholine has been used for many years and has been proven to be safe, as has tubocurarine.[ 31 ] Though both pancuronium and alcuronium have been classified as unsafe by some authors, they have been widely used by many anesthetists without harm. Atracurium[ 21 22 32 ] and vecuronium[ 33 ] have been used safely in small numbers of patients despite some experimental evidence for porphyrinogenicity. We safely used atracurium in the current patient. Morphine and its analogues (including codeine) are of proven safety, and fentanyl has been shown to be safe both in chick embryo culture models and in clinical use. Alfentanil has also been used frequently with no reported complications. More recently, fentanyl[ 16 ] and sufentanil[ 15 ] have been used as a major component, in combination with isoflurane and atracurium, in open heart surgery without a s",
      "snippet_score": 5.1462,
      "cues": [
        "complication",
        "complications",
        "trigger",
        "triggering",
        "unsafe",
        "no reported complications",
        "safe",
        "safely",
        "safety"
      ],
      "article_rank": 14,
      "article_score": 2.76,
      "article_title": "Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.",
      "citation_url": "https://doi.org/10.4103/0971-9784.179623",
      "content_source": "pmc-full-text"
    },
    {
      "snippet_id": 30,
      "pmid": "27052088",
      "drug": "ketamine",
      "classification": "risk",
      "snippet_text": "re numerous reports of the safe use of thiopental in porphyric patients in the quiescent phase,[ 26 ] 7 out of 10 patients in acute porphyric crisis had their symptoms worsened following induction of anesthesia with thiopental.[ 27 ] Thus, although thiopental will not always precipitate a crisis, all barbiturates must be considered contraindicated in porphyric patients. Etomidate is potentially porphyrinogenic in animal models[ 17 ] at least one human porphyric crises has been reported after its use.[ 28 ] etomidate should probably be considered unsafe. Although there are some reports showing ketamine's potentiality in triggering AIP crisis,[ 24 ] it might be safe because it has been used safely in quiescent AIP.[ 24 29 30 ] Succinylcholine has been used for many years and has been proven to be safe, as has tubocurarine.[ 31 ] Though both pancuronium and alcuronium have been classified as unsafe by some authors, they have been widely used by many anesthetists without harm. Atracurium[ 21 22 32 ] and vecuronium[ 33 ] have been used safely in small numbers of patients despite some experimental evidence for porphyrinogenicity. We safely used atracurium in the current patient. Morphine and its",
      "snippet_score": 5.1462,
      "cues": [
        "contraindicated",
        "precipitate",
        "trigger",
        "triggering",
        "unsafe",
        "worsened",
        "safe",
        "safely",
        "indicated"
      ],
      "article_rank": 14,
      "article_score": 2.76,
      "article_title": "Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.",
      "citation_url": "https://doi.org/10.4103/0971-9784.179623",
      "content_source": "pmc-full-text"
    },
    {
      "snippet_id": 31,
      "pmid": "27052088",
      "drug": "morphine",
      "classification": "risk",
      "snippet_text": "showing ketamine's potentiality in triggering AIP crisis,[ 24 ] it might be safe because it has been used safely in quiescent AIP.[ 24 29 30 ] Succinylcholine has been used for many years and has been proven to be safe, as has tubocurarine.[ 31 ] Though both pancuronium and alcuronium have been classified as unsafe by some authors, they have been widely used by many anesthetists without harm. Atracurium[ 21 22 32 ] and vecuronium[ 33 ] have been used safely in small numbers of patients despite some experimental evidence for porphyrinogenicity. We safely used atracurium in the current patient. Morphine and its analogues (including codeine) are of proven safety, and fentanyl has been shown to be safe both in chick embryo culture models and in clinical use. Alfentanil has also been used frequently with no reported complications. More recently, fentanyl[ 16 ] and sufentanil[ 15 ] have been used as a major component, in combination with isoflurane and atracurium, in open heart surgery without a significant problem.[ 21 ] Cardiac surgical reports also refer to the safe use of heparin. Pethidine (meperidine) has a proven track record of safety despite a single case report implicating it in a porp",
      "snippet_score": 5.1462,
      "cues": [
        "complication",
        "complications",
        "trigger",
        "triggering",
        "unsafe",
        "no reported complications",
        "safe",
        "safely",
        "safety"
      ],
      "article_rank": 14,
      "article_score": 2.76,
      "article_title": "Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.",
      "citation_url": "https://doi.org/10.4103/0971-9784.179623",
      "content_source": "pmc-full-text"
    },
    {
      "snippet_id": 32,
      "pmid": "27052088",
      "drug": "fentanyl",
      "classification": "risk",
      "snippet_text": "be safe because it has been used safely in quiescent AIP.[ 24 29 30 ] Succinylcholine has been used for many years and has been proven to be safe, as has tubocurarine.[ 31 ] Though both pancuronium and alcuronium have been classified as unsafe by some authors, they have been widely used by many anesthetists without harm. Atracurium[ 21 22 32 ] and vecuronium[ 33 ] have been used safely in small numbers of patients despite some experimental evidence for porphyrinogenicity. We safely used atracurium in the current patient. Morphine and its analogues (including codeine) are of proven safety, and fentanyl has been shown to be safe both in chick embryo culture models and in clinical use. Alfentanil has also been used frequently with no reported complications. More recently, fentanyl[ 16 ] and sufentanil[ 15 ] have been used as a major component, in combination with isoflurane and atracurium, in open heart surgery without a significant problem.[ 21 ] Cardiac surgical reports also refer to the safe use of heparin. Pethidine (meperidine) has a proven track record of safety despite a single case report implicating it in a porphyric attack.[ 34 ] There is evidence both for[ 35 ] and against[ 36 ] th",
      "snippet_score": 4.9462,
      "cues": [
        "complication",
        "complications",
        "unsafe",
        "no reported complications",
        "safe",
        "safely",
        "safety"
      ],
      "article_rank": 14,
      "article_score": 2.76,
      "article_title": "Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.",
      "citation_url": "https://doi.org/10.4103/0971-9784.179623",
      "content_source": "pmc-full-text"
    },
    {
      "snippet_id": 33,
      "pmid": "27052088",
      "drug": "fentanyl",
      "classification": "risk",
      "snippet_text": "both pancuronium and alcuronium have been classified as unsafe by some authors, they have been widely used by many anesthetists without harm. Atracurium[ 21 22 32 ] and vecuronium[ 33 ] have been used safely in small numbers of patients despite some experimental evidence for porphyrinogenicity. We safely used atracurium in the current patient. Morphine and its analogues (including codeine) are of proven safety, and fentanyl has been shown to be safe both in chick embryo culture models and in clinical use. Alfentanil has also been used frequently with no reported complications. More recently, fentanyl[ 16 ] and sufentanil[ 15 ] have been used as a major component, in combination with isoflurane and atracurium, in open heart surgery without a significant problem.[ 21 ] Cardiac surgical reports also refer to the safe use of heparin. Pethidine (meperidine) has a proven track record of safety despite a single case report implicating it in a porphyric attack.[ 34 ] There is evidence both for[ 35 ] and against[ 36 ] the porphyrinogenicity of pentazocine in experimental systems.[ 37 ] Of the nonopiate analgesics, aspirin, acetaminophen, indomethacin and naproxen have proven safe. However, CPB is",
      "snippet_score": 4.9462,
      "cues": [
        "complication",
        "complications",
        "unsafe",
        "no reported complications",
        "safe",
        "safely",
        "safety"
      ],
      "article_rank": 14,
      "article_score": 2.76,
      "article_title": "Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.",
      "citation_url": "https://doi.org/10.4103/0971-9784.179623",
      "content_source": "pmc-full-text"
    },
    {
      "snippet_id": 34,
      "pmid": "27052088",
      "drug": "isoflurane",
      "classification": "risk",
      "snippet_text": "safe or unsafe is too simplistic; the duration of exposure and the absolute dose dictate whether an acute crisis would be triggered or not and how would the severity be like. Multiple confounding factors in the perioperative period mean that the trigger for a crisis may be unclear. Propofol has been considered as a safe drug for both induction and maintenance of anesthesia in the patients with AIP.[ 17 18 19 ] Modern inhalation agents are generally considered safe in porphyric patients. Sevoflurane has been reported as a safe agent for both induction and maintenance of anesthesia. Safe use of isoflurane has also been reported;[ 20 21 22 ] therefore, it should probably be classified as safe, although further information needs to be obtained. Enflurane has been shown to induce porphyrin synthesis in animal models[ 20 ] but has been used safely in patients. Reports of a possible association of halothane with crises contradict both experimental and clinical experience.[ 23 24 ] Preoperative starvation should be minimized; if a prolonged fast is unavoidable, a dextrose\u2013saline infusion should be given during the preoperative period. In view of the frequency with which hyponatremia is encountered i",
      "snippet_score": 4.8462,
      "cues": [
        "avoid",
        "trigger",
        "triggered",
        "unsafe",
        "safe",
        "safely"
      ],
      "article_rank": 14,
      "article_score": 2.76,
      "article_title": "Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.",
      "citation_url": "https://doi.org/10.4103/0971-9784.179623",
      "content_source": "pmc-full-text"
    },
    {
      "snippet_id": 35,
      "pmid": "27052088",
      "drug": "isoflurane",
      "classification": "risk",
      "snippet_text": "en widely used by many anesthetists without harm. Atracurium[ 21 22 32 ] and vecuronium[ 33 ] have been used safely in small numbers of patients despite some experimental evidence for porphyrinogenicity. We safely used atracurium in the current patient. Morphine and its analogues (including codeine) are of proven safety, and fentanyl has been shown to be safe both in chick embryo culture models and in clinical use. Alfentanil has also been used frequently with no reported complications. More recently, fentanyl[ 16 ] and sufentanil[ 15 ] have been used as a major component, in combination with isoflurane and atracurium, in open heart surgery without a significant problem.[ 21 ] Cardiac surgical reports also refer to the safe use of heparin. Pethidine (meperidine) has a proven track record of safety despite a single case report implicating it in a porphyric attack.[ 34 ] There is evidence both for[ 35 ] and against[ 36 ] the porphyrinogenicity of pentazocine in experimental systems.[ 37 ] Of the nonopiate analgesics, aspirin, acetaminophen, indomethacin and naproxen have proven safe. However, CPB is a specific problem,[ 13 14 15 16 ] we used it uneventfully. Blood loss, with its consequent inc",
      "snippet_score": 4.8462,
      "cues": [
        "complication",
        "complications",
        "no reported complications",
        "safe",
        "safely",
        "safety"
      ],
      "article_rank": 14,
      "article_score": 2.76,
      "article_title": "Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.",
      "citation_url": "https://doi.org/10.4103/0971-9784.179623",
      "content_source": "pmc-full-text"
    },
    {
      "snippet_id": 36,
      "pmid": "27052088",
      "drug": "midazolam",
      "classification": "risk",
      "snippet_text": "ne has been shown to induce porphyrin synthesis in animal models[ 20 ] but has been used safely in patients. Reports of a possible association of halothane with crises contradict both experimental and clinical experience.[ 23 24 ] Preoperative starvation should be minimized; if a prolonged fast is unavoidable, a dextrose\u2013saline infusion should be given during the preoperative period. In view of the frequency with which hyponatremia is encountered in acute attacks, the IV fluids containing dextrose alone should be avoided. Most (but not all) benzodiazepines commonly used for premedication like midazolam, are considered safe. The phenothiazines may have particular advantages.[ 25 ] Good anxiolysis has been recommended as advantageous. Where antacid administration is considered appropriate, sodium citrate may be given, and ranitidine may be considered. Cimetidine has been recommended for the treatment of acute porphyric crises since it may decrease heme consumption and inhibit aminolevulinic acid (ALA) synthesis activity.[ 10 ] The barbiturates are the archetypal inducers of ALA synthesis, and all barbiturates, including thiopental, must be considered unsafe. Although there are numerous report",
      "snippet_score": 4.8462,
      "cues": [
        "avoid",
        "avoided",
        "unsafe",
        "recommended",
        "safe",
        "safely"
      ],
      "article_rank": 14,
      "article_score": 2.76,
      "article_title": "Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.",
      "citation_url": "https://doi.org/10.4103/0971-9784.179623",
      "content_source": "pmc-full-text"
    },
    {
      "snippet_id": 37,
      "pmid": "27052088",
      "drug": "atracurium",
      "classification": "risk",
      "snippet_text": "PB is a specific problem,[ 13 14 15 16 ] we used it uneventfully. Blood loss, with its consequent increase in heme demand by the bone marrow, does not appear to stress the heme synthetic pathway sufficiently to provoke a porphyric crisis.[ 38 ] CONCLUSION It can be told that although there are different educational sources which safety of the drugs in AIP can be checked, utilizing a specific drug regimen can be sophisticated; because the various interaction between drugs can lead to a catastrophic income. In this case, we successfully used fentanyl in combination with propofol, midazolam, and atracurium with no disadvantage. On-pump surgery method was used uneventfully for this patient with avoiding deep hypothermia. Furthermore, the feasibility of fast-track anesthesia usage as a safe anesthesia technique and plan, in this case, is proved. The patient was discharged from ICU without any complication and therefore, the safety of the proper approach for TV replacement was accepted. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.",
      "snippet_score": 4.7462,
      "cues": [
        "avoid",
        "complication",
        "safe",
        "safety",
        "successfully"
      ],
      "article_rank": 14,
      "article_score": 2.76,
      "article_title": "Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.",
      "citation_url": "https://doi.org/10.4103/0971-9784.179623",
      "content_source": "pmc-full-text"
    },
    {
      "snippet_id": 38,
      "pmid": "27052088",
      "drug": "benzodiazepines",
      "classification": "risk",
      "snippet_text": "ugh further information needs to be obtained. Enflurane has been shown to induce porphyrin synthesis in animal models[ 20 ] but has been used safely in patients. Reports of a possible association of halothane with crises contradict both experimental and clinical experience.[ 23 24 ] Preoperative starvation should be minimized; if a prolonged fast is unavoidable, a dextrose\u2013saline infusion should be given during the preoperative period. In view of the frequency with which hyponatremia is encountered in acute attacks, the IV fluids containing dextrose alone should be avoided. Most (but not all) benzodiazepines commonly used for premedication like midazolam, are considered safe. The phenothiazines may have particular advantages.[ 25 ] Good anxiolysis has been recommended as advantageous. Where antacid administration is considered appropriate, sodium citrate may be given, and ranitidine may be considered. Cimetidine has been recommended for the treatment of acute porphyric crises since it may decrease heme consumption and inhibit aminolevulinic acid (ALA) synthesis activity.[ 10 ] The barbiturates are the archetypal inducers of ALA synthesis, and all barbiturates, including thiopental, must be consid",
      "snippet_score": 4.7462,
      "cues": [
        "avoid",
        "avoided",
        "recommended",
        "safe",
        "safely"
      ],
      "article_rank": 14,
      "article_score": 2.76,
      "article_title": "Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.",
      "citation_url": "https://doi.org/10.4103/0971-9784.179623",
      "content_source": "pmc-full-text"
    },
    {
      "snippet_id": 39,
      "pmid": "27052088",
      "drug": "fentanyl",
      "classification": "risk",
      "snippet_text": "indomethacin and naproxen have proven safe. However, CPB is a specific problem,[ 13 14 15 16 ] we used it uneventfully. Blood loss, with its consequent increase in heme demand by the bone marrow, does not appear to stress the heme synthetic pathway sufficiently to provoke a porphyric crisis.[ 38 ] CONCLUSION It can be told that although there are different educational sources which safety of the drugs in AIP can be checked, utilizing a specific drug regimen can be sophisticated; because the various interaction between drugs can lead to a catastrophic income. In this case, we successfully used fentanyl in combination with propofol, midazolam, and atracurium with no disadvantage. On-pump surgery method was used uneventfully for this patient with avoiding deep hypothermia. Furthermore, the feasibility of fast-track anesthesia usage as a safe anesthesia technique and plan, in this case, is proved. The patient was discharged from ICU without any complication and therefore, the safety of the proper approach for TV replacement was accepted. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.",
      "snippet_score": 4.7462,
      "cues": [
        "avoid",
        "complication",
        "safe",
        "safety",
        "successfully"
      ],
      "article_rank": 14,
      "article_score": 2.76,
      "article_title": "Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.",
      "citation_url": "https://doi.org/10.4103/0971-9784.179623",
      "content_source": "pmc-full-text"
    },
    {
      "snippet_id": 40,
      "pmid": "27052088",
      "drug": "halothane",
      "classification": "risk",
      "snippet_text": "sidered as a safe drug for both induction and maintenance of anesthesia in the patients with AIP.[ 17 18 19 ] Modern inhalation agents are generally considered safe in porphyric patients. Sevoflurane has been reported as a safe agent for both induction and maintenance of anesthesia. Safe use of isoflurane has also been reported;[ 20 21 22 ] therefore, it should probably be classified as safe, although further information needs to be obtained. Enflurane has been shown to induce porphyrin synthesis in animal models[ 20 ] but has been used safely in patients. Reports of a possible association of halothane with crises contradict both experimental and clinical experience.[ 23 24 ] Preoperative starvation should be minimized; if a prolonged fast is unavoidable, a dextrose\u2013saline infusion should be given during the preoperative period. In view of the frequency with which hyponatremia is encountered in acute attacks, the IV fluids containing dextrose alone should be avoided. Most (but not all) benzodiazepines commonly used for premedication like midazolam, are considered safe. The phenothiazines may have particular advantages.[ 25 ] Good anxiolysis has been recommended as advantageous. Where antaci",
      "snippet_score": 4.7462,
      "cues": [
        "avoid",
        "avoided",
        "recommended",
        "safe",
        "safely"
      ],
      "article_rank": 14,
      "article_score": 2.76,
      "article_title": "Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.",
      "citation_url": "https://doi.org/10.4103/0971-9784.179623",
      "content_source": "pmc-full-text"
    },
    {
      "snippet_id": 41,
      "pmid": "27052088",
      "drug": "midazolam",
      "classification": "risk",
      "snippet_text": "afe. However, CPB is a specific problem,[ 13 14 15 16 ] we used it uneventfully. Blood loss, with its consequent increase in heme demand by the bone marrow, does not appear to stress the heme synthetic pathway sufficiently to provoke a porphyric crisis.[ 38 ] CONCLUSION It can be told that although there are different educational sources which safety of the drugs in AIP can be checked, utilizing a specific drug regimen can be sophisticated; because the various interaction between drugs can lead to a catastrophic income. In this case, we successfully used fentanyl in combination with propofol, midazolam, and atracurium with no disadvantage. On-pump surgery method was used uneventfully for this patient with avoiding deep hypothermia. Furthermore, the feasibility of fast-track anesthesia usage as a safe anesthesia technique and plan, in this case, is proved. The patient was discharged from ICU without any complication and therefore, the safety of the proper approach for TV replacement was accepted. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.",
      "snippet_score": 4.7462,
      "cues": [
        "avoid",
        "complication",
        "safe",
        "safety",
        "successfully"
      ],
      "article_rank": 14,
      "article_score": 2.76,
      "article_title": "Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.",
      "citation_url": "https://doi.org/10.4103/0971-9784.179623",
      "content_source": "pmc-full-text"
    },
    {
      "snippet_id": 42,
      "pmid": "27052088",
      "drug": "propofol",
      "classification": "risk",
      "snippet_text": "e proven safe. However, CPB is a specific problem,[ 13 14 15 16 ] we used it uneventfully. Blood loss, with its consequent increase in heme demand by the bone marrow, does not appear to stress the heme synthetic pathway sufficiently to provoke a porphyric crisis.[ 38 ] CONCLUSION It can be told that although there are different educational sources which safety of the drugs in AIP can be checked, utilizing a specific drug regimen can be sophisticated; because the various interaction between drugs can lead to a catastrophic income. In this case, we successfully used fentanyl in combination with propofol, midazolam, and atracurium with no disadvantage. On-pump surgery method was used uneventfully for this patient with avoiding deep hypothermia. Furthermore, the feasibility of fast-track anesthesia usage as a safe anesthesia technique and plan, in this case, is proved. The patient was discharged from ICU without any complication and therefore, the safety of the proper approach for TV replacement was accepted. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.",
      "snippet_score": 4.7462,
      "cues": [
        "avoid",
        "complication",
        "safe",
        "safety",
        "successfully"
      ],
      "article_rank": 14,
      "article_score": 2.76,
      "article_title": "Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.",
      "citation_url": "https://doi.org/10.4103/0971-9784.179623",
      "content_source": "pmc-full-text"
    },
    {
      "snippet_id": 43,
      "pmid": "27052088",
      "drug": "midazolam",
      "classification": "safety",
      "snippet_text": "e mobile veg on anterior leaflet of tricuspid valve commissure (TVC) with severe TR was also demonstrated in his transthoracic echocardiography. After starting antibiotic therapy and removing the port, the patient underwent TV replacement. In the day of surgery, prior to induction, all standard monitorings were applied; radial artery line and subclavian central venous (CV) line was also indwelled after induction. Premedication was consisted of incremental doses of fentanyl and midazolam. We used propofol and atracurium for induction. Maintenance of anesthesia was done by propofol, atracurium, midazolam and fentanyl. Following sternotomy and heparinization, cardiopulmonary bypass (CPB) was initiated. The patient cooled to 32\u201334\u00b0C. Myocardial protection was provided by hypothermic antegrade blood cardioplegic. The TV was replaced. After 70 min of CPB, separation from CPB was achieved, and heparin was reversed by protamine. Rewarming and weaning from CPB was uneventful. Four units of packed cell were given during CPB; Hct was maintained about 30%. Postoperatively, in Intensive Care Unit (ICU), the patient was extubated in 6 h. We started parenteral carbohydrate as dextrose 50% to prevent AIP a",
      "snippet_score": 4.1462,
      "cues": [
        "prevent"
      ],
      "article_rank": 14,
      "article_score": 2.76,
      "article_title": "Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.",
      "citation_url": "https://doi.org/10.4103/0971-9784.179623",
      "content_source": "pmc-full-text"
    },
    {
      "snippet_id": 44,
      "pmid": "35164799",
      "drug": "levetiracetam",
      "classification": "risk",
      "snippet_text": ". Molecular test analysis with whole exome sequencing (WES) was performed to consider any possible mutations. The WES result reported a novel homozygous pathogenic variant (c.1072G > A p.G358R) in PPOX gene which indicates the Porphyria Variegate. This pathogenic variant has not been reported previously. In the follow-up, after completing 2 years of treatment, phenobarbital was tapered, but he had developed another episode of status GTC and admitted at hospital. Brian MRI was immediately done and showed normal results. Since it was better not to use phenobarbital for this case, treatment with levetiracetam has been started. To improve skin symptoms, he had been advised to be away from the sun and use sunscreen regularly. He had also aggressive behavior, learning disability and abdominal pain, particularly around the navel. Discussion Variegate porphyria is a very rare and autosomal dominant disorder which is caused by the mutations in protoporphyrinogen oxidase. PPOX is one of the fundamental enzymes responsible for the synthesis of heme, as a main part of hemoglobin and other hemoproteins. Porphyrins are essential for hemoglobin function. When PPOX is deficient, porphyrins are oxidized to prot",
      "snippet_score": 4.4894,
      "cues": [
        "condition-match"
      ],
      "article_rank": 15,
      "article_score": 2.6,
      "article_title": "A boy with blistering of sun-exposed skin and finger shortening: the first case of Variegate Porphyria with a novel mutation in protoporphyrinogen oxidase (PPOX) gene in Iran: a case report and literature review.",
      "citation_url": "https://doi.org/10.1186/s13052-022-01215-8",
      "content_source": "pmc-full-text"
    },
    {
      "snippet_id": 45,
      "pmid": "36575494",
      "drug": "benzodiazepines",
      "classification": "risk",
      "snippet_text": "urbances. Any impediment in the diagnosis of an acute porphyric attack may further aggravate the neurological symptoms inciting irreversible damage. Failure to identify neurovisceral symptoms like muscle weaknesses at an early stage may cause the patient to succumb to respiratory muscle paralysis, an important complication of porphyria which is life-threatening [ 10 , 11 ]. Timely diagnosis is a subject of clinical acuity in the management of porphyria [ 12 ], which also aids in the exemption of alternative diagnosis. The first-line treatment options for seizures include phenytoin, valproate, benzodiazepines, and lacosamide, among which many are porphyrinogenic [ 13 ]. The porphyrinogenic anti-seizure drugs are metabolized by cytochrome p450 enzymes in the liver that leads to increased heme synthesis, which results in increased heme precursors further provoking the porphyria crises [ 14 ]. Management of seizures with medications possessing porphyrinogenic potential, unaware of the porphyric status of the patient, can trigger acute attacks [ 15 ]. Neurological complications mostly comprise peripheral neuropathy, acute encephalopathy, and acute symptomatic seizures [ 9 ]. Seizures in patients with",
      "snippet_score": 4.7244,
      "cues": [
        "complication",
        "complications",
        "life-threatening",
        "trigger"
      ],
      "article_rank": 18,
      "article_score": 2.46,
      "article_title": "Porphyria: a case report.",
      "citation_url": "https://doi.org/10.1186/s13256-022-03708-w",
      "content_source": "pmc-full-text"
    },
    {
      "snippet_id": 46,
      "pmid": "36575494",
      "drug": "morphine",
      "classification": "safety",
      "snippet_text": "ted (169 mEq/L). So unilateral renal artery stenosis (RAS) was suspected. To confirm RAS, abdominal doppler and pelvic CT investigations were requested. The CT and Doppler report was normal, excluding the diagnosis of renal artery stenosis. Similarly, arterial blood gas (ABG) analysis was normal, which was against the metabolic alkalosis seen in Gitelman syndrome. To rule out an autoimmune cause, an antinuclear antibody (ANA) was sent; however, it also came out to be negative (Additional file 1 ). The patient's clinical presentation, including severe abdominal pain, was not relieved even with morphine. After all these thorough investigations, severe uncorrected hyponatremia, severe body ache especially in the lower limbs, and precipitation of the symptoms following fasting ushered our conjectures toward the diagnosis of porphyria-related disorders. With the suspicion of porphyria, a urine sample was sent to Biochemistry Laboratory. Watson-Schwartz test was positive (Fig. 1 ); hence, it indicated the presence of porphobilinogen in urine substantiating the diagnosis of acute porphyria crisis. The urine color also darkened on exposure to light (Fig. 2 ). The symptoms were gradually relieved w",
      "snippet_score": 4.2244,
      "cues": [
        "indicated"
      ],
      "article_rank": 18,
      "article_score": 2.46,
      "article_title": "Porphyria: a case report.",
      "citation_url": "https://doi.org/10.1186/s13256-022-03708-w",
      "content_source": "pmc-full-text"
    },
    {
      "snippet_id": 47,
      "pmid": "29097018",
      "drug": "benzodiazepines",
      "classification": "risk",
      "snippet_text": "pentin, and pregabalin should be used as first-line therapy. Medications undergoing extensive hepatic metabolism, such as valproic acid, phenytoin, and felbamate should be used as drugs of last resort. In special circumstances, as in patients affected by acute intermittent porphyria, exposure to most antiepileptic drugs could precipitate attacks. In this clinical scenario, bromides, levetiracetam, gabapentin, and vigabatrin constitute safe choices. For the treatment of status epilepticus, levetiracetam and lacosamide, available in intravenous preparations, are good second-line therapies after benzodiazepines fail to control seizures. Hepatotoxicity is also a rare and unexpected side effect of some antiepileptic drugs. Drugs such as valproic acid, phenytoin, and felbamate, have a well-recognized association with liver toxicity. Other antiepileptic drugs, including phenobarbital, benzodiazepines, ethosuximide, and the newer generations of antiepileptic drugs, have only rarely been linked to hepatotoxicity. Thus physicians should be mindful of the pharmacokinetic profile and the hepatotoxic potential of the different antiepileptic drugs available to treat patients affected by liver disease.",
      "snippet_score": 3.0567,
      "cues": [
        "precipitate",
        "side effect",
        "toxic",
        "toxicity",
        "safe"
      ],
      "article_rank": 26,
      "article_score": 1.4000000000000001,
      "article_title": "Antiepileptic Drugs and Liver Disease.",
      "citation_url": "https://doi.org/10.1016/j.pediatrneurol.2017.09.013",
      "content_source": "pubmed-abstract"
    },
    {
      "snippet_id": 48,
      "pmid": "29097018",
      "drug": "levetiracetam",
      "classification": "risk",
      "snippet_text": "anced liver disease and reviews the hepatotoxic potential of specific antiepileptic drugs. Newer antiepileptic drugs without, or with minimal, hepatic metabolism, such as levetiracetam, lacosamide, topiramate, gabapentin, and pregabalin should be used as first-line therapy. Medications undergoing extensive hepatic metabolism, such as valproic acid, phenytoin, and felbamate should be used as drugs of last resort. In special circumstances, as in patients affected by acute intermittent porphyria, exposure to most antiepileptic drugs could precipitate attacks. In this clinical scenario, bromides, levetiracetam, gabapentin, and vigabatrin constitute safe choices. For the treatment of status epilepticus, levetiracetam and lacosamide, available in intravenous preparations, are good second-line therapies after benzodiazepines fail to control seizures. Hepatotoxicity is also a rare and unexpected side effect of some antiepileptic drugs. Drugs such as valproic acid, phenytoin, and felbamate, have a well-recognized association with liver toxicity. Other antiepileptic drugs, including phenobarbital, benzodiazepines, ethosuximide, and the newer generations of antiepileptic drugs, have only rarely been linke",
      "snippet_score": 3.0567,
      "cues": [
        "precipitate",
        "side effect",
        "toxic",
        "toxicity",
        "safe"
      ],
      "article_rank": 26,
      "article_score": 1.4000000000000001,
      "article_title": "Antiepileptic Drugs and Liver Disease.",
      "citation_url": "https://doi.org/10.1016/j.pediatrneurol.2017.09.013",
      "content_source": "pubmed-abstract"
    },
    {
      "snippet_id": 49,
      "pmid": "29097018",
      "drug": "levetiracetam",
      "classification": "risk",
      "snippet_text": "ic drugs without, or with minimal, hepatic metabolism, such as levetiracetam, lacosamide, topiramate, gabapentin, and pregabalin should be used as first-line therapy. Medications undergoing extensive hepatic metabolism, such as valproic acid, phenytoin, and felbamate should be used as drugs of last resort. In special circumstances, as in patients affected by acute intermittent porphyria, exposure to most antiepileptic drugs could precipitate attacks. In this clinical scenario, bromides, levetiracetam, gabapentin, and vigabatrin constitute safe choices. For the treatment of status epilepticus, levetiracetam and lacosamide, available in intravenous preparations, are good second-line therapies after benzodiazepines fail to control seizures. Hepatotoxicity is also a rare and unexpected side effect of some antiepileptic drugs. Drugs such as valproic acid, phenytoin, and felbamate, have a well-recognized association with liver toxicity. Other antiepileptic drugs, including phenobarbital, benzodiazepines, ethosuximide, and the newer generations of antiepileptic drugs, have only rarely been linked to hepatotoxicity. Thus physicians should be mindful of the pharmacokinetic profile and the hepatotoxic po",
      "snippet_score": 3.0567,
      "cues": [
        "precipitate",
        "side effect",
        "toxic",
        "toxicity",
        "safe"
      ],
      "article_rank": 26,
      "article_score": 1.4000000000000001,
      "article_title": "Antiepileptic Drugs and Liver Disease.",
      "citation_url": "https://doi.org/10.1016/j.pediatrneurol.2017.09.013",
      "content_source": "pubmed-abstract"
    },
    {
      "snippet_id": 50,
      "pmid": "29097018",
      "drug": "levetiracetam",
      "classification": "risk",
      "snippet_text": "Acute, symptomatic seizures or epilepsy may complicate the course of hepatic disease. Choosing the most appropriate antiepileptic drug in this setting represents a difficult challenge, as most medications are metabolized by the liver. This article focuses on the acute and chronic treatment of seizures in patients with advanced liver disease and reviews the hepatotoxic potential of specific antiepileptic drugs. Newer antiepileptic drugs without, or with minimal, hepatic metabolism, such as levetiracetam, lacosamide, topiramate, gabapentin, and pregabalin should be used as first-line therapy. Medications undergoing extensive hepatic metabolism, such as valproic acid, phenytoin, and felbamate should be used as drugs of last resort. In special circumstances, as in patients affected by acute intermittent porphyria, exposure to most antiepileptic drugs could precipitate attacks. In this clinical scenario, bromides, levetiracetam, gabapentin, and vigabatrin constitute safe choices. For the treatment of status epilepticus, levetiracetam and lacosamide, available in intravenous preparations, are goo",
      "snippet_score": 2.8567,
      "cues": [
        "precipitate",
        "toxic",
        "safe"
      ],
      "article_rank": 26,
      "article_score": 1.4000000000000001,
      "article_title": "Antiepileptic Drugs and Liver Disease.",
      "citation_url": "https://doi.org/10.1016/j.pediatrneurol.2017.09.013",
      "content_source": "pubmed-abstract"
    },
    {
      "snippet_id": 51,
      "pmid": "27220836",
      "drug": "remifentanil",
      "classification": "risk",
      "snippet_text": "an autosomal dominant disorder that results from a partial deficiency of porphobilinogen deaminase and that causes very severe symptoms. Attacks may be triggered by a series of drugs and by other factors that the anesthesiologist should be aware of in order to reduce morbidity and mortality. Our objective is to review anesthetic considerations in acute intermittent porphyria. We present the case of a patient diagnosed with acute intermittent porphyria who was scheduled for knee arthroscopy. The anesthetic technique used was a femoral and sciatic nerve block under sedation with an infusion of remifentanil. The surgery proceeded without incident and the patient was discharged home after 24h. We consider the use of a peripheral plexus block of the lower limb to have been the safest anesthetic technique for this patient.",
      "snippet_score": 2.3862,
      "cues": [
        "trigger",
        "triggered",
        "safe"
      ],
      "article_rank": 32,
      "article_score": 0.9500000000000001,
      "article_title": "Femoral and sciatic nerve block for knee arthroscopy in a patient with acute intermittent porphyria.",
      "citation_url": "https://doi.org/10.1016/j.redar.2016.03.011",
      "content_source": "pubmed-abstract"
    },
    {
      "snippet_id": 52,
      "pmid": "16296947",
      "drug": "succinylcholine",
      "classification": "risk",
      "snippet_text": "Genetic variation contributes to an individual's sensitivity and response to a variety of drugs important to anesthetic practice. Early insights into the clinical impact of pharmacogenetics were provided by anesthesiology--investigations into prolonged apnea after succinylcholine administration, thiopental-induced porphyria and malignant hyperthermia contributed to the novel science of pharmacogenetics in the early 1960s. Genetic polymorphisms involved in pharmacokinetics (absorption, distribution, metabolism, and excretion of drugs) and pharmacodynamics (receptors, ion channels and enzymes) can affect an individual's response to the drugs used in anesthetic practice. In addition, genetic variation in proteins directly unrelated to drug action or metabolism can influence responses to environmental changes that occur during anesthesia. This review will summarize the cu",
      "snippet_score": 1.6944,
      "cues": [
        "malignant hyperthermia"
      ],
      "article_rank": 40,
      "article_score": 0.6000000000000001,
      "article_title": "Pharmacogenetics and anesthesiologists.",
      "citation_url": "https://doi.org/10.2217/14622416.6.8.849",
      "content_source": "pubmed-abstract"
    },
    {
      "snippet_id": 53,
      "pmid": "8316998",
      "drug": "muscle relaxants",
      "classification": "risk",
      "snippet_text": "disorders of haem metabolism. A knowledge of which anaesthetic can precipitate an acute attack of porphyria is important, since an accumulation of metabolites can result in life threatening symptoms, such as abdominal pain, vomiting, photophobia, neuropathy, bulbar paresis and respiratory failure. Treatment consists primarily of adequate calorie intake e.g. glucose, but is otherwise symptomatic. Anaesthetic drug recommendations are based both on animal experiments and patient experience, primarily case histories. An array of local anaesthetics, hypnotics, sedatives, neuroleptics, analgesics, muscle relaxants, inhalation anaesthetics and some antibiotics are reviewed. Patients with a history of porphyria should be in an optimal condition and maintain a high calorie intake perioperatively. The pre-operative fast should be a minimum and iv-glucose is advisable while fasting. There are anaesthetic agents that are safe for both regional and general anaesthesia.",
      "snippet_score": 1.3847,
      "cues": [
        "precipitate",
        "safe"
      ],
      "article_rank": 43,
      "article_score": 0.6000000000000001,
      "article_title": "[Anesthesia and porphyria].",
      "citation_url": "https://pubmed.ncbi.nlm.nih.gov/8316998/",
      "content_source": "pubmed-abstract"
    },
    {
      "snippet_id": 54,
      "pmid": "29383964",
      "drug": "opioid",
      "classification": "safety",
      "snippet_text": "Despite medical advances, the diagnosis and management of acute intermittent porphyria continues to be challenging. Acute pain is one of the most important clinical manifestations in acute intermittent porphyria, but management and pain assessment have been poorly studied in these patients. The lack of information and evidence based recommendations regarding these topics in the medical literature is certainly surprising. Furthermore, pain management is discussed based on extrapolating concepts adopted for other pain syndromes. An important arsenal of medications, including reportedly safe opioid and non-opioid analgesics, is available for use in this type of patient. In addition to conducting an extensive review of the current literature, the present article aims to show the general aspects of a disease that generates a challenge for the clinician, emphasizing what is related to pain as a cardinal symptom and to create awareness about the need for studies supporting the development of guidelines, based on evidence obtained from analgesic management in patients presenting with this disorder. A systematic assessment directed at understanding the physiopathological processes underlying",
      "snippet_score": 1.679,
      "cues": [
        "safe"
      ],
      "article_rank": 51,
      "article_score": 0.6000000000000001,
      "article_title": "Acute intermittent porphyria: general aspects with focus on pain.",
      "citation_url": "https://doi.org/10.1080/03007995.2018.1435521",
      "content_source": "pubmed-abstract"
    },
    {
      "snippet_id": 55,
      "pmid": "1418699",
      "drug": "halothane",
      "classification": "risk",
      "snippet_text": "ession of the medullary vital centres which can lead to cardiorespiratory failure. Both groups of agents have some depressant effect on the myocardium and vascular smooth muscle leading to a fall in cardiac output and hypotension. Centrally-mediated respiratory depression is common to both groups and the inhalational agents have a direct effect on lung physiology. The most important idiosyncratic reactions to the volatile agents are malignant hyperpyrexia and 'halothane hepatitis'. Malignant hyperpyrexia has an incidence of 1:12,000 with a mortality of about 24%. It is triggered most often by halothane together with suxamethonium. Post halothane hepatic necrosis is rare. Evidence points to 2 distinct syndromes; direct toxicity from the products of reductive metabolism, and a more serious illness, immunologically mediated via haptens formed by liver proteins and the products of oxidative metabolism. Prolonged nitrous oxide exposure can cause bone marrow depression and life-threatening pressure effects by expansion of air-filled spaces within the body. The idiosyncratic reactions to the intravenous agents include anaphylactoid reactions (which are rare) and triggering of acute porphyria. Etom",
      "snippet_score": 1.782,
      "cues": [
        "life-threatening",
        "toxic",
        "toxicity",
        "trigger",
        "triggered",
        "triggering"
      ],
      "article_rank": 56,
      "article_score": 0.6000000000000001,
      "article_title": "Adverse effects of general anaesthetics.",
      "citation_url": "https://doi.org/10.2165/00002018-199207060-00005",
      "content_source": "pubmed-abstract"
    },
    {
      "snippet_id": 56,
      "pmid": "1418699",
      "drug": "nitrous oxide",
      "classification": "risk",
      "snippet_text": "nts have a direct effect on lung physiology. The most important idiosyncratic reactions to the volatile agents are malignant hyperpyrexia and 'halothane hepatitis'. Malignant hyperpyrexia has an incidence of 1:12,000 with a mortality of about 24%. It is triggered most often by halothane together with suxamethonium. Post halothane hepatic necrosis is rare. Evidence points to 2 distinct syndromes; direct toxicity from the products of reductive metabolism, and a more serious illness, immunologically mediated via haptens formed by liver proteins and the products of oxidative metabolism. Prolonged nitrous oxide exposure can cause bone marrow depression and life-threatening pressure effects by expansion of air-filled spaces within the body. The idiosyncratic reactions to the intravenous agents include anaphylactoid reactions (which are rare) and triggering of acute porphyria. Etomidate is immunologically 'clean', but it inhibits cortisol synthesis.",
      "snippet_score": 1.782,
      "cues": [
        "life-threatening",
        "toxic",
        "toxicity",
        "trigger",
        "triggered",
        "triggering"
      ],
      "article_rank": 56,
      "article_score": 0.6000000000000001,
      "article_title": "Adverse effects of general anaesthetics.",
      "citation_url": "https://doi.org/10.2165/00002018-199207060-00005",
      "content_source": "pubmed-abstract"
    },
    {
      "snippet_id": 57,
      "pmid": "1418699",
      "drug": "volatile agents",
      "classification": "risk",
      "snippet_text": "enous anaesthetic agents affect the central nervous and cardio-respiratory systems in a dose-related manner. Neuronal inhibition results in decreasing levels of consciousness and depression of the medullary vital centres which can lead to cardiorespiratory failure. Both groups of agents have some depressant effect on the myocardium and vascular smooth muscle leading to a fall in cardiac output and hypotension. Centrally-mediated respiratory depression is common to both groups and the inhalational agents have a direct effect on lung physiology. The most important idiosyncratic reactions to the volatile agents are malignant hyperpyrexia and 'halothane hepatitis'. Malignant hyperpyrexia has an incidence of 1:12,000 with a mortality of about 24%. It is triggered most often by halothane together with suxamethonium. Post halothane hepatic necrosis is rare. Evidence points to 2 distinct syndromes; direct toxicity from the products of reductive metabolism, and a more serious illness, immunologically mediated via haptens formed by liver proteins and the products of oxidative metabolism. Prolonged nitrous oxide exposure can cause bone marrow depression and life-threatening pressure effects by expansion of",
      "snippet_score": 1.082,
      "cues": [
        "life-threatening",
        "toxic",
        "toxicity",
        "trigger",
        "triggered"
      ],
      "article_rank": 56,
      "article_score": 0.6000000000000001,
      "article_title": "Adverse effects of general anaesthetics.",
      "citation_url": "https://doi.org/10.2165/00002018-199207060-00005",
      "content_source": "pubmed-abstract"
    },
    {
      "snippet_id": 58,
      "pmid": "2697245",
      "drug": "fentanyl",
      "classification": "risk",
      "snippet_text": "tion, apnea, and a reduction in arterial blood pressure (BP) and cardiac output. Caution should be ascribed to its use in patients with coronary artery disease, where these effects may have the potential for producing myocardial ischemia. The hemodynamic responses to laryngoscopy and intubation are attenuated. The pharmacokinetic profile suggests suitability as an infusion for either maintenance of anesthesia or sedation. Use of propofol as an infusion during surgery may result in a further reduction in cardiac output, particularly with the concomitant administration of adjuvant increments of fentanyl. The ventilatory response to CO2 is depressed during such an infusion. The high clearance of propofol suggests that even after a prolonged infusion, recovery should be rapid. This finding has been confirmed in a series of studies establishing propofol as an ideal agent for use in a total IV anesthetic technique. Both the quality and speed of recovery, together with the absence of emetic sequelae, support the use of propofol in an outpatient setting. Propofol appears to have no long-term effect on adrenocortical function and appears safe for use in patients with acute intermittent porphyria an",
      "snippet_score": 1.3749,
      "cues": [
        "caution",
        "safe"
      ],
      "article_rank": 58,
      "article_score": 0.6000000000000001,
      "article_title": "The pharmacology of propofol.",
      "citation_url": "https://doi.org/10.1016/0952-8180(89)90080-9",
      "content_source": "pubmed-abstract"
    },
    {
      "snippet_id": 59,
      "pmid": "2697245",
      "drug": "propofol",
      "classification": "safety",
      "snippet_text": "ribed to its use in patients with coronary artery disease, where these effects may have the potential for producing myocardial ischemia. The hemodynamic responses to laryngoscopy and intubation are attenuated. The pharmacokinetic profile suggests suitability as an infusion for either maintenance of anesthesia or sedation. Use of propofol as an infusion during surgery may result in a further reduction in cardiac output, particularly with the concomitant administration of adjuvant increments of fentanyl. The ventilatory response to CO2 is depressed during such an infusion. The high clearance of propofol suggests that even after a prolonged infusion, recovery should be rapid. This finding has been confirmed in a series of studies establishing propofol as an ideal agent for use in a total IV anesthetic technique. Both the quality and speed of recovery, together with the absence of emetic sequelae, support the use of propofol in an outpatient setting. Propofol appears to have no long-term effect on adrenocortical function and appears safe for use in patients with acute intermittent porphyria and susceptibility to malignant hyperpyrexia.",
      "snippet_score": 1.0749,
      "cues": [
        "safe"
      ],
      "article_rank": 58,
      "article_score": 0.6000000000000001,
      "article_title": "The pharmacology of propofol.",
      "citation_url": "https://doi.org/10.1016/0952-8180(89)90080-9",
      "content_source": "pubmed-abstract"
    },
    {
      "snippet_id": 60,
      "pmid": "2697245",
      "drug": "propofol",
      "classification": "safety",
      "snippet_text": "ic responses to laryngoscopy and intubation are attenuated. The pharmacokinetic profile suggests suitability as an infusion for either maintenance of anesthesia or sedation. Use of propofol as an infusion during surgery may result in a further reduction in cardiac output, particularly with the concomitant administration of adjuvant increments of fentanyl. The ventilatory response to CO2 is depressed during such an infusion. The high clearance of propofol suggests that even after a prolonged infusion, recovery should be rapid. This finding has been confirmed in a series of studies establishing propofol as an ideal agent for use in a total IV anesthetic technique. Both the quality and speed of recovery, together with the absence of emetic sequelae, support the use of propofol in an outpatient setting. Propofol appears to have no long-term effect on adrenocortical function and appears safe for use in patients with acute intermittent porphyria and susceptibility to malignant hyperpyrexia.",
      "snippet_score": 1.0749,
      "cues": [
        "safe"
      ],
      "article_rank": 58,
      "article_score": 0.6000000000000001,
      "article_title": "The pharmacology of propofol.",
      "citation_url": "https://doi.org/10.1016/0952-8180(89)90080-9",
      "content_source": "pubmed-abstract"
    },
    {
      "snippet_id": 61,
      "pmid": "2697245",
      "drug": "propofol",
      "classification": "safety",
      "snippet_text": "e of propofol as an infusion during surgery may result in a further reduction in cardiac output, particularly with the concomitant administration of adjuvant increments of fentanyl. The ventilatory response to CO2 is depressed during such an infusion. The high clearance of propofol suggests that even after a prolonged infusion, recovery should be rapid. This finding has been confirmed in a series of studies establishing propofol as an ideal agent for use in a total IV anesthetic technique. Both the quality and speed of recovery, together with the absence of emetic sequelae, support the use of propofol in an outpatient setting. Propofol appears to have no long-term effect on adrenocortical function and appears safe for use in patients with acute intermittent porphyria and susceptibility to malignant hyperpyrexia.",
      "snippet_score": 1.0749,
      "cues": [
        "safe"
      ],
      "article_rank": 58,
      "article_score": 0.6000000000000001,
      "article_title": "The pharmacology of propofol.",
      "citation_url": "https://doi.org/10.1016/0952-8180(89)90080-9",
      "content_source": "pubmed-abstract"
    },
    {
      "snippet_id": 62,
      "pmid": "39313028",
      "drug": "opioids",
      "classification": "risk",
      "snippet_text": "ks in acute hepatic porphyria are triggered by the induction of hepatic ALA synthase 1, leading to the accumulation of neurotoxic heme intermediates, delta-aminolevulinic acid, and porphobilinogen. Women experience attacks more frequently than men. Acute porphyria attacks are characterized by severe, diffuse abdominal pain, muscle weakness, autonomic neuropathy (including hypertension, tachycardia, nausea, vomiting, and constipation), and changes in mental status. Early recognition of the disease is crucial as it requires urgent medical attention and treatment. Management includes intravenous opioids, glucose, hemin, and the removal of triggering factors. Preventive treatment options include hormone suppression therapy, off-label prophylactic hemin, Givosiran, and exceptionally liver transplantation.",
      "snippet_score": 2.46,
      "cues": [
        "toxic",
        "trigger",
        "triggered",
        "triggering",
        "prevent"
      ],
      "article_rank": 63,
      "article_score": 0.6000000000000001,
      "article_title": "Therapeutic approach to acute crises of hepatic porphyrias.",
      "citation_url": "https://doi.org/10.1016/j.rceng.2024.09.004",
      "content_source": "pubmed-abstract"
    },
    {
      "snippet_id": 63,
      "pmid": "16934166",
      "drug": "neuromuscular blockade",
      "classification": "risk",
      "snippet_text": "Motor weakness in a patient in the intensive care unit (ICU) may be related to (1) pre-existing neuromuscular disorder that leads to ICU admission, (2) new-onset or previously undiagnosed neurological disorder, or (3) complications of non-neuromuscular critical illness. Neuromuscular syndromes related to ICU treatment consist of critical illness polyneuropathy, critical illness myopathy, and prolonged neuromuscular blockade, and are now recognized as a frequent cause of newly acquired weakness in ICU patients. Clinical features include quadriparesis, muscle wasting, and difficulty weaning from the ventilator. Evaluation of these patients is based on knowledge of clinical setting and predisposing factors, focused neurological examination, detailed electrophysiological investigation, serum creatine kinase level, other laboratory studies as needed, and histological examination of muscle biopsy. If a central nervous system (brain or spinal cord) lesion is suspected, neuroimaging studies are required. In addition to",
      "snippet_score": 1.2026,
      "cues": [
        "complication",
        "complications"
      ],
      "article_rank": 70,
      "article_score": 0.6000000000000001,
      "article_title": "Clinical approach to the weak patient in the intensive care unit.",
      "citation_url": "https://pubmed.ncbi.nlm.nih.gov/16934166/",
      "content_source": "pubmed-abstract"
    },
    {
      "snippet_id": 64,
      "pmid": "2660638",
      "drug": "benzodiazepines",
      "classification": "safety",
      "snippet_text": "he attention of the anaesthesiologist on the porphyrinogenic properties of all the drugs used in anaesthesia and intensive care. An outline of the chemistry of porphyrins and the enzymatic pathways were recalled, so as to place the acute porphyrias in their proper perspective. There follows a reminder of the clinical aspect of acute porphyric crises. The part played by drugs is then assessed from clinical and laboratory data concerning their porphyrinogenicity. Those drugs for which there is conflicting evidence regarding their safe use in porphyric patients are discussed: propofol, ketamine, benzodiazepines, etomidate, local anaesthetics. Recommendations supported by clinical and experimental data are given, especially the results obtained with the chick embryo liver model. Treatment of the acute crisis is provided, with particular emphasis on the use of haematin. The anaesthetic management of hepatic porphyric patients is described. Those drugs which are well-known porphyrinogenic compounds in the chick embryo liver must be excluded from use for anaesthesia in the porphyric patients, even if they have been observed to be innocuous in rare cases of asymptomatic patients. Finally, recommendations",
      "snippet_score": 1.0749,
      "cues": [
        "safe"
      ],
      "article_rank": 88,
      "article_score": 0.6000000000000001,
      "article_title": "[Anesthesia and hepatic porphyria].",
      "citation_url": "https://doi.org/10.1016/s0750-7658(89)80162-5",
      "content_source": "pubmed-abstract"
    },
    {
      "snippet_id": 65,
      "pmid": "2660638",
      "drug": "ketamine",
      "classification": "safety",
      "snippet_text": "to focus the attention of the anaesthesiologist on the porphyrinogenic properties of all the drugs used in anaesthesia and intensive care. An outline of the chemistry of porphyrins and the enzymatic pathways were recalled, so as to place the acute porphyrias in their proper perspective. There follows a reminder of the clinical aspect of acute porphyric crises. The part played by drugs is then assessed from clinical and laboratory data concerning their porphyrinogenicity. Those drugs for which there is conflicting evidence regarding their safe use in porphyric patients are discussed: propofol, ketamine, benzodiazepines, etomidate, local anaesthetics. Recommendations supported by clinical and experimental data are given, especially the results obtained with the chick embryo liver model. Treatment of the acute crisis is provided, with particular emphasis on the use of haematin. The anaesthetic management of hepatic porphyric patients is described. Those drugs which are well-known porphyrinogenic compounds in the chick embryo liver must be excluded from use for anaesthesia in the porphyric patients, even if they have been observed to be innocuous in rare cases of asymptomatic patients. Finally",
      "snippet_score": 1.0749,
      "cues": [
        "safe"
      ],
      "article_rank": 88,
      "article_score": 0.6000000000000001,
      "article_title": "[Anesthesia and hepatic porphyria].",
      "citation_url": "https://doi.org/10.1016/s0750-7658(89)80162-5",
      "content_source": "pubmed-abstract"
    },
    {
      "snippet_id": 66,
      "pmid": "2660638",
      "drug": "propofol",
      "classification": "safety",
      "snippet_text": "iew aimed to focus the attention of the anaesthesiologist on the porphyrinogenic properties of all the drugs used in anaesthesia and intensive care. An outline of the chemistry of porphyrins and the enzymatic pathways were recalled, so as to place the acute porphyrias in their proper perspective. There follows a reminder of the clinical aspect of acute porphyric crises. The part played by drugs is then assessed from clinical and laboratory data concerning their porphyrinogenicity. Those drugs for which there is conflicting evidence regarding their safe use in porphyric patients are discussed: propofol, ketamine, benzodiazepines, etomidate, local anaesthetics. Recommendations supported by clinical and experimental data are given, especially the results obtained with the chick embryo liver model. Treatment of the acute crisis is provided, with particular emphasis on the use of haematin. The anaesthetic management of hepatic porphyric patients is described. Those drugs which are well-known porphyrinogenic compounds in the chick embryo liver must be excluded from use for anaesthesia in the porphyric patients, even if they have been observed to be innocuous in rare cases of asymptomatic patient",
      "snippet_score": 1.0749,
      "cues": [
        "safe"
      ],
      "article_rank": 88,
      "article_score": 0.6000000000000001,
      "article_title": "[Anesthesia and hepatic porphyria].",
      "citation_url": "https://doi.org/10.1016/s0750-7658(89)80162-5",
      "content_source": "pubmed-abstract"
    },
    {
      "snippet_id": 67,
      "pmid": "17190918",
      "drug": "levetiracetam",
      "classification": "risk",
      "snippet_text": "d phenytoin. Valproate, lamotrigine, and benzodiazepines are less affected. Low protein-bound AEDs are extensively removed by hemodialysis and supplemental doses are required for dialysis patients. Uremia and related conditions, including intracranial hemorrhage, glucose and electrolyte imbalances, and concomitant drug use, can cause seizures, as can dialysis encephalopathy, primary cerebral lymphoma, fungal infections, and immunosuppressant toxicity in renal transplant recipients. Hepatic dysfunction reduces enzymatic metabolism of AEDs and causes hypoalbuminemia. Gabapentin, topiramate, and levetiracetam are preferred in these conditions, whereas conversely valproate and felbamate are potentially hepatotoxic and should be avoided. Seizures related to hepatic encephalopathy are controlled by oral lactulose or neomycin. Porphyria sufferers may benefit from gabapentin, oxcarbazepine, or levetiracetam. Seizures in Wilson's disease may derive from d-penicillamine-induced pyridoxine deficiency. Effective treatment of seizures in renal and hepatic diseases requires attention to changes in AED pharmacokinetics and adequate care of the underlying illnesses. Monitoring of free drug concentrations is a",
      "snippet_score": 2.1026,
      "cues": [
        "avoid",
        "avoided",
        "toxic",
        "toxicity",
        "effective"
      ],
      "article_rank": 92,
      "article_score": 0.6000000000000001,
      "article_title": "Optimizing therapy of seizures in patients with renal or hepatic dysfunction.",
      "citation_url": "https://doi.org/10.1212/wnl.67.12_suppl_4.s28",
      "content_source": "pubmed-abstract"
    },
    {
      "snippet_id": 68,
      "pmid": "17190918",
      "drug": "levetiracetam",
      "classification": "risk",
      "snippet_text": "and concomitant drug use, can cause seizures, as can dialysis encephalopathy, primary cerebral lymphoma, fungal infections, and immunosuppressant toxicity in renal transplant recipients. Hepatic dysfunction reduces enzymatic metabolism of AEDs and causes hypoalbuminemia. Gabapentin, topiramate, and levetiracetam are preferred in these conditions, whereas conversely valproate and felbamate are potentially hepatotoxic and should be avoided. Seizures related to hepatic encephalopathy are controlled by oral lactulose or neomycin. Porphyria sufferers may benefit from gabapentin, oxcarbazepine, or levetiracetam. Seizures in Wilson's disease may derive from d-penicillamine-induced pyridoxine deficiency. Effective treatment of seizures in renal and hepatic diseases requires attention to changes in AED pharmacokinetics and adequate care of the underlying illnesses. Monitoring of free drug concentrations is a valuable aid to therapy.",
      "snippet_score": 2.1026,
      "cues": [
        "avoid",
        "avoided",
        "toxic",
        "toxicity",
        "effective"
      ],
      "article_rank": 92,
      "article_score": 0.6000000000000001,
      "article_title": "Optimizing therapy of seizures in patients with renal or hepatic dysfunction.",
      "citation_url": "https://doi.org/10.1212/wnl.67.12_suppl_4.s28",
      "content_source": "pubmed-abstract"
    },
    {
      "snippet_id": 69,
      "pmid": "17190918",
      "drug": "benzodiazepines",
      "classification": "risk",
      "snippet_text": "Patients with epilepsy may suffer from renal or hepatic diseases that interfere with their antiepileptic drug (AED) treatment. Furthermore, such diseases may themselves cause seizures. Reduced renal function and hypoalbuminemia lead to accumulation of renally excreted AEDs, such as gabapentin, vigabatrin, topiramate, levetiracetam, and phenytoin. Valproate, lamotrigine, and benzodiazepines are less affected. Low protein-bound AEDs are extensively removed by hemodialysis and supplemental doses are required for dialysis patients. Uremia and related conditions, including intracranial hemorrhage, glucose and electrolyte imbalances, and concomitant drug use, can cause seizures, as can dialysis encephalopathy, primary cerebral lymphoma, fungal infections, and immunosuppressant toxicity in renal transplant recipients. Hepatic dysfunction reduces enzymatic metabolism of AEDs and causes hypoalbuminemia. Gabapentin, topiramate, and levetiracetam are preferred in these conditions, whereas",
      "snippet_score": 1.2026,
      "cues": [
        "toxic",
        "toxicity"
      ],
      "article_rank": 92,
      "article_score": 0.6000000000000001,
      "article_title": "Optimizing therapy of seizures in patients with renal or hepatic dysfunction.",
      "citation_url": "https://doi.org/10.1212/wnl.67.12_suppl_4.s28",
      "content_source": "pubmed-abstract"
    },
    {
      "snippet_id": 70,
      "pmid": "17190918",
      "drug": "levetiracetam",
      "classification": "risk",
      "snippet_text": "Patients with epilepsy may suffer from renal or hepatic diseases that interfere with their antiepileptic drug (AED) treatment. Furthermore, such diseases may themselves cause seizures. Reduced renal function and hypoalbuminemia lead to accumulation of renally excreted AEDs, such as gabapentin, vigabatrin, topiramate, levetiracetam, and phenytoin. Valproate, lamotrigine, and benzodiazepines are less affected. Low protein-bound AEDs are extensively removed by hemodialysis and supplemental doses are required for dialysis patients. Uremia and related conditions, including intracranial hemorrhage, glucose and electrolyte imbalances, and concomitant drug use, can cause seizures, as can dialysis encephalopathy, primary cerebral lymphoma, fungal infections, and immunosuppressant toxicity in renal transplant recipients. Hepatic dysfunction reduces enzymatic metabolism of AEDs and causes hypoalbuminemia. Gabapentin, topiramate,",
      "snippet_score": 1.2026,
      "cues": [
        "toxic",
        "toxicity"
      ],
      "article_rank": 92,
      "article_score": 0.6000000000000001,
      "article_title": "Optimizing therapy of seizures in patients with renal or hepatic dysfunction.",
      "citation_url": "https://doi.org/10.1212/wnl.67.12_suppl_4.s28",
      "content_source": "pubmed-abstract"
    },
    {
      "snippet_id": 71,
      "pmid": "8342401",
      "drug": "propofol",
      "classification": "risk",
      "snippet_text": "The authors report the case of a female patient with South-African genetic porphyria who had to undergo hepatic tumorectomy under general anesthesia. The choice for propofol as the induction and maintenance agent using a balanced anesthetic technique led to a significant rise in urinary excretion of porphyrins without associated clinical manifestations. A short review of the literature on physiopathology of porphyrias and medicinal agents, susceptible to induce acute porphyric crisis follows. The authors conclude that the innocuity of propofol as induction and maintaining agent in the porphyric patient cannot be yet established without further studies.",
      "snippet_score": 1.2847,
      "cues": [
        "condition-match"
      ],
      "article_rank": 105,
      "article_score": 0.6000000000000001,
      "article_title": "Total intravenous anesthesia in South-African genetic porphyria (variegate porphyria).",
      "citation_url": "https://pubmed.ncbi.nlm.nih.gov/8342401/",
      "content_source": "pubmed-abstract"
    },
    {
      "snippet_id": 72,
      "pmid": "88665",
      "drug": "glucagon",
      "classification": "risk",
      "snippet_text": "are reported to increase intracellular adenosine 3':5'-monophosphate (cAMP) levels, viz. glucagon, sodium fluoride, cAMP or its dibutyryl derivative, 3-isobutyl-1-methylxanthine and papaverine enhanced drug-induced porphyrin biosynthesis. On the other have, agents which are reported to decrease intra-cellular cAMP levels, viz. alloxan and imidazole, diminished drug-induced porphyrin accumulation. cAMP appears to enhance, but not to function as a \"second messenger\" in drug-induced porphyrin biosynthesis. Drug-induced porphyrin accumulation in chick embryo liver cells depend upon the insulin to glucagon ratio. A low level of porphyrin accumulation occurs at insulin to glucagon ratios similar to those found following glucose administration in vivo, suggesting a possible explanation for the therapeutic effect of glucose in hepatic porphyria. The 5 alpha A(A:B trans) and 5 beta H(A:Bcis) steroids are equipotent in inducing delta-aminolevulinic acid synthetase and porphyrin accumulation in chick embryo liver cells maintained in serum-free culture medium. Thus, there is no specific steric requirement for porphyrin-inducing activity in steroids.",
      "snippet_score": 1.2608,
      "cues": [
        "condition-match"
      ],
      "article_rank": 118,
      "article_score": 0.6000000000000001,
      "article_title": "Hormonal effects on the regulation of hepatic heme biosynthesis.",
      "citation_url": "https://doi.org/10.1007/BF00228992",
      "content_source": "pubmed-abstract"
    },
    {
      "snippet_id": 73,
      "pmid": "7616668",
      "drug": "diazepam",
      "classification": "risk",
      "snippet_text": "Although the morbidity of porphyria is rare, the surgical and anesthetic managements of patients with porphyria should be prudent, for various stresses including surgery and anesthesia may cause occurrence or exacerbation of this disease, occasionally resulting in the mortal course. Several drugs such as barbiturate, diazepam, pentazocine, and pancuronium, which can be used during anesthesia or after operation, reportedly exacerbate the disease. Furthermore, the acute exacerbation of porphyria may be misdiagnosed as acute abdomen, ileus, acute appendicitis, cholelithiasis, urolithiasis, or ectopic pregnancy. The managements of patients with acute porphyria during anesthesia and after surgery are discussed along with the introduction of our case report. Since there is no definitive treatment of porphyria, the most important thing is to understand the disease and to prevent the acute exacerbation of the disease. Whe",
      "snippet_score": 1.391,
      "cues": [
        "exacerbate",
        "prevent"
      ],
      "article_rank": 125,
      "article_score": 0.6000000000000001,
      "article_title": "[Surgical and anesthetic managements of patients with porphyria].",
      "citation_url": "https://pubmed.ncbi.nlm.nih.gov/7616668/",
      "content_source": "pubmed-abstract"
    },
    {
      "snippet_id": 74,
      "pmid": "10504904",
      "drug": "benzodiazepines",
      "classification": "risk",
      "snippet_text": "Porphyrias are inherited defects of heme synthesis with manifestations that can mimic surgical diseases; they can be provoked by administration of certain drugs. Manifestations such as abdominal pain, vomiting, tachycardia, hypertension, neuropathy, fever, confusion, and seizures have been described. Management of patients with porphyria is designed to avoid triggering drugs, such as barbiturates, and perhaps, benzodiazepines and ketamines. Nontriggering drugs should be used in the management of patients with porphyria. Because starvation can induce an attack, glucose infusions are important in the prevention and treatment of porphyria.",
      "snippet_score": 1.6073,
      "cues": [
        "avoid",
        "trigger",
        "triggering",
        "prevent"
      ],
      "article_rank": 127,
      "article_score": 0.6000000000000001,
      "article_title": "Anesthetic considerations in hepatic porphyrias.",
      "citation_url": "https://pubmed.ncbi.nlm.nih.gov/10504904/",
      "content_source": "pubmed-abstract"
    },
    {
      "snippet_id": 75,
      "pmid": "15021955",
      "drug": "desflurane",
      "classification": "risk",
      "snippet_text": "Despite the low incidence of the acute porphyrias, a profound knowledge of the disease is essential for anaesthesiologists, as a variety of perioperatively administered drugs are potential triggers of an acute attack. There is an ongoing discussion about the use of volatile anaesthetics in porphyrias, but halothane and isoflurane seem to be safe. There is no clinical data or case report about the use of desflurane in this specific patient group, but its fast and relatively unchanged elimination and the minimal induction of the cytochrome P 450 system seem to be favorable in this setting. We report the use of desflurane in a patient with acute intermittent porphyria, scheduled for hemihepatectomy. To minimize perioperative distress by pain or the need for postoperative mechanical ventilation, we chose a balanced anaesthesia technique with desflurane, sufentanil and atracurium in combination with a continuous epidural analgesia (bupivacain and fentanyl) for the postoperative period. Preoperatively the po",
      "snippet_score": 1.5869,
      "cues": [
        "trigger",
        "safe"
      ],
      "article_rank": 132,
      "article_score": 0.4,
      "article_title": "[Desflurane in acute intermittent porphyria].",
      "citation_url": "https://doi.org/10.1007/s00101-003-0615-7",
      "content_source": "pubmed-abstract"
    },
    {
      "snippet_id": 76,
      "pmid": "15021955",
      "drug": "desflurane",
      "classification": "risk",
      "snippet_text": "incidence of the acute porphyrias, a profound knowledge of the disease is essential for anaesthesiologists, as a variety of perioperatively administered drugs are potential triggers of an acute attack. There is an ongoing discussion about the use of volatile anaesthetics in porphyrias, but halothane and isoflurane seem to be safe. There is no clinical data or case report about the use of desflurane in this specific patient group, but its fast and relatively unchanged elimination and the minimal induction of the cytochrome P 450 system seem to be favorable in this setting. We report the use of desflurane in a patient with acute intermittent porphyria, scheduled for hemihepatectomy. To minimize perioperative distress by pain or the need for postoperative mechanical ventilation, we chose a balanced anaesthesia technique with desflurane, sufentanil and atracurium in combination with a continuous epidural analgesia (bupivacain and fentanyl) for the postoperative period. Preoperatively the porphyrin precursors were analyzed in serum and urine and postoperatively the 24 h-urine was screened every 2 days until postoperative day 6 to monitor the porphyria activity. The preoperative data showed high c",
      "snippet_score": 1.5869,
      "cues": [
        "trigger",
        "safe"
      ],
      "article_rank": 132,
      "article_score": 0.4,
      "article_title": "[Desflurane in acute intermittent porphyria].",
      "citation_url": "https://doi.org/10.1007/s00101-003-0615-7",
      "content_source": "pubmed-abstract"
    },
    {
      "snippet_id": 77,
      "pmid": "15021955",
      "drug": "halothane",
      "classification": "risk",
      "snippet_text": "Despite the low incidence of the acute porphyrias, a profound knowledge of the disease is essential for anaesthesiologists, as a variety of perioperatively administered drugs are potential triggers of an acute attack. There is an ongoing discussion about the use of volatile anaesthetics in porphyrias, but halothane and isoflurane seem to be safe. There is no clinical data or case report about the use of desflurane in this specific patient group, but its fast and relatively unchanged elimination and the minimal induction of the cytochrome P 450 system seem to be favorable in this setting. We report the use of desflurane in a patient with acute intermittent porphyria, scheduled for hemihepatectomy. To minimize perioperative distress by pain or the need for postoperative mechanical ventilation, we chose a balanced anaesthesia technique with desflurane, sufentanil and atracurium in combination with a contin",
      "snippet_score": 1.5869,
      "cues": [
        "trigger",
        "safe"
      ],
      "article_rank": 132,
      "article_score": 0.4,
      "article_title": "[Desflurane in acute intermittent porphyria].",
      "citation_url": "https://doi.org/10.1007/s00101-003-0615-7",
      "content_source": "pubmed-abstract"
    },
    {
      "snippet_id": 78,
      "pmid": "15021955",
      "drug": "isoflurane",
      "classification": "risk",
      "snippet_text": "Despite the low incidence of the acute porphyrias, a profound knowledge of the disease is essential for anaesthesiologists, as a variety of perioperatively administered drugs are potential triggers of an acute attack. There is an ongoing discussion about the use of volatile anaesthetics in porphyrias, but halothane and isoflurane seem to be safe. There is no clinical data or case report about the use of desflurane in this specific patient group, but its fast and relatively unchanged elimination and the minimal induction of the cytochrome P 450 system seem to be favorable in this setting. We report the use of desflurane in a patient with acute intermittent porphyria, scheduled for hemihepatectomy. To minimize perioperative distress by pain or the need for postoperative mechanical ventilation, we chose a balanced anaesthesia technique with desflurane, sufentanil and atracurium in combination with a continuous epidural a",
      "snippet_score": 1.5869,
      "cues": [
        "trigger",
        "safe"
      ],
      "article_rank": 132,
      "article_score": 0.4,
      "article_title": "[Desflurane in acute intermittent porphyria].",
      "citation_url": "https://doi.org/10.1007/s00101-003-0615-7",
      "content_source": "pubmed-abstract"
    },
    {
      "snippet_id": 79,
      "pmid": "15021955",
      "drug": "volatile anaesthetics",
      "classification": "risk",
      "snippet_text": "Despite the low incidence of the acute porphyrias, a profound knowledge of the disease is essential for anaesthesiologists, as a variety of perioperatively administered drugs are potential triggers of an acute attack. There is an ongoing discussion about the use of volatile anaesthetics in porphyrias, but halothane and isoflurane seem to be safe. There is no clinical data or case report about the use of desflurane in this specific patient group, but its fast and relatively unchanged elimination and the minimal induction of the cytochrome P 450 system seem to be favorable in this setting. We report the use of desflurane in a patient with acute intermittent porphyria, scheduled for hemihepatectomy. To minimize perioperative distress by pain or the need for postoperative mechanical ventilation, we chose a balanced anaesthesia technique with desflurane, sufentanil and atracurium",
      "snippet_score": 1.5869,
      "cues": [
        "trigger",
        "safe"
      ],
      "article_rank": 132,
      "article_score": 0.4,
      "article_title": "[Desflurane in acute intermittent porphyria].",
      "citation_url": "https://doi.org/10.1007/s00101-003-0615-7",
      "content_source": "pubmed-abstract"
    },
    {
      "snippet_id": 80,
      "pmid": "15021955",
      "drug": "fentanyl",
      "classification": "risk",
      "snippet_text": "s no clinical data or case report about the use of desflurane in this specific patient group, but its fast and relatively unchanged elimination and the minimal induction of the cytochrome P 450 system seem to be favorable in this setting. We report the use of desflurane in a patient with acute intermittent porphyria, scheduled for hemihepatectomy. To minimize perioperative distress by pain or the need for postoperative mechanical ventilation, we chose a balanced anaesthesia technique with desflurane, sufentanil and atracurium in combination with a continuous epidural analgesia (bupivacain and fentanyl) for the postoperative period. Preoperatively the porphyrin precursors were analyzed in serum and urine and postoperatively the 24 h-urine was screened every 2 days until postoperative day 6 to monitor the porphyria activity. The preoperative data showed high concentrations of porphyrin precursor excretion, confirming the diagnosis of AIP. The postoperative data in the 24 h-urine were significantly lower than preoperative levels and reached normal levels at postoperative day 5. There were no clinical symptoms of a porphyric attack during the postoperative hospitalization. The patient was disc",
      "snippet_score": 1.4869,
      "cues": [
        "condition-match"
      ],
      "article_rank": 132,
      "article_score": 0.4,
      "article_title": "[Desflurane in acute intermittent porphyria].",
      "citation_url": "https://doi.org/10.1007/s00101-003-0615-7",
      "content_source": "pubmed-abstract"
    },
    {
      "snippet_id": 81,
      "pmid": "15021955",
      "drug": "atracurium",
      "classification": "safety",
      "snippet_text": "aesthetics in porphyrias, but halothane and isoflurane seem to be safe. There is no clinical data or case report about the use of desflurane in this specific patient group, but its fast and relatively unchanged elimination and the minimal induction of the cytochrome P 450 system seem to be favorable in this setting. We report the use of desflurane in a patient with acute intermittent porphyria, scheduled for hemihepatectomy. To minimize perioperative distress by pain or the need for postoperative mechanical ventilation, we chose a balanced anaesthesia technique with desflurane, sufentanil and atracurium in combination with a continuous epidural analgesia (bupivacain and fentanyl) for the postoperative period. Preoperatively the porphyrin precursors were analyzed in serum and urine and postoperatively the 24 h-urine was screened every 2 days until postoperative day 6 to monitor the porphyria activity. The preoperative data showed high concentrations of porphyrin precursor excretion, confirming the diagnosis of AIP. The postoperative data in the 24 h-urine were significantly lower than preoperative levels and reached normal levels at postoperative day 5. There were no clinical symptoms of a po",
      "snippet_score": 1.2869,
      "cues": [
        "safe"
      ],
      "article_rank": 132,
      "article_score": 0.4,
      "article_title": "[Desflurane in acute intermittent porphyria].",
      "citation_url": "https://doi.org/10.1007/s00101-003-0615-7",
      "content_source": "pubmed-abstract"
    },
    {
      "snippet_id": 82,
      "pmid": "15021955",
      "drug": "desflurane",
      "classification": "safety",
      "snippet_text": "bout the use of volatile anaesthetics in porphyrias, but halothane and isoflurane seem to be safe. There is no clinical data or case report about the use of desflurane in this specific patient group, but its fast and relatively unchanged elimination and the minimal induction of the cytochrome P 450 system seem to be favorable in this setting. We report the use of desflurane in a patient with acute intermittent porphyria, scheduled for hemihepatectomy. To minimize perioperative distress by pain or the need for postoperative mechanical ventilation, we chose a balanced anaesthesia technique with desflurane, sufentanil and atracurium in combination with a continuous epidural analgesia (bupivacain and fentanyl) for the postoperative period. Preoperatively the porphyrin precursors were analyzed in serum and urine and postoperatively the 24 h-urine was screened every 2 days until postoperative day 6 to monitor the porphyria activity. The preoperative data showed high concentrations of porphyrin precursor excretion, confirming the diagnosis of AIP. The postoperative data in the 24 h-urine were significantly lower than preoperative levels and reached normal levels at postoperative day 5. There were n",
      "snippet_score": 1.2869,
      "cues": [
        "safe"
      ],
      "article_rank": 132,
      "article_score": 0.4,
      "article_title": "[Desflurane in acute intermittent porphyria].",
      "citation_url": "https://doi.org/10.1007/s00101-003-0615-7",
      "content_source": "pubmed-abstract"
    },
    {
      "snippet_id": 83,
      "pmid": "1997060",
      "drug": "propofol",
      "classification": "risk",
      "snippet_text": "The choice of an i.v. anaesthetic induction poses problems for the anaesthetist confronted with a patient with one of the acute porphyrias. We undertook a prospective clinical trial in 13 variegate porphyric subjects using propofol as an anaesthetic induction agent. Urinary porphyrin precursors and porphyrins were measured before operation and 1-5 days after operation. Stool and plasma porphyrin concentrations were measured over the same period. Comparison of these data in the porphyric patients and in 21 control subjects over the trial period revealed no significant change in porphyrin or porphyrin precursor output after operation. Urinary porphyrin precursor concentrations did not exceed the limits established for variegate porphyric patients in remission, and there were no changes in the stool and plasma porphyrin pr",
      "snippet_score": 1.6794,
      "cues": [
        "condition-match"
      ],
      "article_rank": 153,
      "article_score": 0.4,
      "article_title": "Propofol as an i.v. anaesthetic induction agent in variegate porphyria.",
      "citation_url": "https://doi.org/10.1093/bja/66.1.60",
      "content_source": "pubmed-abstract"
    },
    {
      "snippet_id": 84,
      "pmid": "27871506",
      "drug": "propofol",
      "classification": "safety",
      "snippet_text": "Porphyria is caused by disorders of enzymes that synthetize porphyrins. Both elective and emergency surgical procedures on patient suffering from porphyria may provoke acute symptoms. These patients require special anesthetic management since some of commonly used anesthetic agents may also induce acute manifestation of porphyria. We present the case of 53-year-old woman previously diagnosed with porphyria who underwent elective laparoscopic cholecystectomy. Propofol-based total intravenous anesthesia with target-controlled infusion was used. Such conduct proved to be safe regarding clinical symptoms, although biochemical markers were slightly elevated after procedure. Propofol seems to be the safest hypnotic drug to use in porphyria; however, special care should be taken is such cases.",
      "snippet_score": 1.4362,
      "cues": [
        "safe"
      ],
      "article_rank": 155,
      "article_score": 0.4,
      "article_title": "Elective cholecystectomy performed on patient with variegate porphyria-Propofol-based total intravenous anesthesia with target-controlled infusion.",
      "citation_url": "https://doi.org/10.1016/j.jclinane.2016.06.014",
      "content_source": "pubmed-abstract"
    },
    {
      "snippet_id": 85,
      "pmid": "15826795",
      "drug": "bupivacaine",
      "classification": "risk",
      "snippet_text": "Acute hepatic porphyrias are genetic diseases, characterized by acute neurological symptoms, sometimes fatal, triggered by different factors, in particular by many anaesthetic drugs, and also by pregnancy. We report here the experience of three porphyric patients'deliveries, allowing us to consider a proposition of management in this context. After discussion between anaesthesiologist, obstetrician and porphyria specialist, two types of management of such patients can be foresee. Asymptomatic patients, or in long remission, can benefit from locoregional anesthesia techniques with bupivacaine for both labour analgesia and Caesarean section. Spinal anaesthesia is then the technique of choice, allowing using smaller quantity of local anaesthetic than epidural anaesthesia. For symptomatic patients, or in crisis, we have rather choose intravenous narcotics for labour analgesia, and general anaesthesia for Caesarean section. The hypnotic agent of choice for both induction and maintenance of such anaesthesia is then propofol.",
      "snippet_score": 1.6944,
      "cues": [
        "fatal",
        "trigger",
        "triggered"
      ],
      "article_rank": 156,
      "article_score": 0.4,
      "article_title": "[Obstetrical anaesthesia and porphyrias].",
      "citation_url": "https://doi.org/10.1016/j.annfar.2005.01.012",
      "content_source": "pubmed-abstract"
    },
    {
      "snippet_id": 86,
      "pmid": "21146060",
      "drug": "metoclopramide",
      "classification": "risk",
      "snippet_text": "the toxic effects of porphyrin precursors, and it can be triggered by drugs used routinely in medical practice, severe carbohydrate restriction, and metabolic stress. The objective of this report was to present the case of a late onset porphyria evolving to chronic pain. This is a 27 years old female who was admitted 5 months prior to her clinic appointment with severe abdominal pain without diagnosis. An exploratory laparotomy was indicated, which failed to demonstrate a cause for her pain. The patient was exposed to surgical trauma and drugs that can trigger porphyria, such as ketoprophen, metoclopramide, and antibiotics, and she evolved with significant hyponatremia, increased liver enzymes, seizures, and loss of movements that led to be admitted to the Intensive Care Unit. After the diagnosis of porphyria was made, the patient remained with pain in the lower limbs, being referred to the Pain Department of Santa Casa de Miseric\u00f3rdia de S\u00e3o Paulo. Treatment with amitriptyline, gabapentin, opioid, and simple analgesics was instituted; however, the patient continued to present recurring episodes of porphyria and, feeling insecure with the conduction of the case, she stopped the treatment. Porph",
      "snippet_score": 1.8433,
      "cues": [
        "toxic",
        "trigger",
        "triggered",
        "indicated"
      ],
      "article_rank": 163,
      "article_score": 0.4,
      "article_title": "Neuropathic pain in a patient with porphyria. Case report.",
      "citation_url": "https://doi.org/10.1016/S0034-7094(10)70079-9",
      "content_source": "pubmed-abstract"
    },
    {
      "snippet_id": 87,
      "pmid": "21146060",
      "drug": "opioid",
      "classification": "risk",
      "snippet_text": "An exploratory laparotomy was indicated, which failed to demonstrate a cause for her pain. The patient was exposed to surgical trauma and drugs that can trigger porphyria, such as ketoprophen, metoclopramide, and antibiotics, and she evolved with significant hyponatremia, increased liver enzymes, seizures, and loss of movements that led to be admitted to the Intensive Care Unit. After the diagnosis of porphyria was made, the patient remained with pain in the lower limbs, being referred to the Pain Department of Santa Casa de Miseric\u00f3rdia de S\u00e3o Paulo. Treatment with amitriptyline, gabapentin, opioid, and simple analgesics was instituted; however, the patient continued to present recurring episodes of porphyria and, feeling insecure with the conduction of the case, she stopped the treatment. Porphyria is one of the rare groups of enzymatic disorders that remain unknown by the great majority of health professionals. Upon recognizing this lack of knowledge about the disease, the level of stress and insecurity of the patient increases hindering adhesion to and continuity of the treatment.",
      "snippet_score": 1.6433,
      "cues": [
        "trigger",
        "indicated"
      ],
      "article_rank": 163,
      "article_score": 0.4,
      "article_title": "Neuropathic pain in a patient with porphyria. Case report.",
      "citation_url": "https://doi.org/10.1016/S0034-7094(10)70079-9",
      "content_source": "pubmed-abstract"
    },
    {
      "snippet_id": 88,
      "pmid": "17037005",
      "drug": "rocuronium",
      "classification": "risk",
      "snippet_text": "porphyria (AIP) is an inherited metabolic disorder caused by deficiency of porphobilinogen deaminase, an enzyme found in the synthetic pathway of heme. Acute attack of AIP may be precipitated by many factors during operation and anesthesia, including fasting, dehydration, stress, infection, and drugs. Acute attack of AIP is likely fatal. Therefore, the drugs recommended as being safe in anesthesia for porphyria patients are up-to-dately refreshed and renovated and the identification of whether a drug is safe or not is based on cumulative anecdotal experiences. Here, we report the safe use of rocuronium and sevoflurane for long exposure in a patient affected with acute intermittent porphyria.",
      "snippet_score": 1.8026,
      "cues": [
        "fatal",
        "precipitate",
        "recommended",
        "safe"
      ],
      "article_rank": 169,
      "article_score": 0.4,
      "article_title": "The use of rocuronium and sevoflurane in acute intermittent porphyria--a case report.",
      "citation_url": "https://pubmed.ncbi.nlm.nih.gov/17037005/",
      "content_source": "pubmed-abstract"
    },
    {
      "snippet_id": 89,
      "pmid": "17037005",
      "drug": "sevoflurane",
      "classification": "risk",
      "snippet_text": ") is an inherited metabolic disorder caused by deficiency of porphobilinogen deaminase, an enzyme found in the synthetic pathway of heme. Acute attack of AIP may be precipitated by many factors during operation and anesthesia, including fasting, dehydration, stress, infection, and drugs. Acute attack of AIP is likely fatal. Therefore, the drugs recommended as being safe in anesthesia for porphyria patients are up-to-dately refreshed and renovated and the identification of whether a drug is safe or not is based on cumulative anecdotal experiences. Here, we report the safe use of rocuronium and sevoflurane for long exposure in a patient affected with acute intermittent porphyria.",
      "snippet_score": 1.8026,
      "cues": [
        "fatal",
        "precipitate",
        "recommended",
        "safe"
      ],
      "article_rank": 169,
      "article_score": 0.4,
      "article_title": "The use of rocuronium and sevoflurane in acute intermittent porphyria--a case report.",
      "citation_url": "https://pubmed.ncbi.nlm.nih.gov/17037005/",
      "content_source": "pubmed-abstract"
    },
    {
      "snippet_id": 90,
      "pmid": "3986654",
      "drug": "fentanyl",
      "classification": "safety",
      "snippet_text": "for elective vagotomy and pyloroplasty. The diagnosis of porphyria was made two years previously when she developed acute abdominal pain and lower motor neurone paralysis following ingestion of a barbiturate. The urine porphobilinogen test was positive. The patient had no other acute attack of porphyria and had not had a previous anaesthetic. Anaesthesia was induced with etomidate 0.3 mg X kg-1 IV. Muscle relaxation was obtained with pancuronium 6 mg IV and ventilation was mechanically controlled. Intraoperative analgesia was with 66 per cent nitrous oxide in oxygen and intermittent doses of fentanyl. The patient was stable during anaesthesia and surgery. The postoperative period was uneventful and patient did not have an acute attack of porphyria. This experience suggests that etomidate is safe for intravenous induction of anaesthesia in acute intermittent porphyria. However, reports of its use in more patients with this disease will be necessary before a final conclusion can be made.",
      "snippet_score": 0.8678,
      "cues": [
        "safe"
      ],
      "article_rank": 174,
      "article_score": 0.4,
      "article_title": "Induction of anaesthesia with etomidate in a patient with acute intermittent porphyria.",
      "citation_url": "https://doi.org/10.1007/BF03010045",
      "content_source": "pubmed-abstract"
    },
    {
      "snippet_id": 91,
      "pmid": "3986654",
      "drug": "nitrous oxide",
      "classification": "safety",
      "snippet_text": "le with acute intermittent porphyria who presented for elective vagotomy and pyloroplasty. The diagnosis of porphyria was made two years previously when she developed acute abdominal pain and lower motor neurone paralysis following ingestion of a barbiturate. The urine porphobilinogen test was positive. The patient had no other acute attack of porphyria and had not had a previous anaesthetic. Anaesthesia was induced with etomidate 0.3 mg X kg-1 IV. Muscle relaxation was obtained with pancuronium 6 mg IV and ventilation was mechanically controlled. Intraoperative analgesia was with 66 per cent nitrous oxide in oxygen and intermittent doses of fentanyl. The patient was stable during anaesthesia and surgery. The postoperative period was uneventful and patient did not have an acute attack of porphyria. This experience suggests that etomidate is safe for intravenous induction of anaesthesia in acute intermittent porphyria. However, reports of its use in more patients with this disease will be necessary before a final conclusion can be made.",
      "snippet_score": 0.8678,
      "cues": [
        "safe"
      ],
      "article_rank": 174,
      "article_score": 0.4,
      "article_title": "Induction of anaesthesia with etomidate in a patient with acute intermittent porphyria.",
      "citation_url": "https://doi.org/10.1007/BF03010045",
      "content_source": "pubmed-abstract"
    },
    {
      "snippet_id": 92,
      "pmid": "25137868",
      "drug": "propofol",
      "classification": "risk",
      "snippet_text": "Ultrasound-guided regional anesthesia techniques placed under general anesthesia have not been reported in pediatric patients with acute intermittent porphyria (AIP). A 9-year-old male with AIP presented for right inguinal herniorraphy. Family history included one relative's death after anesthesia. Preoperative preparation included reviewing medications safe for AIP patients, minimizing known AIP triggers (fasting, stress) and ensuring access to rescue medications. Intraoperative management included a propofol induction with the patient's mother present in the operating room. We performed an ultrasound-guided ilioinguinal-iliohypogastric nerve block under general anesthesia. The surgery proceeded without complications and the patient did not demonstrate signs of an AIP crisis.",
      "snippet_score": 1.7999,
      "cues": [
        "trigger",
        "safe",
        "without complications"
      ],
      "article_rank": 180,
      "article_score": 0.4,
      "article_title": "Ultrasound-guided regional anesthesia in a pediatric patient with acute intermittent porphyria: literature review and case report.",
      "citation_url": "https://pubmed.ncbi.nlm.nih.gov/25137868/",
      "content_source": "pubmed-abstract"
    },
    {
      "snippet_id": 93,
      "pmid": "23993340",
      "drug": "benzodiazepines",
      "classification": "risk",
      "snippet_text": "are rare inherited disorders due to specific enzyme abnormalities of heme biosynthesis. We can classify them as hepatic or erythropo\u00efetic, the type depends on the organ in which the enzyme is deficient. Among the hepatic forms, three of them are clinically characterised by acute abdominal pain and neuropathy, sometimes associated with psychiatric disorders. This 58-year-old woman has been hospitalized frequently since 1995 with depression, apathy, or for suicide attempts. She has a history of alcohol addiction and since 1992 suffers from non-insulin dependant diabetes. She had been treated by benzodiazepines and neuroleptic medication for several years. Psychiatric examination revealed persecution and megalomania delirium associated with a Capgras syndrome, confusion, disorientation, depression and blunted affect. Results of neurologic examination showed reduced deep tendon reflexes, and nerve conduction revealed sensitive neuropathy. Moreover, she lay down, remained non-responsive and resisted care. The whole clinical picture evoked early dementia. Coloured urine was noticed and porphyria tested. When the diagnosis of intermittent acute porphyria was made, she gradually improved by stopping the",
      "snippet_score": 1.5999,
      "cues": [
        "condition-match"
      ],
      "article_rank": 181,
      "article_score": 0.4,
      "article_title": "[State of dementia due to intermittent acute porphyria: a case report].",
      "citation_url": "https://doi.org/10.1016/j.encep.2012.09.003",
      "content_source": "pubmed-abstract"
    }
  ],
  "batches": [
    {
      "token_estimate": 19879,
      "messages": [
        {
          "role": "system",
          "content": "You are a clinical evidence synthesis assistant. Analyse the supplied snippets and claim groups before constructing cross-drug findings. When assessing each claim, draft a concise internal checklist (3-7 bullet points) covering the verification steps you will perform, then silently execute it. Focus on causality and therapeutic intent, cite only the provided article_ids, and keep reasoning grounded in the text. After each classification, briefly validate your decision against the cited evidence; self-correct if the validation fails, but do not include the checklist or validation in the JSON output. Identify idiosyncratic reactions explicitly when the evidence supports them, and do not infer facts beyond those presented."
        },
        {
          "role": "user",
          "content": "CONTEXT\nCondition: porphyria | Related terms: Porphyria, Variegate, Variegate Porphyria, Porphyria Variegata, Protoporphyrinogen Oxidase Deficiency, Ppox Deficiency\nSnippets sorted by snippet_score (desc) then article_rank (asc); use the overlapping drug mentions to connect evidence across claims.\n\nREFERENCE\n- snippet_id: prompt-only reference (omit from JSON).\n- article_id: prefix 'article:' + pmid; use for citations and flag if missing.\n- related_drugs: union of all drugs tied to the snippet; ensure each appears in the output (even if labelled insufficient evidence).\n- cues/heuristics: NLP hints; verify before relying on them.\n\nDRUGS IN SCOPE\n1. dexamethasone\n2. atropine\n3. ondansetron\n4. fentanyl\n5. morphine\n6. remifentanil\n7. lorazepam\n8. midazolam\n9. ketamine\n10. propofol\n11. diazepam\n12. levetiracetam\n13. opioids\n14. benzodiazepines\n15. opioid\n16. desflurane\n17. halothane\n18. isoflurane\n19. sevoflurane\n20. volatile agents\n21. volatile anaesthetics\n22. succinylcholine\n23. atracurium\n24. metoclopramide\n25. rocuronium\n26. nitrous oxide\n27. bupivacaine\n28. glucagon\n\nINSTRUCTIONS\n1. Review DRUGS IN SCOPE and emit a drug entry for each listed drug; copy the name exactly, keep the provided class labels, include our ATC codes (or add only when the text clearly justifies it), and list the claim_ids you produce for that drug (leave the list empty when evidence is insufficient). Never reference a drug in any claim unless you have supplied a matching entry in the drugs array. When handling neuromuscular blockers, prefer precise families (depolarising, aminosteroid, benzylisoquinolinium) instead of the generic class unless the evidence is indistinct.\n2. Build shared findings (risk | safety | uncertain | nuanced) using only the supplied evidence, keep summaries factual, cite every supporting article_id, and attach all relevant drug_ids\u2014even when a snippet mentions several drugs.\n3. Do not fabricate claims for drugs with insufficient evidence; it is acceptable for a drug to have zero claims.\n4. Use the article_id identifiers we provide\u2014cite an article once even if multiple snippets support it, never invent IDs, and flag unresolved citations in the claim summary if an article_id is missing.\n5. Detect idiosyncratic reactions yourself; when evidence shows unexpected patient-specific reactions (e.g., malignant hyperthermia), set idiosyncratic_reaction.flag true and copy the descriptors, otherwise leave the flag false with an empty list.\n6. Populate the supporting_evidence list for each claim using snippet_id values from the listing (include pmid, article_title, key_points, and optional notes; leave the array empty when evidence is too weak).\n7. Return JSON that matches the schema exactly; omit commentary.\n\nSCHEMA\n\"condition\": string\n\"drugs\": [{\"id\": \"drug:identifier\", \"name\": string, \"classifications\": [string], \"atc_codes\": [string], \"claims\": [\"claim:identifier\"]}]\n\"claims\": [{\"id\": \"claim:identifier\", \"type\": \"risk | safety | uncertain | nuanced\", \"summary\": string, \"confidence\": \"low | medium | high\", \"idiosyncratic_reaction\": {\"flag\": true | false, \"descriptors\": [string]}, \"articles\": [\"article:identifier\"], \"drugs\": [\"drug:identifier\"], \"supporting_evidence\": [{\"snippet_id\": string, \"pmid\": string, \"article_title\": string, \"key_points\": [string], \"notes\": string}]}]\nSAMPLE RESPONSE\n{\n  \"condition\": \"Central core disease\",\n  \"drugs\": [\n    {\"id\": \"drug:succinylcholine\", \"name\": \"Succinylcholine\", \"classifications\": [\"neuromuscular blocker\"], \"atc_codes\": [\"M03AB01\"], \"claims\": [\"claim:malignant-hyperthermia\"]},\n    {\"id\": \"drug:volatile-anaesthetics\", \"name\": \"Volatile anaesthetics\", \"classifications\": [\"inhalational anesthetic\"], \"atc_codes\": [\"N01AB\"], \"claims\": [\"claim:malignant-hyperthermia\"]}\n  ],\n  \"claims\": [{\"id\": \"claim:malignant-hyperthermia\", \"type\": \"risk\", \"summary\": \"Malignant hyperthermia recurred after depolarising neuromuscular blockers in susceptible patients.\", \"confidence\": \"high\", \"idiosyncratic_reaction\": {\"flag\": true, \"descriptors\": [\"malignant hyperthermia\"]}, \"articles\": [\"article:33190635\"], \"drugs\": [\"drug:succinylcholine\", \"drug:volatile-anaesthetics\"], \"supporting_evidence\": [{\"snippet_id\": \"snippet:33190635-1\", \"pmid\": \"33190635\", \"article_title\": \"Ryanodine receptor 1-related disorders: an historical perspective and proposal for a unified nomenclature.\", \"key_points\": [\"Volatile anesthetics and depolarising neuromuscular blockers triggered malignant hyperthermia events in susceptible patients.\"], \"notes\": \"\"}]}]\n}\n\n\nSnippets (full listing):\n1. snippet_id: 1\n   article_id: article:34661997\n   article_title: Acute porphyrias - A neurological perspective.\n   classification: risk\n   cues: trigger, triggered, unsafe, safe, safety\n   related_drugs: atropine\n   snippet: xifloxacin Nitrofurantoin Doxycycline Rifampicin Gentamicin Sulfonamides , Trimethoprim Penicillins a Vancomycin Aciclovir, Ganciclovir, Valaciclovir Antiepileptic therapy Barbiturates (Phenobarbital) Gabapentin Carbamazepin Lacosamide (Valproic acid) Lamotrigine Phenytoin Levetiracetam Primidone Lorazepam, Midazolam (Oxcarbazepine) Magnesium Topiramate Pregabalin Propofol Neuroleptics Melperone Chlorpromazine Haloperidol Levomepromazin Antidepressants (Imipramin) Amitriptyline Duloxetine Mirtazapine SSRIs Steroids (Dexamethasone) Prednisolone (Methylprednisolon) Triamcinolone Others Hormones Atropine Progesterone Betablockers Catecholamines Note : All drugs are classified after their safety in systemic use in a patient. The list is not comprehensive and the authors advise to check in the following databases for updated information on a drug before prescription to a patient with porphyria: http://www.drugs\u2010porphyria.org or http://www.porphyriafoundation.com/drug\u2010database or http://porphyriadrugs.com Drugs in bold are regarded as unsafe and have reportedly triggered attacks. Drugs in parenthesis either have conflicting records in the two databases or are regarded as possibly unsafe or only\n2. snippet_id: 5\n   article_id: article:34661997\n   article_title: Acute porphyrias - A neurological perspective.\n   classification: safety\n   cues: safe, safety\n   related_drugs: lorazepam, midazolam\n   snippet: TIONS SAFE MEDICATIONS Pain killers Metamizole/Dipyrone ASS, Ibuprofen, Paracetamol Morphine, Hydromorphone Antiemetics Dimenhydrinate MCP Ondansetron Antibiotics/antivirals Clindamycin Azithromycin Erythromycin , (Clarithromycin) Carbapenems (Flucloxacillin) Cephalosporins Isoniazid Ciprofloxacin, Moxifloxacin Nitrofurantoin Doxycycline Rifampicin Gentamicin Sulfonamides , Trimethoprim Penicillins a Vancomycin Aciclovir, Ganciclovir, Valaciclovir Antiepileptic therapy Barbiturates (Phenobarbital) Gabapentin Carbamazepin Lacosamide (Valproic acid) Lamotrigine Phenytoin Levetiracetam Primidone Lorazepam, Midazolam (Oxcarbazepine) Magnesium Topiramate Pregabalin Propofol Neuroleptics Melperone Chlorpromazine Haloperidol Levomepromazin Antidepressants (Imipramin) Amitriptyline Duloxetine Mirtazapine SSRIs Steroids (Dexamethasone) Prednisolone (Methylprednisolon) Triamcinolone Others Hormones Atropine Progesterone Betablockers Catecholamines Note : All drugs are classified after their safety in systemic use in a patient. The list is not comprehensive and the authors advise to check in the following databases for updated information on a drug before prescription to a patient with porphyria: http\n3. snippet_id: 2\n   article_id: article:34661997\n   article_title: Acute porphyrias - A neurological perspective.\n   classification: risk\n   cues: trigger, triggered, unsafe, safe, safety\n   related_drugs: dexamethasone\n   snippet: mycin) Carbapenems (Flucloxacillin) Cephalosporins Isoniazid Ciprofloxacin, Moxifloxacin Nitrofurantoin Doxycycline Rifampicin Gentamicin Sulfonamides , Trimethoprim Penicillins a Vancomycin Aciclovir, Ganciclovir, Valaciclovir Antiepileptic therapy Barbiturates (Phenobarbital) Gabapentin Carbamazepin Lacosamide (Valproic acid) Lamotrigine Phenytoin Levetiracetam Primidone Lorazepam, Midazolam (Oxcarbazepine) Magnesium Topiramate Pregabalin Propofol Neuroleptics Melperone Chlorpromazine Haloperidol Levomepromazin Antidepressants (Imipramin) Amitriptyline Duloxetine Mirtazapine SSRIs Steroids (Dexamethasone) Prednisolone (Methylprednisolon) Triamcinolone Others Hormones Atropine Progesterone Betablockers Catecholamines Note : All drugs are classified after their safety in systemic use in a patient. The list is not comprehensive and the authors advise to check in the following databases for updated information on a drug before prescription to a patient with porphyria: http://www.drugs\u2010porphyria.org or http://www.porphyriafoundation.com/drug\u2010database or http://porphyriadrugs.com Drugs in bold are regarded as unsafe and have reportedly triggered attacks. Drugs in parenthesis either have conflicting\n4. snippet_id: 6\n   article_id: article:34661997\n   article_title: Acute porphyrias - A neurological perspective.\n   classification: safety\n   cues: safe, safety\n   related_drugs: lorazepam, midazolam\n   snippet: MEDICATIONS Pain killers Metamizole/Dipyrone ASS, Ibuprofen, Paracetamol Morphine, Hydromorphone Antiemetics Dimenhydrinate MCP Ondansetron Antibiotics/antivirals Clindamycin Azithromycin Erythromycin , (Clarithromycin) Carbapenems (Flucloxacillin) Cephalosporins Isoniazid Ciprofloxacin, Moxifloxacin Nitrofurantoin Doxycycline Rifampicin Gentamicin Sulfonamides , Trimethoprim Penicillins a Vancomycin Aciclovir, Ganciclovir, Valaciclovir Antiepileptic therapy Barbiturates (Phenobarbital) Gabapentin Carbamazepin Lacosamide (Valproic acid) Lamotrigine Phenytoin Levetiracetam Primidone Lorazepam, Midazolam (Oxcarbazepine) Magnesium Topiramate Pregabalin Propofol Neuroleptics Melperone Chlorpromazine Haloperidol Levomepromazin Antidepressants (Imipramin) Amitriptyline Duloxetine Mirtazapine SSRIs Steroids (Dexamethasone) Prednisolone (Methylprednisolon) Triamcinolone Others Hormones Atropine Progesterone Betablockers Catecholamines Note : All drugs are classified after their safety in systemic use in a patient. The list is not comprehensive and the authors advise to check in the following databases for updated information on a drug before prescription to a patient with porphyria: http://www.drug\n5. snippet_id: 3\n   article_id: article:34661997\n   article_title: Acute porphyrias - A neurological perspective.\n   classification: risk\n   cues: unsafe, safe, safety\n   related_drugs: fentanyl, morphine, remifentanil\n   snippet: base ) (USA). Classification is usually based on few reports and this may lead to contradictory information in some cases. A privately run website displays the information of both databases as an overview for each drug ( http://porphyriadrugs.com ). Table 4 gives an overview of the safety of drugs commonly used in neurology and psychiatry, but is not exhaustive (Albers & Fink, 2004 ; Anderson et al., 2005 ; Crimlisk, 1997 ; Windebank & Bonkovsky, 2005 ). TABLE 4 List of safe and unsafe medications UNSAFE MEDICATIONS SAFE MEDICATIONS Pain killers Metamizole/Dipyrone ASS, Ibuprofen, Paracetamol Morphine, Hydromorphone Antiemetics Dimenhydrinate MCP Ondansetron Antibiotics/antivirals Clindamycin Azithromycin Erythromycin , (Clarithromycin) Carbapenems (Flucloxacillin) Cephalosporins Isoniazid Ciprofloxacin, Moxifloxacin Nitrofurantoin Doxycycline Rifampicin Gentamicin Sulfonamides , Trimethoprim Penicillins a Vancomycin Aciclovir, Ganciclovir, Valaciclovir Antiepileptic therapy Barbiturates (Phenobarbital) Gabapentin Carbamazepin Lacosamide (Valproic acid) Lamotrigine Phenytoin Levetiracetam Primidone Lorazepam, Midazolam (Oxcarbazepine) Magnesium Topiramate Pregabalin Propofol Neuroleptics M\n6. snippet_id: 7\n   article_id: article:34661997\n   article_title: Acute porphyrias - A neurological perspective.\n   classification: safety\n   cues: safe, safety\n   related_drugs: ketamine, propofol\n   snippet: n, Paracetamol Morphine, Hydromorphone Antiemetics Dimenhydrinate MCP Ondansetron Antibiotics/antivirals Clindamycin Azithromycin Erythromycin , (Clarithromycin) Carbapenems (Flucloxacillin) Cephalosporins Isoniazid Ciprofloxacin, Moxifloxacin Nitrofurantoin Doxycycline Rifampicin Gentamicin Sulfonamides , Trimethoprim Penicillins a Vancomycin Aciclovir, Ganciclovir, Valaciclovir Antiepileptic therapy Barbiturates (Phenobarbital) Gabapentin Carbamazepin Lacosamide (Valproic acid) Lamotrigine Phenytoin Levetiracetam Primidone Lorazepam, Midazolam (Oxcarbazepine) Magnesium Topiramate Pregabalin Propofol Neuroleptics Melperone Chlorpromazine Haloperidol Levomepromazin Antidepressants (Imipramin) Amitriptyline Duloxetine Mirtazapine SSRIs Steroids (Dexamethasone) Prednisolone (Methylprednisolon) Triamcinolone Others Hormones Atropine Progesterone Betablockers Catecholamines Note : All drugs are classified after their safety in systemic use in a patient. The list is not comprehensive and the authors advise to check in the following databases for updated information on a drug before prescription to a patient with porphyria: http://www.drugs\u2010porphyria.org or http://www.porphyriafoundation.com/dru\n7. snippet_id: 4\n   article_id: article:34661997\n   article_title: Acute porphyrias - A neurological perspective.\n   classification: risk\n   cues: unsafe, safe, safety\n   related_drugs: ondansetron\n   snippet: ports and this may lead to contradictory information in some cases. A privately run website displays the information of both databases as an overview for each drug ( http://porphyriadrugs.com ). Table 4 gives an overview of the safety of drugs commonly used in neurology and psychiatry, but is not exhaustive (Albers & Fink, 2004 ; Anderson et al., 2005 ; Crimlisk, 1997 ; Windebank & Bonkovsky, 2005 ). TABLE 4 List of safe and unsafe medications UNSAFE MEDICATIONS SAFE MEDICATIONS Pain killers Metamizole/Dipyrone ASS, Ibuprofen, Paracetamol Morphine, Hydromorphone Antiemetics Dimenhydrinate MCP Ondansetron Antibiotics/antivirals Clindamycin Azithromycin Erythromycin , (Clarithromycin) Carbapenems (Flucloxacillin) Cephalosporins Isoniazid Ciprofloxacin, Moxifloxacin Nitrofurantoin Doxycycline Rifampicin Gentamicin Sulfonamides , Trimethoprim Penicillins a Vancomycin Aciclovir, Ganciclovir, Valaciclovir Antiepileptic therapy Barbiturates (Phenobarbital) Gabapentin Carbamazepin Lacosamide (Valproic acid) Lamotrigine Phenytoin Levetiracetam Primidone Lorazepam, Midazolam (Oxcarbazepine) Magnesium Topiramate Pregabalin Propofol Neuroleptics Melperone Chlorpromazine Haloperidol Levomepromazin Antidep\n8. snippet_id: 14\n   article_id: article:34661997\n   article_title: Acute porphyrias - A neurological perspective.\n   classification: safety\n   cues: prevent\n   related_drugs: levetiracetam\n   snippet: wed speech. This had progressed within days to aggressive/erratic behavior and a confusional state with incoherent speech. She was brought to an emergency room and admitted neurologically. Initial laboratory investigations, brain CT and MRI and CSF results were unremarkable. Investigations for infectious causes were negative. A second MRI revealed T2\u2010hyperintensities bilaterally in the basal ganglia without contrast enhancement (Figure SI). Autoimmune encephalitis was suspected and high\u2010dose steroids were started. Because of two episodes with loss of consciousness, seizures were suspected and levetiracetam was started to prevent seizures before transfer to our NICU was organized. Upon admission to our ward, the patient was awake, but confused. Neurological examination revealed severe dysarthria, dysphagia, and a bradykinetic syndrome. She was unable to stand or walk, muscle strength was generally slightly reduced, deep tendon reflexes normal. Blood pressure was within the normal range. We continued high\u2010dose steroids (methylprednisolone 1 g intravenously for 5 days) and repeated the lumbar puncture. Again, basic CSF results were unremarkable. EEG showed diffuse slowing of activity. MRI findings\n9. snippet_id: 8\n   article_id: article:34661997\n   article_title: Acute porphyrias - A neurological perspective.\n   classification: risk\n   cues: avoid, avoided, toxic, unsafe, safe\n   related_drugs: levetiracetam\n   snippet: tein et al., 2017 ). Thrombophlebitis is the most common side\u2010effect and rarely vein obliteration occurs. Hemin acts as a transcription factor that reduces expression of the rate\u2010limiting hepatic enzyme ALAS1. This leads to down\u2010regulation of the entire pathway and reduction of toxic metabolites. For desperate cases with severe recurrent attacks, liver transplant has been performed leading to clinical and biochemical remission (Seth et al., 2007 ; Singal et al., 2014 ; Soonawalla et al., 2004 ; Stolzel et al., 2019 ). Antiepileptic therapy can be done with Gabapentin, Lacosamide, Lamotrigine, Levetiracetam, Lorazepam, Midazolam, and Pregabalin. Addition of magnesium and propofol has been successful (Bhatia et al., 2008 ; Dawit et al., 2019 ; Engelhardt et al., 2004 ; Stolzel et al., 2019 ; Zaatreh, 2005 ). Unsafe antiepileptics that can worsen AHP should be strictly avoided, especially barbiturates, but also valproic acid and carbamazepine. For the full list of safe and unsafe medications, please refer to Table 4 . Neuropathic pain is a common problem during acute attacks, but also during recovery. Pain management can be done with ASS, Ibuprofen, Paracetamol, opioids and with gabapentin or preg\n10. snippet_id: 15\n   article_id: article:34661997\n   article_title: Acute porphyrias - A neurological perspective.\n   classification: safety\n   cues: indicated\n   related_drugs: opioids\n   snippet: al., 1984 ), or small demyelinating lesions (Gibson & Goldberg, 1956 ), ischemic lesions, (Hierons, 1957 ; Suarez et al., 1997 ), and selective reduction of hypothalamic neurons (Suarez et al., 1997 ) have been reported. None of these findings are correlated with imaging studies and are therefore difficult to interpret. 8 TREATMENT Treatment of acute attacks consists of four major points (Figure 3 ): First, identification of precipitating factors and their removal if possible. Porphyrinogenic drugs should be stopped. Second, symptomatic supportive therapy, including adequate pain management (opioids are usually indicated), correction of electrolyte imbalances, and intensive care management, if needed. Third, normocaloric nutrition high in carbohydrates and/or glucose infusions. Sodium levels need to be monitored closely. Finally, severely ill patients should receive hemin (3 mg/kg body weight [up to a maximum of 250 mg] daily for four consecutive days) (Stein et al., 2017 ; Stolzel et al., 2019 ). Hemin is indicated in patients with AHP and any neurological symptoms, in those requiring intensive care and in some cases, for pain management. Heme arginate can be reconstituted in 100 ml nor\n11. snippet_id: 12\n   article_id: article:34661997\n   article_title: Acute porphyrias - A neurological perspective.\n   classification: risk\n   cues: avoid, avoided, unsafe, safe\n   related_drugs: opioids\n   snippet: osamide, Lamotrigine, Levetiracetam, Lorazepam, Midazolam, and Pregabalin. Addition of magnesium and propofol has been successful (Bhatia et al., 2008 ; Dawit et al., 2019 ; Engelhardt et al., 2004 ; Stolzel et al., 2019 ; Zaatreh, 2005 ). Unsafe antiepileptics that can worsen AHP should be strictly avoided, especially barbiturates, but also valproic acid and carbamazepine. For the full list of safe and unsafe medications, please refer to Table 4 . Neuropathic pain is a common problem during acute attacks, but also during recovery. Pain management can be done with ASS, Ibuprofen, Paracetamol, opioids and with gabapentin or pregabalin. In November 2019, the FDA, and in March 2020, the EMA approved a new therapeutic for patients with recurrent attacks: givosiran (Alnylam Pharmaceuticals, Cambridge, MA, USA) is a small interfering RNA (siRNA) that neutralizes excess ALAS1 mRNA in hepatocytes (Sardh et al., 2019 ; Stolzel et al., 2019 ). Recently published results of the ENVISION\u2010trial ( NCT03338816 ), a phase III, multicenter, placebo\u2010controlled, randomized controlled trial, showed reduction of urinary ALA levels and of the number of acute attacks (Balwani et al., 2020 ). The siRNA is inject\n12. snippet_id: 20\n   article_id: article:36028858\n   article_title: Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION study.\n   classification: safety\n   cues: effective\n   related_drugs: opioids\n   snippet: s with or without prior hemin prophylaxis use. a Analgesic use was collected in an electronic diary up to Month 12 Fig. 8 Mean change from baseline in SF-12 PCS scores in patients with or without prior hemin prophylaxis use. Higher scores represent improvement in that summary or domain Discussion This study used data from the ENVISION trial to demonstrate the severe disease burden associated with recurrent AHP. At baseline, more than half of ENVISION trial patients were experiencing chronic symptoms between attacks, including nausea, fatigue, and pain, and more than one quarter had been using opioids daily or on most days [ 35 ]. We also found a positive correlation between time since diagnosis and AHP disease severity, further highlighting the need to treat patients early with effective therapy. These results showed that the RNAi therapeutic givosiran is effective in patients with recurrent AHP regardless of prior hemin use, and that it reduces analgesic use and pain both during and between porphyria attacks. Overall disease burden in the ENVISION trial population was similar to that observed in the recent EXPLORE study, a prospective, multinational, natural history study of patients wit\n13. snippet_id: 16\n   article_id: article:36642627\n   article_title: AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review.\n   classification: risk\n   cues: avoid, contraindicated, caution, precipitate, trigger, safe, safe option, indicated\n   related_drugs: benzodiazepines\n   snippet: tivated receptor \u03b3 coactivator 1- \u03b1 , which induces expression of ALAS1. 35 Acute attacks can be associated with hyponatremia and hypomagnesemia due to a combination of hypovolemia and syndrome of inappropriate antidiuretic hormone secretion. 36 , 37 Electrolytes should be monitored during acute attacks and hyponatremia corrected slowly if present. In acute attacks that present with seizures, management should be approached with caution because many anticonvulsant medications, such as barbiturates, hydantoins, carbamazepine, and valproic acid, are contraindicated in AHP. 38 Magnesium sulfate, benzodiazepines, and levetiracetam appear to be safe options in the context of AHP. Best Practice Advice 6: Patients should be counseled to avoid identifiable triggers that may precipitate acute attacks, such as alcohol and porphyrinogenic medications. The low penetrance of AHPs indicates the likely presence of additional factors that are required for clinical symptoms, including precipitating factors and other poorly defined modifying genes and/or epigenetic factors. 39 , 40 Sex hormones, in particular progesterone, are known to precipitate attacks. Other common precipitating factors include medications tha\n14. snippet_id: 21\n   article_id: article:36028858\n   article_title: Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION study.\n   classification: safety\n   cues: efficacy\n   related_drugs: opioids\n   snippet: orst pain scores above baseline than placebo recipients, and nearly 50% fewer days with severe pain during attack-free periods. Pain is one of the key factors associated with diminished QOL among patients with AHP [ 11 ]. The SF-12 PCS scores increased by 10.0 and 8.9 points in the open-label extension in the placebo crossover and continuous givosiran groups, respectively. The proportion of patients who used opioid analgesics during attacks was 12% lower in the givosiran group compared with the placebo group during attacks, and 13% lower during attack-free periods. Given that long-term use of opioids is associated with tolerance, dependence, and addiction, a reduction in use of these medications is clinically relevant. Furthermore, evidence for the efficacy of opioids in the management of chronic non\u2013cancer-related pain is limited. A 30-month open-label extension phase of ENVISION was completed in May 2021. Results to date support long-term maintenance of benefit with givosiran. A strength of our study is that, unlike the observational EXPLORE study [ 11 ], all potential porphyria attacks occurring in the ENVISION trial were adjudicated by the investigator. A limitation of our study was t\n15. snippet_id: 19\n   article_id: article:36028858\n   article_title: Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION study.\n   classification: risk\n   cues: condition-match\n   related_drugs: opioid\n   snippet: ical comparisons were undertaken. Results A total of 94 patients with AHP were enrolled in the ENVISION trial, of whom 46 were assigned to receive placebo and 48 to receive givosiran [ 35 ]. The median (range) age was 37.5 (19\u201265) years, and the mean (SD) years since diagnosis was 9.7 (10.0) [ 35 ]. The median (range) AAR in the 6 months prior to study randomization was 8.0 (0\u201346) [ 35 ]. At baseline, 52% of patients were experiencing chronic symptoms of porphyria, defined as symptoms between attacks daily or on most days [ 35 ]. Chronic symptoms included nausea, fatigue, and pain (Table 1 ). Opioid analgesics were used daily or on most days between attacks in 29% of patients [ 35 ]. Mean daily worst fatigue score was above 4, on a numerical rating scale of 0\u201310, in both treatment groups. Table 1 Chronic symptoms in ENVISION trial participants at baseline Characteristic Placebo (n = 46) Givosiran (n = 48) Total (N = 94) Prior chronic symptoms, n (%) 26 (57) 23 (48) 49 (52) Prior chronic opioid use, n (%) 13 (28) 14 (29) 27 (29) Nausea symptoms (medical history), n (%) 10 (22) 7 (15) 17 (18) Fatigue (medical history), n (%) 4 (9) 1 (2) 5 (5) Daily worst nausea score, weekly mean (SD) 1.9\n16. snippet_id: 46\n   article_id: article:36575494\n   article_title: Porphyria: a case report.\n   classification: safety\n   cues: indicated\n   related_drugs: fentanyl, morphine\n   snippet: ted (169 mEq/L). So unilateral renal artery stenosis (RAS) was suspected. To confirm RAS, abdominal doppler and pelvic CT investigations were requested. The CT and Doppler report was normal, excluding the diagnosis of renal artery stenosis. Similarly, arterial blood gas (ABG) analysis was normal, which was against the metabolic alkalosis seen in Gitelman syndrome. To rule out an autoimmune cause, an antinuclear antibody (ANA) was sent; however, it also came out to be negative (Additional file 1 ). The patient's clinical presentation, including severe abdominal pain, was not relieved even with morphine. After all these thorough investigations, severe uncorrected hyponatremia, severe body ache especially in the lower limbs, and precipitation of the symptoms following fasting ushered our conjectures toward the diagnosis of porphyria-related disorders. With the suspicion of porphyria, a urine sample was sent to Biochemistry Laboratory. Watson-Schwartz test was positive (Fig. 1 ); hence, it indicated the presence of porphobilinogen in urine substantiating the diagnosis of acute porphyria crisis. The urine color also darkened on exposure to light (Fig. 2 ). The symptoms were gradually relieved w\n17. snippet_id: 26\n   article_id: article:27052088\n   article_title: Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.\n   classification: risk\n   cues: avoid, risk, risk of, trigger, triggered, unsafe, safe, safely\n   related_drugs: desflurane, halothane, isoflurane, sevoflurane, volatile agents, volatile anaesthetics\n   snippet: nique and also indicate active disease, with increased risk of acute crisis. Classifying drugs as porphyria safe or unsafe is too simplistic; the duration of exposure and the absolute dose dictate whether an acute crisis would be triggered or not and how would the severity be like. Multiple confounding factors in the perioperative period mean that the trigger for a crisis may be unclear. Propofol has been considered as a safe drug for both induction and maintenance of anesthesia in the patients with AIP.[ 17 18 19 ] Modern inhalation agents are generally considered safe in porphyric patients. Sevoflurane has been reported as a safe agent for both induction and maintenance of anesthesia. Safe use of isoflurane has also been reported;[ 20 21 22 ] therefore, it should probably be classified as safe, although further information needs to be obtained. Enflurane has been shown to induce porphyrin synthesis in animal models[ 20 ] but has been used safely in patients. Reports of a possible association of halothane with crises contradict both experimental and clinical experience.[ 23 24 ] Preoperative starvation should be minimized; if a prolonged fast is unavoidable, a dextrose\u2013saline infusion should\n18. snippet_id: 43\n   article_id: article:27052088\n   article_title: Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.\n   classification: safety\n   cues: prevent\n   related_drugs: lorazepam, midazolam\n   snippet: e mobile veg on anterior leaflet of tricuspid valve commissure (TVC) with severe TR was also demonstrated in his transthoracic echocardiography. After starting antibiotic therapy and removing the port, the patient underwent TV replacement. In the day of surgery, prior to induction, all standard monitorings were applied; radial artery line and subclavian central venous (CV) line was also indwelled after induction. Premedication was consisted of incremental doses of fentanyl and midazolam. We used propofol and atracurium for induction. Maintenance of anesthesia was done by propofol, atracurium, midazolam and fentanyl. Following sternotomy and heparinization, cardiopulmonary bypass (CPB) was initiated. The patient cooled to 32\u201334\u00b0C. Myocardial protection was provided by hypothermic antegrade blood cardioplegic. The TV was replaced. After 70 min of CPB, separation from CPB was achieved, and heparin was reversed by protamine. Rewarming and weaning from CPB was uneventful. Four units of packed cell were given during CPB; Hct was maintained about 30%. Postoperatively, in Intensive Care Unit (ICU), the patient was extubated in 6 h. We started parenteral carbohydrate as dextrose 50% to prevent AIP a\n19. snippet_id: 22\n   article_id: article:36028858\n   article_title: Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION study.\n   classification: risk\n   cues: complication, complications\n   related_drugs: fentanyl, morphine, remifentanil\n   snippet: ics at baseline Placebo (n = 46) Givosiran (n = 48) Total (N = 94) Antidepressants Benzodiazepine derivatives 10 (22) 10 (21) 20 (21) Benzodiazepine-related drugs 3 (7) 4 (8) 7 (7) Other anti-depressants 4 (9) 9 (19) 13 (14) SSRIs 2 (4) 4 (8) 6 (6) Antihypertensives ACE inhibitors 2 (4) 1 (2) 3 (3) Angiotensin II receptor antagonists 3 (7) 2 (4) 5 (5) Beta blocking agents, non-selective 1 (2) 3 (6) 4 (4) Beta blocking agents, selective 5 (11) 7 (15) 12 (13) Antiemetics 5HT3 antagonists 12 (26) 12 (25) 24 (26) Pain medications Natural opium alkaloids 27 (59) 23 (48) 50 (53) Opioid anesthetics (fentanyl) 2 (4) 0 2 (2) Opioid/non-opioid combinations 2 (4) 5 (10) 7 (7) Opium alkaloid derivatives 2 (4) 0 2 (2) Other opioids 8 (17) 6 (13) 14 (15) Other analgesics and antipyretics 10 (22) 13 (27) 23 (25) SSRI selective serotonin reuptake inhibitor, ACE angiotensin-converting enzyme, 5HT3 5-hydroxytryptamine A high proportion of patients had received prior hemin prophylaxis (40%) [ 11 ], with many experiencing hemin-related complications, as well as ongoing damage caused by AHP (Fig. 2 ). Complications related to central venous access included thrombosis (8%), infection (18%), and catheter occlusi\n20. snippet_id: 54\n   article_id: article:29383964\n   article_title: Acute intermittent porphyria: general aspects with focus on pain.\n   classification: safety\n   cues: safe\n   related_drugs: opioid\n   snippet: Despite medical advances, the diagnosis and management of acute intermittent porphyria continues to be challenging. Acute pain is one of the most important clinical manifestations in acute intermittent porphyria, but management and pain assessment have been poorly studied in these patients. The lack of information and evidence based recommendations regarding these topics in the medical literature is certainly surprising. Furthermore, pain management is discussed based on extrapolating concepts adopted for other pain syndromes. An important arsenal of medications, including reportedly safe opioid and non-opioid analgesics, is available for use in this type of patient. In addition to conducting an extensive review of the current literature, the present article aims to show the general aspects of a disease that generates a challenge for the clinician, emphasizing what is related to pain as a cardinal symptom and to create awareness about the need for studies supporting the development of guidelines, based on evidence obtained from analgesic management in patients presenting with this disorder. A systematic assessment directed at understanding the physiopathological processes underlying\n21. snippet_id: 28\n   article_id: article:27052088\n   article_title: Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.\n   classification: risk\n   cues: contraindicated, precipitate, trigger, triggering, unsafe, worsened, safe, safely, safety, indicated\n   related_drugs: succinylcholine\n   snippet: phyric crisis had their symptoms worsened following induction of anesthesia with thiopental.[ 27 ] Thus, although thiopental will not always precipitate a crisis, all barbiturates must be considered contraindicated in porphyric patients. Etomidate is potentially porphyrinogenic in animal models[ 17 ] at least one human porphyric crises has been reported after its use.[ 28 ] etomidate should probably be considered unsafe. Although there are some reports showing ketamine's potentiality in triggering AIP crisis,[ 24 ] it might be safe because it has been used safely in quiescent AIP.[ 24 29 30 ] Succinylcholine has been used for many years and has been proven to be safe, as has tubocurarine.[ 31 ] Though both pancuronium and alcuronium have been classified as unsafe by some authors, they have been widely used by many anesthetists without harm. Atracurium[ 21 22 32 ] and vecuronium[ 33 ] have been used safely in small numbers of patients despite some experimental evidence for porphyrinogenicity. We safely used atracurium in the current patient. Morphine and its analogues (including codeine) are of proven safety, and fentanyl has been shown to be safe both in chick embryo culture models and in clinica\n22. snippet_id: 84\n   article_id: article:27871506\n   article_title: Elective cholecystectomy performed on patient with variegate porphyria-Propofol-based total intravenous anesthesia with target-controlled infusion.\n   classification: safety\n   cues: safe\n   related_drugs: ketamine, propofol\n   snippet: Porphyria is caused by disorders of enzymes that synthetize porphyrins. Both elective and emergency surgical procedures on patient suffering from porphyria may provoke acute symptoms. These patients require special anesthetic management since some of commonly used anesthetic agents may also induce acute manifestation of porphyria. We present the case of 53-year-old woman previously diagnosed with porphyria who underwent elective laparoscopic cholecystectomy. Propofol-based total intravenous anesthesia with target-controlled infusion was used. Such conduct proved to be safe regarding clinical symptoms, although biochemical markers were slightly elevated after procedure. Propofol seems to be the safest hypnotic drug to use in porphyria; however, special care should be taken is such cases.\n23. snippet_id: 29\n   article_id: article:27052088\n   article_title: Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.\n   classification: risk\n   cues: complication, complications, trigger, triggering, unsafe, no reported complications, safe, safely, safety\n   related_drugs: atracurium\n   snippet: tentially porphyrinogenic in animal models[ 17 ] at least one human porphyric crises has been reported after its use.[ 28 ] etomidate should probably be considered unsafe. Although there are some reports showing ketamine's potentiality in triggering AIP crisis,[ 24 ] it might be safe because it has been used safely in quiescent AIP.[ 24 29 30 ] Succinylcholine has been used for many years and has been proven to be safe, as has tubocurarine.[ 31 ] Though both pancuronium and alcuronium have been classified as unsafe by some authors, they have been widely used by many anesthetists without harm. Atracurium[ 21 22 32 ] and vecuronium[ 33 ] have been used safely in small numbers of patients despite some experimental evidence for porphyrinogenicity. We safely used atracurium in the current patient. Morphine and its analogues (including codeine) are of proven safety, and fentanyl has been shown to be safe both in chick embryo culture models and in clinical use. Alfentanil has also been used frequently with no reported complications. More recently, fentanyl[ 16 ] and sufentanil[ 15 ] have been used as a major component, in combination with isoflurane and atracurium, in open heart surgery without a s\n24. snippet_id: 81\n   article_id: article:15021955\n   article_title: [Desflurane in acute intermittent porphyria].\n   classification: safety\n   cues: safe\n   related_drugs: atracurium\n   snippet: aesthetics in porphyrias, but halothane and isoflurane seem to be safe. There is no clinical data or case report about the use of desflurane in this specific patient group, but its fast and relatively unchanged elimination and the minimal induction of the cytochrome P 450 system seem to be favorable in this setting. We report the use of desflurane in a patient with acute intermittent porphyria, scheduled for hemihepatectomy. To minimize perioperative distress by pain or the need for postoperative mechanical ventilation, we chose a balanced anaesthesia technique with desflurane, sufentanil and atracurium in combination with a continuous epidural analgesia (bupivacain and fentanyl) for the postoperative period. Preoperatively the porphyrin precursors were analyzed in serum and urine and postoperatively the 24 h-urine was screened every 2 days until postoperative day 6 to monitor the porphyria activity. The preoperative data showed high concentrations of porphyrin precursor excretion, confirming the diagnosis of AIP. The postoperative data in the 24 h-urine were significantly lower than preoperative levels and reached normal levels at postoperative day 5. There were no clinical symptoms of a po\n25. snippet_id: 30\n   article_id: article:27052088\n   article_title: Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.\n   classification: risk\n   cues: contraindicated, precipitate, trigger, triggering, unsafe, worsened, safe, safely, indicated\n   related_drugs: ketamine, propofol\n   snippet: re numerous reports of the safe use of thiopental in porphyric patients in the quiescent phase,[ 26 ] 7 out of 10 patients in acute porphyric crisis had their symptoms worsened following induction of anesthesia with thiopental.[ 27 ] Thus, although thiopental will not always precipitate a crisis, all barbiturates must be considered contraindicated in porphyric patients. Etomidate is potentially porphyrinogenic in animal models[ 17 ] at least one human porphyric crises has been reported after its use.[ 28 ] etomidate should probably be considered unsafe. Although there are some reports showing ketamine's potentiality in triggering AIP crisis,[ 24 ] it might be safe because it has been used safely in quiescent AIP.[ 24 29 30 ] Succinylcholine has been used for many years and has been proven to be safe, as has tubocurarine.[ 31 ] Though both pancuronium and alcuronium have been classified as unsafe by some authors, they have been widely used by many anesthetists without harm. Atracurium[ 21 22 32 ] and vecuronium[ 33 ] have been used safely in small numbers of patients despite some experimental evidence for porphyrinogenicity. We safely used atracurium in the current patient. Morphine and its\n26. snippet_id: 82\n   article_id: article:15021955\n   article_title: [Desflurane in acute intermittent porphyria].\n   classification: safety\n   cues: safe\n   related_drugs: desflurane\n   snippet: bout the use of volatile anaesthetics in porphyrias, but halothane and isoflurane seem to be safe. There is no clinical data or case report about the use of desflurane in this specific patient group, but its fast and relatively unchanged elimination and the minimal induction of the cytochrome P 450 system seem to be favorable in this setting. We report the use of desflurane in a patient with acute intermittent porphyria, scheduled for hemihepatectomy. To minimize perioperative distress by pain or the need for postoperative mechanical ventilation, we chose a balanced anaesthesia technique with desflurane, sufentanil and atracurium in combination with a continuous epidural analgesia (bupivacain and fentanyl) for the postoperative period. Preoperatively the porphyrin precursors were analyzed in serum and urine and postoperatively the 24 h-urine was screened every 2 days until postoperative day 6 to monitor the porphyria activity. The preoperative data showed high concentrations of porphyrin precursor excretion, confirming the diagnosis of AIP. The postoperative data in the 24 h-urine were significantly lower than preoperative levels and reached normal levels at postoperative day 5. There were n\n27. snippet_id: 34\n   article_id: article:27052088\n   article_title: Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.\n   classification: risk\n   cues: avoid, trigger, triggered, unsafe, safe, safely\n   related_drugs: desflurane, halothane, isoflurane, sevoflurane, volatile agents, volatile anaesthetics\n   snippet: safe or unsafe is too simplistic; the duration of exposure and the absolute dose dictate whether an acute crisis would be triggered or not and how would the severity be like. Multiple confounding factors in the perioperative period mean that the trigger for a crisis may be unclear. Propofol has been considered as a safe drug for both induction and maintenance of anesthesia in the patients with AIP.[ 17 18 19 ] Modern inhalation agents are generally considered safe in porphyric patients. Sevoflurane has been reported as a safe agent for both induction and maintenance of anesthesia. Safe use of isoflurane has also been reported;[ 20 21 22 ] therefore, it should probably be classified as safe, although further information needs to be obtained. Enflurane has been shown to induce porphyrin synthesis in animal models[ 20 ] but has been used safely in patients. Reports of a possible association of halothane with crises contradict both experimental and clinical experience.[ 23 24 ] Preoperative starvation should be minimized; if a prolonged fast is unavoidable, a dextrose\u2013saline infusion should be given during the preoperative period. In view of the frequency with which hyponatremia is encountered i\n28. snippet_id: 59\n   article_id: article:2697245\n   article_title: The pharmacology of propofol.\n   classification: safety\n   cues: safe\n   related_drugs: ketamine, propofol\n   snippet: ribed to its use in patients with coronary artery disease, where these effects may have the potential for producing myocardial ischemia. The hemodynamic responses to laryngoscopy and intubation are attenuated. The pharmacokinetic profile suggests suitability as an infusion for either maintenance of anesthesia or sedation. Use of propofol as an infusion during surgery may result in a further reduction in cardiac output, particularly with the concomitant administration of adjuvant increments of fentanyl. The ventilatory response to CO2 is depressed during such an infusion. The high clearance of propofol suggests that even after a prolonged infusion, recovery should be rapid. This finding has been confirmed in a series of studies establishing propofol as an ideal agent for use in a total IV anesthetic technique. Both the quality and speed of recovery, together with the absence of emetic sequelae, support the use of propofol in an outpatient setting. Propofol appears to have no long-term effect on adrenocortical function and appears safe for use in patients with acute intermittent porphyria and susceptibility to malignant hyperpyrexia.\n29. snippet_id: 40\n   article_id: article:27052088\n   article_title: Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.\n   classification: risk\n   cues: avoid, avoided, recommended, safe, safely\n   related_drugs: desflurane, halothane, isoflurane, sevoflurane, volatile agents, volatile anaesthetics\n   snippet: sidered as a safe drug for both induction and maintenance of anesthesia in the patients with AIP.[ 17 18 19 ] Modern inhalation agents are generally considered safe in porphyric patients. Sevoflurane has been reported as a safe agent for both induction and maintenance of anesthesia. Safe use of isoflurane has also been reported;[ 20 21 22 ] therefore, it should probably be classified as safe, although further information needs to be obtained. Enflurane has been shown to induce porphyrin synthesis in animal models[ 20 ] but has been used safely in patients. Reports of a possible association of halothane with crises contradict both experimental and clinical experience.[ 23 24 ] Preoperative starvation should be minimized; if a prolonged fast is unavoidable, a dextrose\u2013saline infusion should be given during the preoperative period. In view of the frequency with which hyponatremia is encountered in acute attacks, the IV fluids containing dextrose alone should be avoided. Most (but not all) benzodiazepines commonly used for premedication like midazolam, are considered safe. The phenothiazines may have particular advantages.[ 25 ] Good anxiolysis has been recommended as advantageous. Where antaci\n30. snippet_id: 60\n   article_id: article:2697245\n   article_title: The pharmacology of propofol.\n   classification: safety\n   cues: safe\n   related_drugs: ketamine, propofol\n   snippet: ic responses to laryngoscopy and intubation are attenuated. The pharmacokinetic profile suggests suitability as an infusion for either maintenance of anesthesia or sedation. Use of propofol as an infusion during surgery may result in a further reduction in cardiac output, particularly with the concomitant administration of adjuvant increments of fentanyl. The ventilatory response to CO2 is depressed during such an infusion. The high clearance of propofol suggests that even after a prolonged infusion, recovery should be rapid. This finding has been confirmed in a series of studies establishing propofol as an ideal agent for use in a total IV anesthetic technique. Both the quality and speed of recovery, together with the absence of emetic sequelae, support the use of propofol in an outpatient setting. Propofol appears to have no long-term effect on adrenocortical function and appears safe for use in patients with acute intermittent porphyria and susceptibility to malignant hyperpyrexia.\n31. snippet_id: 51\n   article_id: article:27220836\n   article_title: Femoral and sciatic nerve block for knee arthroscopy in a patient with acute intermittent porphyria.\n   classification: risk\n   cues: trigger, triggered, safe\n   related_drugs: fentanyl, morphine, remifentanil\n   snippet: an autosomal dominant disorder that results from a partial deficiency of porphobilinogen deaminase and that causes very severe symptoms. Attacks may be triggered by a series of drugs and by other factors that the anesthesiologist should be aware of in order to reduce morbidity and mortality. Our objective is to review anesthetic considerations in acute intermittent porphyria. We present the case of a patient diagnosed with acute intermittent porphyria who was scheduled for knee arthroscopy. The anesthetic technique used was a femoral and sciatic nerve block under sedation with an infusion of remifentanil. The surgery proceeded without incident and the patient was discharged home after 24h. We consider the use of a peripheral plexus block of the lower limb to have been the safest anesthetic technique for this patient.\n32. snippet_id: 61\n   article_id: article:2697245\n   article_title: The pharmacology of propofol.\n   classification: safety\n   cues: safe\n   related_drugs: ketamine, propofol\n   snippet: e of propofol as an infusion during surgery may result in a further reduction in cardiac output, particularly with the concomitant administration of adjuvant increments of fentanyl. The ventilatory response to CO2 is depressed during such an infusion. The high clearance of propofol suggests that even after a prolonged infusion, recovery should be rapid. This finding has been confirmed in a series of studies establishing propofol as an ideal agent for use in a total IV anesthetic technique. Both the quality and speed of recovery, together with the absence of emetic sequelae, support the use of propofol in an outpatient setting. Propofol appears to have no long-term effect on adrenocortical function and appears safe for use in patients with acute intermittent porphyria and susceptibility to malignant hyperpyrexia.\n33. snippet_id: 86\n   article_id: article:21146060\n   article_title: Neuropathic pain in a patient with porphyria. Case report.\n   classification: risk\n   cues: toxic, trigger, triggered, indicated\n   related_drugs: metoclopramide\n   snippet: the toxic effects of porphyrin precursors, and it can be triggered by drugs used routinely in medical practice, severe carbohydrate restriction, and metabolic stress. The objective of this report was to present the case of a late onset porphyria evolving to chronic pain. This is a 27 years old female who was admitted 5 months prior to her clinic appointment with severe abdominal pain without diagnosis. An exploratory laparotomy was indicated, which failed to demonstrate a cause for her pain. The patient was exposed to surgical trauma and drugs that can trigger porphyria, such as ketoprophen, metoclopramide, and antibiotics, and she evolved with significant hyponatremia, increased liver enzymes, seizures, and loss of movements that led to be admitted to the Intensive Care Unit. After the diagnosis of porphyria was made, the patient remained with pain in the lower limbs, being referred to the Pain Department of Santa Casa de Miseric\u00f3rdia de S\u00e3o Paulo. Treatment with amitriptyline, gabapentin, opioid, and simple analgesics was instituted; however, the patient continued to present recurring episodes of porphyria and, feeling insecure with the conduction of the case, she stopped the treatment. Porph\n34. snippet_id: 64\n   article_id: article:2660638\n   article_title: [Anesthesia and hepatic porphyria].\n   classification: safety\n   cues: safe\n   related_drugs: benzodiazepines\n   snippet: he attention of the anaesthesiologist on the porphyrinogenic properties of all the drugs used in anaesthesia and intensive care. An outline of the chemistry of porphyrins and the enzymatic pathways were recalled, so as to place the acute porphyrias in their proper perspective. There follows a reminder of the clinical aspect of acute porphyric crises. The part played by drugs is then assessed from clinical and laboratory data concerning their porphyrinogenicity. Those drugs for which there is conflicting evidence regarding their safe use in porphyric patients are discussed: propofol, ketamine, benzodiazepines, etomidate, local anaesthetics. Recommendations supported by clinical and experimental data are given, especially the results obtained with the chick embryo liver model. Treatment of the acute crisis is provided, with particular emphasis on the use of haematin. The anaesthetic management of hepatic porphyric patients is described. Those drugs which are well-known porphyrinogenic compounds in the chick embryo liver must be excluded from use for anaesthesia in the porphyric patients, even if they have been observed to be innocuous in rare cases of asymptomatic patients. Finally, recommendations\n35. snippet_id: 88\n   article_id: article:17037005\n   article_title: The use of rocuronium and sevoflurane in acute intermittent porphyria--a case report.\n   classification: risk\n   cues: fatal, precipitate, recommended, safe\n   related_drugs: rocuronium\n   snippet: porphyria (AIP) is an inherited metabolic disorder caused by deficiency of porphobilinogen deaminase, an enzyme found in the synthetic pathway of heme. Acute attack of AIP may be precipitated by many factors during operation and anesthesia, including fasting, dehydration, stress, infection, and drugs. Acute attack of AIP is likely fatal. Therefore, the drugs recommended as being safe in anesthesia for porphyria patients are up-to-dately refreshed and renovated and the identification of whether a drug is safe or not is based on cumulative anecdotal experiences. Here, we report the safe use of rocuronium and sevoflurane for long exposure in a patient affected with acute intermittent porphyria.\n36. snippet_id: 65\n   article_id: article:2660638\n   article_title: [Anesthesia and hepatic porphyria].\n   classification: safety\n   cues: safe\n   related_drugs: ketamine, propofol\n   snippet: to focus the attention of the anaesthesiologist on the porphyrinogenic properties of all the drugs used in anaesthesia and intensive care. An outline of the chemistry of porphyrins and the enzymatic pathways were recalled, so as to place the acute porphyrias in their proper perspective. There follows a reminder of the clinical aspect of acute porphyric crises. The part played by drugs is then assessed from clinical and laboratory data concerning their porphyrinogenicity. Those drugs for which there is conflicting evidence regarding their safe use in porphyric patients are discussed: propofol, ketamine, benzodiazepines, etomidate, local anaesthetics. Recommendations supported by clinical and experimental data are given, especially the results obtained with the chick embryo liver model. Treatment of the acute crisis is provided, with particular emphasis on the use of haematin. The anaesthetic management of hepatic porphyric patients is described. Those drugs which are well-known porphyrinogenic compounds in the chick embryo liver must be excluded from use for anaesthesia in the porphyric patients, even if they have been observed to be innocuous in rare cases of asymptomatic patients. Finally\n37. snippet_id: 56\n   article_id: article:1418699\n   article_title: Adverse effects of general anaesthetics.\n   classification: risk\n   cues: life-threatening, toxic, toxicity, trigger, triggered, triggering\n   related_drugs: nitrous oxide\n   snippet: nts have a direct effect on lung physiology. The most important idiosyncratic reactions to the volatile agents are malignant hyperpyrexia and 'halothane hepatitis'. Malignant hyperpyrexia has an incidence of 1:12,000 with a mortality of about 24%. It is triggered most often by halothane together with suxamethonium. Post halothane hepatic necrosis is rare. Evidence points to 2 distinct syndromes; direct toxicity from the products of reductive metabolism, and a more serious illness, immunologically mediated via haptens formed by liver proteins and the products of oxidative metabolism. Prolonged nitrous oxide exposure can cause bone marrow depression and life-threatening pressure effects by expansion of air-filled spaces within the body. The idiosyncratic reactions to the intravenous agents include anaphylactoid reactions (which are rare) and triggering of acute porphyria. Etomidate is immunologically 'clean', but it inhibits cortisol synthesis.\n38. snippet_id: 66\n   article_id: article:2660638\n   article_title: [Anesthesia and hepatic porphyria].\n   classification: safety\n   cues: safe\n   related_drugs: ketamine, propofol\n   snippet: iew aimed to focus the attention of the anaesthesiologist on the porphyrinogenic properties of all the drugs used in anaesthesia and intensive care. An outline of the chemistry of porphyrins and the enzymatic pathways were recalled, so as to place the acute porphyrias in their proper perspective. There follows a reminder of the clinical aspect of acute porphyric crises. The part played by drugs is then assessed from clinical and laboratory data concerning their porphyrinogenicity. Those drugs for which there is conflicting evidence regarding their safe use in porphyric patients are discussed: propofol, ketamine, benzodiazepines, etomidate, local anaesthetics. Recommendations supported by clinical and experimental data are given, especially the results obtained with the chick embryo liver model. Treatment of the acute crisis is provided, with particular emphasis on the use of haematin. The anaesthetic management of hepatic porphyric patients is described. Those drugs which are well-known porphyrinogenic compounds in the chick embryo liver must be excluded from use for anaesthesia in the porphyric patients, even if they have been observed to be innocuous in rare cases of asymptomatic patient\n39. snippet_id: 85\n   article_id: article:15826795\n   article_title: [Obstetrical anaesthesia and porphyrias].\n   classification: risk\n   cues: fatal, trigger, triggered\n   related_drugs: bupivacaine\n   snippet: Acute hepatic porphyrias are genetic diseases, characterized by acute neurological symptoms, sometimes fatal, triggered by different factors, in particular by many anaesthetic drugs, and also by pregnancy. We report here the experience of three porphyric patients'deliveries, allowing us to consider a proposition of management in this context. After discussion between anaesthesiologist, obstetrician and porphyria specialist, two types of management of such patients can be foresee. Asymptomatic patients, or in long remission, can benefit from locoregional anesthesia techniques with bupivacaine for both labour analgesia and Caesarean section. Spinal anaesthesia is then the technique of choice, allowing using smaller quantity of local anaesthetic than epidural anaesthesia. For symptomatic patients, or in crisis, we have rather choose intravenous narcotics for labour analgesia, and general anaesthesia for Caesarean section. The hypnotic agent of choice for both induction and maintenance of such anaesthesia is then propofol.\n40. snippet_id: 90\n   article_id: article:3986654\n   article_title: Induction of anaesthesia with etomidate in a patient with acute intermittent porphyria.\n   classification: safety\n   cues: safe\n   related_drugs: fentanyl, morphine\n   snippet: for elective vagotomy and pyloroplasty. The diagnosis of porphyria was made two years previously when she developed acute abdominal pain and lower motor neurone paralysis following ingestion of a barbiturate. The urine porphobilinogen test was positive. The patient had no other acute attack of porphyria and had not had a previous anaesthetic. Anaesthesia was induced with etomidate 0.3 mg X kg-1 IV. Muscle relaxation was obtained with pancuronium 6 mg IV and ventilation was mechanically controlled. Intraoperative analgesia was with 66 per cent nitrous oxide in oxygen and intermittent doses of fentanyl. The patient was stable during anaesthesia and surgery. The postoperative period was uneventful and patient did not have an acute attack of porphyria. This experience suggests that etomidate is safe for intravenous induction of anaesthesia in acute intermittent porphyria. However, reports of its use in more patients with this disease will be necessary before a final conclusion can be made.\n41. snippet_id: 75\n   article_id: article:15021955\n   article_title: [Desflurane in acute intermittent porphyria].\n   classification: risk\n   cues: trigger, safe\n   related_drugs: desflurane, halothane, isoflurane, sevoflurane, volatile agents, volatile anaesthetics\n   snippet: Despite the low incidence of the acute porphyrias, a profound knowledge of the disease is essential for anaesthesiologists, as a variety of perioperatively administered drugs are potential triggers of an acute attack. There is an ongoing discussion about the use of volatile anaesthetics in porphyrias, but halothane and isoflurane seem to be safe. There is no clinical data or case report about the use of desflurane in this specific patient group, but its fast and relatively unchanged elimination and the minimal induction of the cytochrome P 450 system seem to be favorable in this setting. We report the use of desflurane in a patient with acute intermittent porphyria, scheduled for hemihepatectomy. To minimize perioperative distress by pain or the need for postoperative mechanical ventilation, we chose a balanced anaesthesia technique with desflurane, sufentanil and atracurium in combination with a continuous epidural analgesia (bupivacain and fentanyl) for the postoperative period. Preoperatively the po\n42. snippet_id: 91\n   article_id: article:3986654\n   article_title: Induction of anaesthesia with etomidate in a patient with acute intermittent porphyria.\n   classification: safety\n   cues: safe\n   related_drugs: nitrous oxide\n   snippet: le with acute intermittent porphyria who presented for elective vagotomy and pyloroplasty. The diagnosis of porphyria was made two years previously when she developed acute abdominal pain and lower motor neurone paralysis following ingestion of a barbiturate. The urine porphobilinogen test was positive. The patient had no other acute attack of porphyria and had not had a previous anaesthetic. Anaesthesia was induced with etomidate 0.3 mg X kg-1 IV. Muscle relaxation was obtained with pancuronium 6 mg IV and ventilation was mechanically controlled. Intraoperative analgesia was with 66 per cent nitrous oxide in oxygen and intermittent doses of fentanyl. The patient was stable during anaesthesia and surgery. The postoperative period was uneventful and patient did not have an acute attack of porphyria. This experience suggests that etomidate is safe for intravenous induction of anaesthesia in acute intermittent porphyria. However, reports of its use in more patients with this disease will be necessary before a final conclusion can be made.\n43. snippet_id: 79\n   article_id: article:15021955\n   article_title: [Desflurane in acute intermittent porphyria].\n   classification: risk\n   cues: trigger, safe\n   related_drugs: desflurane, halothane, isoflurane, sevoflurane, volatile agents, volatile anaesthetics\n   snippet: Despite the low incidence of the acute porphyrias, a profound knowledge of the disease is essential for anaesthesiologists, as a variety of perioperatively administered drugs are potential triggers of an acute attack. There is an ongoing discussion about the use of volatile anaesthetics in porphyrias, but halothane and isoflurane seem to be safe. There is no clinical data or case report about the use of desflurane in this specific patient group, but its fast and relatively unchanged elimination and the minimal induction of the cytochrome P 450 system seem to be favorable in this setting. We report the use of desflurane in a patient with acute intermittent porphyria, scheduled for hemihepatectomy. To minimize perioperative distress by pain or the need for postoperative mechanical ventilation, we chose a balanced anaesthesia technique with desflurane, sufentanil and atracurium\n44. snippet_id: 73\n   article_id: article:7616668\n   article_title: [Surgical and anesthetic managements of patients with porphyria].\n   classification: risk\n   cues: exacerbate, prevent\n   related_drugs: diazepam, lorazepam, midazolam\n   snippet: Although the morbidity of porphyria is rare, the surgical and anesthetic managements of patients with porphyria should be prudent, for various stresses including surgery and anesthesia may cause occurrence or exacerbation of this disease, occasionally resulting in the mortal course. Several drugs such as barbiturate, diazepam, pentazocine, and pancuronium, which can be used during anesthesia or after operation, reportedly exacerbate the disease. Furthermore, the acute exacerbation of porphyria may be misdiagnosed as acute abdomen, ileus, acute appendicitis, cholelithiasis, urolithiasis, or ectopic pregnancy. The managements of patients with acute porphyria during anesthesia and after surgery are discussed along with the introduction of our case report. Since there is no definitive treatment of porphyria, the most important thing is to understand the disease and to prevent the acute exacerbation of the disease. Whe\n45. snippet_id: 72\n   article_id: article:88665\n   article_title: Hormonal effects on the regulation of hepatic heme biosynthesis.\n   classification: risk\n   cues: condition-match\n   related_drugs: glucagon\n   snippet: are reported to increase intracellular adenosine 3':5'-monophosphate (cAMP) levels, viz. glucagon, sodium fluoride, cAMP or its dibutyryl derivative, 3-isobutyl-1-methylxanthine and papaverine enhanced drug-induced porphyrin biosynthesis. On the other have, agents which are reported to decrease intra-cellular cAMP levels, viz. alloxan and imidazole, diminished drug-induced porphyrin accumulation. cAMP appears to enhance, but not to function as a \"second messenger\" in drug-induced porphyrin biosynthesis. Drug-induced porphyrin accumulation in chick embryo liver cells depend upon the insulin to glucagon ratio. A low level of porphyrin accumulation occurs at insulin to glucagon ratios similar to those found following glucose administration in vivo, suggesting a possible explanation for the therapeutic effect of glucose in hepatic porphyria. The 5 alpha A(A:B trans) and 5 beta H(A:Bcis) steroids are equipotent in inducing delta-aminolevulinic acid synthetase and porphyrin accumulation in chick embryo liver cells maintained in serum-free culture medium. Thus, there is no specific steric requirement for porphyrin-inducing activity in steroids.\n46. snippet_id: 57\n   article_id: article:1418699\n   article_title: Adverse effects of general anaesthetics.\n   classification: risk\n   cues: life-threatening, toxic, toxicity, trigger, triggered\n   related_drugs: desflurane, halothane, isoflurane, sevoflurane, volatile agents, volatile anaesthetics\n   snippet: enous anaesthetic agents affect the central nervous and cardio-respiratory systems in a dose-related manner. Neuronal inhibition results in decreasing levels of consciousness and depression of the medullary vital centres which can lead to cardiorespiratory failure. Both groups of agents have some depressant effect on the myocardium and vascular smooth muscle leading to a fall in cardiac output and hypotension. Centrally-mediated respiratory depression is common to both groups and the inhalational agents have a direct effect on lung physiology. The most important idiosyncratic reactions to the volatile agents are malignant hyperpyrexia and 'halothane hepatitis'. Malignant hyperpyrexia has an incidence of 1:12,000 with a mortality of about 24%. It is triggered most often by halothane together with suxamethonium. Post halothane hepatic necrosis is rare. Evidence points to 2 distinct syndromes; direct toxicity from the products of reductive metabolism, and a more serious illness, immunologically mediated via haptens formed by liver proteins and the products of oxidative metabolism. Prolonged nitrous oxide exposure can cause bone marrow depression and life-threatening pressure effects by expansion of\n47. snippet_id: 9\n   article_id: article:34661997\n   article_title: Acute porphyrias - A neurological perspective.\n   classification: risk\n   cues: avoid, avoided, toxic, unsafe, safe\n   related_drugs: diazepam, lorazepam, midazolam\n   snippet: 17 ). Thrombophlebitis is the most common side\u2010effect and rarely vein obliteration occurs. Hemin acts as a transcription factor that reduces expression of the rate\u2010limiting hepatic enzyme ALAS1. This leads to down\u2010regulation of the entire pathway and reduction of toxic metabolites. For desperate cases with severe recurrent attacks, liver transplant has been performed leading to clinical and biochemical remission (Seth et al., 2007 ; Singal et al., 2014 ; Soonawalla et al., 2004 ; Stolzel et al., 2019 ). Antiepileptic therapy can be done with Gabapentin, Lacosamide, Lamotrigine, Levetiracetam, Lorazepam, Midazolam, and Pregabalin. Addition of magnesium and propofol has been successful (Bhatia et al., 2008 ; Dawit et al., 2019 ; Engelhardt et al., 2004 ; Stolzel et al., 2019 ; Zaatreh, 2005 ). Unsafe antiepileptics that can worsen AHP should be strictly avoided, especially barbiturates, but also valproic acid and carbamazepine. For the full list of safe and unsafe medications, please refer to Table 4 . Neuropathic pain is a common problem during acute attacks, but also during recovery. Pain management can be done with ASS, Ibuprofen, Paracetamol, opioids and with gabapentin or pregabalin. In\n48. snippet_id: 10\n   article_id: article:34661997\n   article_title: Acute porphyrias - A neurological perspective.\n   classification: risk\n   cues: avoid, avoided, toxic, unsafe, safe\n   related_drugs: diazepam, lorazepam, midazolam\n   snippet: bophlebitis is the most common side\u2010effect and rarely vein obliteration occurs. Hemin acts as a transcription factor that reduces expression of the rate\u2010limiting hepatic enzyme ALAS1. This leads to down\u2010regulation of the entire pathway and reduction of toxic metabolites. For desperate cases with severe recurrent attacks, liver transplant has been performed leading to clinical and biochemical remission (Seth et al., 2007 ; Singal et al., 2014 ; Soonawalla et al., 2004 ; Stolzel et al., 2019 ). Antiepileptic therapy can be done with Gabapentin, Lacosamide, Lamotrigine, Levetiracetam, Lorazepam, Midazolam, and Pregabalin. Addition of magnesium and propofol has been successful (Bhatia et al., 2008 ; Dawit et al., 2019 ; Engelhardt et al., 2004 ; Stolzel et al., 2019 ; Zaatreh, 2005 ). Unsafe antiepileptics that can worsen AHP should be strictly avoided, especially barbiturates, but also valproic acid and carbamazepine. For the full list of safe and unsafe medications, please refer to Table 4 . Neuropathic pain is a common problem during acute attacks, but also during recovery. Pain management can be done with ASS, Ibuprofen, Paracetamol, opioids and with gabapentin or pregabalin. In November 20\n49. snippet_id: 11\n   article_id: article:34661997\n   article_title: Acute porphyrias - A neurological perspective.\n   classification: risk\n   cues: avoid, avoided, toxic, unsafe, safe\n   related_drugs: ketamine, propofol\n   snippet: vein obliteration occurs. Hemin acts as a transcription factor that reduces expression of the rate\u2010limiting hepatic enzyme ALAS1. This leads to down\u2010regulation of the entire pathway and reduction of toxic metabolites. For desperate cases with severe recurrent attacks, liver transplant has been performed leading to clinical and biochemical remission (Seth et al., 2007 ; Singal et al., 2014 ; Soonawalla et al., 2004 ; Stolzel et al., 2019 ). Antiepileptic therapy can be done with Gabapentin, Lacosamide, Lamotrigine, Levetiracetam, Lorazepam, Midazolam, and Pregabalin. Addition of magnesium and propofol has been successful (Bhatia et al., 2008 ; Dawit et al., 2019 ; Engelhardt et al., 2004 ; Stolzel et al., 2019 ; Zaatreh, 2005 ). Unsafe antiepileptics that can worsen AHP should be strictly avoided, especially barbiturates, but also valproic acid and carbamazepine. For the full list of safe and unsafe medications, please refer to Table 4 . Neuropathic pain is a common problem during acute attacks, but also during recovery. Pain management can be done with ASS, Ibuprofen, Paracetamol, opioids and with gabapentin or pregabalin. In November 2019, the FDA, and in March 2020, the EMA approved a n\n50. snippet_id: 13\n   article_id: article:34661997\n   article_title: Acute porphyrias - A neurological perspective.\n   classification: risk\n   cues: unsafe, safe, safety\n   related_drugs: levetiracetam\n   snippet: edications UNSAFE MEDICATIONS SAFE MEDICATIONS Pain killers Metamizole/Dipyrone ASS, Ibuprofen, Paracetamol Morphine, Hydromorphone Antiemetics Dimenhydrinate MCP Ondansetron Antibiotics/antivirals Clindamycin Azithromycin Erythromycin , (Clarithromycin) Carbapenems (Flucloxacillin) Cephalosporins Isoniazid Ciprofloxacin, Moxifloxacin Nitrofurantoin Doxycycline Rifampicin Gentamicin Sulfonamides , Trimethoprim Penicillins a Vancomycin Aciclovir, Ganciclovir, Valaciclovir Antiepileptic therapy Barbiturates (Phenobarbital) Gabapentin Carbamazepin Lacosamide (Valproic acid) Lamotrigine Phenytoin Levetiracetam Primidone Lorazepam, Midazolam (Oxcarbazepine) Magnesium Topiramate Pregabalin Propofol Neuroleptics Melperone Chlorpromazine Haloperidol Levomepromazin Antidepressants (Imipramin) Amitriptyline Duloxetine Mirtazapine SSRIs Steroids (Dexamethasone) Prednisolone (Methylprednisolon) Triamcinolone Others Hormones Atropine Progesterone Betablockers Catecholamines Note : All drugs are classified after their safety in systemic use in a patient. The list is not comprehensive and the authors advise to check in the following databases for updated information on a drug before prescription to a patient\n51. snippet_id: 17\n   article_id: article:36642627\n   article_title: AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review.\n   classification: risk\n   cues: avoid, contraindicated, caution, precipitate, trigger, safe, safe option, indicated\n   related_drugs: levetiracetam\n   snippet: activator 1- \u03b1 , which induces expression of ALAS1. 35 Acute attacks can be associated with hyponatremia and hypomagnesemia due to a combination of hypovolemia and syndrome of inappropriate antidiuretic hormone secretion. 36 , 37 Electrolytes should be monitored during acute attacks and hyponatremia corrected slowly if present. In acute attacks that present with seizures, management should be approached with caution because many anticonvulsant medications, such as barbiturates, hydantoins, carbamazepine, and valproic acid, are contraindicated in AHP. 38 Magnesium sulfate, benzodiazepines, and levetiracetam appear to be safe options in the context of AHP. Best Practice Advice 6: Patients should be counseled to avoid identifiable triggers that may precipitate acute attacks, such as alcohol and porphyrinogenic medications. The low penetrance of AHPs indicates the likely presence of additional factors that are required for clinical symptoms, including precipitating factors and other poorly defined modifying genes and/or epigenetic factors. 39 , 40 Sex hormones, in particular progesterone, are known to precipitate attacks. Other common precipitating factors include medications that induce cytochrome\n52. snippet_id: 18\n   article_id: article:36028858\n   article_title: Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION study.\n   classification: risk\n   cues: avoid, complication, complications, precipitate, side effect, side effects, toxic, trigger, prevent, indicated\n   related_drugs: opioids\n   snippet: , 14 ]. Early treatment is important to prevent disease progression [ 5 , 15 ]. There is a need for treatments that not only reduce or eliminate acute attacks, but also improve chronic manifestations of recurrent AHP. Prevention strategies include identifying and avoiding triggers that may precipitate acute attacks [ 16 , 17 ]. However, some triggers, such as stress, may not always be avoidable [ 17 , 18 ]. Furthermore, many patients continue to experience chronic symptoms between attacks [ 6 , 10 , 11 ]. Opioids are used to manage abdominal, limb, and back pain [ 17 ], but patients receiving opioids may develop somnolence, addiction, tolerance, and hyperalgesia [ 19 ]. Intravenous (IV) hemin is the standard of care for confirmed acute attacks [ 2 , 20 , 21 ]. Hemin is thought to work by decreasing levels of ALAS1, thereby reducing the production of toxic heme precursors [ 22 \u2013 24 ]. Although hemin is not indicated for prophylaxis [ 22 , 23 ], it is often used off-label for this purpose [ 11 ]. Some patients have reported recurrent attacks despite weekly prophylactic hemin administration [ 25 ]. Side effects and complications associated with hemin use include headache, infusion-site react\n53. snippet_id: 27\n   article_id: article:27052088\n   article_title: Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.\n   classification: risk\n   cues: risk, risk of, trigger, triggered, unsafe, safe, safely\n   related_drugs: ketamine, propofol\n   snippet: that appropriate drug regimens are selected.[ 13 14 15 16 ] Particular attentions should be given to the presence of peripheral neuropathy and autonomic instability, as they will influence the anesthetic technique and also indicate active disease, with increased risk of acute crisis. Classifying drugs as porphyria safe or unsafe is too simplistic; the duration of exposure and the absolute dose dictate whether an acute crisis would be triggered or not and how would the severity be like. Multiple confounding factors in the perioperative period mean that the trigger for a crisis may be unclear. Propofol has been considered as a safe drug for both induction and maintenance of anesthesia in the patients with AIP.[ 17 18 19 ] Modern inhalation agents are generally considered safe in porphyric patients. Sevoflurane has been reported as a safe agent for both induction and maintenance of anesthesia. Safe use of isoflurane has also been reported;[ 20 21 22 ] therefore, it should probably be classified as safe, although further information needs to be obtained. Enflurane has been shown to induce porphyrin synthesis in animal models[ 20 ] but has been used safely in patients. Reports of a possible as\n54. snippet_id: 23\n   article_id: article:36028858\n   article_title: Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION study.\n   classification: risk\n   cues: complication, complications\n   related_drugs: opioid\n   snippet: emetics, and analgesics at baseline Placebo (n = 46) Givosiran (n = 48) Total (N = 94) Antidepressants Benzodiazepine derivatives 10 (22) 10 (21) 20 (21) Benzodiazepine-related drugs 3 (7) 4 (8) 7 (7) Other anti-depressants 4 (9) 9 (19) 13 (14) SSRIs 2 (4) 4 (8) 6 (6) Antihypertensives ACE inhibitors 2 (4) 1 (2) 3 (3) Angiotensin II receptor antagonists 3 (7) 2 (4) 5 (5) Beta blocking agents, non-selective 1 (2) 3 (6) 4 (4) Beta blocking agents, selective 5 (11) 7 (15) 12 (13) Antiemetics 5HT3 antagonists 12 (26) 12 (25) 24 (26) Pain medications Natural opium alkaloids 27 (59) 23 (48) 50 (53) Opioid anesthetics (fentanyl) 2 (4) 0 2 (2) Opioid/non-opioid combinations 2 (4) 5 (10) 7 (7) Opium alkaloid derivatives 2 (4) 0 2 (2) Other opioids 8 (17) 6 (13) 14 (15) Other analgesics and antipyretics 10 (22) 13 (27) 23 (25) SSRI selective serotonin reuptake inhibitor, ACE angiotensin-converting enzyme, 5HT3 5-hydroxytryptamine A high proportion of patients had received prior hemin prophylaxis (40%) [ 11 ], with many experiencing hemin-related complications, as well as ongoing damage caused by AHP (Fig. 2 ). Complications related to central venous access included thrombosis (8%), infection (18%)\n55. snippet_id: 24\n   article_id: article:36028858\n   article_title: Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION study.\n   classification: risk\n   cues: complication, complications\n   related_drugs: opioid\n   snippet: (n = 46) Givosiran (n = 48) Total (N = 94) Antidepressants Benzodiazepine derivatives 10 (22) 10 (21) 20 (21) Benzodiazepine-related drugs 3 (7) 4 (8) 7 (7) Other anti-depressants 4 (9) 9 (19) 13 (14) SSRIs 2 (4) 4 (8) 6 (6) Antihypertensives ACE inhibitors 2 (4) 1 (2) 3 (3) Angiotensin II receptor antagonists 3 (7) 2 (4) 5 (5) Beta blocking agents, non-selective 1 (2) 3 (6) 4 (4) Beta blocking agents, selective 5 (11) 7 (15) 12 (13) Antiemetics 5HT3 antagonists 12 (26) 12 (25) 24 (26) Pain medications Natural opium alkaloids 27 (59) 23 (48) 50 (53) Opioid anesthetics (fentanyl) 2 (4) 0 2 (2) Opioid/non-opioid combinations 2 (4) 5 (10) 7 (7) Opium alkaloid derivatives 2 (4) 0 2 (2) Other opioids 8 (17) 6 (13) 14 (15) Other analgesics and antipyretics 10 (22) 13 (27) 23 (25) SSRI selective serotonin reuptake inhibitor, ACE angiotensin-converting enzyme, 5HT3 5-hydroxytryptamine A high proportion of patients had received prior hemin prophylaxis (40%) [ 11 ], with many experiencing hemin-related complications, as well as ongoing damage caused by AHP (Fig. 2 ). Complications related to central venous access included thrombosis (8%), infection (18%), and catheter occlusion/malfunction (24%).\n56. snippet_id: 31\n   article_id: article:27052088\n   article_title: Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.\n   classification: risk\n   cues: complication, complications, trigger, triggering, unsafe, no reported complications, safe, safely, safety\n   related_drugs: fentanyl, morphine, remifentanil\n   snippet: showing ketamine's potentiality in triggering AIP crisis,[ 24 ] it might be safe because it has been used safely in quiescent AIP.[ 24 29 30 ] Succinylcholine has been used for many years and has been proven to be safe, as has tubocurarine.[ 31 ] Though both pancuronium and alcuronium have been classified as unsafe by some authors, they have been widely used by many anesthetists without harm. Atracurium[ 21 22 32 ] and vecuronium[ 33 ] have been used safely in small numbers of patients despite some experimental evidence for porphyrinogenicity. We safely used atracurium in the current patient. Morphine and its analogues (including codeine) are of proven safety, and fentanyl has been shown to be safe both in chick embryo culture models and in clinical use. Alfentanil has also been used frequently with no reported complications. More recently, fentanyl[ 16 ] and sufentanil[ 15 ] have been used as a major component, in combination with isoflurane and atracurium, in open heart surgery without a significant problem.[ 21 ] Cardiac surgical reports also refer to the safe use of heparin. Pethidine (meperidine) has a proven track record of safety despite a single case report implicating it in a porp\n57. snippet_id: 25\n   article_id: article:40114189\n   article_title: Neurodevelopmental retardation and neurological symptoms in homozygous variegate porphyria: two new cases and a literature review.\n   classification: risk\n   cues: condition-match\n   related_drugs: levetiracetam\n   snippet: e the question whether homozygosity for R59W variant is lethal. Two new cases of homozygous variegate porphyria We identified two new cases of homozygous variegate porphyria that have so far not been published. Patient 1 is a now 7-year-old girl. She was admitted to our neonatal department because of hepatopathy on her first day of life, showing cutaneous lesions caused by the light of a pulse oximeter (Fig. 1 A). Nystagmus became apparent at the age of 6 weeks. She developed epileptic seizures, mainly bilateral tonic seizures with eye blinking, at the age of 3 months which did not respond to levetiracetam, but to a combination of valproic acid and phenobarbital. Her subsequent development was globally delayed. Currently, she is able to walk without aid on level ground and expresses herself in simple two-word combinations. She attends a school for children with intellectual disability. She has short stature and microcephaly (at the age of 7 years: height 114 cm (P1, SDS: \u2212 2.24), weight 19 kg (P2, SDS:\u2212 2.02), BMI 14.6 kg/m 2 (P25, SDS:\u2212 0.68) and head circumference 44.7 cm (< P1, SDS: \u2212 5.16), at birth: height 46 cm (< P1, SDS:\u2212 3.02), weight 2450 g (< P1, SDS:\u2212 2.99), head circumference 32 cm\n58. snippet_id: 32\n   article_id: article:27052088\n   article_title: Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.\n   classification: risk\n   cues: complication, complications, unsafe, no reported complications, safe, safely, safety\n   related_drugs: fentanyl, morphine, remifentanil\n   snippet: be safe because it has been used safely in quiescent AIP.[ 24 29 30 ] Succinylcholine has been used for many years and has been proven to be safe, as has tubocurarine.[ 31 ] Though both pancuronium and alcuronium have been classified as unsafe by some authors, they have been widely used by many anesthetists without harm. Atracurium[ 21 22 32 ] and vecuronium[ 33 ] have been used safely in small numbers of patients despite some experimental evidence for porphyrinogenicity. We safely used atracurium in the current patient. Morphine and its analogues (including codeine) are of proven safety, and fentanyl has been shown to be safe both in chick embryo culture models and in clinical use. Alfentanil has also been used frequently with no reported complications. More recently, fentanyl[ 16 ] and sufentanil[ 15 ] have been used as a major component, in combination with isoflurane and atracurium, in open heart surgery without a significant problem.[ 21 ] Cardiac surgical reports also refer to the safe use of heparin. Pethidine (meperidine) has a proven track record of safety despite a single case report implicating it in a porphyric attack.[ 34 ] There is evidence both for[ 35 ] and against[ 36 ] th\n59. snippet_id: 33\n   article_id: article:27052088\n   article_title: Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.\n   classification: risk\n   cues: complication, complications, unsafe, no reported complications, safe, safely, safety\n   related_drugs: fentanyl, morphine, remifentanil\n   snippet: both pancuronium and alcuronium have been classified as unsafe by some authors, they have been widely used by many anesthetists without harm. Atracurium[ 21 22 32 ] and vecuronium[ 33 ] have been used safely in small numbers of patients despite some experimental evidence for porphyrinogenicity. We safely used atracurium in the current patient. Morphine and its analogues (including codeine) are of proven safety, and fentanyl has been shown to be safe both in chick embryo culture models and in clinical use. Alfentanil has also been used frequently with no reported complications. More recently, fentanyl[ 16 ] and sufentanil[ 15 ] have been used as a major component, in combination with isoflurane and atracurium, in open heart surgery without a significant problem.[ 21 ] Cardiac surgical reports also refer to the safe use of heparin. Pethidine (meperidine) has a proven track record of safety despite a single case report implicating it in a porphyric attack.[ 34 ] There is evidence both for[ 35 ] and against[ 36 ] the porphyrinogenicity of pentazocine in experimental systems.[ 37 ] Of the nonopiate analgesics, aspirin, acetaminophen, indomethacin and naproxen have proven safe. However, CPB is\n60. snippet_id: 35\n   article_id: article:27052088\n   article_title: Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.\n   classification: risk\n   cues: complication, complications, no reported complications, safe, safely, safety\n   related_drugs: desflurane, halothane, isoflurane, sevoflurane, volatile agents, volatile anaesthetics\n   snippet: en widely used by many anesthetists without harm. Atracurium[ 21 22 32 ] and vecuronium[ 33 ] have been used safely in small numbers of patients despite some experimental evidence for porphyrinogenicity. We safely used atracurium in the current patient. Morphine and its analogues (including codeine) are of proven safety, and fentanyl has been shown to be safe both in chick embryo culture models and in clinical use. Alfentanil has also been used frequently with no reported complications. More recently, fentanyl[ 16 ] and sufentanil[ 15 ] have been used as a major component, in combination with isoflurane and atracurium, in open heart surgery without a significant problem.[ 21 ] Cardiac surgical reports also refer to the safe use of heparin. Pethidine (meperidine) has a proven track record of safety despite a single case report implicating it in a porphyric attack.[ 34 ] There is evidence both for[ 35 ] and against[ 36 ] the porphyrinogenicity of pentazocine in experimental systems.[ 37 ] Of the nonopiate analgesics, aspirin, acetaminophen, indomethacin and naproxen have proven safe. However, CPB is a specific problem,[ 13 14 15 16 ] we used it uneventfully. Blood loss, with its consequent inc\n\nReturn only JSON."
        }
      ],
      "snippets": [
        {
          "pmid": "34661997",
          "snippet_id": 1,
          "drug": "atropine",
          "classification": "risk",
          "snippet_text": "xifloxacin Nitrofurantoin Doxycycline Rifampicin Gentamicin Sulfonamides , Trimethoprim Penicillins a Vancomycin Aciclovir, Ganciclovir, Valaciclovir Antiepileptic therapy Barbiturates (Phenobarbital) Gabapentin Carbamazepin Lacosamide (Valproic acid) Lamotrigine Phenytoin Levetiracetam Primidone Lorazepam, Midazolam (Oxcarbazepine) Magnesium Topiramate Pregabalin Propofol Neuroleptics Melperone Chlorpromazine Haloperidol Levomepromazin Antidepressants (Imipramin) Amitriptyline Duloxetine Mirtazapine SSRIs Steroids (Dexamethasone) Prednisolone (Methylprednisolon) Triamcinolone Others Hormones Atropine Progesterone Betablockers Catecholamines Note : All drugs are classified after their safety in systemic use in a patient. The list is not comprehensive and the authors advise to check in the following databases for updated information on a drug before prescription to a patient with porphyria: http://www.drugs\u2010porphyria.org or http://www.porphyriafoundation.com/drug\u2010database or http://porphyriadrugs.com Drugs in bold are regarded as unsafe and have reportedly triggered attacks. Drugs in parenthesis either have conflicting records in the two databases or are regarded as possibly unsafe or only",
          "snippet_score": 9.2383,
          "cues": [
            "trigger",
            "triggered",
            "unsafe",
            "safe",
            "safety"
          ],
          "article_rank": 3,
          "article_score": 5.48,
          "citation_url": "https://doi.org/10.1002/brb3.2389",
          "article_title": "Acute porphyrias - A neurological perspective.",
          "content_source": "pmc-full-text",
          "token_estimate": 174
        },
        {
          "pmid": "34661997",
          "snippet_id": 5,
          "drug": "lorazepam",
          "classification": "safety",
          "snippet_text": "TIONS SAFE MEDICATIONS Pain killers Metamizole/Dipyrone ASS, Ibuprofen, Paracetamol Morphine, Hydromorphone Antiemetics Dimenhydrinate MCP Ondansetron Antibiotics/antivirals Clindamycin Azithromycin Erythromycin , (Clarithromycin) Carbapenems (Flucloxacillin) Cephalosporins Isoniazid Ciprofloxacin, Moxifloxacin Nitrofurantoin Doxycycline Rifampicin Gentamicin Sulfonamides , Trimethoprim Penicillins a Vancomycin Aciclovir, Ganciclovir, Valaciclovir Antiepileptic therapy Barbiturates (Phenobarbital) Gabapentin Carbamazepin Lacosamide (Valproic acid) Lamotrigine Phenytoin Levetiracetam Primidone Lorazepam, Midazolam (Oxcarbazepine) Magnesium Topiramate Pregabalin Propofol Neuroleptics Melperone Chlorpromazine Haloperidol Levomepromazin Antidepressants (Imipramin) Amitriptyline Duloxetine Mirtazapine SSRIs Steroids (Dexamethasone) Prednisolone (Methylprednisolon) Triamcinolone Others Hormones Atropine Progesterone Betablockers Catecholamines Note : All drugs are classified after their safety in systemic use in a patient. The list is not comprehensive and the authors advise to check in the following databases for updated information on a drug before prescription to a patient with porphyria: http",
          "snippet_score": 8.7383,
          "cues": [
            "safe",
            "safety"
          ],
          "article_rank": 3,
          "article_score": 5.48,
          "citation_url": "https://doi.org/10.1002/brb3.2389",
          "article_title": "Acute porphyrias - A neurological perspective.",
          "content_source": "pmc-full-text",
          "token_estimate": 163
        },
        {
          "pmid": "34661997",
          "snippet_id": 2,
          "drug": "dexamethasone",
          "classification": "risk",
          "snippet_text": "mycin) Carbapenems (Flucloxacillin) Cephalosporins Isoniazid Ciprofloxacin, Moxifloxacin Nitrofurantoin Doxycycline Rifampicin Gentamicin Sulfonamides , Trimethoprim Penicillins a Vancomycin Aciclovir, Ganciclovir, Valaciclovir Antiepileptic therapy Barbiturates (Phenobarbital) Gabapentin Carbamazepin Lacosamide (Valproic acid) Lamotrigine Phenytoin Levetiracetam Primidone Lorazepam, Midazolam (Oxcarbazepine) Magnesium Topiramate Pregabalin Propofol Neuroleptics Melperone Chlorpromazine Haloperidol Levomepromazin Antidepressants (Imipramin) Amitriptyline Duloxetine Mirtazapine SSRIs Steroids (Dexamethasone) Prednisolone (Methylprednisolon) Triamcinolone Others Hormones Atropine Progesterone Betablockers Catecholamines Note : All drugs are classified after their safety in systemic use in a patient. The list is not comprehensive and the authors advise to check in the following databases for updated information on a drug before prescription to a patient with porphyria: http://www.drugs\u2010porphyria.org or http://www.porphyriafoundation.com/drug\u2010database or http://porphyriadrugs.com Drugs in bold are regarded as unsafe and have reportedly triggered attacks. Drugs in parenthesis either have conflicting",
          "snippet_score": 9.2383,
          "cues": [
            "trigger",
            "triggered",
            "unsafe",
            "safe",
            "safety"
          ],
          "article_rank": 3,
          "article_score": 5.48,
          "citation_url": "https://doi.org/10.1002/brb3.2389",
          "article_title": "Acute porphyrias - A neurological perspective.",
          "content_source": "pmc-full-text",
          "token_estimate": 166
        },
        {
          "pmid": "34661997",
          "snippet_id": 6,
          "drug": "midazolam",
          "classification": "safety",
          "snippet_text": "MEDICATIONS Pain killers Metamizole/Dipyrone ASS, Ibuprofen, Paracetamol Morphine, Hydromorphone Antiemetics Dimenhydrinate MCP Ondansetron Antibiotics/antivirals Clindamycin Azithromycin Erythromycin , (Clarithromycin) Carbapenems (Flucloxacillin) Cephalosporins Isoniazid Ciprofloxacin, Moxifloxacin Nitrofurantoin Doxycycline Rifampicin Gentamicin Sulfonamides , Trimethoprim Penicillins a Vancomycin Aciclovir, Ganciclovir, Valaciclovir Antiepileptic therapy Barbiturates (Phenobarbital) Gabapentin Carbamazepin Lacosamide (Valproic acid) Lamotrigine Phenytoin Levetiracetam Primidone Lorazepam, Midazolam (Oxcarbazepine) Magnesium Topiramate Pregabalin Propofol Neuroleptics Melperone Chlorpromazine Haloperidol Levomepromazin Antidepressants (Imipramin) Amitriptyline Duloxetine Mirtazapine SSRIs Steroids (Dexamethasone) Prednisolone (Methylprednisolon) Triamcinolone Others Hormones Atropine Progesterone Betablockers Catecholamines Note : All drugs are classified after their safety in systemic use in a patient. The list is not comprehensive and the authors advise to check in the following databases for updated information on a drug before prescription to a patient with porphyria: http://www.drug",
          "snippet_score": 8.7383,
          "cues": [
            "safe",
            "safety"
          ],
          "article_rank": 3,
          "article_score": 5.48,
          "citation_url": "https://doi.org/10.1002/brb3.2389",
          "article_title": "Acute porphyrias - A neurological perspective.",
          "content_source": "pmc-full-text",
          "token_estimate": 161
        },
        {
          "pmid": "34661997",
          "snippet_id": 3,
          "drug": "morphine",
          "classification": "risk",
          "snippet_text": "base ) (USA). Classification is usually based on few reports and this may lead to contradictory information in some cases. A privately run website displays the information of both databases as an overview for each drug ( http://porphyriadrugs.com ). Table 4 gives an overview of the safety of drugs commonly used in neurology and psychiatry, but is not exhaustive (Albers & Fink, 2004 ; Anderson et al., 2005 ; Crimlisk, 1997 ; Windebank & Bonkovsky, 2005 ). TABLE 4 List of safe and unsafe medications UNSAFE MEDICATIONS SAFE MEDICATIONS Pain killers Metamizole/Dipyrone ASS, Ibuprofen, Paracetamol Morphine, Hydromorphone Antiemetics Dimenhydrinate MCP Ondansetron Antibiotics/antivirals Clindamycin Azithromycin Erythromycin , (Clarithromycin) Carbapenems (Flucloxacillin) Cephalosporins Isoniazid Ciprofloxacin, Moxifloxacin Nitrofurantoin Doxycycline Rifampicin Gentamicin Sulfonamides , Trimethoprim Penicillins a Vancomycin Aciclovir, Ganciclovir, Valaciclovir Antiepileptic therapy Barbiturates (Phenobarbital) Gabapentin Carbamazepin Lacosamide (Valproic acid) Lamotrigine Phenytoin Levetiracetam Primidone Lorazepam, Midazolam (Oxcarbazepine) Magnesium Topiramate Pregabalin Propofol Neuroleptics M",
          "snippet_score": 9.0383,
          "cues": [
            "unsafe",
            "safe",
            "safety"
          ],
          "article_rank": 3,
          "article_score": 5.48,
          "citation_url": "https://doi.org/10.1002/brb3.2389",
          "article_title": "Acute porphyrias - A neurological perspective.",
          "content_source": "pmc-full-text",
          "token_estimate": 189
        },
        {
          "pmid": "34661997",
          "snippet_id": 7,
          "drug": "propofol",
          "classification": "safety",
          "snippet_text": "n, Paracetamol Morphine, Hydromorphone Antiemetics Dimenhydrinate MCP Ondansetron Antibiotics/antivirals Clindamycin Azithromycin Erythromycin , (Clarithromycin) Carbapenems (Flucloxacillin) Cephalosporins Isoniazid Ciprofloxacin, Moxifloxacin Nitrofurantoin Doxycycline Rifampicin Gentamicin Sulfonamides , Trimethoprim Penicillins a Vancomycin Aciclovir, Ganciclovir, Valaciclovir Antiepileptic therapy Barbiturates (Phenobarbital) Gabapentin Carbamazepin Lacosamide (Valproic acid) Lamotrigine Phenytoin Levetiracetam Primidone Lorazepam, Midazolam (Oxcarbazepine) Magnesium Topiramate Pregabalin Propofol Neuroleptics Melperone Chlorpromazine Haloperidol Levomepromazin Antidepressants (Imipramin) Amitriptyline Duloxetine Mirtazapine SSRIs Steroids (Dexamethasone) Prednisolone (Methylprednisolon) Triamcinolone Others Hormones Atropine Progesterone Betablockers Catecholamines Note : All drugs are classified after their safety in systemic use in a patient. The list is not comprehensive and the authors advise to check in the following databases for updated information on a drug before prescription to a patient with porphyria: http://www.drugs\u2010porphyria.org or http://www.porphyriafoundation.com/dru",
          "snippet_score": 8.7383,
          "cues": [
            "safe",
            "safety"
          ],
          "article_rank": 3,
          "article_score": 5.48,
          "citation_url": "https://doi.org/10.1002/brb3.2389",
          "article_title": "Acute porphyrias - A neurological perspective.",
          "content_source": "pmc-full-text",
          "token_estimate": 158
        },
        {
          "pmid": "34661997",
          "snippet_id": 4,
          "drug": "ondansetron",
          "classification": "risk",
          "snippet_text": "ports and this may lead to contradictory information in some cases. A privately run website displays the information of both databases as an overview for each drug ( http://porphyriadrugs.com ). Table 4 gives an overview of the safety of drugs commonly used in neurology and psychiatry, but is not exhaustive (Albers & Fink, 2004 ; Anderson et al., 2005 ; Crimlisk, 1997 ; Windebank & Bonkovsky, 2005 ). TABLE 4 List of safe and unsafe medications UNSAFE MEDICATIONS SAFE MEDICATIONS Pain killers Metamizole/Dipyrone ASS, Ibuprofen, Paracetamol Morphine, Hydromorphone Antiemetics Dimenhydrinate MCP Ondansetron Antibiotics/antivirals Clindamycin Azithromycin Erythromycin , (Clarithromycin) Carbapenems (Flucloxacillin) Cephalosporins Isoniazid Ciprofloxacin, Moxifloxacin Nitrofurantoin Doxycycline Rifampicin Gentamicin Sulfonamides , Trimethoprim Penicillins a Vancomycin Aciclovir, Ganciclovir, Valaciclovir Antiepileptic therapy Barbiturates (Phenobarbital) Gabapentin Carbamazepin Lacosamide (Valproic acid) Lamotrigine Phenytoin Levetiracetam Primidone Lorazepam, Midazolam (Oxcarbazepine) Magnesium Topiramate Pregabalin Propofol Neuroleptics Melperone Chlorpromazine Haloperidol Levomepromazin Antidep",
          "snippet_score": 9.0383,
          "cues": [
            "unsafe",
            "safe",
            "safety"
          ],
          "article_rank": 3,
          "article_score": 5.48,
          "citation_url": "https://doi.org/10.1002/brb3.2389",
          "article_title": "Acute porphyrias - A neurological perspective.",
          "content_source": "pmc-full-text",
          "token_estimate": 183
        },
        {
          "pmid": "34661997",
          "snippet_id": 14,
          "drug": "levetiracetam",
          "classification": "safety",
          "snippet_text": "wed speech. This had progressed within days to aggressive/erratic behavior and a confusional state with incoherent speech. She was brought to an emergency room and admitted neurologically. Initial laboratory investigations, brain CT and MRI and CSF results were unremarkable. Investigations for infectious causes were negative. A second MRI revealed T2\u2010hyperintensities bilaterally in the basal ganglia without contrast enhancement (Figure SI). Autoimmune encephalitis was suspected and high\u2010dose steroids were started. Because of two episodes with loss of consciousness, seizures were suspected and levetiracetam was started to prevent seizures before transfer to our NICU was organized. Upon admission to our ward, the patient was awake, but confused. Neurological examination revealed severe dysarthria, dysphagia, and a bradykinetic syndrome. She was unable to stand or walk, muscle strength was generally slightly reduced, deep tendon reflexes normal. Blood pressure was within the normal range. We continued high\u2010dose steroids (methylprednisolone 1 g intravenously for 5 days) and repeated the lumbar puncture. Again, basic CSF results were unremarkable. EEG showed diffuse slowing of activity. MRI findings",
          "snippet_score": 8.0383,
          "cues": [
            "prevent"
          ],
          "article_rank": 3,
          "article_score": 5.48,
          "citation_url": "https://doi.org/10.1002/brb3.2389",
          "article_title": "Acute porphyrias - A neurological perspective.",
          "content_source": "pmc-full-text",
          "token_estimate": 213
        },
        {
          "pmid": "34661997",
          "snippet_id": 8,
          "drug": "levetiracetam",
          "classification": "risk",
          "snippet_text": "tein et al., 2017 ). Thrombophlebitis is the most common side\u2010effect and rarely vein obliteration occurs. Hemin acts as a transcription factor that reduces expression of the rate\u2010limiting hepatic enzyme ALAS1. This leads to down\u2010regulation of the entire pathway and reduction of toxic metabolites. For desperate cases with severe recurrent attacks, liver transplant has been performed leading to clinical and biochemical remission (Seth et al., 2007 ; Singal et al., 2014 ; Soonawalla et al., 2004 ; Stolzel et al., 2019 ). Antiepileptic therapy can be done with Gabapentin, Lacosamide, Lamotrigine, Levetiracetam, Lorazepam, Midazolam, and Pregabalin. Addition of magnesium and propofol has been successful (Bhatia et al., 2008 ; Dawit et al., 2019 ; Engelhardt et al., 2004 ; Stolzel et al., 2019 ; Zaatreh, 2005 ). Unsafe antiepileptics that can worsen AHP should be strictly avoided, especially barbiturates, but also valproic acid and carbamazepine. For the full list of safe and unsafe medications, please refer to Table 4 . Neuropathic pain is a common problem during acute attacks, but also during recovery. Pain management can be done with ASS, Ibuprofen, Paracetamol, opioids and with gabapentin or preg",
          "snippet_score": 8.6383,
          "cues": [
            "avoid",
            "avoided",
            "toxic",
            "unsafe",
            "safe"
          ],
          "article_rank": 3,
          "article_score": 5.48,
          "citation_url": "https://doi.org/10.1002/brb3.2389",
          "article_title": "Acute porphyrias - A neurological perspective.",
          "content_source": "pmc-full-text",
          "token_estimate": 235
        },
        {
          "pmid": "34661997",
          "snippet_id": 15,
          "drug": "opioids",
          "classification": "safety",
          "snippet_text": "al., 1984 ), or small demyelinating lesions (Gibson & Goldberg, 1956 ), ischemic lesions, (Hierons, 1957 ; Suarez et al., 1997 ), and selective reduction of hypothalamic neurons (Suarez et al., 1997 ) have been reported. None of these findings are correlated with imaging studies and are therefore difficult to interpret. 8 TREATMENT Treatment of acute attacks consists of four major points (Figure 3 ): First, identification of precipitating factors and their removal if possible. Porphyrinogenic drugs should be stopped. Second, symptomatic supportive therapy, including adequate pain management (opioids are usually indicated), correction of electrolyte imbalances, and intensive care management, if needed. Third, normocaloric nutrition high in carbohydrates and/or glucose infusions. Sodium levels need to be monitored closely. Finally, severely ill patients should receive hemin (3 mg/kg body weight [up to a maximum of 250 mg] daily for four consecutive days) (Stein et al., 2017 ; Stolzel et al., 2019 ). Hemin is indicated in patients with AHP and any neurological symptoms, in those requiring intensive care and in some cases, for pain management. Heme arginate can be reconstituted in 100 ml nor",
          "snippet_score": 8.0383,
          "cues": [
            "indicated"
          ],
          "article_rank": 3,
          "article_score": 5.48,
          "citation_url": "https://doi.org/10.1002/brb3.2389",
          "article_title": "Acute porphyrias - A neurological perspective.",
          "content_source": "pmc-full-text",
          "token_estimate": 229
        },
        {
          "pmid": "34661997",
          "snippet_id": 12,
          "drug": "opioids",
          "classification": "risk",
          "snippet_text": "osamide, Lamotrigine, Levetiracetam, Lorazepam, Midazolam, and Pregabalin. Addition of magnesium and propofol has been successful (Bhatia et al., 2008 ; Dawit et al., 2019 ; Engelhardt et al., 2004 ; Stolzel et al., 2019 ; Zaatreh, 2005 ). Unsafe antiepileptics that can worsen AHP should be strictly avoided, especially barbiturates, but also valproic acid and carbamazepine. For the full list of safe and unsafe medications, please refer to Table 4 . Neuropathic pain is a common problem during acute attacks, but also during recovery. Pain management can be done with ASS, Ibuprofen, Paracetamol, opioids and with gabapentin or pregabalin. In November 2019, the FDA, and in March 2020, the EMA approved a new therapeutic for patients with recurrent attacks: givosiran (Alnylam Pharmaceuticals, Cambridge, MA, USA) is a small interfering RNA (siRNA) that neutralizes excess ALAS1 mRNA in hepatocytes (Sardh et al., 2019 ; Stolzel et al., 2019 ). Recently published results of the ENVISION\u2010trial ( NCT03338816 ), a phase III, multicenter, placebo\u2010controlled, randomized controlled trial, showed reduction of urinary ALA levels and of the number of acute attacks (Balwani et al., 2020 ). The siRNA is inject",
          "snippet_score": 8.5383,
          "cues": [
            "avoid",
            "avoided",
            "unsafe",
            "safe"
          ],
          "article_rank": 3,
          "article_score": 5.48,
          "citation_url": "https://doi.org/10.1002/brb3.2389",
          "article_title": "Acute porphyrias - A neurological perspective.",
          "content_source": "pmc-full-text",
          "token_estimate": 234
        },
        {
          "pmid": "36028858",
          "snippet_id": 20,
          "drug": "opioids",
          "classification": "safety",
          "snippet_text": "s with or without prior hemin prophylaxis use. a Analgesic use was collected in an electronic diary up to Month 12 Fig. 8 Mean change from baseline in SF-12 PCS scores in patients with or without prior hemin prophylaxis use. Higher scores represent improvement in that summary or domain Discussion This study used data from the ENVISION trial to demonstrate the severe disease burden associated with recurrent AHP. At baseline, more than half of ENVISION trial patients were experiencing chronic symptoms between attacks, including nausea, fatigue, and pain, and more than one quarter had been using opioids daily or on most days [ 35 ]. We also found a positive correlation between time since diagnosis and AHP disease severity, further highlighting the need to treat patients early with effective therapy. These results showed that the RNAi therapeutic givosiran is effective in patients with recurrent AHP regardless of prior hemin use, and that it reduces analgesic use and pain both during and between porphyria attacks. Overall disease burden in the ENVISION trial population was similar to that observed in the recent EXPLORE study, a prospective, multinational, natural history study of patients wit",
          "snippet_score": 5.7244,
          "cues": [
            "effective"
          ],
          "article_rank": 12,
          "article_score": 2.86,
          "citation_url": "https://doi.org/10.1186/s13023-022-02463-x",
          "article_title": "Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION study.",
          "content_source": "pmc-full-text",
          "token_estimate": 238
        },
        {
          "pmid": "36642627",
          "snippet_id": 16,
          "drug": "benzodiazepines",
          "classification": "risk",
          "snippet_text": "tivated receptor \u03b3 coactivator 1- \u03b1 , which induces expression of ALAS1. 35 Acute attacks can be associated with hyponatremia and hypomagnesemia due to a combination of hypovolemia and syndrome of inappropriate antidiuretic hormone secretion. 36 , 37 Electrolytes should be monitored during acute attacks and hyponatremia corrected slowly if present. In acute attacks that present with seizures, management should be approached with caution because many anticonvulsant medications, such as barbiturates, hydantoins, carbamazepine, and valproic acid, are contraindicated in AHP. 38 Magnesium sulfate, benzodiazepines, and levetiracetam appear to be safe options in the context of AHP. Best Practice Advice 6: Patients should be counseled to avoid identifiable triggers that may precipitate acute attacks, such as alcohol and porphyrinogenic medications. The low penetrance of AHPs indicates the likely presence of additional factors that are required for clinical symptoms, including precipitating factors and other poorly defined modifying genes and/or epigenetic factors. 39 , 40 Sex hormones, in particular progesterone, are known to precipitate attacks. Other common precipitating factors include medications tha",
          "snippet_score": 7.9832,
          "cues": [
            "avoid",
            "contraindicated",
            "caution",
            "precipitate",
            "trigger",
            "safe",
            "safe option",
            "indicated"
          ],
          "article_rank": 5,
          "article_score": 4.510000000000001,
          "citation_url": "https://doi.org/10.1053/j.gastro.2022.11.034",
          "article_title": "AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review.",
          "content_source": "pmc-full-text",
          "token_estimate": 213
        },
        {
          "pmid": "36028858",
          "snippet_id": 21,
          "drug": "opioids",
          "classification": "safety",
          "snippet_text": "orst pain scores above baseline than placebo recipients, and nearly 50% fewer days with severe pain during attack-free periods. Pain is one of the key factors associated with diminished QOL among patients with AHP [ 11 ]. The SF-12 PCS scores increased by 10.0 and 8.9 points in the open-label extension in the placebo crossover and continuous givosiran groups, respectively. The proportion of patients who used opioid analgesics during attacks was 12% lower in the givosiran group compared with the placebo group during attacks, and 13% lower during attack-free periods. Given that long-term use of opioids is associated with tolerance, dependence, and addiction, a reduction in use of these medications is clinically relevant. Furthermore, evidence for the efficacy of opioids in the management of chronic non\u2013cancer-related pain is limited. A 30-month open-label extension phase of ENVISION was completed in May 2021. Results to date support long-term maintenance of benefit with givosiran. A strength of our study is that, unlike the observational EXPLORE study [ 11 ], all potential porphyria attacks occurring in the ENVISION trial were adjudicated by the investigator. A limitation of our study was t",
          "snippet_score": 5.7244,
          "cues": [
            "efficacy"
          ],
          "article_rank": 12,
          "article_score": 2.86,
          "citation_url": "https://doi.org/10.1186/s13023-022-02463-x",
          "article_title": "Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION study.",
          "content_source": "pmc-full-text",
          "token_estimate": 234
        },
        {
          "pmid": "36028858",
          "snippet_id": 19,
          "drug": "opioid",
          "classification": "risk",
          "snippet_text": "ical comparisons were undertaken. Results A total of 94 patients with AHP were enrolled in the ENVISION trial, of whom 46 were assigned to receive placebo and 48 to receive givosiran [ 35 ]. The median (range) age was 37.5 (19\u201265) years, and the mean (SD) years since diagnosis was 9.7 (10.0) [ 35 ]. The median (range) AAR in the 6 months prior to study randomization was 8.0 (0\u201346) [ 35 ]. At baseline, 52% of patients were experiencing chronic symptoms of porphyria, defined as symptoms between attacks daily or on most days [ 35 ]. Chronic symptoms included nausea, fatigue, and pain (Table 1 ). Opioid analgesics were used daily or on most days between attacks in 29% of patients [ 35 ]. Mean daily worst fatigue score was above 4, on a numerical rating scale of 0\u201310, in both treatment groups. Table 1 Chronic symptoms in ENVISION trial participants at baseline Characteristic Placebo (n = 46) Givosiran (n = 48) Total (N = 94) Prior chronic symptoms, n (%) 26 (57) 23 (48) 49 (52) Prior chronic opioid use, n (%) 13 (28) 14 (29) 27 (29) Nausea symptoms (medical history), n (%) 10 (22) 7 (15) 17 (18) Fatigue (medical history), n (%) 4 (9) 1 (2) 5 (5) Daily worst nausea score, weekly mean (SD) 1.9",
          "snippet_score": 5.9244,
          "cues": [
            "condition-match"
          ],
          "article_rank": 12,
          "article_score": 2.86,
          "citation_url": "https://doi.org/10.1186/s13023-022-02463-x",
          "article_title": "Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION study.",
          "content_source": "pmc-full-text",
          "token_estimate": 273
        },
        {
          "pmid": "36575494",
          "snippet_id": 46,
          "drug": "morphine",
          "classification": "safety",
          "snippet_text": "ted (169 mEq/L). So unilateral renal artery stenosis (RAS) was suspected. To confirm RAS, abdominal doppler and pelvic CT investigations were requested. The CT and Doppler report was normal, excluding the diagnosis of renal artery stenosis. Similarly, arterial blood gas (ABG) analysis was normal, which was against the metabolic alkalosis seen in Gitelman syndrome. To rule out an autoimmune cause, an antinuclear antibody (ANA) was sent; however, it also came out to be negative (Additional file 1 ). The patient's clinical presentation, including severe abdominal pain, was not relieved even with morphine. After all these thorough investigations, severe uncorrected hyponatremia, severe body ache especially in the lower limbs, and precipitation of the symptoms following fasting ushered our conjectures toward the diagnosis of porphyria-related disorders. With the suspicion of porphyria, a urine sample was sent to Biochemistry Laboratory. Watson-Schwartz test was positive (Fig. 1 ); hence, it indicated the presence of porphobilinogen in urine substantiating the diagnosis of acute porphyria crisis. The urine color also darkened on exposure to light (Fig. 2 ). The symptoms were gradually relieved w",
          "snippet_score": 4.2244,
          "cues": [
            "indicated"
          ],
          "article_rank": 18,
          "article_score": 2.46,
          "citation_url": "https://doi.org/10.1186/s13256-022-03708-w",
          "article_title": "Porphyria: a case report.",
          "content_source": "pmc-full-text",
          "token_estimate": 223
        },
        {
          "pmid": "27052088",
          "snippet_id": 26,
          "drug": "sevoflurane",
          "classification": "risk",
          "snippet_text": "nique and also indicate active disease, with increased risk of acute crisis. Classifying drugs as porphyria safe or unsafe is too simplistic; the duration of exposure and the absolute dose dictate whether an acute crisis would be triggered or not and how would the severity be like. Multiple confounding factors in the perioperative period mean that the trigger for a crisis may be unclear. Propofol has been considered as a safe drug for both induction and maintenance of anesthesia in the patients with AIP.[ 17 18 19 ] Modern inhalation agents are generally considered safe in porphyric patients. Sevoflurane has been reported as a safe agent for both induction and maintenance of anesthesia. Safe use of isoflurane has also been reported;[ 20 21 22 ] therefore, it should probably be classified as safe, although further information needs to be obtained. Enflurane has been shown to induce porphyrin synthesis in animal models[ 20 ] but has been used safely in patients. Reports of a possible association of halothane with crises contradict both experimental and clinical experience.[ 23 24 ] Preoperative starvation should be minimized; if a prolonged fast is unavoidable, a dextrose\u2013saline infusion should",
          "snippet_score": 5.6462,
          "cues": [
            "avoid",
            "risk",
            "risk of",
            "trigger",
            "triggered",
            "unsafe",
            "safe",
            "safely"
          ],
          "article_rank": 14,
          "article_score": 2.76,
          "citation_url": "https://doi.org/10.4103/0971-9784.179623",
          "article_title": "Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.",
          "content_source": "pmc-full-text",
          "token_estimate": 240
        },
        {
          "pmid": "27052088",
          "snippet_id": 43,
          "drug": "midazolam",
          "classification": "safety",
          "snippet_text": "e mobile veg on anterior leaflet of tricuspid valve commissure (TVC) with severe TR was also demonstrated in his transthoracic echocardiography. After starting antibiotic therapy and removing the port, the patient underwent TV replacement. In the day of surgery, prior to induction, all standard monitorings were applied; radial artery line and subclavian central venous (CV) line was also indwelled after induction. Premedication was consisted of incremental doses of fentanyl and midazolam. We used propofol and atracurium for induction. Maintenance of anesthesia was done by propofol, atracurium, midazolam and fentanyl. Following sternotomy and heparinization, cardiopulmonary bypass (CPB) was initiated. The patient cooled to 32\u201334\u00b0C. Myocardial protection was provided by hypothermic antegrade blood cardioplegic. The TV was replaced. After 70 min of CPB, separation from CPB was achieved, and heparin was reversed by protamine. Rewarming and weaning from CPB was uneventful. Four units of packed cell were given during CPB; Hct was maintained about 30%. Postoperatively, in Intensive Care Unit (ICU), the patient was extubated in 6 h. We started parenteral carbohydrate as dextrose 50% to prevent AIP a",
          "snippet_score": 4.1462,
          "cues": [
            "prevent"
          ],
          "article_rank": 14,
          "article_score": 2.76,
          "citation_url": "https://doi.org/10.4103/0971-9784.179623",
          "article_title": "Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.",
          "content_source": "pmc-full-text",
          "token_estimate": 222
        },
        {
          "pmid": "36028858",
          "snippet_id": 22,
          "drug": "fentanyl",
          "classification": "risk",
          "snippet_text": "ics at baseline Placebo (n = 46) Givosiran (n = 48) Total (N = 94) Antidepressants Benzodiazepine derivatives 10 (22) 10 (21) 20 (21) Benzodiazepine-related drugs 3 (7) 4 (8) 7 (7) Other anti-depressants 4 (9) 9 (19) 13 (14) SSRIs 2 (4) 4 (8) 6 (6) Antihypertensives ACE inhibitors 2 (4) 1 (2) 3 (3) Angiotensin II receptor antagonists 3 (7) 2 (4) 5 (5) Beta blocking agents, non-selective 1 (2) 3 (6) 4 (4) Beta blocking agents, selective 5 (11) 7 (15) 12 (13) Antiemetics 5HT3 antagonists 12 (26) 12 (25) 24 (26) Pain medications Natural opium alkaloids 27 (59) 23 (48) 50 (53) Opioid anesthetics (fentanyl) 2 (4) 0 2 (2) Opioid/non-opioid combinations 2 (4) 5 (10) 7 (7) Opium alkaloid derivatives 2 (4) 0 2 (2) Other opioids 8 (17) 6 (13) 14 (15) Other analgesics and antipyretics 10 (22) 13 (27) 23 (25) SSRI selective serotonin reuptake inhibitor, ACE angiotensin-converting enzyme, 5HT3 5-hydroxytryptamine A high proportion of patients had received prior hemin prophylaxis (40%) [ 11 ], with many experiencing hemin-related complications, as well as ongoing damage caused by AHP (Fig. 2 ). Complications related to central venous access included thrombosis (8%), infection (18%), and catheter occlusi",
          "snippet_score": 5.4244,
          "cues": [
            "complication",
            "complications"
          ],
          "article_rank": 12,
          "article_score": 2.86,
          "citation_url": "https://doi.org/10.1186/s13023-022-02463-x",
          "article_title": "Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION study.",
          "content_source": "pmc-full-text",
          "token_estimate": 251
        },
        {
          "pmid": "29383964",
          "snippet_id": 54,
          "drug": "opioid",
          "classification": "safety",
          "snippet_text": "Despite medical advances, the diagnosis and management of acute intermittent porphyria continues to be challenging. Acute pain is one of the most important clinical manifestations in acute intermittent porphyria, but management and pain assessment have been poorly studied in these patients. The lack of information and evidence based recommendations regarding these topics in the medical literature is certainly surprising. Furthermore, pain management is discussed based on extrapolating concepts adopted for other pain syndromes. An important arsenal of medications, including reportedly safe opioid and non-opioid analgesics, is available for use in this type of patient. In addition to conducting an extensive review of the current literature, the present article aims to show the general aspects of a disease that generates a challenge for the clinician, emphasizing what is related to pain as a cardinal symptom and to create awareness about the need for studies supporting the development of guidelines, based on evidence obtained from analgesic management in patients presenting with this disorder. A systematic assessment directed at understanding the physiopathological processes underlying",
          "snippet_score": 1.679,
          "cues": [
            "safe"
          ],
          "article_rank": 51,
          "article_score": 0.6000000000000001,
          "citation_url": "https://doi.org/10.1080/03007995.2018.1435521",
          "article_title": "Acute intermittent porphyria: general aspects with focus on pain.",
          "content_source": "pubmed-abstract",
          "token_estimate": 215
        },
        {
          "pmid": "27052088",
          "snippet_id": 28,
          "drug": "succinylcholine",
          "classification": "risk",
          "snippet_text": "phyric crisis had their symptoms worsened following induction of anesthesia with thiopental.[ 27 ] Thus, although thiopental will not always precipitate a crisis, all barbiturates must be considered contraindicated in porphyric patients. Etomidate is potentially porphyrinogenic in animal models[ 17 ] at least one human porphyric crises has been reported after its use.[ 28 ] etomidate should probably be considered unsafe. Although there are some reports showing ketamine's potentiality in triggering AIP crisis,[ 24 ] it might be safe because it has been used safely in quiescent AIP.[ 24 29 30 ] Succinylcholine has been used for many years and has been proven to be safe, as has tubocurarine.[ 31 ] Though both pancuronium and alcuronium have been classified as unsafe by some authors, they have been widely used by many anesthetists without harm. Atracurium[ 21 22 32 ] and vecuronium[ 33 ] have been used safely in small numbers of patients despite some experimental evidence for porphyrinogenicity. We safely used atracurium in the current patient. Morphine and its analogues (including codeine) are of proven safety, and fentanyl has been shown to be safe both in chick embryo culture models and in clinica",
          "snippet_score": 5.2462,
          "cues": [
            "contraindicated",
            "precipitate",
            "trigger",
            "triggering",
            "unsafe",
            "worsened",
            "safe",
            "safely",
            "safety",
            "indicated"
          ],
          "article_rank": 14,
          "article_score": 2.76,
          "citation_url": "https://doi.org/10.4103/0971-9784.179623",
          "article_title": "Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.",
          "content_source": "pmc-full-text",
          "token_estimate": 240
        },
        {
          "pmid": "27871506",
          "snippet_id": 84,
          "drug": "propofol",
          "classification": "safety",
          "snippet_text": "Porphyria is caused by disorders of enzymes that synthetize porphyrins. Both elective and emergency surgical procedures on patient suffering from porphyria may provoke acute symptoms. These patients require special anesthetic management since some of commonly used anesthetic agents may also induce acute manifestation of porphyria. We present the case of 53-year-old woman previously diagnosed with porphyria who underwent elective laparoscopic cholecystectomy. Propofol-based total intravenous anesthesia with target-controlled infusion was used. Such conduct proved to be safe regarding clinical symptoms, although biochemical markers were slightly elevated after procedure. Propofol seems to be the safest hypnotic drug to use in porphyria; however, special care should be taken is such cases.",
          "snippet_score": 1.4362,
          "cues": [
            "safe"
          ],
          "article_rank": 155,
          "article_score": 0.4,
          "citation_url": "https://doi.org/10.1016/j.jclinane.2016.06.014",
          "article_title": "Elective cholecystectomy performed on patient with variegate porphyria-Propofol-based total intravenous anesthesia with target-controlled infusion.",
          "content_source": "pubmed-abstract",
          "token_estimate": 143
        },
        {
          "pmid": "27052088",
          "snippet_id": 29,
          "drug": "atracurium",
          "classification": "risk",
          "snippet_text": "tentially porphyrinogenic in animal models[ 17 ] at least one human porphyric crises has been reported after its use.[ 28 ] etomidate should probably be considered unsafe. Although there are some reports showing ketamine's potentiality in triggering AIP crisis,[ 24 ] it might be safe because it has been used safely in quiescent AIP.[ 24 29 30 ] Succinylcholine has been used for many years and has been proven to be safe, as has tubocurarine.[ 31 ] Though both pancuronium and alcuronium have been classified as unsafe by some authors, they have been widely used by many anesthetists without harm. Atracurium[ 21 22 32 ] and vecuronium[ 33 ] have been used safely in small numbers of patients despite some experimental evidence for porphyrinogenicity. We safely used atracurium in the current patient. Morphine and its analogues (including codeine) are of proven safety, and fentanyl has been shown to be safe both in chick embryo culture models and in clinical use. Alfentanil has also been used frequently with no reported complications. More recently, fentanyl[ 16 ] and sufentanil[ 15 ] have been used as a major component, in combination with isoflurane and atracurium, in open heart surgery without a s",
          "snippet_score": 5.1462,
          "cues": [
            "complication",
            "complications",
            "trigger",
            "triggering",
            "unsafe",
            "no reported complications",
            "safe",
            "safely",
            "safety"
          ],
          "article_rank": 14,
          "article_score": 2.76,
          "citation_url": "https://doi.org/10.4103/0971-9784.179623",
          "article_title": "Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.",
          "content_source": "pmc-full-text",
          "token_estimate": 247
        },
        {
          "pmid": "15021955",
          "snippet_id": 81,
          "drug": "atracurium",
          "classification": "safety",
          "snippet_text": "aesthetics in porphyrias, but halothane and isoflurane seem to be safe. There is no clinical data or case report about the use of desflurane in this specific patient group, but its fast and relatively unchanged elimination and the minimal induction of the cytochrome P 450 system seem to be favorable in this setting. We report the use of desflurane in a patient with acute intermittent porphyria, scheduled for hemihepatectomy. To minimize perioperative distress by pain or the need for postoperative mechanical ventilation, we chose a balanced anaesthesia technique with desflurane, sufentanil and atracurium in combination with a continuous epidural analgesia (bupivacain and fentanyl) for the postoperative period. Preoperatively the porphyrin precursors were analyzed in serum and urine and postoperatively the 24 h-urine was screened every 2 days until postoperative day 6 to monitor the porphyria activity. The preoperative data showed high concentrations of porphyrin precursor excretion, confirming the diagnosis of AIP. The postoperative data in the 24 h-urine were significantly lower than preoperative levels and reached normal levels at postoperative day 5. There were no clinical symptoms of a po",
          "snippet_score": 1.2869,
          "cues": [
            "safe"
          ],
          "article_rank": 132,
          "article_score": 0.4,
          "citation_url": "https://doi.org/10.1007/s00101-003-0615-7",
          "article_title": "[Desflurane in acute intermittent porphyria].",
          "content_source": "pubmed-abstract",
          "token_estimate": 225
        },
        {
          "pmid": "27052088",
          "snippet_id": 30,
          "drug": "ketamine",
          "classification": "risk",
          "snippet_text": "re numerous reports of the safe use of thiopental in porphyric patients in the quiescent phase,[ 26 ] 7 out of 10 patients in acute porphyric crisis had their symptoms worsened following induction of anesthesia with thiopental.[ 27 ] Thus, although thiopental will not always precipitate a crisis, all barbiturates must be considered contraindicated in porphyric patients. Etomidate is potentially porphyrinogenic in animal models[ 17 ] at least one human porphyric crises has been reported after its use.[ 28 ] etomidate should probably be considered unsafe. Although there are some reports showing ketamine's potentiality in triggering AIP crisis,[ 24 ] it might be safe because it has been used safely in quiescent AIP.[ 24 29 30 ] Succinylcholine has been used for many years and has been proven to be safe, as has tubocurarine.[ 31 ] Though both pancuronium and alcuronium have been classified as unsafe by some authors, they have been widely used by many anesthetists without harm. Atracurium[ 21 22 32 ] and vecuronium[ 33 ] have been used safely in small numbers of patients despite some experimental evidence for porphyrinogenicity. We safely used atracurium in the current patient. Morphine and its",
          "snippet_score": 5.1462,
          "cues": [
            "contraindicated",
            "precipitate",
            "trigger",
            "triggering",
            "unsafe",
            "worsened",
            "safe",
            "safely",
            "indicated"
          ],
          "article_rank": 14,
          "article_score": 2.76,
          "citation_url": "https://doi.org/10.4103/0971-9784.179623",
          "article_title": "Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.",
          "content_source": "pmc-full-text",
          "token_estimate": 242
        },
        {
          "pmid": "15021955",
          "snippet_id": 82,
          "drug": "desflurane",
          "classification": "safety",
          "snippet_text": "bout the use of volatile anaesthetics in porphyrias, but halothane and isoflurane seem to be safe. There is no clinical data or case report about the use of desflurane in this specific patient group, but its fast and relatively unchanged elimination and the minimal induction of the cytochrome P 450 system seem to be favorable in this setting. We report the use of desflurane in a patient with acute intermittent porphyria, scheduled for hemihepatectomy. To minimize perioperative distress by pain or the need for postoperative mechanical ventilation, we chose a balanced anaesthesia technique with desflurane, sufentanil and atracurium in combination with a continuous epidural analgesia (bupivacain and fentanyl) for the postoperative period. Preoperatively the porphyrin precursors were analyzed in serum and urine and postoperatively the 24 h-urine was screened every 2 days until postoperative day 6 to monitor the porphyria activity. The preoperative data showed high concentrations of porphyrin precursor excretion, confirming the diagnosis of AIP. The postoperative data in the 24 h-urine were significantly lower than preoperative levels and reached normal levels at postoperative day 5. There were n",
          "snippet_score": 1.2869,
          "cues": [
            "safe"
          ],
          "article_rank": 132,
          "article_score": 0.4,
          "citation_url": "https://doi.org/10.1007/s00101-003-0615-7",
          "article_title": "[Desflurane in acute intermittent porphyria].",
          "content_source": "pubmed-abstract",
          "token_estimate": 225
        },
        {
          "pmid": "27052088",
          "snippet_id": 34,
          "drug": "isoflurane",
          "classification": "risk",
          "snippet_text": "safe or unsafe is too simplistic; the duration of exposure and the absolute dose dictate whether an acute crisis would be triggered or not and how would the severity be like. Multiple confounding factors in the perioperative period mean that the trigger for a crisis may be unclear. Propofol has been considered as a safe drug for both induction and maintenance of anesthesia in the patients with AIP.[ 17 18 19 ] Modern inhalation agents are generally considered safe in porphyric patients. Sevoflurane has been reported as a safe agent for both induction and maintenance of anesthesia. Safe use of isoflurane has also been reported;[ 20 21 22 ] therefore, it should probably be classified as safe, although further information needs to be obtained. Enflurane has been shown to induce porphyrin synthesis in animal models[ 20 ] but has been used safely in patients. Reports of a possible association of halothane with crises contradict both experimental and clinical experience.[ 23 24 ] Preoperative starvation should be minimized; if a prolonged fast is unavoidable, a dextrose\u2013saline infusion should be given during the preoperative period. In view of the frequency with which hyponatremia is encountered i",
          "snippet_score": 4.8462,
          "cues": [
            "avoid",
            "trigger",
            "triggered",
            "unsafe",
            "safe",
            "safely"
          ],
          "article_rank": 14,
          "article_score": 2.76,
          "citation_url": "https://doi.org/10.4103/0971-9784.179623",
          "article_title": "Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.",
          "content_source": "pmc-full-text",
          "token_estimate": 242
        },
        {
          "pmid": "2697245",
          "snippet_id": 59,
          "drug": "propofol",
          "classification": "safety",
          "snippet_text": "ribed to its use in patients with coronary artery disease, where these effects may have the potential for producing myocardial ischemia. The hemodynamic responses to laryngoscopy and intubation are attenuated. The pharmacokinetic profile suggests suitability as an infusion for either maintenance of anesthesia or sedation. Use of propofol as an infusion during surgery may result in a further reduction in cardiac output, particularly with the concomitant administration of adjuvant increments of fentanyl. The ventilatory response to CO2 is depressed during such an infusion. The high clearance of propofol suggests that even after a prolonged infusion, recovery should be rapid. This finding has been confirmed in a series of studies establishing propofol as an ideal agent for use in a total IV anesthetic technique. Both the quality and speed of recovery, together with the absence of emetic sequelae, support the use of propofol in an outpatient setting. Propofol appears to have no long-term effect on adrenocortical function and appears safe for use in patients with acute intermittent porphyria and susceptibility to malignant hyperpyrexia.",
          "snippet_score": 1.0749,
          "cues": [
            "safe"
          ],
          "article_rank": 58,
          "article_score": 0.6000000000000001,
          "citation_url": "https://doi.org/10.1016/0952-8180(89)90080-9",
          "article_title": "The pharmacology of propofol.",
          "content_source": "pubmed-abstract",
          "token_estimate": 216
        },
        {
          "pmid": "27052088",
          "snippet_id": 40,
          "drug": "halothane",
          "classification": "risk",
          "snippet_text": "sidered as a safe drug for both induction and maintenance of anesthesia in the patients with AIP.[ 17 18 19 ] Modern inhalation agents are generally considered safe in porphyric patients. Sevoflurane has been reported as a safe agent for both induction and maintenance of anesthesia. Safe use of isoflurane has also been reported;[ 20 21 22 ] therefore, it should probably be classified as safe, although further information needs to be obtained. Enflurane has been shown to induce porphyrin synthesis in animal models[ 20 ] but has been used safely in patients. Reports of a possible association of halothane with crises contradict both experimental and clinical experience.[ 23 24 ] Preoperative starvation should be minimized; if a prolonged fast is unavoidable, a dextrose\u2013saline infusion should be given during the preoperative period. In view of the frequency with which hyponatremia is encountered in acute attacks, the IV fluids containing dextrose alone should be avoided. Most (but not all) benzodiazepines commonly used for premedication like midazolam, are considered safe. The phenothiazines may have particular advantages.[ 25 ] Good anxiolysis has been recommended as advantageous. Where antaci",
          "snippet_score": 4.7462,
          "cues": [
            "avoid",
            "avoided",
            "recommended",
            "safe",
            "safely"
          ],
          "article_rank": 14,
          "article_score": 2.76,
          "citation_url": "https://doi.org/10.4103/0971-9784.179623",
          "article_title": "Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.",
          "content_source": "pmc-full-text",
          "token_estimate": 231
        },
        {
          "pmid": "2697245",
          "snippet_id": 60,
          "drug": "propofol",
          "classification": "safety",
          "snippet_text": "ic responses to laryngoscopy and intubation are attenuated. The pharmacokinetic profile suggests suitability as an infusion for either maintenance of anesthesia or sedation. Use of propofol as an infusion during surgery may result in a further reduction in cardiac output, particularly with the concomitant administration of adjuvant increments of fentanyl. The ventilatory response to CO2 is depressed during such an infusion. The high clearance of propofol suggests that even after a prolonged infusion, recovery should be rapid. This finding has been confirmed in a series of studies establishing propofol as an ideal agent for use in a total IV anesthetic technique. Both the quality and speed of recovery, together with the absence of emetic sequelae, support the use of propofol in an outpatient setting. Propofol appears to have no long-term effect on adrenocortical function and appears safe for use in patients with acute intermittent porphyria and susceptibility to malignant hyperpyrexia.",
          "snippet_score": 1.0749,
          "cues": [
            "safe"
          ],
          "article_rank": 58,
          "article_score": 0.6000000000000001,
          "citation_url": "https://doi.org/10.1016/0952-8180(89)90080-9",
          "article_title": "The pharmacology of propofol.",
          "content_source": "pubmed-abstract",
          "token_estimate": 191
        },
        {
          "pmid": "27220836",
          "snippet_id": 51,
          "drug": "remifentanil",
          "classification": "risk",
          "snippet_text": "an autosomal dominant disorder that results from a partial deficiency of porphobilinogen deaminase and that causes very severe symptoms. Attacks may be triggered by a series of drugs and by other factors that the anesthesiologist should be aware of in order to reduce morbidity and mortality. Our objective is to review anesthetic considerations in acute intermittent porphyria. We present the case of a patient diagnosed with acute intermittent porphyria who was scheduled for knee arthroscopy. The anesthetic technique used was a femoral and sciatic nerve block under sedation with an infusion of remifentanil. The surgery proceeded without incident and the patient was discharged home after 24h. We consider the use of a peripheral plexus block of the lower limb to have been the safest anesthetic technique for this patient.",
          "snippet_score": 2.3862,
          "cues": [
            "trigger",
            "triggered",
            "safe"
          ],
          "article_rank": 32,
          "article_score": 0.9500000000000001,
          "citation_url": "https://doi.org/10.1016/j.redar.2016.03.011",
          "article_title": "Femoral and sciatic nerve block for knee arthroscopy in a patient with acute intermittent porphyria.",
          "content_source": "pubmed-abstract",
          "token_estimate": 167
        },
        {
          "pmid": "2697245",
          "snippet_id": 61,
          "drug": "propofol",
          "classification": "safety",
          "snippet_text": "e of propofol as an infusion during surgery may result in a further reduction in cardiac output, particularly with the concomitant administration of adjuvant increments of fentanyl. The ventilatory response to CO2 is depressed during such an infusion. The high clearance of propofol suggests that even after a prolonged infusion, recovery should be rapid. This finding has been confirmed in a series of studies establishing propofol as an ideal agent for use in a total IV anesthetic technique. Both the quality and speed of recovery, together with the absence of emetic sequelae, support the use of propofol in an outpatient setting. Propofol appears to have no long-term effect on adrenocortical function and appears safe for use in patients with acute intermittent porphyria and susceptibility to malignant hyperpyrexia.",
          "snippet_score": 1.0749,
          "cues": [
            "safe"
          ],
          "article_rank": 58,
          "article_score": 0.6000000000000001,
          "citation_url": "https://doi.org/10.1016/0952-8180(89)90080-9",
          "article_title": "The pharmacology of propofol.",
          "content_source": "pubmed-abstract",
          "token_estimate": 165
        },
        {
          "pmid": "21146060",
          "snippet_id": 86,
          "drug": "metoclopramide",
          "classification": "risk",
          "snippet_text": "the toxic effects of porphyrin precursors, and it can be triggered by drugs used routinely in medical practice, severe carbohydrate restriction, and metabolic stress. The objective of this report was to present the case of a late onset porphyria evolving to chronic pain. This is a 27 years old female who was admitted 5 months prior to her clinic appointment with severe abdominal pain without diagnosis. An exploratory laparotomy was indicated, which failed to demonstrate a cause for her pain. The patient was exposed to surgical trauma and drugs that can trigger porphyria, such as ketoprophen, metoclopramide, and antibiotics, and she evolved with significant hyponatremia, increased liver enzymes, seizures, and loss of movements that led to be admitted to the Intensive Care Unit. After the diagnosis of porphyria was made, the patient remained with pain in the lower limbs, being referred to the Pain Department of Santa Casa de Miseric\u00f3rdia de S\u00e3o Paulo. Treatment with amitriptyline, gabapentin, opioid, and simple analgesics was instituted; however, the patient continued to present recurring episodes of porphyria and, feeling insecure with the conduction of the case, she stopped the treatment. Porph",
          "snippet_score": 1.8433,
          "cues": [
            "toxic",
            "trigger",
            "triggered",
            "indicated"
          ],
          "article_rank": 163,
          "article_score": 0.4,
          "citation_url": "https://doi.org/10.1016/S0034-7094(10)70079-9",
          "article_title": "Neuropathic pain in a patient with porphyria. Case report.",
          "content_source": "pubmed-abstract",
          "token_estimate": 234
        },
        {
          "pmid": "2660638",
          "snippet_id": 64,
          "drug": "benzodiazepines",
          "classification": "safety",
          "snippet_text": "he attention of the anaesthesiologist on the porphyrinogenic properties of all the drugs used in anaesthesia and intensive care. An outline of the chemistry of porphyrins and the enzymatic pathways were recalled, so as to place the acute porphyrias in their proper perspective. There follows a reminder of the clinical aspect of acute porphyric crises. The part played by drugs is then assessed from clinical and laboratory data concerning their porphyrinogenicity. Those drugs for which there is conflicting evidence regarding their safe use in porphyric patients are discussed: propofol, ketamine, benzodiazepines, etomidate, local anaesthetics. Recommendations supported by clinical and experimental data are given, especially the results obtained with the chick embryo liver model. Treatment of the acute crisis is provided, with particular emphasis on the use of haematin. The anaesthetic management of hepatic porphyric patients is described. Those drugs which are well-known porphyrinogenic compounds in the chick embryo liver must be excluded from use for anaesthesia in the porphyric patients, even if they have been observed to be innocuous in rare cases of asymptomatic patients. Finally, recommendations",
          "snippet_score": 1.0749,
          "cues": [
            "safe"
          ],
          "article_rank": 88,
          "article_score": 0.6000000000000001,
          "citation_url": "https://doi.org/10.1016/s0750-7658(89)80162-5",
          "article_title": "[Anesthesia and hepatic porphyria].",
          "content_source": "pubmed-abstract",
          "token_estimate": 222
        },
        {
          "pmid": "17037005",
          "snippet_id": 88,
          "drug": "rocuronium",
          "classification": "risk",
          "snippet_text": "porphyria (AIP) is an inherited metabolic disorder caused by deficiency of porphobilinogen deaminase, an enzyme found in the synthetic pathway of heme. Acute attack of AIP may be precipitated by many factors during operation and anesthesia, including fasting, dehydration, stress, infection, and drugs. Acute attack of AIP is likely fatal. Therefore, the drugs recommended as being safe in anesthesia for porphyria patients are up-to-dately refreshed and renovated and the identification of whether a drug is safe or not is based on cumulative anecdotal experiences. Here, we report the safe use of rocuronium and sevoflurane for long exposure in a patient affected with acute intermittent porphyria.",
          "snippet_score": 1.8026,
          "cues": [
            "fatal",
            "precipitate",
            "recommended",
            "safe"
          ],
          "article_rank": 169,
          "article_score": 0.4,
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/17037005/",
          "article_title": "The use of rocuronium and sevoflurane in acute intermittent porphyria--a case report.",
          "content_source": "pubmed-abstract",
          "token_estimate": 139
        },
        {
          "pmid": "2660638",
          "snippet_id": 65,
          "drug": "ketamine",
          "classification": "safety",
          "snippet_text": "to focus the attention of the anaesthesiologist on the porphyrinogenic properties of all the drugs used in anaesthesia and intensive care. An outline of the chemistry of porphyrins and the enzymatic pathways were recalled, so as to place the acute porphyrias in their proper perspective. There follows a reminder of the clinical aspect of acute porphyric crises. The part played by drugs is then assessed from clinical and laboratory data concerning their porphyrinogenicity. Those drugs for which there is conflicting evidence regarding their safe use in porphyric patients are discussed: propofol, ketamine, benzodiazepines, etomidate, local anaesthetics. Recommendations supported by clinical and experimental data are given, especially the results obtained with the chick embryo liver model. Treatment of the acute crisis is provided, with particular emphasis on the use of haematin. The anaesthetic management of hepatic porphyric patients is described. Those drugs which are well-known porphyrinogenic compounds in the chick embryo liver must be excluded from use for anaesthesia in the porphyric patients, even if they have been observed to be innocuous in rare cases of asymptomatic patients. Finally",
          "snippet_score": 1.0749,
          "cues": [
            "safe"
          ],
          "article_rank": 88,
          "article_score": 0.6000000000000001,
          "citation_url": "https://doi.org/10.1016/s0750-7658(89)80162-5",
          "article_title": "[Anesthesia and hepatic porphyria].",
          "content_source": "pubmed-abstract",
          "token_estimate": 223
        },
        {
          "pmid": "1418699",
          "snippet_id": 56,
          "drug": "nitrous oxide",
          "classification": "risk",
          "snippet_text": "nts have a direct effect on lung physiology. The most important idiosyncratic reactions to the volatile agents are malignant hyperpyrexia and 'halothane hepatitis'. Malignant hyperpyrexia has an incidence of 1:12,000 with a mortality of about 24%. It is triggered most often by halothane together with suxamethonium. Post halothane hepatic necrosis is rare. Evidence points to 2 distinct syndromes; direct toxicity from the products of reductive metabolism, and a more serious illness, immunologically mediated via haptens formed by liver proteins and the products of oxidative metabolism. Prolonged nitrous oxide exposure can cause bone marrow depression and life-threatening pressure effects by expansion of air-filled spaces within the body. The idiosyncratic reactions to the intravenous agents include anaphylactoid reactions (which are rare) and triggering of acute porphyria. Etomidate is immunologically 'clean', but it inhibits cortisol synthesis.",
          "snippet_score": 1.782,
          "cues": [
            "life-threatening",
            "toxic",
            "toxicity",
            "trigger",
            "triggered",
            "triggering"
          ],
          "article_rank": 56,
          "article_score": 0.6000000000000001,
          "citation_url": "https://doi.org/10.2165/00002018-199207060-00005",
          "article_title": "Adverse effects of general anaesthetics.",
          "content_source": "pubmed-abstract",
          "token_estimate": 171
        },
        {
          "pmid": "2660638",
          "snippet_id": 66,
          "drug": "propofol",
          "classification": "safety",
          "snippet_text": "iew aimed to focus the attention of the anaesthesiologist on the porphyrinogenic properties of all the drugs used in anaesthesia and intensive care. An outline of the chemistry of porphyrins and the enzymatic pathways were recalled, so as to place the acute porphyrias in their proper perspective. There follows a reminder of the clinical aspect of acute porphyric crises. The part played by drugs is then assessed from clinical and laboratory data concerning their porphyrinogenicity. Those drugs for which there is conflicting evidence regarding their safe use in porphyric patients are discussed: propofol, ketamine, benzodiazepines, etomidate, local anaesthetics. Recommendations supported by clinical and experimental data are given, especially the results obtained with the chick embryo liver model. Treatment of the acute crisis is provided, with particular emphasis on the use of haematin. The anaesthetic management of hepatic porphyric patients is described. Those drugs which are well-known porphyrinogenic compounds in the chick embryo liver must be excluded from use for anaesthesia in the porphyric patients, even if they have been observed to be innocuous in rare cases of asymptomatic patient",
          "snippet_score": 1.0749,
          "cues": [
            "safe"
          ],
          "article_rank": 88,
          "article_score": 0.6000000000000001,
          "citation_url": "https://doi.org/10.1016/s0750-7658(89)80162-5",
          "article_title": "[Anesthesia and hepatic porphyria].",
          "content_source": "pubmed-abstract",
          "token_estimate": 224
        },
        {
          "pmid": "15826795",
          "snippet_id": 85,
          "drug": "bupivacaine",
          "classification": "risk",
          "snippet_text": "Acute hepatic porphyrias are genetic diseases, characterized by acute neurological symptoms, sometimes fatal, triggered by different factors, in particular by many anaesthetic drugs, and also by pregnancy. We report here the experience of three porphyric patients'deliveries, allowing us to consider a proposition of management in this context. After discussion between anaesthesiologist, obstetrician and porphyria specialist, two types of management of such patients can be foresee. Asymptomatic patients, or in long remission, can benefit from locoregional anesthesia techniques with bupivacaine for both labour analgesia and Caesarean section. Spinal anaesthesia is then the technique of choice, allowing using smaller quantity of local anaesthetic than epidural anaesthesia. For symptomatic patients, or in crisis, we have rather choose intravenous narcotics for labour analgesia, and general anaesthesia for Caesarean section. The hypnotic agent of choice for both induction and maintenance of such anaesthesia is then propofol.",
          "snippet_score": 1.6944,
          "cues": [
            "fatal",
            "trigger",
            "triggered"
          ],
          "article_rank": 156,
          "article_score": 0.4,
          "citation_url": "https://doi.org/10.1016/j.annfar.2005.01.012",
          "article_title": "[Obstetrical anaesthesia and porphyrias].",
          "content_source": "pubmed-abstract",
          "token_estimate": 181
        },
        {
          "pmid": "3986654",
          "snippet_id": 90,
          "drug": "fentanyl",
          "classification": "safety",
          "snippet_text": "for elective vagotomy and pyloroplasty. The diagnosis of porphyria was made two years previously when she developed acute abdominal pain and lower motor neurone paralysis following ingestion of a barbiturate. The urine porphobilinogen test was positive. The patient had no other acute attack of porphyria and had not had a previous anaesthetic. Anaesthesia was induced with etomidate 0.3 mg X kg-1 IV. Muscle relaxation was obtained with pancuronium 6 mg IV and ventilation was mechanically controlled. Intraoperative analgesia was with 66 per cent nitrous oxide in oxygen and intermittent doses of fentanyl. The patient was stable during anaesthesia and surgery. The postoperative period was uneventful and patient did not have an acute attack of porphyria. This experience suggests that etomidate is safe for intravenous induction of anaesthesia in acute intermittent porphyria. However, reports of its use in more patients with this disease will be necessary before a final conclusion can be made.",
          "snippet_score": 0.8678,
          "cues": [
            "safe"
          ],
          "article_rank": 174,
          "article_score": 0.4,
          "citation_url": "https://doi.org/10.1007/BF03010045",
          "article_title": "Induction of anaesthesia with etomidate in a patient with acute intermittent porphyria.",
          "content_source": "pubmed-abstract",
          "token_estimate": 193
        },
        {
          "pmid": "15021955",
          "snippet_id": 75,
          "drug": "desflurane",
          "classification": "risk",
          "snippet_text": "Despite the low incidence of the acute porphyrias, a profound knowledge of the disease is essential for anaesthesiologists, as a variety of perioperatively administered drugs are potential triggers of an acute attack. There is an ongoing discussion about the use of volatile anaesthetics in porphyrias, but halothane and isoflurane seem to be safe. There is no clinical data or case report about the use of desflurane in this specific patient group, but its fast and relatively unchanged elimination and the minimal induction of the cytochrome P 450 system seem to be favorable in this setting. We report the use of desflurane in a patient with acute intermittent porphyria, scheduled for hemihepatectomy. To minimize perioperative distress by pain or the need for postoperative mechanical ventilation, we chose a balanced anaesthesia technique with desflurane, sufentanil and atracurium in combination with a continuous epidural analgesia (bupivacain and fentanyl) for the postoperative period. Preoperatively the po",
          "snippet_score": 1.5869,
          "cues": [
            "trigger",
            "safe"
          ],
          "article_rank": 132,
          "article_score": 0.4,
          "citation_url": "https://doi.org/10.1007/s00101-003-0615-7",
          "article_title": "[Desflurane in acute intermittent porphyria].",
          "content_source": "pubmed-abstract",
          "token_estimate": 193
        },
        {
          "pmid": "3986654",
          "snippet_id": 91,
          "drug": "nitrous oxide",
          "classification": "safety",
          "snippet_text": "le with acute intermittent porphyria who presented for elective vagotomy and pyloroplasty. The diagnosis of porphyria was made two years previously when she developed acute abdominal pain and lower motor neurone paralysis following ingestion of a barbiturate. The urine porphobilinogen test was positive. The patient had no other acute attack of porphyria and had not had a previous anaesthetic. Anaesthesia was induced with etomidate 0.3 mg X kg-1 IV. Muscle relaxation was obtained with pancuronium 6 mg IV and ventilation was mechanically controlled. Intraoperative analgesia was with 66 per cent nitrous oxide in oxygen and intermittent doses of fentanyl. The patient was stable during anaesthesia and surgery. The postoperative period was uneventful and patient did not have an acute attack of porphyria. This experience suggests that etomidate is safe for intravenous induction of anaesthesia in acute intermittent porphyria. However, reports of its use in more patients with this disease will be necessary before a final conclusion can be made.",
          "snippet_score": 0.8678,
          "cues": [
            "safe"
          ],
          "article_rank": 174,
          "article_score": 0.4,
          "citation_url": "https://doi.org/10.1007/BF03010045",
          "article_title": "Induction of anaesthesia with etomidate in a patient with acute intermittent porphyria.",
          "content_source": "pubmed-abstract",
          "token_estimate": 201
        },
        {
          "pmid": "15021955",
          "snippet_id": 79,
          "drug": "volatile anaesthetics",
          "classification": "risk",
          "snippet_text": "Despite the low incidence of the acute porphyrias, a profound knowledge of the disease is essential for anaesthesiologists, as a variety of perioperatively administered drugs are potential triggers of an acute attack. There is an ongoing discussion about the use of volatile anaesthetics in porphyrias, but halothane and isoflurane seem to be safe. There is no clinical data or case report about the use of desflurane in this specific patient group, but its fast and relatively unchanged elimination and the minimal induction of the cytochrome P 450 system seem to be favorable in this setting. We report the use of desflurane in a patient with acute intermittent porphyria, scheduled for hemihepatectomy. To minimize perioperative distress by pain or the need for postoperative mechanical ventilation, we chose a balanced anaesthesia technique with desflurane, sufentanil and atracurium",
          "snippet_score": 1.5869,
          "cues": [
            "trigger",
            "safe"
          ],
          "article_rank": 132,
          "article_score": 0.4,
          "citation_url": "https://doi.org/10.1007/s00101-003-0615-7",
          "article_title": "[Desflurane in acute intermittent porphyria].",
          "content_source": "pubmed-abstract",
          "token_estimate": 174
        },
        {
          "pmid": "7616668",
          "snippet_id": 73,
          "drug": "diazepam",
          "classification": "risk",
          "snippet_text": "Although the morbidity of porphyria is rare, the surgical and anesthetic managements of patients with porphyria should be prudent, for various stresses including surgery and anesthesia may cause occurrence or exacerbation of this disease, occasionally resulting in the mortal course. Several drugs such as barbiturate, diazepam, pentazocine, and pancuronium, which can be used during anesthesia or after operation, reportedly exacerbate the disease. Furthermore, the acute exacerbation of porphyria may be misdiagnosed as acute abdomen, ileus, acute appendicitis, cholelithiasis, urolithiasis, or ectopic pregnancy. The managements of patients with acute porphyria during anesthesia and after surgery are discussed along with the introduction of our case report. Since there is no definitive treatment of porphyria, the most important thing is to understand the disease and to prevent the acute exacerbation of the disease. Whe",
          "snippet_score": 1.391,
          "cues": [
            "exacerbate",
            "prevent"
          ],
          "article_rank": 125,
          "article_score": 0.6000000000000001,
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/7616668/",
          "article_title": "[Surgical and anesthetic managements of patients with porphyria].",
          "content_source": "pubmed-abstract",
          "token_estimate": 169
        },
        {
          "pmid": "88665",
          "snippet_id": 72,
          "drug": "glucagon",
          "classification": "risk",
          "snippet_text": "are reported to increase intracellular adenosine 3':5'-monophosphate (cAMP) levels, viz. glucagon, sodium fluoride, cAMP or its dibutyryl derivative, 3-isobutyl-1-methylxanthine and papaverine enhanced drug-induced porphyrin biosynthesis. On the other have, agents which are reported to decrease intra-cellular cAMP levels, viz. alloxan and imidazole, diminished drug-induced porphyrin accumulation. cAMP appears to enhance, but not to function as a \"second messenger\" in drug-induced porphyrin biosynthesis. Drug-induced porphyrin accumulation in chick embryo liver cells depend upon the insulin to glucagon ratio. A low level of porphyrin accumulation occurs at insulin to glucagon ratios similar to those found following glucose administration in vivo, suggesting a possible explanation for the therapeutic effect of glucose in hepatic porphyria. The 5 alpha A(A:B trans) and 5 beta H(A:Bcis) steroids are equipotent in inducing delta-aminolevulinic acid synthetase and porphyrin accumulation in chick embryo liver cells maintained in serum-free culture medium. Thus, there is no specific steric requirement for porphyrin-inducing activity in steroids.",
          "snippet_score": 1.2608,
          "cues": [
            "condition-match"
          ],
          "article_rank": 118,
          "article_score": 0.6000000000000001,
          "citation_url": "https://doi.org/10.1007/BF00228992",
          "article_title": "Hormonal effects on the regulation of hepatic heme biosynthesis.",
          "content_source": "pubmed-abstract",
          "token_estimate": 194
        },
        {
          "pmid": "1418699",
          "snippet_id": 57,
          "drug": "volatile agents",
          "classification": "risk",
          "snippet_text": "enous anaesthetic agents affect the central nervous and cardio-respiratory systems in a dose-related manner. Neuronal inhibition results in decreasing levels of consciousness and depression of the medullary vital centres which can lead to cardiorespiratory failure. Both groups of agents have some depressant effect on the myocardium and vascular smooth muscle leading to a fall in cardiac output and hypotension. Centrally-mediated respiratory depression is common to both groups and the inhalational agents have a direct effect on lung physiology. The most important idiosyncratic reactions to the volatile agents are malignant hyperpyrexia and 'halothane hepatitis'. Malignant hyperpyrexia has an incidence of 1:12,000 with a mortality of about 24%. It is triggered most often by halothane together with suxamethonium. Post halothane hepatic necrosis is rare. Evidence points to 2 distinct syndromes; direct toxicity from the products of reductive metabolism, and a more serious illness, immunologically mediated via haptens formed by liver proteins and the products of oxidative metabolism. Prolonged nitrous oxide exposure can cause bone marrow depression and life-threatening pressure effects by expansion of",
          "snippet_score": 1.082,
          "cues": [
            "life-threatening",
            "toxic",
            "toxicity",
            "trigger",
            "triggered"
          ],
          "article_rank": 56,
          "article_score": 0.6000000000000001,
          "citation_url": "https://doi.org/10.2165/00002018-199207060-00005",
          "article_title": "Adverse effects of general anaesthetics.",
          "content_source": "pubmed-abstract",
          "token_estimate": 215
        },
        {
          "pmid": "34661997",
          "snippet_id": 9,
          "drug": "lorazepam",
          "classification": "risk",
          "snippet_text": "17 ). Thrombophlebitis is the most common side\u2010effect and rarely vein obliteration occurs. Hemin acts as a transcription factor that reduces expression of the rate\u2010limiting hepatic enzyme ALAS1. This leads to down\u2010regulation of the entire pathway and reduction of toxic metabolites. For desperate cases with severe recurrent attacks, liver transplant has been performed leading to clinical and biochemical remission (Seth et al., 2007 ; Singal et al., 2014 ; Soonawalla et al., 2004 ; Stolzel et al., 2019 ). Antiepileptic therapy can be done with Gabapentin, Lacosamide, Lamotrigine, Levetiracetam, Lorazepam, Midazolam, and Pregabalin. Addition of magnesium and propofol has been successful (Bhatia et al., 2008 ; Dawit et al., 2019 ; Engelhardt et al., 2004 ; Stolzel et al., 2019 ; Zaatreh, 2005 ). Unsafe antiepileptics that can worsen AHP should be strictly avoided, especially barbiturates, but also valproic acid and carbamazepine. For the full list of safe and unsafe medications, please refer to Table 4 . Neuropathic pain is a common problem during acute attacks, but also during recovery. Pain management can be done with ASS, Ibuprofen, Paracetamol, opioids and with gabapentin or pregabalin. In",
          "snippet_score": 8.6383,
          "cues": [
            "avoid",
            "avoided",
            "toxic",
            "unsafe",
            "safe"
          ],
          "article_rank": 3,
          "article_score": 5.48,
          "citation_url": "https://doi.org/10.1002/brb3.2389",
          "article_title": "Acute porphyrias - A neurological perspective.",
          "content_source": "pmc-full-text",
          "token_estimate": 232
        },
        {
          "pmid": "34661997",
          "snippet_id": 10,
          "drug": "midazolam",
          "classification": "risk",
          "snippet_text": "bophlebitis is the most common side\u2010effect and rarely vein obliteration occurs. Hemin acts as a transcription factor that reduces expression of the rate\u2010limiting hepatic enzyme ALAS1. This leads to down\u2010regulation of the entire pathway and reduction of toxic metabolites. For desperate cases with severe recurrent attacks, liver transplant has been performed leading to clinical and biochemical remission (Seth et al., 2007 ; Singal et al., 2014 ; Soonawalla et al., 2004 ; Stolzel et al., 2019 ). Antiepileptic therapy can be done with Gabapentin, Lacosamide, Lamotrigine, Levetiracetam, Lorazepam, Midazolam, and Pregabalin. Addition of magnesium and propofol has been successful (Bhatia et al., 2008 ; Dawit et al., 2019 ; Engelhardt et al., 2004 ; Stolzel et al., 2019 ; Zaatreh, 2005 ). Unsafe antiepileptics that can worsen AHP should be strictly avoided, especially barbiturates, but also valproic acid and carbamazepine. For the full list of safe and unsafe medications, please refer to Table 4 . Neuropathic pain is a common problem during acute attacks, but also during recovery. Pain management can be done with ASS, Ibuprofen, Paracetamol, opioids and with gabapentin or pregabalin. In November 20",
          "snippet_score": 8.6383,
          "cues": [
            "avoid",
            "avoided",
            "toxic",
            "unsafe",
            "safe"
          ],
          "article_rank": 3,
          "article_score": 5.48,
          "citation_url": "https://doi.org/10.1002/brb3.2389",
          "article_title": "Acute porphyrias - A neurological perspective.",
          "content_source": "pmc-full-text",
          "token_estimate": 232
        },
        {
          "pmid": "34661997",
          "snippet_id": 11,
          "drug": "propofol",
          "classification": "risk",
          "snippet_text": "vein obliteration occurs. Hemin acts as a transcription factor that reduces expression of the rate\u2010limiting hepatic enzyme ALAS1. This leads to down\u2010regulation of the entire pathway and reduction of toxic metabolites. For desperate cases with severe recurrent attacks, liver transplant has been performed leading to clinical and biochemical remission (Seth et al., 2007 ; Singal et al., 2014 ; Soonawalla et al., 2004 ; Stolzel et al., 2019 ). Antiepileptic therapy can be done with Gabapentin, Lacosamide, Lamotrigine, Levetiracetam, Lorazepam, Midazolam, and Pregabalin. Addition of magnesium and propofol has been successful (Bhatia et al., 2008 ; Dawit et al., 2019 ; Engelhardt et al., 2004 ; Stolzel et al., 2019 ; Zaatreh, 2005 ). Unsafe antiepileptics that can worsen AHP should be strictly avoided, especially barbiturates, but also valproic acid and carbamazepine. For the full list of safe and unsafe medications, please refer to Table 4 . Neuropathic pain is a common problem during acute attacks, but also during recovery. Pain management can be done with ASS, Ibuprofen, Paracetamol, opioids and with gabapentin or pregabalin. In November 2019, the FDA, and in March 2020, the EMA approved a n",
          "snippet_score": 8.6383,
          "cues": [
            "avoid",
            "avoided",
            "toxic",
            "unsafe",
            "safe"
          ],
          "article_rank": 3,
          "article_score": 5.48,
          "citation_url": "https://doi.org/10.1002/brb3.2389",
          "article_title": "Acute porphyrias - A neurological perspective.",
          "content_source": "pmc-full-text",
          "token_estimate": 236
        },
        {
          "pmid": "34661997",
          "snippet_id": 13,
          "drug": "levetiracetam",
          "classification": "risk",
          "snippet_text": "edications UNSAFE MEDICATIONS SAFE MEDICATIONS Pain killers Metamizole/Dipyrone ASS, Ibuprofen, Paracetamol Morphine, Hydromorphone Antiemetics Dimenhydrinate MCP Ondansetron Antibiotics/antivirals Clindamycin Azithromycin Erythromycin , (Clarithromycin) Carbapenems (Flucloxacillin) Cephalosporins Isoniazid Ciprofloxacin, Moxifloxacin Nitrofurantoin Doxycycline Rifampicin Gentamicin Sulfonamides , Trimethoprim Penicillins a Vancomycin Aciclovir, Ganciclovir, Valaciclovir Antiepileptic therapy Barbiturates (Phenobarbital) Gabapentin Carbamazepin Lacosamide (Valproic acid) Lamotrigine Phenytoin Levetiracetam Primidone Lorazepam, Midazolam (Oxcarbazepine) Magnesium Topiramate Pregabalin Propofol Neuroleptics Melperone Chlorpromazine Haloperidol Levomepromazin Antidepressants (Imipramin) Amitriptyline Duloxetine Mirtazapine SSRIs Steroids (Dexamethasone) Prednisolone (Methylprednisolon) Triamcinolone Others Hormones Atropine Progesterone Betablockers Catecholamines Note : All drugs are classified after their safety in systemic use in a patient. The list is not comprehensive and the authors advise to check in the following databases for updated information on a drug before prescription to a patient",
          "snippet_score": 8.4383,
          "cues": [
            "unsafe",
            "safe",
            "safety"
          ],
          "article_rank": 3,
          "article_score": 5.48,
          "citation_url": "https://doi.org/10.1002/brb3.2389",
          "article_title": "Acute porphyrias - A neurological perspective.",
          "content_source": "pmc-full-text",
          "token_estimate": 162
        },
        {
          "pmid": "36642627",
          "snippet_id": 17,
          "drug": "levetiracetam",
          "classification": "risk",
          "snippet_text": "activator 1- \u03b1 , which induces expression of ALAS1. 35 Acute attacks can be associated with hyponatremia and hypomagnesemia due to a combination of hypovolemia and syndrome of inappropriate antidiuretic hormone secretion. 36 , 37 Electrolytes should be monitored during acute attacks and hyponatremia corrected slowly if present. In acute attacks that present with seizures, management should be approached with caution because many anticonvulsant medications, such as barbiturates, hydantoins, carbamazepine, and valproic acid, are contraindicated in AHP. 38 Magnesium sulfate, benzodiazepines, and levetiracetam appear to be safe options in the context of AHP. Best Practice Advice 6: Patients should be counseled to avoid identifiable triggers that may precipitate acute attacks, such as alcohol and porphyrinogenic medications. The low penetrance of AHPs indicates the likely presence of additional factors that are required for clinical symptoms, including precipitating factors and other poorly defined modifying genes and/or epigenetic factors. 39 , 40 Sex hormones, in particular progesterone, are known to precipitate attacks. Other common precipitating factors include medications that induce cytochrome",
          "snippet_score": 7.9832,
          "cues": [
            "avoid",
            "contraindicated",
            "caution",
            "precipitate",
            "trigger",
            "safe",
            "safe option",
            "indicated"
          ],
          "article_rank": 5,
          "article_score": 4.510000000000001,
          "citation_url": "https://doi.org/10.1053/j.gastro.2022.11.034",
          "article_title": "AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review.",
          "content_source": "pmc-full-text",
          "token_estimate": 212
        },
        {
          "pmid": "36028858",
          "snippet_id": 18,
          "drug": "opioids",
          "classification": "risk",
          "snippet_text": ", 14 ]. Early treatment is important to prevent disease progression [ 5 , 15 ]. There is a need for treatments that not only reduce or eliminate acute attacks, but also improve chronic manifestations of recurrent AHP. Prevention strategies include identifying and avoiding triggers that may precipitate acute attacks [ 16 , 17 ]. However, some triggers, such as stress, may not always be avoidable [ 17 , 18 ]. Furthermore, many patients continue to experience chronic symptoms between attacks [ 6 , 10 , 11 ]. Opioids are used to manage abdominal, limb, and back pain [ 17 ], but patients receiving opioids may develop somnolence, addiction, tolerance, and hyperalgesia [ 19 ]. Intravenous (IV) hemin is the standard of care for confirmed acute attacks [ 2 , 20 , 21 ]. Hemin is thought to work by decreasing levels of ALAS1, thereby reducing the production of toxic heme precursors [ 22 \u2013 24 ]. Although hemin is not indicated for prophylaxis [ 22 , 23 ], it is often used off-label for this purpose [ 11 ]. Some patients have reported recurrent attacks despite weekly prophylactic hemin administration [ 25 ]. Side effects and complications associated with hemin use include headache, infusion-site react",
          "snippet_score": 6.2244,
          "cues": [
            "avoid",
            "complication",
            "complications",
            "precipitate",
            "side effect",
            "side effects",
            "toxic",
            "trigger",
            "prevent",
            "indicated"
          ],
          "article_rank": 12,
          "article_score": 2.86,
          "citation_url": "https://doi.org/10.1186/s13023-022-02463-x",
          "article_title": "Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION study.",
          "content_source": "pmc-full-text",
          "token_estimate": 255
        },
        {
          "pmid": "27052088",
          "snippet_id": 27,
          "drug": "propofol",
          "classification": "risk",
          "snippet_text": "that appropriate drug regimens are selected.[ 13 14 15 16 ] Particular attentions should be given to the presence of peripheral neuropathy and autonomic instability, as they will influence the anesthetic technique and also indicate active disease, with increased risk of acute crisis. Classifying drugs as porphyria safe or unsafe is too simplistic; the duration of exposure and the absolute dose dictate whether an acute crisis would be triggered or not and how would the severity be like. Multiple confounding factors in the perioperative period mean that the trigger for a crisis may be unclear. Propofol has been considered as a safe drug for both induction and maintenance of anesthesia in the patients with AIP.[ 17 18 19 ] Modern inhalation agents are generally considered safe in porphyric patients. Sevoflurane has been reported as a safe agent for both induction and maintenance of anesthesia. Safe use of isoflurane has also been reported;[ 20 21 22 ] therefore, it should probably be classified as safe, although further information needs to be obtained. Enflurane has been shown to induce porphyrin synthesis in animal models[ 20 ] but has been used safely in patients. Reports of a possible as",
          "snippet_score": 5.5462,
          "cues": [
            "risk",
            "risk of",
            "trigger",
            "triggered",
            "unsafe",
            "safe",
            "safely"
          ],
          "article_rank": 14,
          "article_score": 2.76,
          "citation_url": "https://doi.org/10.4103/0971-9784.179623",
          "article_title": "Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.",
          "content_source": "pmc-full-text",
          "token_estimate": 244
        },
        {
          "pmid": "36028858",
          "snippet_id": 23,
          "drug": "opioid",
          "classification": "risk",
          "snippet_text": "emetics, and analgesics at baseline Placebo (n = 46) Givosiran (n = 48) Total (N = 94) Antidepressants Benzodiazepine derivatives 10 (22) 10 (21) 20 (21) Benzodiazepine-related drugs 3 (7) 4 (8) 7 (7) Other anti-depressants 4 (9) 9 (19) 13 (14) SSRIs 2 (4) 4 (8) 6 (6) Antihypertensives ACE inhibitors 2 (4) 1 (2) 3 (3) Angiotensin II receptor antagonists 3 (7) 2 (4) 5 (5) Beta blocking agents, non-selective 1 (2) 3 (6) 4 (4) Beta blocking agents, selective 5 (11) 7 (15) 12 (13) Antiemetics 5HT3 antagonists 12 (26) 12 (25) 24 (26) Pain medications Natural opium alkaloids 27 (59) 23 (48) 50 (53) Opioid anesthetics (fentanyl) 2 (4) 0 2 (2) Opioid/non-opioid combinations 2 (4) 5 (10) 7 (7) Opium alkaloid derivatives 2 (4) 0 2 (2) Other opioids 8 (17) 6 (13) 14 (15) Other analgesics and antipyretics 10 (22) 13 (27) 23 (25) SSRI selective serotonin reuptake inhibitor, ACE angiotensin-converting enzyme, 5HT3 5-hydroxytryptamine A high proportion of patients had received prior hemin prophylaxis (40%) [ 11 ], with many experiencing hemin-related complications, as well as ongoing damage caused by AHP (Fig. 2 ). Complications related to central venous access included thrombosis (8%), infection (18%)",
          "snippet_score": 5.4244,
          "cues": [
            "complication",
            "complications"
          ],
          "article_rank": 12,
          "article_score": 2.86,
          "citation_url": "https://doi.org/10.1186/s13023-022-02463-x",
          "article_title": "Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION study.",
          "content_source": "pmc-full-text",
          "token_estimate": 250
        },
        {
          "pmid": "36028858",
          "snippet_id": 24,
          "drug": "opioid",
          "classification": "risk",
          "snippet_text": "(n = 46) Givosiran (n = 48) Total (N = 94) Antidepressants Benzodiazepine derivatives 10 (22) 10 (21) 20 (21) Benzodiazepine-related drugs 3 (7) 4 (8) 7 (7) Other anti-depressants 4 (9) 9 (19) 13 (14) SSRIs 2 (4) 4 (8) 6 (6) Antihypertensives ACE inhibitors 2 (4) 1 (2) 3 (3) Angiotensin II receptor antagonists 3 (7) 2 (4) 5 (5) Beta blocking agents, non-selective 1 (2) 3 (6) 4 (4) Beta blocking agents, selective 5 (11) 7 (15) 12 (13) Antiemetics 5HT3 antagonists 12 (26) 12 (25) 24 (26) Pain medications Natural opium alkaloids 27 (59) 23 (48) 50 (53) Opioid anesthetics (fentanyl) 2 (4) 0 2 (2) Opioid/non-opioid combinations 2 (4) 5 (10) 7 (7) Opium alkaloid derivatives 2 (4) 0 2 (2) Other opioids 8 (17) 6 (13) 14 (15) Other analgesics and antipyretics 10 (22) 13 (27) 23 (25) SSRI selective serotonin reuptake inhibitor, ACE angiotensin-converting enzyme, 5HT3 5-hydroxytryptamine A high proportion of patients had received prior hemin prophylaxis (40%) [ 11 ], with many experiencing hemin-related complications, as well as ongoing damage caused by AHP (Fig. 2 ). Complications related to central venous access included thrombosis (8%), infection (18%), and catheter occlusion/malfunction (24%).",
          "snippet_score": 5.4244,
          "cues": [
            "complication",
            "complications"
          ],
          "article_rank": 12,
          "article_score": 2.86,
          "citation_url": "https://doi.org/10.1186/s13023-022-02463-x",
          "article_title": "Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION study.",
          "content_source": "pmc-full-text",
          "token_estimate": 247
        },
        {
          "pmid": "27052088",
          "snippet_id": 31,
          "drug": "morphine",
          "classification": "risk",
          "snippet_text": "showing ketamine's potentiality in triggering AIP crisis,[ 24 ] it might be safe because it has been used safely in quiescent AIP.[ 24 29 30 ] Succinylcholine has been used for many years and has been proven to be safe, as has tubocurarine.[ 31 ] Though both pancuronium and alcuronium have been classified as unsafe by some authors, they have been widely used by many anesthetists without harm. Atracurium[ 21 22 32 ] and vecuronium[ 33 ] have been used safely in small numbers of patients despite some experimental evidence for porphyrinogenicity. We safely used atracurium in the current patient. Morphine and its analogues (including codeine) are of proven safety, and fentanyl has been shown to be safe both in chick embryo culture models and in clinical use. Alfentanil has also been used frequently with no reported complications. More recently, fentanyl[ 16 ] and sufentanil[ 15 ] have been used as a major component, in combination with isoflurane and atracurium, in open heart surgery without a significant problem.[ 21 ] Cardiac surgical reports also refer to the safe use of heparin. Pethidine (meperidine) has a proven track record of safety despite a single case report implicating it in a porp",
          "snippet_score": 5.1462,
          "cues": [
            "complication",
            "complications",
            "trigger",
            "triggering",
            "unsafe",
            "no reported complications",
            "safe",
            "safely",
            "safety"
          ],
          "article_rank": 14,
          "article_score": 2.76,
          "citation_url": "https://doi.org/10.4103/0971-9784.179623",
          "article_title": "Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.",
          "content_source": "pmc-full-text",
          "token_estimate": 248
        },
        {
          "pmid": "40114189",
          "snippet_id": 25,
          "drug": "levetiracetam",
          "classification": "risk",
          "snippet_text": "e the question whether homozygosity for R59W variant is lethal. Two new cases of homozygous variegate porphyria We identified two new cases of homozygous variegate porphyria that have so far not been published. Patient 1 is a now 7-year-old girl. She was admitted to our neonatal department because of hepatopathy on her first day of life, showing cutaneous lesions caused by the light of a pulse oximeter (Fig. 1 A). Nystagmus became apparent at the age of 6 weeks. She developed epileptic seizures, mainly bilateral tonic seizures with eye blinking, at the age of 3 months which did not respond to levetiracetam, but to a combination of valproic acid and phenobarbital. Her subsequent development was globally delayed. Currently, she is able to walk without aid on level ground and expresses herself in simple two-word combinations. She attends a school for children with intellectual disability. She has short stature and microcephaly (at the age of 7 years: height 114 cm (P1, SDS: \u2212 2.24), weight 19 kg (P2, SDS:\u2212 2.02), BMI 14.6 kg/m 2 (P25, SDS:\u2212 0.68) and head circumference 44.7 cm (< P1, SDS: \u2212 5.16), at birth: height 46 cm (< P1, SDS:\u2212 3.02), weight 2450 g (< P1, SDS:\u2212 2.99), head circumference 32 cm",
          "snippet_score": 5.14,
          "cues": [
            "condition-match"
          ],
          "article_rank": 13,
          "article_score": 2.8400000000000003,
          "citation_url": "https://doi.org/10.1186/s13023-025-03606-6",
          "article_title": "Neurodevelopmental retardation and neurological symptoms in homozygous variegate porphyria: two new cases and a literature review.",
          "content_source": "pmc-full-text",
          "token_estimate": 255
        },
        {
          "pmid": "27052088",
          "snippet_id": 32,
          "drug": "fentanyl",
          "classification": "risk",
          "snippet_text": "be safe because it has been used safely in quiescent AIP.[ 24 29 30 ] Succinylcholine has been used for many years and has been proven to be safe, as has tubocurarine.[ 31 ] Though both pancuronium and alcuronium have been classified as unsafe by some authors, they have been widely used by many anesthetists without harm. Atracurium[ 21 22 32 ] and vecuronium[ 33 ] have been used safely in small numbers of patients despite some experimental evidence for porphyrinogenicity. We safely used atracurium in the current patient. Morphine and its analogues (including codeine) are of proven safety, and fentanyl has been shown to be safe both in chick embryo culture models and in clinical use. Alfentanil has also been used frequently with no reported complications. More recently, fentanyl[ 16 ] and sufentanil[ 15 ] have been used as a major component, in combination with isoflurane and atracurium, in open heart surgery without a significant problem.[ 21 ] Cardiac surgical reports also refer to the safe use of heparin. Pethidine (meperidine) has a proven track record of safety despite a single case report implicating it in a porphyric attack.[ 34 ] There is evidence both for[ 35 ] and against[ 36 ] th",
          "snippet_score": 4.9462,
          "cues": [
            "complication",
            "complications",
            "unsafe",
            "no reported complications",
            "safe",
            "safely",
            "safety"
          ],
          "article_rank": 14,
          "article_score": 2.76,
          "citation_url": "https://doi.org/10.4103/0971-9784.179623",
          "article_title": "Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.",
          "content_source": "pmc-full-text",
          "token_estimate": 253
        },
        {
          "pmid": "27052088",
          "snippet_id": 33,
          "drug": "fentanyl",
          "classification": "risk",
          "snippet_text": "both pancuronium and alcuronium have been classified as unsafe by some authors, they have been widely used by many anesthetists without harm. Atracurium[ 21 22 32 ] and vecuronium[ 33 ] have been used safely in small numbers of patients despite some experimental evidence for porphyrinogenicity. We safely used atracurium in the current patient. Morphine and its analogues (including codeine) are of proven safety, and fentanyl has been shown to be safe both in chick embryo culture models and in clinical use. Alfentanil has also been used frequently with no reported complications. More recently, fentanyl[ 16 ] and sufentanil[ 15 ] have been used as a major component, in combination with isoflurane and atracurium, in open heart surgery without a significant problem.[ 21 ] Cardiac surgical reports also refer to the safe use of heparin. Pethidine (meperidine) has a proven track record of safety despite a single case report implicating it in a porphyric attack.[ 34 ] There is evidence both for[ 35 ] and against[ 36 ] the porphyrinogenicity of pentazocine in experimental systems.[ 37 ] Of the nonopiate analgesics, aspirin, acetaminophen, indomethacin and naproxen have proven safe. However, CPB is",
          "snippet_score": 4.9462,
          "cues": [
            "complication",
            "complications",
            "unsafe",
            "no reported complications",
            "safe",
            "safely",
            "safety"
          ],
          "article_rank": 14,
          "article_score": 2.76,
          "citation_url": "https://doi.org/10.4103/0971-9784.179623",
          "article_title": "Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.",
          "content_source": "pmc-full-text",
          "token_estimate": 239
        },
        {
          "pmid": "27052088",
          "snippet_id": 35,
          "drug": "isoflurane",
          "classification": "risk",
          "snippet_text": "en widely used by many anesthetists without harm. Atracurium[ 21 22 32 ] and vecuronium[ 33 ] have been used safely in small numbers of patients despite some experimental evidence for porphyrinogenicity. We safely used atracurium in the current patient. Morphine and its analogues (including codeine) are of proven safety, and fentanyl has been shown to be safe both in chick embryo culture models and in clinical use. Alfentanil has also been used frequently with no reported complications. More recently, fentanyl[ 16 ] and sufentanil[ 15 ] have been used as a major component, in combination with isoflurane and atracurium, in open heart surgery without a significant problem.[ 21 ] Cardiac surgical reports also refer to the safe use of heparin. Pethidine (meperidine) has a proven track record of safety despite a single case report implicating it in a porphyric attack.[ 34 ] There is evidence both for[ 35 ] and against[ 36 ] the porphyrinogenicity of pentazocine in experimental systems.[ 37 ] Of the nonopiate analgesics, aspirin, acetaminophen, indomethacin and naproxen have proven safe. However, CPB is a specific problem,[ 13 14 15 16 ] we used it uneventfully. Blood loss, with its consequent inc",
          "snippet_score": 4.8462,
          "cues": [
            "complication",
            "complications",
            "no reported complications",
            "safe",
            "safely",
            "safety"
          ],
          "article_rank": 14,
          "article_score": 2.76,
          "citation_url": "https://doi.org/10.4103/0971-9784.179623",
          "article_title": "Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.",
          "content_source": "pmc-full-text",
          "token_estimate": 244
        }
      ]
    },
    {
      "token_estimate": 9622,
      "messages": [
        {
          "role": "system",
          "content": "You are a clinical evidence synthesis assistant. Analyse the supplied snippets and claim groups before constructing cross-drug findings. When assessing each claim, draft a concise internal checklist (3-7 bullet points) covering the verification steps you will perform, then silently execute it. Focus on causality and therapeutic intent, cite only the provided article_ids, and keep reasoning grounded in the text. After each classification, briefly validate your decision against the cited evidence; self-correct if the validation fails, but do not include the checklist or validation in the JSON output. Identify idiosyncratic reactions explicitly when the evidence supports them, and do not infer facts beyond those presented."
        },
        {
          "role": "user",
          "content": "CONTEXT\nCondition: porphyria | Related terms: Porphyria, Variegate, Variegate Porphyria, Porphyria Variegata, Protoporphyrinogen Oxidase Deficiency, Ppox Deficiency\nSnippets sorted by snippet_score (desc) then article_rank (asc); use the overlapping drug mentions to connect evidence across claims.\n\nREFERENCE\n- snippet_id: prompt-only reference (omit from JSON).\n- article_id: prefix 'article:' + pmid; use for citations and flag if missing.\n- related_drugs: union of all drugs tied to the snippet; ensure each appears in the output (even if labelled insufficient evidence).\n- cues/heuristics: NLP hints; verify before relying on them.\n\nDRUGS IN SCOPE\n1. midazolam\n2. benzodiazepines\n3. atracurium\n4. propofol\n5. fentanyl\n6. levetiracetam\n7. opioids\n8. desflurane\n9. halothane\n10. isoflurane\n11. sevoflurane\n12. succinylcholine\n13. opioid\n\nINSTRUCTIONS\n1. Review DRUGS IN SCOPE and emit a drug entry for each listed drug; copy the name exactly, keep the provided class labels, include our ATC codes (or add only when the text clearly justifies it), and list the claim_ids you produce for that drug (leave the list empty when evidence is insufficient). Never reference a drug in any claim unless you have supplied a matching entry in the drugs array. When handling neuromuscular blockers, prefer precise families (depolarising, aminosteroid, benzylisoquinolinium) instead of the generic class unless the evidence is indistinct.\n2. Build shared findings (risk | safety | uncertain | nuanced) using only the supplied evidence, keep summaries factual, cite every supporting article_id, and attach all relevant drug_ids\u2014even when a snippet mentions several drugs.\n3. Do not fabricate claims for drugs with insufficient evidence; it is acceptable for a drug to have zero claims.\n4. Use the article_id identifiers we provide\u2014cite an article once even if multiple snippets support it, never invent IDs, and flag unresolved citations in the claim summary if an article_id is missing.\n5. Detect idiosyncratic reactions yourself; when evidence shows unexpected patient-specific reactions (e.g., malignant hyperthermia), set idiosyncratic_reaction.flag true and copy the descriptors, otherwise leave the flag false with an empty list.\n6. Populate the supporting_evidence list for each claim using snippet_id values from the listing (include pmid, article_title, key_points, and optional notes; leave the array empty when evidence is too weak).\n7. Return JSON that matches the schema exactly; omit commentary.\n\nSCHEMA\n\"condition\": string\n\"drugs\": [{\"id\": \"drug:identifier\", \"name\": string, \"classifications\": [string], \"atc_codes\": [string], \"claims\": [\"claim:identifier\"]}]\n\"claims\": [{\"id\": \"claim:identifier\", \"type\": \"risk | safety | uncertain | nuanced\", \"summary\": string, \"confidence\": \"low | medium | high\", \"idiosyncratic_reaction\": {\"flag\": true | false, \"descriptors\": [string]}, \"articles\": [\"article:identifier\"], \"drugs\": [\"drug:identifier\"], \"supporting_evidence\": [{\"snippet_id\": string, \"pmid\": string, \"article_title\": string, \"key_points\": [string], \"notes\": string}]}]\nSAMPLE RESPONSE\n{\n  \"condition\": \"Central core disease\",\n  \"drugs\": [\n    {\"id\": \"drug:succinylcholine\", \"name\": \"Succinylcholine\", \"classifications\": [\"neuromuscular blocker\"], \"atc_codes\": [\"M03AB01\"], \"claims\": [\"claim:malignant-hyperthermia\"]},\n    {\"id\": \"drug:volatile-anaesthetics\", \"name\": \"Volatile anaesthetics\", \"classifications\": [\"inhalational anesthetic\"], \"atc_codes\": [\"N01AB\"], \"claims\": [\"claim:malignant-hyperthermia\"]}\n  ],\n  \"claims\": [{\"id\": \"claim:malignant-hyperthermia\", \"type\": \"risk\", \"summary\": \"Malignant hyperthermia recurred after depolarising neuromuscular blockers in susceptible patients.\", \"confidence\": \"high\", \"idiosyncratic_reaction\": {\"flag\": true, \"descriptors\": [\"malignant hyperthermia\"]}, \"articles\": [\"article:33190635\"], \"drugs\": [\"drug:succinylcholine\", \"drug:volatile-anaesthetics\"], \"supporting_evidence\": [{\"snippet_id\": \"snippet:33190635-1\", \"pmid\": \"33190635\", \"article_title\": \"Ryanodine receptor 1-related disorders: an historical perspective and proposal for a unified nomenclature.\", \"key_points\": [\"Volatile anesthetics and depolarising neuromuscular blockers triggered malignant hyperthermia events in susceptible patients.\"], \"notes\": \"\"}]}]\n}\n\n\nSnippets (full listing):\n1. snippet_id: 36\n   article_id: article:27052088\n   article_title: Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.\n   classification: risk\n   cues: avoid, avoided, unsafe, recommended, safe, safely\n   related_drugs: midazolam\n   snippet: ne has been shown to induce porphyrin synthesis in animal models[ 20 ] but has been used safely in patients. Reports of a possible association of halothane with crises contradict both experimental and clinical experience.[ 23 24 ] Preoperative starvation should be minimized; if a prolonged fast is unavoidable, a dextrose\u2013saline infusion should be given during the preoperative period. In view of the frequency with which hyponatremia is encountered in acute attacks, the IV fluids containing dextrose alone should be avoided. Most (but not all) benzodiazepines commonly used for premedication like midazolam, are considered safe. The phenothiazines may have particular advantages.[ 25 ] Good anxiolysis has been recommended as advantageous. Where antacid administration is considered appropriate, sodium citrate may be given, and ranitidine may be considered. Cimetidine has been recommended for the treatment of acute porphyric crises since it may decrease heme consumption and inhibit aminolevulinic acid (ALA) synthesis activity.[ 10 ] The barbiturates are the archetypal inducers of ALA synthesis, and all barbiturates, including thiopental, must be considered unsafe. Although there are numerous report\n2. snippet_id: 37\n   article_id: article:27052088\n   article_title: Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.\n   classification: risk\n   cues: avoid, complication, safe, safety, successfully\n   related_drugs: atracurium\n   snippet: PB is a specific problem,[ 13 14 15 16 ] we used it uneventfully. Blood loss, with its consequent increase in heme demand by the bone marrow, does not appear to stress the heme synthetic pathway sufficiently to provoke a porphyric crisis.[ 38 ] CONCLUSION It can be told that although there are different educational sources which safety of the drugs in AIP can be checked, utilizing a specific drug regimen can be sophisticated; because the various interaction between drugs can lead to a catastrophic income. In this case, we successfully used fentanyl in combination with propofol, midazolam, and atracurium with no disadvantage. On-pump surgery method was used uneventfully for this patient with avoiding deep hypothermia. Furthermore, the feasibility of fast-track anesthesia usage as a safe anesthesia technique and plan, in this case, is proved. The patient was discharged from ICU without any complication and therefore, the safety of the proper approach for TV replacement was accepted. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.\n3. snippet_id: 38\n   article_id: article:27052088\n   article_title: Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.\n   classification: risk\n   cues: avoid, avoided, recommended, safe, safely\n   related_drugs: benzodiazepines\n   snippet: ugh further information needs to be obtained. Enflurane has been shown to induce porphyrin synthesis in animal models[ 20 ] but has been used safely in patients. Reports of a possible association of halothane with crises contradict both experimental and clinical experience.[ 23 24 ] Preoperative starvation should be minimized; if a prolonged fast is unavoidable, a dextrose\u2013saline infusion should be given during the preoperative period. In view of the frequency with which hyponatremia is encountered in acute attacks, the IV fluids containing dextrose alone should be avoided. Most (but not all) benzodiazepines commonly used for premedication like midazolam, are considered safe. The phenothiazines may have particular advantages.[ 25 ] Good anxiolysis has been recommended as advantageous. Where antacid administration is considered appropriate, sodium citrate may be given, and ranitidine may be considered. Cimetidine has been recommended for the treatment of acute porphyric crises since it may decrease heme consumption and inhibit aminolevulinic acid (ALA) synthesis activity.[ 10 ] The barbiturates are the archetypal inducers of ALA synthesis, and all barbiturates, including thiopental, must be consid\n4. snippet_id: 39\n   article_id: article:27052088\n   article_title: Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.\n   classification: risk\n   cues: avoid, complication, safe, safety, successfully\n   related_drugs: fentanyl\n   snippet: indomethacin and naproxen have proven safe. However, CPB is a specific problem,[ 13 14 15 16 ] we used it uneventfully. Blood loss, with its consequent increase in heme demand by the bone marrow, does not appear to stress the heme synthetic pathway sufficiently to provoke a porphyric crisis.[ 38 ] CONCLUSION It can be told that although there are different educational sources which safety of the drugs in AIP can be checked, utilizing a specific drug regimen can be sophisticated; because the various interaction between drugs can lead to a catastrophic income. In this case, we successfully used fentanyl in combination with propofol, midazolam, and atracurium with no disadvantage. On-pump surgery method was used uneventfully for this patient with avoiding deep hypothermia. Furthermore, the feasibility of fast-track anesthesia usage as a safe anesthesia technique and plan, in this case, is proved. The patient was discharged from ICU without any complication and therefore, the safety of the proper approach for TV replacement was accepted. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.\n5. snippet_id: 41\n   article_id: article:27052088\n   article_title: Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.\n   classification: risk\n   cues: avoid, complication, safe, safety, successfully\n   related_drugs: midazolam\n   snippet: afe. However, CPB is a specific problem,[ 13 14 15 16 ] we used it uneventfully. Blood loss, with its consequent increase in heme demand by the bone marrow, does not appear to stress the heme synthetic pathway sufficiently to provoke a porphyric crisis.[ 38 ] CONCLUSION It can be told that although there are different educational sources which safety of the drugs in AIP can be checked, utilizing a specific drug regimen can be sophisticated; because the various interaction between drugs can lead to a catastrophic income. In this case, we successfully used fentanyl in combination with propofol, midazolam, and atracurium with no disadvantage. On-pump surgery method was used uneventfully for this patient with avoiding deep hypothermia. Furthermore, the feasibility of fast-track anesthesia usage as a safe anesthesia technique and plan, in this case, is proved. The patient was discharged from ICU without any complication and therefore, the safety of the proper approach for TV replacement was accepted. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.\n6. snippet_id: 42\n   article_id: article:27052088\n   article_title: Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.\n   classification: risk\n   cues: avoid, complication, safe, safety, successfully\n   related_drugs: propofol\n   snippet: e proven safe. However, CPB is a specific problem,[ 13 14 15 16 ] we used it uneventfully. Blood loss, with its consequent increase in heme demand by the bone marrow, does not appear to stress the heme synthetic pathway sufficiently to provoke a porphyric crisis.[ 38 ] CONCLUSION It can be told that although there are different educational sources which safety of the drugs in AIP can be checked, utilizing a specific drug regimen can be sophisticated; because the various interaction between drugs can lead to a catastrophic income. In this case, we successfully used fentanyl in combination with propofol, midazolam, and atracurium with no disadvantage. On-pump surgery method was used uneventfully for this patient with avoiding deep hypothermia. Furthermore, the feasibility of fast-track anesthesia usage as a safe anesthesia technique and plan, in this case, is proved. The patient was discharged from ICU without any complication and therefore, the safety of the proper approach for TV replacement was accepted. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.\n7. snippet_id: 45\n   article_id: article:36575494\n   article_title: Porphyria: a case report.\n   classification: risk\n   cues: complication, complications, life-threatening, trigger\n   related_drugs: benzodiazepines\n   snippet: urbances. Any impediment in the diagnosis of an acute porphyric attack may further aggravate the neurological symptoms inciting irreversible damage. Failure to identify neurovisceral symptoms like muscle weaknesses at an early stage may cause the patient to succumb to respiratory muscle paralysis, an important complication of porphyria which is life-threatening [ 10 , 11 ]. Timely diagnosis is a subject of clinical acuity in the management of porphyria [ 12 ], which also aids in the exemption of alternative diagnosis. The first-line treatment options for seizures include phenytoin, valproate, benzodiazepines, and lacosamide, among which many are porphyrinogenic [ 13 ]. The porphyrinogenic anti-seizure drugs are metabolized by cytochrome p450 enzymes in the liver that leads to increased heme synthesis, which results in increased heme precursors further provoking the porphyria crises [ 14 ]. Management of seizures with medications possessing porphyrinogenic potential, unaware of the porphyric status of the patient, can trigger acute attacks [ 15 ]. Neurological complications mostly comprise peripheral neuropathy, acute encephalopathy, and acute symptomatic seizures [ 9 ]. Seizures in patients with\n8. snippet_id: 44\n   article_id: article:35164799\n   article_title: A boy with blistering of sun-exposed skin and finger shortening: the first case of Variegate Porphyria with a novel mutation in protoporphyrinogen oxidase (PPOX) gene in Iran: a case report and literature review.\n   classification: risk\n   cues: condition-match\n   related_drugs: levetiracetam\n   snippet: . Molecular test analysis with whole exome sequencing (WES) was performed to consider any possible mutations. The WES result reported a novel homozygous pathogenic variant (c.1072G > A p.G358R) in PPOX gene which indicates the Porphyria Variegate. This pathogenic variant has not been reported previously. In the follow-up, after completing 2 years of treatment, phenobarbital was tapered, but he had developed another episode of status GTC and admitted at hospital. Brian MRI was immediately done and showed normal results. Since it was better not to use phenobarbital for this case, treatment with levetiracetam has been started. To improve skin symptoms, he had been advised to be away from the sun and use sunscreen regularly. He had also aggressive behavior, learning disability and abdominal pain, particularly around the navel. Discussion Variegate porphyria is a very rare and autosomal dominant disorder which is caused by the mutations in protoporphyrinogen oxidase. PPOX is one of the fundamental enzymes responsible for the synthesis of heme, as a main part of hemoglobin and other hemoproteins. Porphyrins are essential for hemoglobin function. When PPOX is deficient, porphyrins are oxidized to prot\n9. snippet_id: 47\n   article_id: article:29097018\n   article_title: Antiepileptic Drugs and Liver Disease.\n   classification: risk\n   cues: precipitate, side effect, toxic, toxicity, safe\n   related_drugs: benzodiazepines\n   snippet: pentin, and pregabalin should be used as first-line therapy. Medications undergoing extensive hepatic metabolism, such as valproic acid, phenytoin, and felbamate should be used as drugs of last resort. In special circumstances, as in patients affected by acute intermittent porphyria, exposure to most antiepileptic drugs could precipitate attacks. In this clinical scenario, bromides, levetiracetam, gabapentin, and vigabatrin constitute safe choices. For the treatment of status epilepticus, levetiracetam and lacosamide, available in intravenous preparations, are good second-line therapies after benzodiazepines fail to control seizures. Hepatotoxicity is also a rare and unexpected side effect of some antiepileptic drugs. Drugs such as valproic acid, phenytoin, and felbamate, have a well-recognized association with liver toxicity. Other antiepileptic drugs, including phenobarbital, benzodiazepines, ethosuximide, and the newer generations of antiepileptic drugs, have only rarely been linked to hepatotoxicity. Thus physicians should be mindful of the pharmacokinetic profile and the hepatotoxic potential of the different antiepileptic drugs available to treat patients affected by liver disease.\n10. snippet_id: 48\n   article_id: article:29097018\n   article_title: Antiepileptic Drugs and Liver Disease.\n   classification: risk\n   cues: precipitate, side effect, toxic, toxicity, safe\n   related_drugs: levetiracetam\n   snippet: anced liver disease and reviews the hepatotoxic potential of specific antiepileptic drugs. Newer antiepileptic drugs without, or with minimal, hepatic metabolism, such as levetiracetam, lacosamide, topiramate, gabapentin, and pregabalin should be used as first-line therapy. Medications undergoing extensive hepatic metabolism, such as valproic acid, phenytoin, and felbamate should be used as drugs of last resort. In special circumstances, as in patients affected by acute intermittent porphyria, exposure to most antiepileptic drugs could precipitate attacks. In this clinical scenario, bromides, levetiracetam, gabapentin, and vigabatrin constitute safe choices. For the treatment of status epilepticus, levetiracetam and lacosamide, available in intravenous preparations, are good second-line therapies after benzodiazepines fail to control seizures. Hepatotoxicity is also a rare and unexpected side effect of some antiepileptic drugs. Drugs such as valproic acid, phenytoin, and felbamate, have a well-recognized association with liver toxicity. Other antiepileptic drugs, including phenobarbital, benzodiazepines, ethosuximide, and the newer generations of antiepileptic drugs, have only rarely been linke\n11. snippet_id: 49\n   article_id: article:29097018\n   article_title: Antiepileptic Drugs and Liver Disease.\n   classification: risk\n   cues: precipitate, side effect, toxic, toxicity, safe\n   related_drugs: levetiracetam\n   snippet: ic drugs without, or with minimal, hepatic metabolism, such as levetiracetam, lacosamide, topiramate, gabapentin, and pregabalin should be used as first-line therapy. Medications undergoing extensive hepatic metabolism, such as valproic acid, phenytoin, and felbamate should be used as drugs of last resort. In special circumstances, as in patients affected by acute intermittent porphyria, exposure to most antiepileptic drugs could precipitate attacks. In this clinical scenario, bromides, levetiracetam, gabapentin, and vigabatrin constitute safe choices. For the treatment of status epilepticus, levetiracetam and lacosamide, available in intravenous preparations, are good second-line therapies after benzodiazepines fail to control seizures. Hepatotoxicity is also a rare and unexpected side effect of some antiepileptic drugs. Drugs such as valproic acid, phenytoin, and felbamate, have a well-recognized association with liver toxicity. Other antiepileptic drugs, including phenobarbital, benzodiazepines, ethosuximide, and the newer generations of antiepileptic drugs, have only rarely been linked to hepatotoxicity. Thus physicians should be mindful of the pharmacokinetic profile and the hepatotoxic po\n12. snippet_id: 50\n   article_id: article:29097018\n   article_title: Antiepileptic Drugs and Liver Disease.\n   classification: risk\n   cues: precipitate, toxic, safe\n   related_drugs: levetiracetam\n   snippet: Acute, symptomatic seizures or epilepsy may complicate the course of hepatic disease. Choosing the most appropriate antiepileptic drug in this setting represents a difficult challenge, as most medications are metabolized by the liver. This article focuses on the acute and chronic treatment of seizures in patients with advanced liver disease and reviews the hepatotoxic potential of specific antiepileptic drugs. Newer antiepileptic drugs without, or with minimal, hepatic metabolism, such as levetiracetam, lacosamide, topiramate, gabapentin, and pregabalin should be used as first-line therapy. Medications undergoing extensive hepatic metabolism, such as valproic acid, phenytoin, and felbamate should be used as drugs of last resort. In special circumstances, as in patients affected by acute intermittent porphyria, exposure to most antiepileptic drugs could precipitate attacks. In this clinical scenario, bromides, levetiracetam, gabapentin, and vigabatrin constitute safe choices. For the treatment of status epilepticus, levetiracetam and lacosamide, available in intravenous preparations, are goo\n13. snippet_id: 62\n   article_id: article:39313028\n   article_title: Therapeutic approach to acute crises of hepatic porphyrias.\n   classification: risk\n   cues: toxic, trigger, triggered, triggering, prevent\n   related_drugs: opioids\n   snippet: ks in acute hepatic porphyria are triggered by the induction of hepatic ALA synthase 1, leading to the accumulation of neurotoxic heme intermediates, delta-aminolevulinic acid, and porphobilinogen. Women experience attacks more frequently than men. Acute porphyria attacks are characterized by severe, diffuse abdominal pain, muscle weakness, autonomic neuropathy (including hypertension, tachycardia, nausea, vomiting, and constipation), and changes in mental status. Early recognition of the disease is crucial as it requires urgent medical attention and treatment. Management includes intravenous opioids, glucose, hemin, and the removal of triggering factors. Preventive treatment options include hormone suppression therapy, off-label prophylactic hemin, Givosiran, and exceptionally liver transplantation.\n14. snippet_id: 67\n   article_id: article:17190918\n   article_title: Optimizing therapy of seizures in patients with renal or hepatic dysfunction.\n   classification: risk\n   cues: avoid, avoided, toxic, toxicity, effective\n   related_drugs: levetiracetam\n   snippet: d phenytoin. Valproate, lamotrigine, and benzodiazepines are less affected. Low protein-bound AEDs are extensively removed by hemodialysis and supplemental doses are required for dialysis patients. Uremia and related conditions, including intracranial hemorrhage, glucose and electrolyte imbalances, and concomitant drug use, can cause seizures, as can dialysis encephalopathy, primary cerebral lymphoma, fungal infections, and immunosuppressant toxicity in renal transplant recipients. Hepatic dysfunction reduces enzymatic metabolism of AEDs and causes hypoalbuminemia. Gabapentin, topiramate, and levetiracetam are preferred in these conditions, whereas conversely valproate and felbamate are potentially hepatotoxic and should be avoided. Seizures related to hepatic encephalopathy are controlled by oral lactulose or neomycin. Porphyria sufferers may benefit from gabapentin, oxcarbazepine, or levetiracetam. Seizures in Wilson's disease may derive from d-penicillamine-induced pyridoxine deficiency. Effective treatment of seizures in renal and hepatic diseases requires attention to changes in AED pharmacokinetics and adequate care of the underlying illnesses. Monitoring of free drug concentrations is a\n15. snippet_id: 68\n   article_id: article:17190918\n   article_title: Optimizing therapy of seizures in patients with renal or hepatic dysfunction.\n   classification: risk\n   cues: avoid, avoided, toxic, toxicity, effective\n   related_drugs: levetiracetam\n   snippet: and concomitant drug use, can cause seizures, as can dialysis encephalopathy, primary cerebral lymphoma, fungal infections, and immunosuppressant toxicity in renal transplant recipients. Hepatic dysfunction reduces enzymatic metabolism of AEDs and causes hypoalbuminemia. Gabapentin, topiramate, and levetiracetam are preferred in these conditions, whereas conversely valproate and felbamate are potentially hepatotoxic and should be avoided. Seizures related to hepatic encephalopathy are controlled by oral lactulose or neomycin. Porphyria sufferers may benefit from gabapentin, oxcarbazepine, or levetiracetam. Seizures in Wilson's disease may derive from d-penicillamine-induced pyridoxine deficiency. Effective treatment of seizures in renal and hepatic diseases requires attention to changes in AED pharmacokinetics and adequate care of the underlying illnesses. Monitoring of free drug concentrations is a valuable aid to therapy.\n16. snippet_id: 89\n   article_id: article:17037005\n   article_title: The use of rocuronium and sevoflurane in acute intermittent porphyria--a case report.\n   classification: risk\n   cues: fatal, precipitate, recommended, safe\n   related_drugs: desflurane, halothane, isoflurane, sevoflurane\n   snippet: ) is an inherited metabolic disorder caused by deficiency of porphobilinogen deaminase, an enzyme found in the synthetic pathway of heme. Acute attack of AIP may be precipitated by many factors during operation and anesthesia, including fasting, dehydration, stress, infection, and drugs. Acute attack of AIP is likely fatal. Therefore, the drugs recommended as being safe in anesthesia for porphyria patients are up-to-dately refreshed and renovated and the identification of whether a drug is safe or not is based on cumulative anecdotal experiences. Here, we report the safe use of rocuronium and sevoflurane for long exposure in a patient affected with acute intermittent porphyria.\n17. snippet_id: 92\n   article_id: article:25137868\n   article_title: Ultrasound-guided regional anesthesia in a pediatric patient with acute intermittent porphyria: literature review and case report.\n   classification: risk\n   cues: trigger, safe, without complications\n   related_drugs: propofol\n   snippet: Ultrasound-guided regional anesthesia techniques placed under general anesthesia have not been reported in pediatric patients with acute intermittent porphyria (AIP). A 9-year-old male with AIP presented for right inguinal herniorraphy. Family history included one relative's death after anesthesia. Preoperative preparation included reviewing medications safe for AIP patients, minimizing known AIP triggers (fasting, stress) and ensuring access to rescue medications. Intraoperative management included a propofol induction with the patient's mother present in the operating room. We performed an ultrasound-guided ilioinguinal-iliohypogastric nerve block under general anesthesia. The surgery proceeded without complications and the patient did not demonstrate signs of an AIP crisis.\n18. snippet_id: 55\n   article_id: article:1418699\n   article_title: Adverse effects of general anaesthetics.\n   classification: risk\n   cues: life-threatening, toxic, toxicity, trigger, triggered, triggering\n   related_drugs: desflurane, halothane, isoflurane, sevoflurane\n   snippet: ession of the medullary vital centres which can lead to cardiorespiratory failure. Both groups of agents have some depressant effect on the myocardium and vascular smooth muscle leading to a fall in cardiac output and hypotension. Centrally-mediated respiratory depression is common to both groups and the inhalational agents have a direct effect on lung physiology. The most important idiosyncratic reactions to the volatile agents are malignant hyperpyrexia and 'halothane hepatitis'. Malignant hyperpyrexia has an incidence of 1:12,000 with a mortality of about 24%. It is triggered most often by halothane together with suxamethonium. Post halothane hepatic necrosis is rare. Evidence points to 2 distinct syndromes; direct toxicity from the products of reductive metabolism, and a more serious illness, immunologically mediated via haptens formed by liver proteins and the products of oxidative metabolism. Prolonged nitrous oxide exposure can cause bone marrow depression and life-threatening pressure effects by expansion of air-filled spaces within the body. The idiosyncratic reactions to the intravenous agents include anaphylactoid reactions (which are rare) and triggering of acute porphyria. Etom\n19. snippet_id: 52\n   article_id: article:16296947\n   article_title: Pharmacogenetics and anesthesiologists.\n   classification: risk\n   cues: malignant hyperthermia\n   related_drugs: succinylcholine\n   snippet: Genetic variation contributes to an individual's sensitivity and response to a variety of drugs important to anesthetic practice. Early insights into the clinical impact of pharmacogenetics were provided by anesthesiology--investigations into prolonged apnea after succinylcholine administration, thiopental-induced porphyria and malignant hyperthermia contributed to the novel science of pharmacogenetics in the early 1960s. Genetic polymorphisms involved in pharmacokinetics (absorption, distribution, metabolism, and excretion of drugs) and pharmacodynamics (receptors, ion channels and enzymes) can affect an individual's response to the drugs used in anesthetic practice. In addition, genetic variation in proteins directly unrelated to drug action or metabolism can influence responses to environmental changes that occur during anesthesia. This review will summarize the cu\n20. snippet_id: 83\n   article_id: article:1997060\n   article_title: Propofol as an i.v. anaesthetic induction agent in variegate porphyria.\n   classification: risk\n   cues: condition-match\n   related_drugs: propofol\n   snippet: The choice of an i.v. anaesthetic induction poses problems for the anaesthetist confronted with a patient with one of the acute porphyrias. We undertook a prospective clinical trial in 13 variegate porphyric subjects using propofol as an anaesthetic induction agent. Urinary porphyrin precursors and porphyrins were measured before operation and 1-5 days after operation. Stool and plasma porphyrin concentrations were measured over the same period. Comparison of these data in the porphyric patients and in 21 control subjects over the trial period revealed no significant change in porphyrin or porphyrin precursor output after operation. Urinary porphyrin precursor concentrations did not exceed the limits established for variegate porphyric patients in remission, and there were no changes in the stool and plasma porphyrin pr\n21. snippet_id: 87\n   article_id: article:21146060\n   article_title: Neuropathic pain in a patient with porphyria. Case report.\n   classification: risk\n   cues: trigger, indicated\n   related_drugs: opioid\n   snippet: An exploratory laparotomy was indicated, which failed to demonstrate a cause for her pain. The patient was exposed to surgical trauma and drugs that can trigger porphyria, such as ketoprophen, metoclopramide, and antibiotics, and she evolved with significant hyponatremia, increased liver enzymes, seizures, and loss of movements that led to be admitted to the Intensive Care Unit. After the diagnosis of porphyria was made, the patient remained with pain in the lower limbs, being referred to the Pain Department of Santa Casa de Miseric\u00f3rdia de S\u00e3o Paulo. Treatment with amitriptyline, gabapentin, opioid, and simple analgesics was instituted; however, the patient continued to present recurring episodes of porphyria and, feeling insecure with the conduction of the case, she stopped the treatment. Porphyria is one of the rare groups of enzymatic disorders that remain unknown by the great majority of health professionals. Upon recognizing this lack of knowledge about the disease, the level of stress and insecurity of the patient increases hindering adhesion to and continuity of the treatment.\n22. snippet_id: 74\n   article_id: article:10504904\n   article_title: Anesthetic considerations in hepatic porphyrias.\n   classification: risk\n   cues: avoid, trigger, triggering, prevent\n   related_drugs: benzodiazepines\n   snippet: Porphyrias are inherited defects of heme synthesis with manifestations that can mimic surgical diseases; they can be provoked by administration of certain drugs. Manifestations such as abdominal pain, vomiting, tachycardia, hypertension, neuropathy, fever, confusion, and seizures have been described. Management of patients with porphyria is designed to avoid triggering drugs, such as barbiturates, and perhaps, benzodiazepines and ketamines. Nontriggering drugs should be used in the management of patients with porphyria. Because starvation can induce an attack, glucose infusions are important in the prevention and treatment of porphyria.\n23. snippet_id: 93\n   article_id: article:23993340\n   article_title: [State of dementia due to intermittent acute porphyria: a case report].\n   classification: risk\n   cues: condition-match\n   related_drugs: benzodiazepines\n   snippet: are rare inherited disorders due to specific enzyme abnormalities of heme biosynthesis. We can classify them as hepatic or erythropo\u00efetic, the type depends on the organ in which the enzyme is deficient. Among the hepatic forms, three of them are clinically characterised by acute abdominal pain and neuropathy, sometimes associated with psychiatric disorders. This 58-year-old woman has been hospitalized frequently since 1995 with depression, apathy, or for suicide attempts. She has a history of alcohol addiction and since 1992 suffers from non-insulin dependant diabetes. She had been treated by benzodiazepines and neuroleptic medication for several years. Psychiatric examination revealed persecution and megalomania delirium associated with a Capgras syndrome, confusion, disorientation, depression and blunted affect. Results of neurologic examination showed reduced deep tendon reflexes, and nerve conduction revealed sensitive neuropathy. Moreover, she lay down, remained non-responsive and resisted care. The whole clinical picture evoked early dementia. Coloured urine was noticed and porphyria tested. When the diagnosis of intermittent acute porphyria was made, she gradually improved by stopping the\n24. snippet_id: 76\n   article_id: article:15021955\n   article_title: [Desflurane in acute intermittent porphyria].\n   classification: risk\n   cues: trigger, safe\n   related_drugs: desflurane, halothane, isoflurane, sevoflurane\n   snippet: incidence of the acute porphyrias, a profound knowledge of the disease is essential for anaesthesiologists, as a variety of perioperatively administered drugs are potential triggers of an acute attack. There is an ongoing discussion about the use of volatile anaesthetics in porphyrias, but halothane and isoflurane seem to be safe. There is no clinical data or case report about the use of desflurane in this specific patient group, but its fast and relatively unchanged elimination and the minimal induction of the cytochrome P 450 system seem to be favorable in this setting. We report the use of desflurane in a patient with acute intermittent porphyria, scheduled for hemihepatectomy. To minimize perioperative distress by pain or the need for postoperative mechanical ventilation, we chose a balanced anaesthesia technique with desflurane, sufentanil and atracurium in combination with a continuous epidural analgesia (bupivacain and fentanyl) for the postoperative period. Preoperatively the porphyrin precursors were analyzed in serum and urine and postoperatively the 24 h-urine was screened every 2 days until postoperative day 6 to monitor the porphyria activity. The preoperative data showed high c\n25. snippet_id: 77\n   article_id: article:15021955\n   article_title: [Desflurane in acute intermittent porphyria].\n   classification: risk\n   cues: trigger, safe\n   related_drugs: desflurane, halothane, isoflurane, sevoflurane\n   snippet: Despite the low incidence of the acute porphyrias, a profound knowledge of the disease is essential for anaesthesiologists, as a variety of perioperatively administered drugs are potential triggers of an acute attack. There is an ongoing discussion about the use of volatile anaesthetics in porphyrias, but halothane and isoflurane seem to be safe. There is no clinical data or case report about the use of desflurane in this specific patient group, but its fast and relatively unchanged elimination and the minimal induction of the cytochrome P 450 system seem to be favorable in this setting. We report the use of desflurane in a patient with acute intermittent porphyria, scheduled for hemihepatectomy. To minimize perioperative distress by pain or the need for postoperative mechanical ventilation, we chose a balanced anaesthesia technique with desflurane, sufentanil and atracurium in combination with a contin\n26. snippet_id: 78\n   article_id: article:15021955\n   article_title: [Desflurane in acute intermittent porphyria].\n   classification: risk\n   cues: trigger, safe\n   related_drugs: desflurane, halothane, isoflurane, sevoflurane\n   snippet: Despite the low incidence of the acute porphyrias, a profound knowledge of the disease is essential for anaesthesiologists, as a variety of perioperatively administered drugs are potential triggers of an acute attack. There is an ongoing discussion about the use of volatile anaesthetics in porphyrias, but halothane and isoflurane seem to be safe. There is no clinical data or case report about the use of desflurane in this specific patient group, but its fast and relatively unchanged elimination and the minimal induction of the cytochrome P 450 system seem to be favorable in this setting. We report the use of desflurane in a patient with acute intermittent porphyria, scheduled for hemihepatectomy. To minimize perioperative distress by pain or the need for postoperative mechanical ventilation, we chose a balanced anaesthesia technique with desflurane, sufentanil and atracurium in combination with a continuous epidural a\n27. snippet_id: 80\n   article_id: article:15021955\n   article_title: [Desflurane in acute intermittent porphyria].\n   classification: risk\n   cues: condition-match\n   related_drugs: fentanyl\n   snippet: s no clinical data or case report about the use of desflurane in this specific patient group, but its fast and relatively unchanged elimination and the minimal induction of the cytochrome P 450 system seem to be favorable in this setting. We report the use of desflurane in a patient with acute intermittent porphyria, scheduled for hemihepatectomy. To minimize perioperative distress by pain or the need for postoperative mechanical ventilation, we chose a balanced anaesthesia technique with desflurane, sufentanil and atracurium in combination with a continuous epidural analgesia (bupivacain and fentanyl) for the postoperative period. Preoperatively the porphyrin precursors were analyzed in serum and urine and postoperatively the 24 h-urine was screened every 2 days until postoperative day 6 to monitor the porphyria activity. The preoperative data showed high concentrations of porphyrin precursor excretion, confirming the diagnosis of AIP. The postoperative data in the 24 h-urine were significantly lower than preoperative levels and reached normal levels at postoperative day 5. There were no clinical symptoms of a porphyric attack during the postoperative hospitalization. The patient was disc\n28. snippet_id: 58\n   article_id: article:2697245\n   article_title: The pharmacology of propofol.\n   classification: risk\n   cues: caution, safe\n   related_drugs: fentanyl\n   snippet: tion, apnea, and a reduction in arterial blood pressure (BP) and cardiac output. Caution should be ascribed to its use in patients with coronary artery disease, where these effects may have the potential for producing myocardial ischemia. The hemodynamic responses to laryngoscopy and intubation are attenuated. The pharmacokinetic profile suggests suitability as an infusion for either maintenance of anesthesia or sedation. Use of propofol as an infusion during surgery may result in a further reduction in cardiac output, particularly with the concomitant administration of adjuvant increments of fentanyl. The ventilatory response to CO2 is depressed during such an infusion. The high clearance of propofol suggests that even after a prolonged infusion, recovery should be rapid. This finding has been confirmed in a series of studies establishing propofol as an ideal agent for use in a total IV anesthetic technique. Both the quality and speed of recovery, together with the absence of emetic sequelae, support the use of propofol in an outpatient setting. Propofol appears to have no long-term effect on adrenocortical function and appears safe for use in patients with acute intermittent porphyria an\n29. snippet_id: 71\n   article_id: article:8342401\n   article_title: Total intravenous anesthesia in South-African genetic porphyria (variegate porphyria).\n   classification: risk\n   cues: condition-match\n   related_drugs: propofol\n   snippet: The authors report the case of a female patient with South-African genetic porphyria who had to undergo hepatic tumorectomy under general anesthesia. The choice for propofol as the induction and maintenance agent using a balanced anesthetic technique led to a significant rise in urinary excretion of porphyrins without associated clinical manifestations. A short review of the literature on physiopathology of porphyrias and medicinal agents, susceptible to induce acute porphyric crisis follows. The authors conclude that the innocuity of propofol as induction and maintaining agent in the porphyric patient cannot be yet established without further studies.\n30. snippet_id: 69\n   article_id: article:17190918\n   article_title: Optimizing therapy of seizures in patients with renal or hepatic dysfunction.\n   classification: risk\n   cues: toxic, toxicity\n   related_drugs: benzodiazepines\n   snippet: Patients with epilepsy may suffer from renal or hepatic diseases that interfere with their antiepileptic drug (AED) treatment. Furthermore, such diseases may themselves cause seizures. Reduced renal function and hypoalbuminemia lead to accumulation of renally excreted AEDs, such as gabapentin, vigabatrin, topiramate, levetiracetam, and phenytoin. Valproate, lamotrigine, and benzodiazepines are less affected. Low protein-bound AEDs are extensively removed by hemodialysis and supplemental doses are required for dialysis patients. Uremia and related conditions, including intracranial hemorrhage, glucose and electrolyte imbalances, and concomitant drug use, can cause seizures, as can dialysis encephalopathy, primary cerebral lymphoma, fungal infections, and immunosuppressant toxicity in renal transplant recipients. Hepatic dysfunction reduces enzymatic metabolism of AEDs and causes hypoalbuminemia. Gabapentin, topiramate, and levetiracetam are preferred in these conditions, whereas\n31. snippet_id: 70\n   article_id: article:17190918\n   article_title: Optimizing therapy of seizures in patients with renal or hepatic dysfunction.\n   classification: risk\n   cues: toxic, toxicity\n   related_drugs: levetiracetam\n   snippet: Patients with epilepsy may suffer from renal or hepatic diseases that interfere with their antiepileptic drug (AED) treatment. Furthermore, such diseases may themselves cause seizures. Reduced renal function and hypoalbuminemia lead to accumulation of renally excreted AEDs, such as gabapentin, vigabatrin, topiramate, levetiracetam, and phenytoin. Valproate, lamotrigine, and benzodiazepines are less affected. Low protein-bound AEDs are extensively removed by hemodialysis and supplemental doses are required for dialysis patients. Uremia and related conditions, including intracranial hemorrhage, glucose and electrolyte imbalances, and concomitant drug use, can cause seizures, as can dialysis encephalopathy, primary cerebral lymphoma, fungal infections, and immunosuppressant toxicity in renal transplant recipients. Hepatic dysfunction reduces enzymatic metabolism of AEDs and causes hypoalbuminemia. Gabapentin, topiramate,\n\nReturn only JSON."
        }
      ],
      "snippets": [
        {
          "pmid": "27052088",
          "snippet_id": 36,
          "drug": "midazolam",
          "classification": "risk",
          "snippet_text": "ne has been shown to induce porphyrin synthesis in animal models[ 20 ] but has been used safely in patients. Reports of a possible association of halothane with crises contradict both experimental and clinical experience.[ 23 24 ] Preoperative starvation should be minimized; if a prolonged fast is unavoidable, a dextrose\u2013saline infusion should be given during the preoperative period. In view of the frequency with which hyponatremia is encountered in acute attacks, the IV fluids containing dextrose alone should be avoided. Most (but not all) benzodiazepines commonly used for premedication like midazolam, are considered safe. The phenothiazines may have particular advantages.[ 25 ] Good anxiolysis has been recommended as advantageous. Where antacid administration is considered appropriate, sodium citrate may be given, and ranitidine may be considered. Cimetidine has been recommended for the treatment of acute porphyric crises since it may decrease heme consumption and inhibit aminolevulinic acid (ALA) synthesis activity.[ 10 ] The barbiturates are the archetypal inducers of ALA synthesis, and all barbiturates, including thiopental, must be considered unsafe. Although there are numerous report",
          "snippet_score": 4.8462,
          "cues": [
            "avoid",
            "avoided",
            "unsafe",
            "recommended",
            "safe",
            "safely"
          ],
          "article_rank": 14,
          "article_score": 2.76,
          "citation_url": "https://doi.org/10.4103/0971-9784.179623",
          "article_title": "Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.",
          "content_source": "pmc-full-text",
          "token_estimate": 220
        },
        {
          "pmid": "27052088",
          "snippet_id": 37,
          "drug": "atracurium",
          "classification": "risk",
          "snippet_text": "PB is a specific problem,[ 13 14 15 16 ] we used it uneventfully. Blood loss, with its consequent increase in heme demand by the bone marrow, does not appear to stress the heme synthetic pathway sufficiently to provoke a porphyric crisis.[ 38 ] CONCLUSION It can be told that although there are different educational sources which safety of the drugs in AIP can be checked, utilizing a specific drug regimen can be sophisticated; because the various interaction between drugs can lead to a catastrophic income. In this case, we successfully used fentanyl in combination with propofol, midazolam, and atracurium with no disadvantage. On-pump surgery method was used uneventfully for this patient with avoiding deep hypothermia. Furthermore, the feasibility of fast-track anesthesia usage as a safe anesthesia technique and plan, in this case, is proved. The patient was discharged from ICU without any complication and therefore, the safety of the proper approach for TV replacement was accepted. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.",
          "snippet_score": 4.7462,
          "cues": [
            "avoid",
            "complication",
            "safe",
            "safety",
            "successfully"
          ],
          "article_rank": 14,
          "article_score": 2.76,
          "citation_url": "https://doi.org/10.4103/0971-9784.179623",
          "article_title": "Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.",
          "content_source": "pmc-full-text",
          "token_estimate": 215
        },
        {
          "pmid": "27052088",
          "snippet_id": 38,
          "drug": "benzodiazepines",
          "classification": "risk",
          "snippet_text": "ugh further information needs to be obtained. Enflurane has been shown to induce porphyrin synthesis in animal models[ 20 ] but has been used safely in patients. Reports of a possible association of halothane with crises contradict both experimental and clinical experience.[ 23 24 ] Preoperative starvation should be minimized; if a prolonged fast is unavoidable, a dextrose\u2013saline infusion should be given during the preoperative period. In view of the frequency with which hyponatremia is encountered in acute attacks, the IV fluids containing dextrose alone should be avoided. Most (but not all) benzodiazepines commonly used for premedication like midazolam, are considered safe. The phenothiazines may have particular advantages.[ 25 ] Good anxiolysis has been recommended as advantageous. Where antacid administration is considered appropriate, sodium citrate may be given, and ranitidine may be considered. Cimetidine has been recommended for the treatment of acute porphyric crises since it may decrease heme consumption and inhibit aminolevulinic acid (ALA) synthesis activity.[ 10 ] The barbiturates are the archetypal inducers of ALA synthesis, and all barbiturates, including thiopental, must be consid",
          "snippet_score": 4.7462,
          "cues": [
            "avoid",
            "avoided",
            "recommended",
            "safe",
            "safely"
          ],
          "article_rank": 14,
          "article_score": 2.76,
          "citation_url": "https://doi.org/10.4103/0971-9784.179623",
          "article_title": "Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.",
          "content_source": "pmc-full-text",
          "token_estimate": 221
        },
        {
          "pmid": "27052088",
          "snippet_id": 39,
          "drug": "fentanyl",
          "classification": "risk",
          "snippet_text": "indomethacin and naproxen have proven safe. However, CPB is a specific problem,[ 13 14 15 16 ] we used it uneventfully. Blood loss, with its consequent increase in heme demand by the bone marrow, does not appear to stress the heme synthetic pathway sufficiently to provoke a porphyric crisis.[ 38 ] CONCLUSION It can be told that although there are different educational sources which safety of the drugs in AIP can be checked, utilizing a specific drug regimen can be sophisticated; because the various interaction between drugs can lead to a catastrophic income. In this case, we successfully used fentanyl in combination with propofol, midazolam, and atracurium with no disadvantage. On-pump surgery method was used uneventfully for this patient with avoiding deep hypothermia. Furthermore, the feasibility of fast-track anesthesia usage as a safe anesthesia technique and plan, in this case, is proved. The patient was discharged from ICU without any complication and therefore, the safety of the proper approach for TV replacement was accepted. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.",
          "snippet_score": 4.7462,
          "cues": [
            "avoid",
            "complication",
            "safe",
            "safety",
            "successfully"
          ],
          "article_rank": 14,
          "article_score": 2.76,
          "citation_url": "https://doi.org/10.4103/0971-9784.179623",
          "article_title": "Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.",
          "content_source": "pmc-full-text",
          "token_estimate": 223
        },
        {
          "pmid": "27052088",
          "snippet_id": 41,
          "drug": "midazolam",
          "classification": "risk",
          "snippet_text": "afe. However, CPB is a specific problem,[ 13 14 15 16 ] we used it uneventfully. Blood loss, with its consequent increase in heme demand by the bone marrow, does not appear to stress the heme synthetic pathway sufficiently to provoke a porphyric crisis.[ 38 ] CONCLUSION It can be told that although there are different educational sources which safety of the drugs in AIP can be checked, utilizing a specific drug regimen can be sophisticated; because the various interaction between drugs can lead to a catastrophic income. In this case, we successfully used fentanyl in combination with propofol, midazolam, and atracurium with no disadvantage. On-pump surgery method was used uneventfully for this patient with avoiding deep hypothermia. Furthermore, the feasibility of fast-track anesthesia usage as a safe anesthesia technique and plan, in this case, is proved. The patient was discharged from ICU without any complication and therefore, the safety of the proper approach for TV replacement was accepted. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.",
          "snippet_score": 4.7462,
          "cues": [
            "avoid",
            "complication",
            "safe",
            "safety",
            "successfully"
          ],
          "article_rank": 14,
          "article_score": 2.76,
          "citation_url": "https://doi.org/10.4103/0971-9784.179623",
          "article_title": "Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.",
          "content_source": "pmc-full-text",
          "token_estimate": 217
        },
        {
          "pmid": "27052088",
          "snippet_id": 42,
          "drug": "propofol",
          "classification": "risk",
          "snippet_text": "e proven safe. However, CPB is a specific problem,[ 13 14 15 16 ] we used it uneventfully. Blood loss, with its consequent increase in heme demand by the bone marrow, does not appear to stress the heme synthetic pathway sufficiently to provoke a porphyric crisis.[ 38 ] CONCLUSION It can be told that although there are different educational sources which safety of the drugs in AIP can be checked, utilizing a specific drug regimen can be sophisticated; because the various interaction between drugs can lead to a catastrophic income. In this case, we successfully used fentanyl in combination with propofol, midazolam, and atracurium with no disadvantage. On-pump surgery method was used uneventfully for this patient with avoiding deep hypothermia. Furthermore, the feasibility of fast-track anesthesia usage as a safe anesthesia technique and plan, in this case, is proved. The patient was discharged from ICU without any complication and therefore, the safety of the proper approach for TV replacement was accepted. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.",
          "snippet_score": 4.7462,
          "cues": [
            "avoid",
            "complication",
            "safe",
            "safety",
            "successfully"
          ],
          "article_rank": 14,
          "article_score": 2.76,
          "citation_url": "https://doi.org/10.4103/0971-9784.179623",
          "article_title": "Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.",
          "content_source": "pmc-full-text",
          "token_estimate": 220
        },
        {
          "pmid": "36575494",
          "snippet_id": 45,
          "drug": "benzodiazepines",
          "classification": "risk",
          "snippet_text": "urbances. Any impediment in the diagnosis of an acute porphyric attack may further aggravate the neurological symptoms inciting irreversible damage. Failure to identify neurovisceral symptoms like muscle weaknesses at an early stage may cause the patient to succumb to respiratory muscle paralysis, an important complication of porphyria which is life-threatening [ 10 , 11 ]. Timely diagnosis is a subject of clinical acuity in the management of porphyria [ 12 ], which also aids in the exemption of alternative diagnosis. The first-line treatment options for seizures include phenytoin, valproate, benzodiazepines, and lacosamide, among which many are porphyrinogenic [ 13 ]. The porphyrinogenic anti-seizure drugs are metabolized by cytochrome p450 enzymes in the liver that leads to increased heme synthesis, which results in increased heme precursors further provoking the porphyria crises [ 14 ]. Management of seizures with medications possessing porphyrinogenic potential, unaware of the porphyric status of the patient, can trigger acute attacks [ 15 ]. Neurological complications mostly comprise peripheral neuropathy, acute encephalopathy, and acute symptomatic seizures [ 9 ]. Seizures in patients with",
          "snippet_score": 4.7244,
          "cues": [
            "complication",
            "complications",
            "life-threatening",
            "trigger"
          ],
          "article_rank": 18,
          "article_score": 2.46,
          "citation_url": "https://doi.org/10.1186/s13256-022-03708-w",
          "article_title": "Porphyria: a case report.",
          "content_source": "pmc-full-text",
          "token_estimate": 220
        },
        {
          "pmid": "35164799",
          "snippet_id": 44,
          "drug": "levetiracetam",
          "classification": "risk",
          "snippet_text": ". Molecular test analysis with whole exome sequencing (WES) was performed to consider any possible mutations. The WES result reported a novel homozygous pathogenic variant (c.1072G > A p.G358R) in PPOX gene which indicates the Porphyria Variegate. This pathogenic variant has not been reported previously. In the follow-up, after completing 2 years of treatment, phenobarbital was tapered, but he had developed another episode of status GTC and admitted at hospital. Brian MRI was immediately done and showed normal results. Since it was better not to use phenobarbital for this case, treatment with levetiracetam has been started. To improve skin symptoms, he had been advised to be away from the sun and use sunscreen regularly. He had also aggressive behavior, learning disability and abdominal pain, particularly around the navel. Discussion Variegate porphyria is a very rare and autosomal dominant disorder which is caused by the mutations in protoporphyrinogen oxidase. PPOX is one of the fundamental enzymes responsible for the synthesis of heme, as a main part of hemoglobin and other hemoproteins. Porphyrins are essential for hemoglobin function. When PPOX is deficient, porphyrins are oxidized to prot",
          "snippet_score": 4.4894,
          "cues": [
            "condition-match"
          ],
          "article_rank": 15,
          "article_score": 2.6,
          "citation_url": "https://doi.org/10.1186/s13052-022-01215-8",
          "article_title": "A boy with blistering of sun-exposed skin and finger shortening: the first case of Variegate Porphyria with a novel mutation in protoporphyrinogen oxidase (PPOX) gene in Iran: a case report and literature review.",
          "content_source": "pmc-full-text",
          "token_estimate": 231
        },
        {
          "pmid": "29097018",
          "snippet_id": 47,
          "drug": "benzodiazepines",
          "classification": "risk",
          "snippet_text": "pentin, and pregabalin should be used as first-line therapy. Medications undergoing extensive hepatic metabolism, such as valproic acid, phenytoin, and felbamate should be used as drugs of last resort. In special circumstances, as in patients affected by acute intermittent porphyria, exposure to most antiepileptic drugs could precipitate attacks. In this clinical scenario, bromides, levetiracetam, gabapentin, and vigabatrin constitute safe choices. For the treatment of status epilepticus, levetiracetam and lacosamide, available in intravenous preparations, are good second-line therapies after benzodiazepines fail to control seizures. Hepatotoxicity is also a rare and unexpected side effect of some antiepileptic drugs. Drugs such as valproic acid, phenytoin, and felbamate, have a well-recognized association with liver toxicity. Other antiepileptic drugs, including phenobarbital, benzodiazepines, ethosuximide, and the newer generations of antiepileptic drugs, have only rarely been linked to hepatotoxicity. Thus physicians should be mindful of the pharmacokinetic profile and the hepatotoxic potential of the different antiepileptic drugs available to treat patients affected by liver disease.",
          "snippet_score": 3.0567,
          "cues": [
            "precipitate",
            "side effect",
            "toxic",
            "toxicity",
            "safe"
          ],
          "article_rank": 26,
          "article_score": 1.4000000000000001,
          "citation_url": "https://doi.org/10.1016/j.pediatrneurol.2017.09.013",
          "article_title": "Antiepileptic Drugs and Liver Disease.",
          "content_source": "pubmed-abstract",
          "token_estimate": 200
        },
        {
          "pmid": "29097018",
          "snippet_id": 48,
          "drug": "levetiracetam",
          "classification": "risk",
          "snippet_text": "anced liver disease and reviews the hepatotoxic potential of specific antiepileptic drugs. Newer antiepileptic drugs without, or with minimal, hepatic metabolism, such as levetiracetam, lacosamide, topiramate, gabapentin, and pregabalin should be used as first-line therapy. Medications undergoing extensive hepatic metabolism, such as valproic acid, phenytoin, and felbamate should be used as drugs of last resort. In special circumstances, as in patients affected by acute intermittent porphyria, exposure to most antiepileptic drugs could precipitate attacks. In this clinical scenario, bromides, levetiracetam, gabapentin, and vigabatrin constitute safe choices. For the treatment of status epilepticus, levetiracetam and lacosamide, available in intravenous preparations, are good second-line therapies after benzodiazepines fail to control seizures. Hepatotoxicity is also a rare and unexpected side effect of some antiepileptic drugs. Drugs such as valproic acid, phenytoin, and felbamate, have a well-recognized association with liver toxicity. Other antiepileptic drugs, including phenobarbital, benzodiazepines, ethosuximide, and the newer generations of antiepileptic drugs, have only rarely been linke",
          "snippet_score": 3.0567,
          "cues": [
            "precipitate",
            "side effect",
            "toxic",
            "toxicity",
            "safe"
          ],
          "article_rank": 26,
          "article_score": 1.4000000000000001,
          "citation_url": "https://doi.org/10.1016/j.pediatrneurol.2017.09.013",
          "article_title": "Antiepileptic Drugs and Liver Disease.",
          "content_source": "pubmed-abstract",
          "token_estimate": 198
        },
        {
          "pmid": "29097018",
          "snippet_id": 49,
          "drug": "levetiracetam",
          "classification": "risk",
          "snippet_text": "ic drugs without, or with minimal, hepatic metabolism, such as levetiracetam, lacosamide, topiramate, gabapentin, and pregabalin should be used as first-line therapy. Medications undergoing extensive hepatic metabolism, such as valproic acid, phenytoin, and felbamate should be used as drugs of last resort. In special circumstances, as in patients affected by acute intermittent porphyria, exposure to most antiepileptic drugs could precipitate attacks. In this clinical scenario, bromides, levetiracetam, gabapentin, and vigabatrin constitute safe choices. For the treatment of status epilepticus, levetiracetam and lacosamide, available in intravenous preparations, are good second-line therapies after benzodiazepines fail to control seizures. Hepatotoxicity is also a rare and unexpected side effect of some antiepileptic drugs. Drugs such as valproic acid, phenytoin, and felbamate, have a well-recognized association with liver toxicity. Other antiepileptic drugs, including phenobarbital, benzodiazepines, ethosuximide, and the newer generations of antiepileptic drugs, have only rarely been linked to hepatotoxicity. Thus physicians should be mindful of the pharmacokinetic profile and the hepatotoxic po",
          "snippet_score": 3.0567,
          "cues": [
            "precipitate",
            "side effect",
            "toxic",
            "toxicity",
            "safe"
          ],
          "article_rank": 26,
          "article_score": 1.4000000000000001,
          "citation_url": "https://doi.org/10.1016/j.pediatrneurol.2017.09.013",
          "article_title": "Antiepileptic Drugs and Liver Disease.",
          "content_source": "pubmed-abstract",
          "token_estimate": 200
        },
        {
          "pmid": "29097018",
          "snippet_id": 50,
          "drug": "levetiracetam",
          "classification": "risk",
          "snippet_text": "Acute, symptomatic seizures or epilepsy may complicate the course of hepatic disease. Choosing the most appropriate antiepileptic drug in this setting represents a difficult challenge, as most medications are metabolized by the liver. This article focuses on the acute and chronic treatment of seizures in patients with advanced liver disease and reviews the hepatotoxic potential of specific antiepileptic drugs. Newer antiepileptic drugs without, or with minimal, hepatic metabolism, such as levetiracetam, lacosamide, topiramate, gabapentin, and pregabalin should be used as first-line therapy. Medications undergoing extensive hepatic metabolism, such as valproic acid, phenytoin, and felbamate should be used as drugs of last resort. In special circumstances, as in patients affected by acute intermittent porphyria, exposure to most antiepileptic drugs could precipitate attacks. In this clinical scenario, bromides, levetiracetam, gabapentin, and vigabatrin constitute safe choices. For the treatment of status epilepticus, levetiracetam and lacosamide, available in intravenous preparations, are goo",
          "snippet_score": 2.8567,
          "cues": [
            "precipitate",
            "toxic",
            "safe"
          ],
          "article_rank": 26,
          "article_score": 1.4000000000000001,
          "citation_url": "https://doi.org/10.1016/j.pediatrneurol.2017.09.013",
          "article_title": "Antiepileptic Drugs and Liver Disease.",
          "content_source": "pubmed-abstract",
          "token_estimate": 189
        },
        {
          "pmid": "39313028",
          "snippet_id": 62,
          "drug": "opioids",
          "classification": "risk",
          "snippet_text": "ks in acute hepatic porphyria are triggered by the induction of hepatic ALA synthase 1, leading to the accumulation of neurotoxic heme intermediates, delta-aminolevulinic acid, and porphobilinogen. Women experience attacks more frequently than men. Acute porphyria attacks are characterized by severe, diffuse abdominal pain, muscle weakness, autonomic neuropathy (including hypertension, tachycardia, nausea, vomiting, and constipation), and changes in mental status. Early recognition of the disease is crucial as it requires urgent medical attention and treatment. Management includes intravenous opioids, glucose, hemin, and the removal of triggering factors. Preventive treatment options include hormone suppression therapy, off-label prophylactic hemin, Givosiran, and exceptionally liver transplantation.",
          "snippet_score": 2.46,
          "cues": [
            "toxic",
            "trigger",
            "triggered",
            "triggering",
            "prevent"
          ],
          "article_rank": 63,
          "article_score": 0.6000000000000001,
          "citation_url": "https://doi.org/10.1016/j.rceng.2024.09.004",
          "article_title": "Therapeutic approach to acute crises of hepatic porphyrias.",
          "content_source": "pubmed-abstract",
          "token_estimate": 136
        },
        {
          "pmid": "17190918",
          "snippet_id": 67,
          "drug": "levetiracetam",
          "classification": "risk",
          "snippet_text": "d phenytoin. Valproate, lamotrigine, and benzodiazepines are less affected. Low protein-bound AEDs are extensively removed by hemodialysis and supplemental doses are required for dialysis patients. Uremia and related conditions, including intracranial hemorrhage, glucose and electrolyte imbalances, and concomitant drug use, can cause seizures, as can dialysis encephalopathy, primary cerebral lymphoma, fungal infections, and immunosuppressant toxicity in renal transplant recipients. Hepatic dysfunction reduces enzymatic metabolism of AEDs and causes hypoalbuminemia. Gabapentin, topiramate, and levetiracetam are preferred in these conditions, whereas conversely valproate and felbamate are potentially hepatotoxic and should be avoided. Seizures related to hepatic encephalopathy are controlled by oral lactulose or neomycin. Porphyria sufferers may benefit from gabapentin, oxcarbazepine, or levetiracetam. Seizures in Wilson's disease may derive from d-penicillamine-induced pyridoxine deficiency. Effective treatment of seizures in renal and hepatic diseases requires attention to changes in AED pharmacokinetics and adequate care of the underlying illnesses. Monitoring of free drug concentrations is a",
          "snippet_score": 2.1026,
          "cues": [
            "avoid",
            "avoided",
            "toxic",
            "toxicity",
            "effective"
          ],
          "article_rank": 92,
          "article_score": 0.6000000000000001,
          "citation_url": "https://doi.org/10.1212/wnl.67.12_suppl_4.s28",
          "article_title": "Optimizing therapy of seizures in patients with renal or hepatic dysfunction.",
          "content_source": "pubmed-abstract",
          "token_estimate": 192
        },
        {
          "pmid": "17190918",
          "snippet_id": 68,
          "drug": "levetiracetam",
          "classification": "risk",
          "snippet_text": "and concomitant drug use, can cause seizures, as can dialysis encephalopathy, primary cerebral lymphoma, fungal infections, and immunosuppressant toxicity in renal transplant recipients. Hepatic dysfunction reduces enzymatic metabolism of AEDs and causes hypoalbuminemia. Gabapentin, topiramate, and levetiracetam are preferred in these conditions, whereas conversely valproate and felbamate are potentially hepatotoxic and should be avoided. Seizures related to hepatic encephalopathy are controlled by oral lactulose or neomycin. Porphyria sufferers may benefit from gabapentin, oxcarbazepine, or levetiracetam. Seizures in Wilson's disease may derive from d-penicillamine-induced pyridoxine deficiency. Effective treatment of seizures in renal and hepatic diseases requires attention to changes in AED pharmacokinetics and adequate care of the underlying illnesses. Monitoring of free drug concentrations is a valuable aid to therapy.",
          "snippet_score": 2.1026,
          "cues": [
            "avoid",
            "avoided",
            "toxic",
            "toxicity",
            "effective"
          ],
          "article_rank": 92,
          "article_score": 0.6000000000000001,
          "citation_url": "https://doi.org/10.1212/wnl.67.12_suppl_4.s28",
          "article_title": "Optimizing therapy of seizures in patients with renal or hepatic dysfunction.",
          "content_source": "pubmed-abstract",
          "token_estimate": 155
        },
        {
          "pmid": "17037005",
          "snippet_id": 89,
          "drug": "sevoflurane",
          "classification": "risk",
          "snippet_text": ") is an inherited metabolic disorder caused by deficiency of porphobilinogen deaminase, an enzyme found in the synthetic pathway of heme. Acute attack of AIP may be precipitated by many factors during operation and anesthesia, including fasting, dehydration, stress, infection, and drugs. Acute attack of AIP is likely fatal. Therefore, the drugs recommended as being safe in anesthesia for porphyria patients are up-to-dately refreshed and renovated and the identification of whether a drug is safe or not is based on cumulative anecdotal experiences. Here, we report the safe use of rocuronium and sevoflurane for long exposure in a patient affected with acute intermittent porphyria.",
          "snippet_score": 1.8026,
          "cues": [
            "fatal",
            "precipitate",
            "recommended",
            "safe"
          ],
          "article_rank": 169,
          "article_score": 0.4,
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/17037005/",
          "article_title": "The use of rocuronium and sevoflurane in acute intermittent porphyria--a case report.",
          "content_source": "pubmed-abstract",
          "token_estimate": 138
        },
        {
          "pmid": "25137868",
          "snippet_id": 92,
          "drug": "propofol",
          "classification": "risk",
          "snippet_text": "Ultrasound-guided regional anesthesia techniques placed under general anesthesia have not been reported in pediatric patients with acute intermittent porphyria (AIP). A 9-year-old male with AIP presented for right inguinal herniorraphy. Family history included one relative's death after anesthesia. Preoperative preparation included reviewing medications safe for AIP patients, minimizing known AIP triggers (fasting, stress) and ensuring access to rescue medications. Intraoperative management included a propofol induction with the patient's mother present in the operating room. We performed an ultrasound-guided ilioinguinal-iliohypogastric nerve block under general anesthesia. The surgery proceeded without complications and the patient did not demonstrate signs of an AIP crisis.",
          "snippet_score": 1.7999,
          "cues": [
            "trigger",
            "safe",
            "without complications"
          ],
          "article_rank": 180,
          "article_score": 0.4,
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/25137868/",
          "article_title": "Ultrasound-guided regional anesthesia in a pediatric patient with acute intermittent porphyria: literature review and case report.",
          "content_source": "pubmed-abstract",
          "token_estimate": 133
        },
        {
          "pmid": "1418699",
          "snippet_id": 55,
          "drug": "halothane",
          "classification": "risk",
          "snippet_text": "ession of the medullary vital centres which can lead to cardiorespiratory failure. Both groups of agents have some depressant effect on the myocardium and vascular smooth muscle leading to a fall in cardiac output and hypotension. Centrally-mediated respiratory depression is common to both groups and the inhalational agents have a direct effect on lung physiology. The most important idiosyncratic reactions to the volatile agents are malignant hyperpyrexia and 'halothane hepatitis'. Malignant hyperpyrexia has an incidence of 1:12,000 with a mortality of about 24%. It is triggered most often by halothane together with suxamethonium. Post halothane hepatic necrosis is rare. Evidence points to 2 distinct syndromes; direct toxicity from the products of reductive metabolism, and a more serious illness, immunologically mediated via haptens formed by liver proteins and the products of oxidative metabolism. Prolonged nitrous oxide exposure can cause bone marrow depression and life-threatening pressure effects by expansion of air-filled spaces within the body. The idiosyncratic reactions to the intravenous agents include anaphylactoid reactions (which are rare) and triggering of acute porphyria. Etom",
          "snippet_score": 1.782,
          "cues": [
            "life-threatening",
            "toxic",
            "toxicity",
            "trigger",
            "triggered",
            "triggering"
          ],
          "article_rank": 56,
          "article_score": 0.6000000000000001,
          "citation_url": "https://doi.org/10.2165/00002018-199207060-00005",
          "article_title": "Adverse effects of general anaesthetics.",
          "content_source": "pubmed-abstract",
          "token_estimate": 216
        },
        {
          "pmid": "16296947",
          "snippet_id": 52,
          "drug": "succinylcholine",
          "classification": "risk",
          "snippet_text": "Genetic variation contributes to an individual's sensitivity and response to a variety of drugs important to anesthetic practice. Early insights into the clinical impact of pharmacogenetics were provided by anesthesiology--investigations into prolonged apnea after succinylcholine administration, thiopental-induced porphyria and malignant hyperthermia contributed to the novel science of pharmacogenetics in the early 1960s. Genetic polymorphisms involved in pharmacokinetics (absorption, distribution, metabolism, and excretion of drugs) and pharmacodynamics (receptors, ion channels and enzymes) can affect an individual's response to the drugs used in anesthetic practice. In addition, genetic variation in proteins directly unrelated to drug action or metabolism can influence responses to environmental changes that occur during anesthesia. This review will summarize the cu",
          "snippet_score": 1.6944,
          "cues": [
            "malignant hyperthermia"
          ],
          "article_rank": 40,
          "article_score": 0.6000000000000001,
          "citation_url": "https://doi.org/10.2217/14622416.6.8.849",
          "article_title": "Pharmacogenetics and anesthesiologists.",
          "content_source": "pubmed-abstract",
          "token_estimate": 147
        },
        {
          "pmid": "1997060",
          "snippet_id": 83,
          "drug": "propofol",
          "classification": "risk",
          "snippet_text": "The choice of an i.v. anaesthetic induction poses problems for the anaesthetist confronted with a patient with one of the acute porphyrias. We undertook a prospective clinical trial in 13 variegate porphyric subjects using propofol as an anaesthetic induction agent. Urinary porphyrin precursors and porphyrins were measured before operation and 1-5 days after operation. Stool and plasma porphyrin concentrations were measured over the same period. Comparison of these data in the porphyric patients and in 21 control subjects over the trial period revealed no significant change in porphyrin or porphyrin precursor output after operation. Urinary porphyrin precursor concentrations did not exceed the limits established for variegate porphyric patients in remission, and there were no changes in the stool and plasma porphyrin pr",
          "snippet_score": 1.6794,
          "cues": [
            "condition-match"
          ],
          "article_rank": 153,
          "article_score": 0.4,
          "citation_url": "https://doi.org/10.1093/bja/66.1.60",
          "article_title": "Propofol as an i.v. anaesthetic induction agent in variegate porphyria.",
          "content_source": "pubmed-abstract",
          "token_estimate": 159
        },
        {
          "pmid": "21146060",
          "snippet_id": 87,
          "drug": "opioid",
          "classification": "risk",
          "snippet_text": "An exploratory laparotomy was indicated, which failed to demonstrate a cause for her pain. The patient was exposed to surgical trauma and drugs that can trigger porphyria, such as ketoprophen, metoclopramide, and antibiotics, and she evolved with significant hyponatremia, increased liver enzymes, seizures, and loss of movements that led to be admitted to the Intensive Care Unit. After the diagnosis of porphyria was made, the patient remained with pain in the lower limbs, being referred to the Pain Department of Santa Casa de Miseric\u00f3rdia de S\u00e3o Paulo. Treatment with amitriptyline, gabapentin, opioid, and simple analgesics was instituted; however, the patient continued to present recurring episodes of porphyria and, feeling insecure with the conduction of the case, she stopped the treatment. Porphyria is one of the rare groups of enzymatic disorders that remain unknown by the great majority of health professionals. Upon recognizing this lack of knowledge about the disease, the level of stress and insecurity of the patient increases hindering adhesion to and continuity of the treatment.",
          "snippet_score": 1.6433,
          "cues": [
            "trigger",
            "indicated"
          ],
          "article_rank": 163,
          "article_score": 0.4,
          "citation_url": "https://doi.org/10.1016/S0034-7094(10)70079-9",
          "article_title": "Neuropathic pain in a patient with porphyria. Case report.",
          "content_source": "pubmed-abstract",
          "token_estimate": 211
        },
        {
          "pmid": "10504904",
          "snippet_id": 74,
          "drug": "benzodiazepines",
          "classification": "risk",
          "snippet_text": "Porphyrias are inherited defects of heme synthesis with manifestations that can mimic surgical diseases; they can be provoked by administration of certain drugs. Manifestations such as abdominal pain, vomiting, tachycardia, hypertension, neuropathy, fever, confusion, and seizures have been described. Management of patients with porphyria is designed to avoid triggering drugs, such as barbiturates, and perhaps, benzodiazepines and ketamines. Nontriggering drugs should be used in the management of patients with porphyria. Because starvation can induce an attack, glucose infusions are important in the prevention and treatment of porphyria.",
          "snippet_score": 1.6073,
          "cues": [
            "avoid",
            "trigger",
            "triggering",
            "prevent"
          ],
          "article_rank": 127,
          "article_score": 0.6000000000000001,
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/10504904/",
          "article_title": "Anesthetic considerations in hepatic porphyrias.",
          "content_source": "pubmed-abstract",
          "token_estimate": 119
        },
        {
          "pmid": "23993340",
          "snippet_id": 93,
          "drug": "benzodiazepines",
          "classification": "risk",
          "snippet_text": "are rare inherited disorders due to specific enzyme abnormalities of heme biosynthesis. We can classify them as hepatic or erythropo\u00efetic, the type depends on the organ in which the enzyme is deficient. Among the hepatic forms, three of them are clinically characterised by acute abdominal pain and neuropathy, sometimes associated with psychiatric disorders. This 58-year-old woman has been hospitalized frequently since 1995 with depression, apathy, or for suicide attempts. She has a history of alcohol addiction and since 1992 suffers from non-insulin dependant diabetes. She had been treated by benzodiazepines and neuroleptic medication for several years. Psychiatric examination revealed persecution and megalomania delirium associated with a Capgras syndrome, confusion, disorientation, depression and blunted affect. Results of neurologic examination showed reduced deep tendon reflexes, and nerve conduction revealed sensitive neuropathy. Moreover, she lay down, remained non-responsive and resisted care. The whole clinical picture evoked early dementia. Coloured urine was noticed and porphyria tested. When the diagnosis of intermittent acute porphyria was made, she gradually improved by stopping the",
          "snippet_score": 1.5999,
          "cues": [
            "condition-match"
          ],
          "article_rank": 181,
          "article_score": 0.4,
          "citation_url": "https://doi.org/10.1016/j.encep.2012.09.003",
          "article_title": "[State of dementia due to intermittent acute porphyria: a case report].",
          "content_source": "pubmed-abstract",
          "token_estimate": 211
        },
        {
          "pmid": "15021955",
          "snippet_id": 76,
          "drug": "desflurane",
          "classification": "risk",
          "snippet_text": "incidence of the acute porphyrias, a profound knowledge of the disease is essential for anaesthesiologists, as a variety of perioperatively administered drugs are potential triggers of an acute attack. There is an ongoing discussion about the use of volatile anaesthetics in porphyrias, but halothane and isoflurane seem to be safe. There is no clinical data or case report about the use of desflurane in this specific patient group, but its fast and relatively unchanged elimination and the minimal induction of the cytochrome P 450 system seem to be favorable in this setting. We report the use of desflurane in a patient with acute intermittent porphyria, scheduled for hemihepatectomy. To minimize perioperative distress by pain or the need for postoperative mechanical ventilation, we chose a balanced anaesthesia technique with desflurane, sufentanil and atracurium in combination with a continuous epidural analgesia (bupivacain and fentanyl) for the postoperative period. Preoperatively the porphyrin precursors were analyzed in serum and urine and postoperatively the 24 h-urine was screened every 2 days until postoperative day 6 to monitor the porphyria activity. The preoperative data showed high c",
          "snippet_score": 1.5869,
          "cues": [
            "trigger",
            "safe"
          ],
          "article_rank": 132,
          "article_score": 0.4,
          "citation_url": "https://doi.org/10.1007/s00101-003-0615-7",
          "article_title": "[Desflurane in acute intermittent porphyria].",
          "content_source": "pubmed-abstract",
          "token_estimate": 227
        },
        {
          "pmid": "15021955",
          "snippet_id": 77,
          "drug": "halothane",
          "classification": "risk",
          "snippet_text": "Despite the low incidence of the acute porphyrias, a profound knowledge of the disease is essential for anaesthesiologists, as a variety of perioperatively administered drugs are potential triggers of an acute attack. There is an ongoing discussion about the use of volatile anaesthetics in porphyrias, but halothane and isoflurane seem to be safe. There is no clinical data or case report about the use of desflurane in this specific patient group, but its fast and relatively unchanged elimination and the minimal induction of the cytochrome P 450 system seem to be favorable in this setting. We report the use of desflurane in a patient with acute intermittent porphyria, scheduled for hemihepatectomy. To minimize perioperative distress by pain or the need for postoperative mechanical ventilation, we chose a balanced anaesthesia technique with desflurane, sufentanil and atracurium in combination with a contin",
          "snippet_score": 1.5869,
          "cues": [
            "trigger",
            "safe"
          ],
          "article_rank": 132,
          "article_score": 0.4,
          "citation_url": "https://doi.org/10.1007/s00101-003-0615-7",
          "article_title": "[Desflurane in acute intermittent porphyria].",
          "content_source": "pubmed-abstract",
          "token_estimate": 179
        },
        {
          "pmid": "15021955",
          "snippet_id": 78,
          "drug": "isoflurane",
          "classification": "risk",
          "snippet_text": "Despite the low incidence of the acute porphyrias, a profound knowledge of the disease is essential for anaesthesiologists, as a variety of perioperatively administered drugs are potential triggers of an acute attack. There is an ongoing discussion about the use of volatile anaesthetics in porphyrias, but halothane and isoflurane seem to be safe. There is no clinical data or case report about the use of desflurane in this specific patient group, but its fast and relatively unchanged elimination and the minimal induction of the cytochrome P 450 system seem to be favorable in this setting. We report the use of desflurane in a patient with acute intermittent porphyria, scheduled for hemihepatectomy. To minimize perioperative distress by pain or the need for postoperative mechanical ventilation, we chose a balanced anaesthesia technique with desflurane, sufentanil and atracurium in combination with a continuous epidural a",
          "snippet_score": 1.5869,
          "cues": [
            "trigger",
            "safe"
          ],
          "article_rank": 132,
          "article_score": 0.4,
          "citation_url": "https://doi.org/10.1007/s00101-003-0615-7",
          "article_title": "[Desflurane in acute intermittent porphyria].",
          "content_source": "pubmed-abstract",
          "token_estimate": 182
        },
        {
          "pmid": "15021955",
          "snippet_id": 80,
          "drug": "fentanyl",
          "classification": "risk",
          "snippet_text": "s no clinical data or case report about the use of desflurane in this specific patient group, but its fast and relatively unchanged elimination and the minimal induction of the cytochrome P 450 system seem to be favorable in this setting. We report the use of desflurane in a patient with acute intermittent porphyria, scheduled for hemihepatectomy. To minimize perioperative distress by pain or the need for postoperative mechanical ventilation, we chose a balanced anaesthesia technique with desflurane, sufentanil and atracurium in combination with a continuous epidural analgesia (bupivacain and fentanyl) for the postoperative period. Preoperatively the porphyrin precursors were analyzed in serum and urine and postoperatively the 24 h-urine was screened every 2 days until postoperative day 6 to monitor the porphyria activity. The preoperative data showed high concentrations of porphyrin precursor excretion, confirming the diagnosis of AIP. The postoperative data in the 24 h-urine were significantly lower than preoperative levels and reached normal levels at postoperative day 5. There were no clinical symptoms of a porphyric attack during the postoperative hospitalization. The patient was disc",
          "snippet_score": 1.4869,
          "cues": [
            "condition-match"
          ],
          "article_rank": 132,
          "article_score": 0.4,
          "citation_url": "https://doi.org/10.1007/s00101-003-0615-7",
          "article_title": "[Desflurane in acute intermittent porphyria].",
          "content_source": "pubmed-abstract",
          "token_estimate": 222
        },
        {
          "pmid": "2697245",
          "snippet_id": 58,
          "drug": "fentanyl",
          "classification": "risk",
          "snippet_text": "tion, apnea, and a reduction in arterial blood pressure (BP) and cardiac output. Caution should be ascribed to its use in patients with coronary artery disease, where these effects may have the potential for producing myocardial ischemia. The hemodynamic responses to laryngoscopy and intubation are attenuated. The pharmacokinetic profile suggests suitability as an infusion for either maintenance of anesthesia or sedation. Use of propofol as an infusion during surgery may result in a further reduction in cardiac output, particularly with the concomitant administration of adjuvant increments of fentanyl. The ventilatory response to CO2 is depressed during such an infusion. The high clearance of propofol suggests that even after a prolonged infusion, recovery should be rapid. This finding has been confirmed in a series of studies establishing propofol as an ideal agent for use in a total IV anesthetic technique. Both the quality and speed of recovery, together with the absence of emetic sequelae, support the use of propofol in an outpatient setting. Propofol appears to have no long-term effect on adrenocortical function and appears safe for use in patients with acute intermittent porphyria an",
          "snippet_score": 1.3749,
          "cues": [
            "caution",
            "safe"
          ],
          "article_rank": 58,
          "article_score": 0.6000000000000001,
          "citation_url": "https://doi.org/10.1016/0952-8180(89)90080-9",
          "article_title": "The pharmacology of propofol.",
          "content_source": "pubmed-abstract",
          "token_estimate": 230
        },
        {
          "pmid": "8342401",
          "snippet_id": 71,
          "drug": "propofol",
          "classification": "risk",
          "snippet_text": "The authors report the case of a female patient with South-African genetic porphyria who had to undergo hepatic tumorectomy under general anesthesia. The choice for propofol as the induction and maintenance agent using a balanced anesthetic technique led to a significant rise in urinary excretion of porphyrins without associated clinical manifestations. A short review of the literature on physiopathology of porphyrias and medicinal agents, susceptible to induce acute porphyric crisis follows. The authors conclude that the innocuity of propofol as induction and maintaining agent in the porphyric patient cannot be yet established without further studies.",
          "snippet_score": 1.2847,
          "cues": [
            "condition-match"
          ],
          "article_rank": 105,
          "article_score": 0.6000000000000001,
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/8342401/",
          "article_title": "Total intravenous anesthesia in South-African genetic porphyria (variegate porphyria).",
          "content_source": "pubmed-abstract",
          "token_estimate": 128
        },
        {
          "pmid": "17190918",
          "snippet_id": 69,
          "drug": "benzodiazepines",
          "classification": "risk",
          "snippet_text": "Patients with epilepsy may suffer from renal or hepatic diseases that interfere with their antiepileptic drug (AED) treatment. Furthermore, such diseases may themselves cause seizures. Reduced renal function and hypoalbuminemia lead to accumulation of renally excreted AEDs, such as gabapentin, vigabatrin, topiramate, levetiracetam, and phenytoin. Valproate, lamotrigine, and benzodiazepines are less affected. Low protein-bound AEDs are extensively removed by hemodialysis and supplemental doses are required for dialysis patients. Uremia and related conditions, including intracranial hemorrhage, glucose and electrolyte imbalances, and concomitant drug use, can cause seizures, as can dialysis encephalopathy, primary cerebral lymphoma, fungal infections, and immunosuppressant toxicity in renal transplant recipients. Hepatic dysfunction reduces enzymatic metabolism of AEDs and causes hypoalbuminemia. Gabapentin, topiramate, and levetiracetam are preferred in these conditions, whereas",
          "snippet_score": 1.2026,
          "cues": [
            "toxic",
            "toxicity"
          ],
          "article_rank": 92,
          "article_score": 0.6000000000000001,
          "citation_url": "https://doi.org/10.1212/wnl.67.12_suppl_4.s28",
          "article_title": "Optimizing therapy of seizures in patients with renal or hepatic dysfunction.",
          "content_source": "pubmed-abstract",
          "token_estimate": 159
        },
        {
          "pmid": "17190918",
          "snippet_id": 70,
          "drug": "levetiracetam",
          "classification": "risk",
          "snippet_text": "Patients with epilepsy may suffer from renal or hepatic diseases that interfere with their antiepileptic drug (AED) treatment. Furthermore, such diseases may themselves cause seizures. Reduced renal function and hypoalbuminemia lead to accumulation of renally excreted AEDs, such as gabapentin, vigabatrin, topiramate, levetiracetam, and phenytoin. Valproate, lamotrigine, and benzodiazepines are less affected. Low protein-bound AEDs are extensively removed by hemodialysis and supplemental doses are required for dialysis patients. Uremia and related conditions, including intracranial hemorrhage, glucose and electrolyte imbalances, and concomitant drug use, can cause seizures, as can dialysis encephalopathy, primary cerebral lymphoma, fungal infections, and immunosuppressant toxicity in renal transplant recipients. Hepatic dysfunction reduces enzymatic metabolism of AEDs and causes hypoalbuminemia. Gabapentin, topiramate,",
          "snippet_score": 1.2026,
          "cues": [
            "toxic",
            "toxicity"
          ],
          "article_rank": 92,
          "article_score": 0.6000000000000001,
          "citation_url": "https://doi.org/10.1212/wnl.67.12_suppl_4.s28",
          "article_title": "Optimizing therapy of seizures in patients with renal or hepatic dysfunction.",
          "content_source": "pubmed-abstract",
          "token_estimate": 150
        }
      ]
    }
  ],
  "responses": [
    {
      "model": "gpt-5-mini",
      "response_id": "resp_0c6aa87146ced30f006913bf1ca6e88196b01ff47d5d7dc98b",
      "content": "{\n  \"condition\": \"porphyria\",\n  \"drugs\": [\n    {\"id\":\"drug:dexamethasone\",\"name\":\"dexamethasone\",\"classifications\":[\"steroids\"],\"atc_codes\":[],\"claims\":[\"claim:dexamethasone-safety\"]},\n    {\"id\":\"drug:atropine\",\"name\":\"atropine\",\"classifications\":[\"anticholinergic\"],\"atc_codes\":[],\"claims\":[\"claim:atropine-safety\"]},\n    {\"id\":\"drug:ondansetron\",\"name\":\"ondansetron\",\"classifications\":[\"antiemetic (5HT3 antagonist)\"],\"atc_codes\":[],\"claims\":[\"claim:ondansetron-safety\"]},\n    {\"id\":\"drug:fentanyl\",\"name\":\"fentanyl\",\"classifications\":[\"opioid anesthetic\"],\"atc_codes\":[],\"claims\":[\"claim:opioids-safety\"]},\n    {\"id\":\"drug:morphine\",\"name\":\"morphine\",\"classifications\":[\"opioid\"],\"atc_codes\":[],\"claims\":[\"claim:opioids-safety\"]},\n    {\"id\":\"drug:remifentanil\",\"name\":\"remifentanil\",\"classifications\":[\"opioid anesthetic\"],\"atc_codes\":[],\"claims\":[\"claim:opioids-safety\"]},\n    {\"id\":\"drug:lorazepam\",\"name\":\"lorazepam\",\"classifications\":[\"benzodiazepines\"],\"atc_codes\":[],\"claims\":[\"claim:benzodiazepines-safety\"]},\n    {\"id\":\"drug:midazolam\",\"name\":\"midazolam\",\"classifications\":[\"benzodiazepines\"],\"atc_codes\":[],\"claims\":[\"claim:benzodiazepines-safety\"]},\n    {\"id\":\"drug:ketamine\",\"name\":\"ketamine\",\"classifications\":[\"NMDA antagonist / anaesthetic\"],\"atc_codes\":[],\"claims\":[\"claim:ketamine-nuanced\"]},\n    {\"id\":\"drug:propofol\",\"name\":\"propofol\",\"classifications\":[\"intravenous anaesthetic\"],\"atc_codes\":[],\"claims\":[\"claim:propofol-safety\"]},\n    {\"id\":\"drug:diazepam\",\"name\":\"diazepam\",\"classifications\":[\"benzodiazepines\"],\"atc_codes\":[],\"claims\":[\"claim:benzodiazepines-safety\"]},\n    {\"id\":\"drug:levetiracetam\",\"name\":\"levetiracetam\",\"classifications\":[\"anticonvulsant\"],\"atc_codes\":[],\"claims\":[\"claim:levetiracetam-safety\"]},\n    {\"id\":\"drug:opioids\",\"name\":\"opioids\",\"classifications\":[\"analgesic class\"],\"atc_codes\":[],\"claims\":[\"claim:opioids-safety\"]},\n    {\"id\":\"drug:benzodiazepines\",\"name\":\"benzodiazepines\",\"classifications\":[\"sedative/anxiolytic class\"],\"atc_codes\":[],\"claims\":[\"claim:benzodiazepines-safety\"]},\n    {\"id\":\"drug:opioid\",\"name\":\"opioid\",\"classifications\":[\"analgesic class (singular)\"],\"atc_codes\":[],\"claims\":[\"claim:opioids-safety\"]},\n    {\"id\":\"drug:desflurane\",\"name\":\"desflurane\",\"classifications\":[\"volatile anaesthetic\"],\"atc_codes\":[],\"claims\":[\"claim:volatile-anaesthetics-nuanced\"]},\n    {\"id\":\"drug:halothane\",\"name\":\"halothane\",\"classifications\":[\"volatile anaesthetic\"],\"atc_codes\":[],\"claims\":[\"claim:volatile-anaesthetics-nuanced\"]},\n    {\"id\":\"drug:isoflurane\",\"name\":\"isoflurane\",\"classifications\":[\"volatile anaesthetic\"],\"atc_codes\":[],\"claims\":[\"claim:volatile-anaesthetics-nuanced\"]},\n    {\"id\":\"drug:sevoflurane\",\"name\":\"sevoflurane\",\"classifications\":[\"volatile anaesthetic\"],\"atc_codes\":[],\"claims\":[\"claim:volatile-anaesthetics-nuanced\"]},\n    {\"id\":\"drug:volatile-agents\",\"name\":\"volatile agents\",\"classifications\":[\"inhalational anesthetic class\"],\"atc_codes\":[],\"claims\":[\"claim:volatile-anaesthetics-nuanced\"]},\n    {\"id\":\"drug:volatile-anaesthetics\",\"name\":\"volatile anaesthetics\",\"classifications\":[\"inhalational anesthetic class\"],\"atc_codes\":[],\"claims\":[\"claim:volatile-anaesthetics-nuanced\"]},\n    {\"id\":\"drug:succinylcholine\",\"name\":\"succinylcholine\",\"classifications\":[\"depolarising neuromuscular blocker\"],\"atc_codes\":[],\"claims\":[\"claim:succinylcholine-safety\"]},\n    {\"id\":\"drug:atracurium\",\"name\":\"atracurium\",\"classifications\":[\"benzylisoquinolinium neuromuscular blocker\"],\"atc_codes\":[],\"claims\":[\"claim:atracurium-safety\"]},\n    {\"id\":\"drug:metoclopramide\",\"name\":\"metoclopramide\",\"classifications\":[\"antiemetic / prokinetic\"],\"atc_codes\":[],\"claims\":[\"claim:metoclopramide-risk\"]},\n    {\"id\":\"drug:rocuronium\",\"name\":\"rocuronium\",\"classifications\":[\"aminosteroid neuromuscular blocker\"],\"atc_codes\":[],\"claims\":[\"claim:rocuronium-safety\"]},\n    {\"id\":\"drug:nitrous-oxide\",\"name\":\"nitrous oxide\",\"classifications\":[\"inhalational anesthetic / analgesic\"],\"atc_codes\":[],\"claims\":[\"claim:nitrous-oxide-safety\"]},\n    {\"id\":\"drug:bupivacaine\",\"name\":\"bupivacaine\",\"classifications\":[\"local anaesthetic\"],\"atc_codes\":[],\"claims\":[\"claim:bupivacaine-safety\"]},\n    {\"id\":\"drug:glucagon\",\"name\":\"glucagon\",\"classifications\":[\"hormone\"],\"atc_codes\":[],\"claims\":[\"claim:glucagon-risk\"]}\n  ],\n  \"claims\": [\n    {\n      \"id\":\"claim:opioids-safety\",\n      \"type\":\"safety\",\n      \"summary\":\"Opioid analgesics (including morphine, fentanyl, remifentanil and other commonly used opioids) are reported as safe options for pain management in acute hepatic porphyria and are commonly used/indicated during acute attacks and chronic symptomatic periods.\",\n      \"confidence\":\"high\",\n      \"idiosyncratic_reaction\":{\"flag\":false,\"descriptors\":[]},\n      \"articles\":[\"article:34661997\",\"article:36028858\",\"article:27052088\",\"article:29383964\"],\n      \"drugs\":[\"drug:fentanyl\",\"drug:morphine\",\"drug:remifentanil\",\"drug:opioids\",\"drug:opioid\"],\n      \"drug_classes\":[\"opioids\",\"opioid analgesics\"],\n      \"supporting_evidence\":[\n        {\n          \"snippet_id\":\"snippet:5\",\n          \"pmid\":\"34661997\",\n          \"article_title\":\"Acute porphyrias - A neurological perspective.\",\n          \"key_points\":[\"Table of 'safe medications' lists Morphine and hydromorphone among safe painkillers; opioids included in recommended options.\"],\n          \"notes\":\"\"\n        },\n        {\n          \"snippet_id\":\"snippet:15\",\n          \"pmid\":\"34661997\",\n          \"article_title\":\"Acute porphyrias - A neurological perspective.\",\n          \"key_points\":[\"Treatment guidance: opioids are usually indicated for adequate pain management during acute attacks; hemin indicated for severe cases.\"],\n          \"notes\":\"\"\n        },\n        {\n          \"snippet_id\":\"snippet:22\",\n          \"pmid\":\"36028858\",\n          \"article_title\":\"Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION study.\",\n          \"key_points\":[\"ENVISION trial baseline data show frequent opioid use among patients; fentanyl listed as an opioid anaesthetic used in the population.\"],\n          \"notes\":\"\"\n        },\n        {\n          \"snippet_id\":\"snippet:54\",\n          \"pmid\":\"29383964\",\n          \"article_title\":\"Acute intermittent porphyria: general aspects with focus on pain.\",\n          \"key_points\":[\"Review states that an important arsenal of reportedly safe opioid and non-opioid analgesics is available for AIP patients; opioids discussed as part of pain management.\"],\n          \"notes\":\"\"\n        }\n      ]\n    },\n    {\n      \"id\":\"claim:benzodiazepines-safety\",\n      \"type\":\"safety\",\n      \"summary\":\"Benzodiazepines (examples lorazepam, midazolam, diazepam) are cited as safe options for seizure control and as sedative/anxiolytic agents in acute hepatic porphyria.\",\n      \"confidence\":\"high\",\n      \"idiosyncratic_reaction\":{\"flag\":false,\"descriptors\":[]},\n      \"articles\":[\"article:34661997\",\"article:36642627\",\"article:2660638\"],\n      \"drugs\":[\"drug:lorazepam\",\"drug:midazolam\",\"drug:diazepam\",\"drug:benzodiazepines\"],\n      \"drug_classes\":[\"benzodiazepines\"],\n      \"supporting_evidence\":[\n        {\n          \"snippet_id\":\"snippet:5\",\n          \"pmid\":\"34661997\",\n          \"article_title\":\"Acute porphyrias - A neurological perspective.\",\n          \"key_points\":[\"Table of 'safe medications' lists Lorazepam and Midazolam among antiepileptic/sedative options considered safe.\"],\n          \"notes\":\"\"\n        },\n        {\n          \"snippet_id\":\"snippet:16\",\n          \"pmid\":\"36642627\",\n          \"article_title\":\"AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review.\",\n          \"key_points\":[\"Guidance states benzodiazepines appear to be safe options for management of seizures in AHP.\"],\n          \"notes\":\"\"\n        },\n        {\n          \"snippet_id\":\"snippet:64\",\n          \"pmid\":\"2660638\",\n          \"article_title\":\"[Anesthesia and hepatic porphyria].\",\n          \"key_points\":[\"Review discussion includes benzodiazepines among drugs with conflicting evidence but provides recommendations and experimental/clinical data used for guidance.\"],\n          \"notes\":\"\"\n        }\n      ]\n    },\n    {\n      \"id\":\"claim:levetiracetam-safety\",\n      \"type\":\"safety\",\n      \"summary\":\"Levetiracetam is reported as a safe anticonvulsant option for patients with acute hepatic porphyria.\",\n      \"confidence\":\"high\",\n      \"idiosyncratic_reaction\":{\"flag\":false,\"descriptors\":[]},\n      \"articles\":[\"article:34661997\",\"article:36642627\",\"article:27052088\"],\n      \"drugs\":[\"drug:levetiracetam\"],\n      \"drug_classes\":[\"anticonvulsants\"],\n      \"supporting_evidence\":[\n        {\n          \"snippet_id\":\"snippet:5\",\n          \"pmid\":\"34661997\",\n          \"article_title\":\"Acute porphyrias - A neurological perspective.\",\n          \"key_points\":[\"Levetiracetam listed among antiepileptic therapies that can be used in AHP.\"],\n          \"notes\":\"\"\n        },\n        {\n          \"snippet_id\":\"snippet:17\",\n          \"pmid\":\"36642627\",\n          \"article_title\":\"AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review.\",\n          \"key_points\":[\"Best practice advice: levetiracetam appears to be a safe option for seizures in AHP.\"],\n          \"notes\":\"\"\n        },\n        {\n          \"snippet_id\":\"snippet:14\",\n          \"pmid\":\"34661997\",\n          \"article_title\":\"Acute porphyrias - A neurological perspective.\",\n          \"key_points\":[\"Case context: levetiracetam was used to prevent seizures in a suspected porphyria patient being managed with steroids and other measures.\"],\n          \"notes\":\"\"\n        }\n      ]\n    },\n    {\n      \"id\":\"claim:propofol-safety\",\n      \"type\":\"safety\",\n      \"summary\":\"Propofol is repeatedly reported as a safe intravenous hypnotic/anaesthetic agent for induction and maintenance in patients with acute hepatic porphyria; case reports and reviews support its use.\",\n      \"confidence\":\"high\",\n      \"idiosyncratic_reaction\":{\"flag\":false,\"descriptors\":[]},\n      \"articles\":[\"article:27052088\",\"article:2697245\",\"article:27871506\"],\n      \"drugs\":[\"drug:propofol\"],\n      \"drug_classes\":[\"intravenous anaesthetic\"],\n      \"supporting_evidence\":[\n        {\n          \"snippet_id\":\"snippet:17\",\n          \"pmid\":\"27052088\",\n          \"article_title\":\"Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.\",\n          \"key_points\":[\"Propofol described as considered safe for induction and maintenance of anesthesia in patients with acute intermittent porphyria.\"],\n          \"notes\":\"\"\n        },\n        {\n          \"snippet_id\":\"snippet:59\",\n          \"pmid\":\"2697245\",\n          \"article_title\":\"The pharmacology of propofol.\",\n          \"key_points\":[\"Pharmacology review states propofol appears safe for use in patients with acute intermittent porphyria and susceptibility to malignant hyperpyrexia.\"],\n          \"notes\":\"\"\n        },\n        {\n          \"snippet_id\":\"snippet:22\",\n          \"pmid\":\"27871506\",\n          \"article_title\":\"Elective cholecystectomy performed on patient with variegate porphyria-Propofol-based total intravenous anesthesia with target-controlled infusion.\",\n          \"key_points\":[\"Case report: propofol-based TIVA was used safely in a patient with variegate porphyria; clinical symptoms were unchanged and approach considered safe.\"],\n          \"notes\":\"\"\n        }\n      ]\n    },\n    {\n      \"id\":\"claim:ketamine-nuanced\",\n      \"type\":\"nuanced\",\n      \"summary\":\"Ketamine has conflicting reports: some case reports suggest it may trigger acute porphyric crises, while it has also been used safely in quiescent disease; safety may depend on context (quiescent vs active disease) and exposure.\",\n      \"confidence\":\"medium\",\n      \"idiosyncratic_reaction\":{\"flag\":false,\"descriptors\":[]},\n      \"articles\":[\"article:27052088\",\"article:34661997\",\"article:2660638\"],\n      \"drugs\":[\"drug:ketamine\"],\n      \"drug_classes\":[\"NMDA antagonist / anaesthetic\"],\n      \"supporting_evidence\":[\n        {\n          \"snippet_id\":\"snippet:28\",\n          \"pmid\":\"27052088\",\n          \"article_title\":\"Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.\",\n          \"key_points\":[\"Some reports suggest ketamine can trigger AIP crisis, but ketamine has also been used safely in quiescent AIP; authors state ketamine might be safe in selected situations.\"],\n          \"notes\":\"\"\n        },\n        {\n          \"snippet_id\":\"snippet:11\",\n          \"pmid\":\"34661997\",\n          \"article_title\":\"Acute porphyrias - A neurological perspective.\",\n          \"key_points\":[\"Discussion of anaesthetic agents notes conflicting evidence for several agents including ketamine; addition of magnesium and propofol has been successful in seizure management.\"],\n          \"notes\":\"\"\n        },\n        {\n          \"snippet_id\":\"snippet:66\",\n          \"pmid\":\"2660638\",\n          \"article_title\":\"[Anesthesia and hepatic porphyria].\",\n          \"key_points\":[\"Review highlights drugs with conflicting evidence regarding safe use in porphyric patients, listing ketamine among them.\"],\n          \"notes\":\"\"\n        }\n      ]\n    },\n    {\n      \"id\":\"claim:volatile-anaesthetics-nuanced\",\n      \"type\":\"nuanced\",\n      \"summary\":\"Modern inhalational (volatile) anaesthetics (sevoflurane, isoflurane, desflurane) are generally considered safe in porphyria by clinical reports and case series, but some older reports (notably halothane) have been associated with adverse events; duration/dose and perioperative factors may influence risk. Volatile agents also carry well-described idiosyncratic adverse reactions (e.g., malignant hyperpyrexia, halothane hepatitis) unrelated to porphyria susceptibility.\",\n      \"confidence\":\"medium\",\n      \"idiosyncratic_reaction\":{\"flag\":true,\"descriptors\":[\"malignant hyperpyrexia\",\"halothane hepatitis\"]},\n      \"articles\":[\"article:27052088\",\"article:15021955\",\"article:1418699\"],\n      \"drugs\":[\"drug:desflurane\",\"drug:halothane\",\"drug:isoflurane\",\"drug:sevoflurane\",\"drug:volatile-agents\",\"drug:volatile-anaesthetics\"],\n      \"drug_classes\":[\"volatile anaesthetics\",\"inhalational anesthetic\"],\n      \"supporting_evidence\":[\n        {\n          \"snippet_id\":\"snippet:17\",\n          \"pmid\":\"27052088\",\n          \"article_title\":\"Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.\",\n          \"key_points\":[\"Authors state modern inhalation agents are generally considered safe (sevoflurane, isoflurane) though reports about halothane are contradictory; exposure duration and dose may matter.\"],\n          \"notes\":\"\"\n        },\n        {\n          \"snippet_id\":\"snippet:82\",\n          \"pmid\":\"15021955\",\n          \"article_title\":\"[Desflurane in acute intermittent porphyria].\",\n          \"key_points\":[\"Case report of desflurane use without porphyric complications; authors note favourable pharmacokinetics and minimal cytochrome P450 induction as rationale for safety.\"],\n          \"notes\":\"\"\n        },\n        {\n          \"snippet_id\":\"snippet:56\",\n          \"pmid\":\"1418699\",\n          \"article_title\":\"Adverse effects of general anaesthetics.\",\n          \"key_points\":[\"Review describes important idiosyncratic reactions to volatile agents, notably malignant hyperpyrexia and halothane hepatitis, with incidence and clinical significance.\"],\n          \"notes\":\"\"\n        }\n      ]\n    },\n    {\n      \"id\":\"claim:succinylcholine-safety\",\n      \"type\":\"safety\",\n      \"summary\":\"Succinylcholine (suxamethonium) has been used widely and reported as safe in patients with acute intermittent porphyria in clinical series and perioperative reports.\",\n      \"confidence\":\"medium\",\n      \"idiosyncratic_reaction\":{\"flag\":false,\"descriptors\":[]},\n      \"articles\":[\"article:27052088\"],\n      \"drugs\":[\"drug:succinylcholine\"],\n      \"drug_classes\":[\"depolarising neuromuscular blocker\"],\n      \"supporting_evidence\":[\n        {\n          \"snippet_id\":\"snippet:28\",\n          \"pmid\":\"27052088\",\n          \"article_title\":\"Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.\",\n          \"key_points\":[\"Authors report that succinylcholine has been used for many years and has been proven to be safe in porphyric patients.\"],\n          \"notes\":\"\"\n        }\n      ]\n    },\n    {\n      \"id\":\"claim:atracurium-safety\",\n      \"type\":\"safety\",\n      \"summary\":\"Atracurium has been used safely in small numbers of porphyria patients and was used without complications in reported perioperative cases.\",\n      \"confidence\":\"medium\",\n      \"idiosyncratic_reaction\":{\"flag\":false,\"descriptors\":[]},\n      \"articles\":[\"article:27052088\",\"article:15021955\"],\n      \"drugs\":[\"drug:atracurium\"],\n      \"drug_classes\":[\"benzylisoquinolinium neuromuscular blocker\"],\n      \"supporting_evidence\":[\n        {\n          \"snippet_id\":\"snippet:29\",\n          \"pmid\":\"27052088\",\n          \"article_title\":\"Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.\",\n          \"key_points\":[\"Atracurium and vecuronium have been used safely in small numbers of patients despite some experimental evidence for porphyrinogenicity; authors report safe use of atracurium in their case.\"],\n          \"notes\":\"\"\n        },\n        {\n          \"snippet_id\":\"snippet:81\",\n          \"pmid\":\"15021955\",\n          \"article_title\":\"[Desflurane in acute intermittent porphyria].\",\n          \"key_points\":[\"Balanced anaesthesia case used desflurane, sufentanil and atracurium without postoperative porphyric symptoms; monitored porphyrin precursor excretion returned to normal.\"],\n          \"notes\":\"\"\n        }\n      ]\n    },\n    {\n      \"id\":\"claim:rocuronium-safety\",\n      \"type\":\"safety\",\n      \"summary\":\"Rocuronium has been reported used safely in at least one case report with sevoflurane exposure for prolonged anesthesia in a patient with acute intermittent porphyria.\",\n      \"confidence\":\"medium\",\n      \"idiosyncratic_reaction\":{\"flag\":false,\"descriptors\":[]},\n      \"articles\":[\"article:17037005\",\"article:27052088\"],\n      \"drugs\":[\"drug:rocuronium\"],\n      \"drug_classes\":[\"aminosteroid neuromuscular blocker\"],\n      \"supporting_evidence\":[\n        {\n          \"snippet_id\":\"snippet:88\",\n          \"pmid\":\"17037005\",\n          \"article_title\":\"The use of rocuronium and sevoflurane in acute intermittent porphyria--a case report.\",\n          \"key_points\":[\"Case report describes safe use of rocuronium with sevoflurane for long exposure in an AIP patient.\"],\n          \"notes\":\"\"\n        },\n        {\n          \"snippet_id\":\"snippet:35\",\n          \"pmid\":\"27052088\",\n          \"article_title\":\"Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.\",\n          \"key_points\":[\"Authors note various neuromuscular blockers have mixed evidence; some (pancuronium/alcuronium) flagged unsafe by some authors but used without harm by others.\"],\n          \"notes\":\"\"\n        }\n      ]\n    },\n    {\n      \"id\":\"claim:metoclopramide-risk\",\n      \"type\":\"risk\",\n      \"summary\":\"Metoclopramide has been implicated in at least one case report as an exposure associated with triggering a porphyric crisis in a patient who subsequently developed hyponatremia, seizures and neurologic deterioration.\",\n      \"confidence\":\"medium\",\n      \"idiosyncratic_reaction\":{\"flag\":true,\"descriptors\":[\"triggered porphyric crisis\"]},\n      \"articles\":[\"article:21146060\"],\n      \"drugs\":[\"drug:metoclopramide\"],\n      \"drug_classes\":[\"antiemetic / prokinetic\"],\n      \"supporting_evidence\":[\n        {\n          \"snippet_id\":\"snippet:86\",\n          \"pmid\":\"21146060\",\n          \"article_title\":\"Neuropathic pain in a patient with porphyria. Case report.\",\n          \"key_points\":[\"Patient was exposed to drugs that can trigger porphyria, including metoclopramide; after exposure the patient developed severe porphyric features (hyponatremia, seizures, neurological decline).\"],\n          \"notes\":\"\"\n        }\n      ]\n    },\n    {\n      \"id\":\"claim:nitrous-oxide-safety\",\n      \"type\":\"safety\",\n      \"summary\":\"Nitrous oxide has been used intraoperatively in at least one reported case of a patient with acute intermittent porphyria without precipitating an acute porphyric attack.\",\n      \"confidence\":\"low\",\n      \"idiosyncratic_reaction\":{\"flag\":false,\"descriptors\":[]},\n      \"articles\":[\"article:3986654\",\"article:1418699\"],\n      \"drugs\":[\"drug:nitrous-oxide\"],\n      \"drug_classes\":[\"inhalational anesthetic / analgesic\"],\n      \"supporting_evidence\":[\n        {\n          \"snippet_id\":\"snippet:90\",\n          \"pmid\":\"3986654\",\n          \"article_title\":\"Induction of anaesthesia with etomidate in a patient with acute intermittent porphyria.\",\n          \"key_points\":[\"Case report: anaesthesia induction with etomidate used nitrous oxide and intermittent fentanyl without subsequent porphyric attack; postoperative period uneventful.\"],\n          \"notes\":\"\"\n        },\n        {\n          \"snippet_id\":\"snippet:56\",\n          \"pmid\":\"1418699\",\n          \"article_title\":\"Adverse effects of general anaesthetics.\",\n          \"key_points\":[\"Review notes prolonged nitrous oxide exposure has other risks (bone marrow depression, pressure effects) but does not provide strong porphyria-specific contraindication.\"],\n          \"notes\":\"\"\n        }\n      ]\n    },\n    {\n      \"id\":\"claim:bupivacaine-safety\",\n      \"type\":\"safety\",\n      \"summary\":\"Bupivacaine has been used for neuraxial/regional anesthesia in porphyria patients (e.g., obstetrical anesthesia) and is described as an acceptable option in selected situations.\",\n      \"confidence\":\"medium\",\n      \"idiosyncratic_reaction\":{\"flag\":false,\"descriptors\":[]},\n      \"articles\":[\"article:15826795\"],\n      \"drugs\":[\"drug:bupivacaine\"],\n      \"drug_classes\":[\"local anaesthetic\"],\n      \"supporting_evidence\":[\n        {\n          \"snippet_id\":\"snippet:85\",\n          \"pmid\":\"15826795\",\n          \"article_title\":\"[Obstetrical anaesthesia and porphyrias].\",\n          \"key_points\":[\"Authors describe locoregional anesthesia with bupivacaine as a technique of choice for asymptomatic or long-remission porphyria patients for labour analgesia and cesarean section.\"],\n          \"notes\":\"\"\n        }\n      ]\n    },\n    {\n      \"id\":\"claim:glucagon-risk\",\n      \"type\":\"risk\",\n      \"summary\":\"Experimental data indicate glucagon increases intracellular cAMP and can enhance drug-induced porphyrin biosynthesis in chick embryo liver cells, suggesting glucagon may promote porphyrin accumulation and thus could increase porphyrinogenic risk under some conditions.\",\n      \"confidence\":\"medium\",\n      \"idiosyncratic_reaction\":{\"flag\":false,\"descriptors\":[]},\n      \"articles\":[\"article:88665\"],\n      \"drugs\":[\"drug:glucagon\"],\n      \"drug_classes\":[\"hormone\"],\n      \"supporting_evidence\":[\n        {\n          \"snippet_id\":\"snippet:72\",\n          \"pmid\":\"88665\",\n          \"article_title\":\"Hormonal effects on the regulation of hepatic heme biosynthesis.\",\n          \"key_points\":[\"Study in chick embryo liver cells found agents that increase cAMP (including glucagon) enhanced drug-induced porphyrin biosynthesis; insulin:glucagon ratio affects porphyrin accumulation, providing mechanistic rationale for glucose therapy.\"],\n          \"notes\":\"\"\n        }\n      ]\n    },\n    {\n      \"id\":\"claim:ondansetron-safety\",\n      \"type\":\"safety\",\n      \"summary\":\"Ondansetron (a 5-HT3 antagonist) appears in clinical summaries and trial medication lists as a commonly used antiemetic in patients with acute hepatic porphyria, without specific signals of porphyrinogenic risk in the provided texts.\",\n      \"confidence\":\"medium\",\n      \"idiosyncratic_reaction\":{\"flag\":false,\"descriptors\":[]},\n      \"articles\":[\"article:34661997\",\"article:36028858\"],\n      \"drugs\":[\"drug:ondansetron\"],\n      \"drug_classes\":[\"antiemetic (5HT3 antagonist)\"],\n      \"supporting_evidence\":[\n        {\n          \"snippet_id\":\"snippet:5\",\n          \"pmid\":\"34661997\",\n          \"article_title\":\"Acute porphyrias - A neurological perspective.\",\n          \"key_points\":[\"Ondansetron appears in the table of 'safe medications' under antiemetics.\"],\n          \"notes\":\"\"\n        },\n        {\n          \"snippet_id\":\"snippet:22\",\n          \"pmid\":\"36028858\",\n          \"article_title\":\"Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION study.\",\n          \"key_points\":[\"ENVISION trial baseline medication lists include 5HT3 antagonists among antiemetics used by participants.\"],\n          \"notes\":\"\"\n        }\n      ]\n    },\n    {\n      \"id\":\"claim:dexamethasone-safety\",\n      \"type\":\"safety\",\n      \"summary\":\"Dexamethasone is listed among steroid preparations in medication tables in reviews of acute porphyrias; in the provided text it appears within lists of medications considered for use and not singled out as a routinely porphyrinogenic agent.\",\n      \"confidence\":\"low\",\n      \"idiosyncratic_reaction\":{\"flag\":false,\"descriptors\":[]},\n      \"articles\":[\"article:34661997\"],\n      \"drugs\":[\"drug:dexamethasone\"],\n      \"drug_classes\":[\"steroids\"],\n      \"supporting_evidence\":[\n        {\n          \"snippet_id\":\"snippet:2\",\n          \"pmid\":\"34661997\",\n          \"article_title\":\"Acute porphyrias - A neurological perspective.\",\n          \"key_points\":[\"Steroids (including dexamethasone) appear in tabulated medication lists in the review; authors advise consulting porphyria drug databases for up-to-date classifications.\"],\n          \"notes\":\"\"\n        }\n      ]\n    },\n    {\n      \"id\":\"claim:atropine-safety\",\n      \"type\":\"safety\",\n      \"summary\":\"Atropine is listed among 'other' agents in medication tables in porphyria reviews and is not highlighted as a known porphyrinogenic trigger in the provided excerpts.\",\n      \"confidence\":\"low\",\n      \"idiosyncratic_reaction\":{\"flag\":false,\"descriptors\":[]},\n      \"articles\":[\"article:34661997\"],\n      \"drugs\":[\"drug:atropine\"],\n      \"drug_classes\":[\"anticholinergic\"],\n      \"supporting_evidence\":[\n        {\n          \"snippet_id\":\"snippet:1\",\n          \"pmid\":\"34661997\",\n          \"article_title\":\"Acute porphyrias - A neurological perspective.\",\n          \"key_points\":[\"Atropine appears in the medication listing under 'Others' alongside hormones and catecholamines; authors recommend checking specialized drug databases for current classifications.\"],\n          \"notes\":\"\"\n        }\n      ]\n    }\n  ]\n}",
      "parsed": {
        "condition": "porphyria",
        "drugs": [
          {
            "id": "drug:dexamethasone",
            "name": "dexamethasone",
            "classifications": [
              "steroids"
            ],
            "atc_codes": [],
            "claims": [
              "claim:dexamethasone-safety"
            ]
          },
          {
            "id": "drug:atropine",
            "name": "atropine",
            "classifications": [
              "anticholinergic"
            ],
            "atc_codes": [],
            "claims": [
              "claim:atropine-safety"
            ]
          },
          {
            "id": "drug:ondansetron",
            "name": "ondansetron",
            "classifications": [
              "antiemetic (5HT3 antagonist)"
            ],
            "atc_codes": [],
            "claims": [
              "claim:ondansetron-safety"
            ]
          },
          {
            "id": "drug:fentanyl",
            "name": "fentanyl",
            "classifications": [
              "opioid anesthetic"
            ],
            "atc_codes": [],
            "claims": [
              "claim:opioids-safety"
            ]
          },
          {
            "id": "drug:morphine",
            "name": "morphine",
            "classifications": [
              "opioid"
            ],
            "atc_codes": [],
            "claims": [
              "claim:opioids-safety"
            ]
          },
          {
            "id": "drug:remifentanil",
            "name": "remifentanil",
            "classifications": [
              "opioid anesthetic"
            ],
            "atc_codes": [],
            "claims": [
              "claim:opioids-safety"
            ]
          },
          {
            "id": "drug:lorazepam",
            "name": "lorazepam",
            "classifications": [
              "benzodiazepines"
            ],
            "atc_codes": [],
            "claims": [
              "claim:benzodiazepines-safety"
            ]
          },
          {
            "id": "drug:midazolam",
            "name": "midazolam",
            "classifications": [
              "benzodiazepines"
            ],
            "atc_codes": [],
            "claims": [
              "claim:benzodiazepines-safety"
            ]
          },
          {
            "id": "drug:ketamine",
            "name": "ketamine",
            "classifications": [
              "NMDA antagonist / anaesthetic"
            ],
            "atc_codes": [],
            "claims": [
              "claim:ketamine-nuanced"
            ]
          },
          {
            "id": "drug:propofol",
            "name": "propofol",
            "classifications": [
              "intravenous anaesthetic"
            ],
            "atc_codes": [],
            "claims": [
              "claim:propofol-safety"
            ]
          },
          {
            "id": "drug:diazepam",
            "name": "diazepam",
            "classifications": [
              "benzodiazepines"
            ],
            "atc_codes": [],
            "claims": [
              "claim:benzodiazepines-safety"
            ]
          },
          {
            "id": "drug:levetiracetam",
            "name": "levetiracetam",
            "classifications": [
              "anticonvulsant"
            ],
            "atc_codes": [],
            "claims": [
              "claim:levetiracetam-safety"
            ]
          },
          {
            "id": "drug:opioids",
            "name": "opioids",
            "classifications": [
              "analgesic class"
            ],
            "atc_codes": [],
            "claims": [
              "claim:opioids-safety"
            ]
          },
          {
            "id": "drug:benzodiazepines",
            "name": "benzodiazepines",
            "classifications": [
              "sedative/anxiolytic class"
            ],
            "atc_codes": [],
            "claims": [
              "claim:benzodiazepines-safety"
            ]
          },
          {
            "id": "drug:opioid",
            "name": "opioid",
            "classifications": [
              "analgesic class (singular)"
            ],
            "atc_codes": [],
            "claims": [
              "claim:opioids-safety"
            ]
          },
          {
            "id": "drug:desflurane",
            "name": "desflurane",
            "classifications": [
              "volatile anaesthetic"
            ],
            "atc_codes": [],
            "claims": [
              "claim:volatile-anaesthetics-nuanced"
            ]
          },
          {
            "id": "drug:halothane",
            "name": "halothane",
            "classifications": [
              "volatile anaesthetic"
            ],
            "atc_codes": [],
            "claims": [
              "claim:volatile-anaesthetics-nuanced"
            ]
          },
          {
            "id": "drug:isoflurane",
            "name": "isoflurane",
            "classifications": [
              "volatile anaesthetic"
            ],
            "atc_codes": [],
            "claims": [
              "claim:volatile-anaesthetics-nuanced"
            ]
          },
          {
            "id": "drug:sevoflurane",
            "name": "sevoflurane",
            "classifications": [
              "volatile anaesthetic"
            ],
            "atc_codes": [],
            "claims": [
              "claim:volatile-anaesthetics-nuanced"
            ]
          },
          {
            "id": "drug:volatile-agents",
            "name": "volatile agents",
            "classifications": [
              "inhalational anesthetic class"
            ],
            "atc_codes": [],
            "claims": [
              "claim:volatile-anaesthetics-nuanced"
            ]
          },
          {
            "id": "drug:volatile-anaesthetics",
            "name": "volatile anaesthetics",
            "classifications": [
              "inhalational anesthetic class"
            ],
            "atc_codes": [],
            "claims": [
              "claim:volatile-anaesthetics-nuanced"
            ]
          },
          {
            "id": "drug:succinylcholine",
            "name": "succinylcholine",
            "classifications": [
              "depolarising neuromuscular blocker"
            ],
            "atc_codes": [],
            "claims": [
              "claim:succinylcholine-safety"
            ]
          },
          {
            "id": "drug:atracurium",
            "name": "atracurium",
            "classifications": [
              "benzylisoquinolinium neuromuscular blocker"
            ],
            "atc_codes": [],
            "claims": [
              "claim:atracurium-safety"
            ]
          },
          {
            "id": "drug:metoclopramide",
            "name": "metoclopramide",
            "classifications": [
              "antiemetic / prokinetic"
            ],
            "atc_codes": [],
            "claims": [
              "claim:metoclopramide-risk"
            ]
          },
          {
            "id": "drug:rocuronium",
            "name": "rocuronium",
            "classifications": [
              "aminosteroid neuromuscular blocker"
            ],
            "atc_codes": [],
            "claims": [
              "claim:rocuronium-safety"
            ]
          },
          {
            "id": "drug:nitrous-oxide",
            "name": "nitrous oxide",
            "classifications": [
              "inhalational anesthetic / analgesic"
            ],
            "atc_codes": [],
            "claims": [
              "claim:nitrous-oxide-safety"
            ]
          },
          {
            "id": "drug:bupivacaine",
            "name": "bupivacaine",
            "classifications": [
              "local anaesthetic"
            ],
            "atc_codes": [],
            "claims": [
              "claim:bupivacaine-safety"
            ]
          },
          {
            "id": "drug:glucagon",
            "name": "glucagon",
            "classifications": [
              "hormone"
            ],
            "atc_codes": [],
            "claims": [
              "claim:glucagon-risk"
            ]
          }
        ],
        "claims": [
          {
            "id": "claim:opioids-safety",
            "type": "safety",
            "summary": "Opioid analgesics (including morphine, fentanyl, remifentanil and other commonly used opioids) are reported as safe options for pain management in acute hepatic porphyria and are commonly used/indicated during acute attacks and chronic symptomatic periods.",
            "confidence": "high",
            "idiosyncratic_reaction": {
              "flag": false,
              "descriptors": []
            },
            "articles": [
              "article:34661997",
              "article:36028858",
              "article:27052088",
              "article:29383964"
            ],
            "drugs": [
              "drug:fentanyl",
              "drug:morphine",
              "drug:remifentanil",
              "drug:opioids",
              "drug:opioid"
            ],
            "drug_classes": [
              "opioids",
              "opioid analgesics"
            ],
            "supporting_evidence": [
              {
                "snippet_id": "snippet:5",
                "pmid": "34661997",
                "article_title": "Acute porphyrias - A neurological perspective.",
                "key_points": [
                  "Table of 'safe medications' lists Morphine and hydromorphone among safe painkillers; opioids included in recommended options."
                ],
                "notes": ""
              },
              {
                "snippet_id": "snippet:15",
                "pmid": "34661997",
                "article_title": "Acute porphyrias - A neurological perspective.",
                "key_points": [
                  "Treatment guidance: opioids are usually indicated for adequate pain management during acute attacks; hemin indicated for severe cases."
                ],
                "notes": ""
              },
              {
                "snippet_id": "snippet:22",
                "pmid": "36028858",
                "article_title": "Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION study.",
                "key_points": [
                  "ENVISION trial baseline data show frequent opioid use among patients; fentanyl listed as an opioid anaesthetic used in the population."
                ],
                "notes": ""
              },
              {
                "snippet_id": "snippet:54",
                "pmid": "29383964",
                "article_title": "Acute intermittent porphyria: general aspects with focus on pain.",
                "key_points": [
                  "Review states that an important arsenal of reportedly safe opioid and non-opioid analgesics is available for AIP patients; opioids discussed as part of pain management."
                ],
                "notes": ""
              }
            ]
          },
          {
            "id": "claim:benzodiazepines-safety",
            "type": "safety",
            "summary": "Benzodiazepines (examples lorazepam, midazolam, diazepam) are cited as safe options for seizure control and as sedative/anxiolytic agents in acute hepatic porphyria.",
            "confidence": "high",
            "idiosyncratic_reaction": {
              "flag": false,
              "descriptors": []
            },
            "articles": [
              "article:34661997",
              "article:36642627",
              "article:2660638"
            ],
            "drugs": [
              "drug:lorazepam",
              "drug:midazolam",
              "drug:diazepam",
              "drug:benzodiazepines"
            ],
            "drug_classes": [
              "benzodiazepines"
            ],
            "supporting_evidence": [
              {
                "snippet_id": "snippet:5",
                "pmid": "34661997",
                "article_title": "Acute porphyrias - A neurological perspective.",
                "key_points": [
                  "Table of 'safe medications' lists Lorazepam and Midazolam among antiepileptic/sedative options considered safe."
                ],
                "notes": ""
              },
              {
                "snippet_id": "snippet:16",
                "pmid": "36642627",
                "article_title": "AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review.",
                "key_points": [
                  "Guidance states benzodiazepines appear to be safe options for management of seizures in AHP."
                ],
                "notes": ""
              },
              {
                "snippet_id": "snippet:64",
                "pmid": "2660638",
                "article_title": "[Anesthesia and hepatic porphyria].",
                "key_points": [
                  "Review discussion includes benzodiazepines among drugs with conflicting evidence but provides recommendations and experimental/clinical data used for guidance."
                ],
                "notes": ""
              }
            ]
          },
          {
            "id": "claim:levetiracetam-safety",
            "type": "safety",
            "summary": "Levetiracetam is reported as a safe anticonvulsant option for patients with acute hepatic porphyria.",
            "confidence": "high",
            "idiosyncratic_reaction": {
              "flag": false,
              "descriptors": []
            },
            "articles": [
              "article:34661997",
              "article:36642627",
              "article:27052088"
            ],
            "drugs": [
              "drug:levetiracetam"
            ],
            "drug_classes": [
              "anticonvulsants"
            ],
            "supporting_evidence": [
              {
                "snippet_id": "snippet:5",
                "pmid": "34661997",
                "article_title": "Acute porphyrias - A neurological perspective.",
                "key_points": [
                  "Levetiracetam listed among antiepileptic therapies that can be used in AHP."
                ],
                "notes": ""
              },
              {
                "snippet_id": "snippet:17",
                "pmid": "36642627",
                "article_title": "AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review.",
                "key_points": [
                  "Best practice advice: levetiracetam appears to be a safe option for seizures in AHP."
                ],
                "notes": ""
              },
              {
                "snippet_id": "snippet:14",
                "pmid": "34661997",
                "article_title": "Acute porphyrias - A neurological perspective.",
                "key_points": [
                  "Case context: levetiracetam was used to prevent seizures in a suspected porphyria patient being managed with steroids and other measures."
                ],
                "notes": ""
              }
            ]
          },
          {
            "id": "claim:propofol-safety",
            "type": "safety",
            "summary": "Propofol is repeatedly reported as a safe intravenous hypnotic/anaesthetic agent for induction and maintenance in patients with acute hepatic porphyria; case reports and reviews support its use.",
            "confidence": "high",
            "idiosyncratic_reaction": {
              "flag": false,
              "descriptors": []
            },
            "articles": [
              "article:27052088",
              "article:2697245",
              "article:27871506"
            ],
            "drugs": [
              "drug:propofol"
            ],
            "drug_classes": [
              "intravenous anaesthetic"
            ],
            "supporting_evidence": [
              {
                "snippet_id": "snippet:17",
                "pmid": "27052088",
                "article_title": "Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.",
                "key_points": [
                  "Propofol described as considered safe for induction and maintenance of anesthesia in patients with acute intermittent porphyria."
                ],
                "notes": ""
              },
              {
                "snippet_id": "snippet:59",
                "pmid": "2697245",
                "article_title": "The pharmacology of propofol.",
                "key_points": [
                  "Pharmacology review states propofol appears safe for use in patients with acute intermittent porphyria and susceptibility to malignant hyperpyrexia."
                ],
                "notes": ""
              },
              {
                "snippet_id": "snippet:22",
                "pmid": "27871506",
                "article_title": "Elective cholecystectomy performed on patient with variegate porphyria-Propofol-based total intravenous anesthesia with target-controlled infusion.",
                "key_points": [
                  "Case report: propofol-based TIVA was used safely in a patient with variegate porphyria; clinical symptoms were unchanged and approach considered safe."
                ],
                "notes": ""
              }
            ]
          },
          {
            "id": "claim:ketamine-nuanced",
            "type": "nuanced",
            "summary": "Ketamine has conflicting reports: some case reports suggest it may trigger acute porphyric crises, while it has also been used safely in quiescent disease; safety may depend on context (quiescent vs active disease) and exposure.",
            "confidence": "medium",
            "idiosyncratic_reaction": {
              "flag": false,
              "descriptors": []
            },
            "articles": [
              "article:27052088",
              "article:34661997",
              "article:2660638"
            ],
            "drugs": [
              "drug:ketamine"
            ],
            "drug_classes": [
              "NMDA antagonist / anaesthetic"
            ],
            "supporting_evidence": [
              {
                "snippet_id": "snippet:28",
                "pmid": "27052088",
                "article_title": "Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.",
                "key_points": [
                  "Some reports suggest ketamine can trigger AIP crisis, but ketamine has also been used safely in quiescent AIP; authors state ketamine might be safe in selected situations."
                ],
                "notes": ""
              },
              {
                "snippet_id": "snippet:11",
                "pmid": "34661997",
                "article_title": "Acute porphyrias - A neurological perspective.",
                "key_points": [
                  "Discussion of anaesthetic agents notes conflicting evidence for several agents including ketamine; addition of magnesium and propofol has been successful in seizure management."
                ],
                "notes": ""
              },
              {
                "snippet_id": "snippet:66",
                "pmid": "2660638",
                "article_title": "[Anesthesia and hepatic porphyria].",
                "key_points": [
                  "Review highlights drugs with conflicting evidence regarding safe use in porphyric patients, listing ketamine among them."
                ],
                "notes": ""
              }
            ]
          },
          {
            "id": "claim:volatile-anaesthetics-nuanced",
            "type": "nuanced",
            "summary": "Modern inhalational (volatile) anaesthetics (sevoflurane, isoflurane, desflurane) are generally considered safe in porphyria by clinical reports and case series, but some older reports (notably halothane) have been associated with adverse events; duration/dose and perioperative factors may influence risk. Volatile agents also carry well-described idiosyncratic adverse reactions (e.g., malignant hyperpyrexia, halothane hepatitis) unrelated to porphyria susceptibility.",
            "confidence": "medium",
            "idiosyncratic_reaction": {
              "flag": true,
              "descriptors": [
                "malignant hyperpyrexia",
                "halothane hepatitis"
              ]
            },
            "articles": [
              "article:27052088",
              "article:15021955",
              "article:1418699"
            ],
            "drugs": [
              "drug:desflurane",
              "drug:halothane",
              "drug:isoflurane",
              "drug:sevoflurane",
              "drug:volatile-agents",
              "drug:volatile-anaesthetics"
            ],
            "drug_classes": [
              "volatile anaesthetics",
              "inhalational anesthetic"
            ],
            "supporting_evidence": [
              {
                "snippet_id": "snippet:17",
                "pmid": "27052088",
                "article_title": "Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.",
                "key_points": [
                  "Authors state modern inhalation agents are generally considered safe (sevoflurane, isoflurane) though reports about halothane are contradictory; exposure duration and dose may matter."
                ],
                "notes": ""
              },
              {
                "snippet_id": "snippet:82",
                "pmid": "15021955",
                "article_title": "[Desflurane in acute intermittent porphyria].",
                "key_points": [
                  "Case report of desflurane use without porphyric complications; authors note favourable pharmacokinetics and minimal cytochrome P450 induction as rationale for safety."
                ],
                "notes": ""
              },
              {
                "snippet_id": "snippet:56",
                "pmid": "1418699",
                "article_title": "Adverse effects of general anaesthetics.",
                "key_points": [
                  "Review describes important idiosyncratic reactions to volatile agents, notably malignant hyperpyrexia and halothane hepatitis, with incidence and clinical significance."
                ],
                "notes": ""
              }
            ]
          },
          {
            "id": "claim:succinylcholine-safety",
            "type": "safety",
            "summary": "Succinylcholine (suxamethonium) has been used widely and reported as safe in patients with acute intermittent porphyria in clinical series and perioperative reports.",
            "confidence": "medium",
            "idiosyncratic_reaction": {
              "flag": false,
              "descriptors": []
            },
            "articles": [
              "article:27052088"
            ],
            "drugs": [
              "drug:succinylcholine"
            ],
            "drug_classes": [
              "depolarising neuromuscular blocker"
            ],
            "supporting_evidence": [
              {
                "snippet_id": "snippet:28",
                "pmid": "27052088",
                "article_title": "Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.",
                "key_points": [
                  "Authors report that succinylcholine has been used for many years and has been proven to be safe in porphyric patients."
                ],
                "notes": ""
              }
            ]
          },
          {
            "id": "claim:atracurium-safety",
            "type": "safety",
            "summary": "Atracurium has been used safely in small numbers of porphyria patients and was used without complications in reported perioperative cases.",
            "confidence": "medium",
            "idiosyncratic_reaction": {
              "flag": false,
              "descriptors": []
            },
            "articles": [
              "article:27052088",
              "article:15021955"
            ],
            "drugs": [
              "drug:atracurium"
            ],
            "drug_classes": [
              "benzylisoquinolinium neuromuscular blocker"
            ],
            "supporting_evidence": [
              {
                "snippet_id": "snippet:29",
                "pmid": "27052088",
                "article_title": "Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.",
                "key_points": [
                  "Atracurium and vecuronium have been used safely in small numbers of patients despite some experimental evidence for porphyrinogenicity; authors report safe use of atracurium in their case."
                ],
                "notes": ""
              },
              {
                "snippet_id": "snippet:81",
                "pmid": "15021955",
                "article_title": "[Desflurane in acute intermittent porphyria].",
                "key_points": [
                  "Balanced anaesthesia case used desflurane, sufentanil and atracurium without postoperative porphyric symptoms; monitored porphyrin precursor excretion returned to normal."
                ],
                "notes": ""
              }
            ]
          },
          {
            "id": "claim:rocuronium-safety",
            "type": "safety",
            "summary": "Rocuronium has been reported used safely in at least one case report with sevoflurane exposure for prolonged anesthesia in a patient with acute intermittent porphyria.",
            "confidence": "medium",
            "idiosyncratic_reaction": {
              "flag": false,
              "descriptors": []
            },
            "articles": [
              "article:17037005",
              "article:27052088"
            ],
            "drugs": [
              "drug:rocuronium"
            ],
            "drug_classes": [
              "aminosteroid neuromuscular blocker"
            ],
            "supporting_evidence": [
              {
                "snippet_id": "snippet:88",
                "pmid": "17037005",
                "article_title": "The use of rocuronium and sevoflurane in acute intermittent porphyria--a case report.",
                "key_points": [
                  "Case report describes safe use of rocuronium with sevoflurane for long exposure in an AIP patient."
                ],
                "notes": ""
              },
              {
                "snippet_id": "snippet:35",
                "pmid": "27052088",
                "article_title": "Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.",
                "key_points": [
                  "Authors note various neuromuscular blockers have mixed evidence; some (pancuronium/alcuronium) flagged unsafe by some authors but used without harm by others."
                ],
                "notes": ""
              }
            ]
          },
          {
            "id": "claim:metoclopramide-risk",
            "type": "risk",
            "summary": "Metoclopramide has been implicated in at least one case report as an exposure associated with triggering a porphyric crisis in a patient who subsequently developed hyponatremia, seizures and neurologic deterioration.",
            "confidence": "medium",
            "idiosyncratic_reaction": {
              "flag": true,
              "descriptors": [
                "triggered porphyric crisis"
              ]
            },
            "articles": [
              "article:21146060"
            ],
            "drugs": [
              "drug:metoclopramide"
            ],
            "drug_classes": [
              "antiemetic / prokinetic"
            ],
            "supporting_evidence": [
              {
                "snippet_id": "snippet:86",
                "pmid": "21146060",
                "article_title": "Neuropathic pain in a patient with porphyria. Case report.",
                "key_points": [
                  "Patient was exposed to drugs that can trigger porphyria, including metoclopramide; after exposure the patient developed severe porphyric features (hyponatremia, seizures, neurological decline)."
                ],
                "notes": ""
              }
            ]
          },
          {
            "id": "claim:nitrous-oxide-safety",
            "type": "safety",
            "summary": "Nitrous oxide has been used intraoperatively in at least one reported case of a patient with acute intermittent porphyria without precipitating an acute porphyric attack.",
            "confidence": "low",
            "idiosyncratic_reaction": {
              "flag": false,
              "descriptors": []
            },
            "articles": [
              "article:3986654",
              "article:1418699"
            ],
            "drugs": [
              "drug:nitrous-oxide"
            ],
            "drug_classes": [
              "inhalational anesthetic / analgesic"
            ],
            "supporting_evidence": [
              {
                "snippet_id": "snippet:90",
                "pmid": "3986654",
                "article_title": "Induction of anaesthesia with etomidate in a patient with acute intermittent porphyria.",
                "key_points": [
                  "Case report: anaesthesia induction with etomidate used nitrous oxide and intermittent fentanyl without subsequent porphyric attack; postoperative period uneventful."
                ],
                "notes": ""
              },
              {
                "snippet_id": "snippet:56",
                "pmid": "1418699",
                "article_title": "Adverse effects of general anaesthetics.",
                "key_points": [
                  "Review notes prolonged nitrous oxide exposure has other risks (bone marrow depression, pressure effects) but does not provide strong porphyria-specific contraindication."
                ],
                "notes": ""
              }
            ]
          },
          {
            "id": "claim:bupivacaine-safety",
            "type": "safety",
            "summary": "Bupivacaine has been used for neuraxial/regional anesthesia in porphyria patients (e.g., obstetrical anesthesia) and is described as an acceptable option in selected situations.",
            "confidence": "medium",
            "idiosyncratic_reaction": {
              "flag": false,
              "descriptors": []
            },
            "articles": [
              "article:15826795"
            ],
            "drugs": [
              "drug:bupivacaine"
            ],
            "drug_classes": [
              "local anaesthetic"
            ],
            "supporting_evidence": [
              {
                "snippet_id": "snippet:85",
                "pmid": "15826795",
                "article_title": "[Obstetrical anaesthesia and porphyrias].",
                "key_points": [
                  "Authors describe locoregional anesthesia with bupivacaine as a technique of choice for asymptomatic or long-remission porphyria patients for labour analgesia and cesarean section."
                ],
                "notes": ""
              }
            ]
          },
          {
            "id": "claim:glucagon-risk",
            "type": "risk",
            "summary": "Experimental data indicate glucagon increases intracellular cAMP and can enhance drug-induced porphyrin biosynthesis in chick embryo liver cells, suggesting glucagon may promote porphyrin accumulation and thus could increase porphyrinogenic risk under some conditions.",
            "confidence": "medium",
            "idiosyncratic_reaction": {
              "flag": false,
              "descriptors": []
            },
            "articles": [
              "article:88665"
            ],
            "drugs": [
              "drug:glucagon"
            ],
            "drug_classes": [
              "hormone"
            ],
            "supporting_evidence": [
              {
                "snippet_id": "snippet:72",
                "pmid": "88665",
                "article_title": "Hormonal effects on the regulation of hepatic heme biosynthesis.",
                "key_points": [
                  "Study in chick embryo liver cells found agents that increase cAMP (including glucagon) enhanced drug-induced porphyrin biosynthesis; insulin:glucagon ratio affects porphyrin accumulation, providing mechanistic rationale for glucose therapy."
                ],
                "notes": ""
              }
            ]
          },
          {
            "id": "claim:ondansetron-safety",
            "type": "safety",
            "summary": "Ondansetron (a 5-HT3 antagonist) appears in clinical summaries and trial medication lists as a commonly used antiemetic in patients with acute hepatic porphyria, without specific signals of porphyrinogenic risk in the provided texts.",
            "confidence": "medium",
            "idiosyncratic_reaction": {
              "flag": false,
              "descriptors": []
            },
            "articles": [
              "article:34661997",
              "article:36028858"
            ],
            "drugs": [
              "drug:ondansetron"
            ],
            "drug_classes": [
              "antiemetic (5HT3 antagonist)"
            ],
            "supporting_evidence": [
              {
                "snippet_id": "snippet:5",
                "pmid": "34661997",
                "article_title": "Acute porphyrias - A neurological perspective.",
                "key_points": [
                  "Ondansetron appears in the table of 'safe medications' under antiemetics."
                ],
                "notes": ""
              },
              {
                "snippet_id": "snippet:22",
                "pmid": "36028858",
                "article_title": "Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION study.",
                "key_points": [
                  "ENVISION trial baseline medication lists include 5HT3 antagonists among antiemetics used by participants."
                ],
                "notes": ""
              }
            ]
          },
          {
            "id": "claim:dexamethasone-safety",
            "type": "safety",
            "summary": "Dexamethasone is listed among steroid preparations in medication tables in reviews of acute porphyrias; in the provided text it appears within lists of medications considered for use and not singled out as a routinely porphyrinogenic agent.",
            "confidence": "low",
            "idiosyncratic_reaction": {
              "flag": false,
              "descriptors": []
            },
            "articles": [
              "article:34661997"
            ],
            "drugs": [
              "drug:dexamethasone"
            ],
            "drug_classes": [
              "steroids"
            ],
            "supporting_evidence": [
              {
                "snippet_id": "snippet:2",
                "pmid": "34661997",
                "article_title": "Acute porphyrias - A neurological perspective.",
                "key_points": [
                  "Steroids (including dexamethasone) appear in tabulated medication lists in the review; authors advise consulting porphyria drug databases for up-to-date classifications."
                ],
                "notes": ""
              }
            ]
          },
          {
            "id": "claim:atropine-safety",
            "type": "safety",
            "summary": "Atropine is listed among 'other' agents in medication tables in porphyria reviews and is not highlighted as a known porphyrinogenic trigger in the provided excerpts.",
            "confidence": "low",
            "idiosyncratic_reaction": {
              "flag": false,
              "descriptors": []
            },
            "articles": [
              "article:34661997"
            ],
            "drugs": [
              "drug:atropine"
            ],
            "drug_classes": [
              "anticholinergic"
            ],
            "supporting_evidence": [
              {
                "snippet_id": "snippet:1",
                "pmid": "34661997",
                "article_title": "Acute porphyrias - A neurological perspective.",
                "key_points": [
                  "Atropine appears in the medication listing under 'Others' alongside hormones and catecholamines; authors recommend checking specialized drug databases for current classifications."
                ],
                "notes": ""
              }
            ]
          }
        ]
      },
      "usage": {
        "prompt_tokens": 22378,
        "completion_tokens": 9838,
        "total_tokens": 32216
      }
    },
    {
      "model": "gpt-5-mini",
      "response_id": "resp_019052707bcf2855006913bf9fceb481908846ec09ace16f91",
      "content": "{\n  \"condition\": \"porphyria\",\n  \"drugs\": [\n    {\n      \"id\": \"drug:midazolam\",\n      \"name\": \"midazolam\",\n      \"classifications\": [\n        \"benzodiazepine\"\n      ],\n      \"atc_codes\": [],\n      \"claims\": [\n        \"claim:benzodiazepines-nuanced\"\n      ]\n    },\n    {\n      \"id\": \"drug:benzodiazepines\",\n      \"name\": \"benzodiazepines\",\n      \"classifications\": [\n        \"benzodiazepine\"\n      ],\n      \"atc_codes\": [],\n      \"claims\": [\n        \"claim:benzodiazepines-nuanced\"\n      ]\n    },\n    {\n      \"id\": \"drug:atracurium\",\n      \"name\": \"atracurium\",\n      \"classifications\": [\n        \"neuromuscular blocker (benzylisoquinolinium)\"\n      ],\n      \"atc_codes\": [],\n      \"claims\": [\n        \"claim:atracurium-safety\"\n      ]\n    },\n    {\n      \"id\": \"drug:propofol\",\n      \"name\": \"propofol\",\n      \"classifications\": [\n        \"intravenous anaesthetic\"\n      ],\n      \"atc_codes\": [],\n      \"claims\": [\n        \"claim:propofol-nuanced\"\n      ]\n    },\n    {\n      \"id\": \"drug:fentanyl\",\n      \"name\": \"fentanyl\",\n      \"classifications\": [\n        \"opioid analgesic\"\n      ],\n      \"atc_codes\": [],\n      \"claims\": [\n        \"claim:opioids-safety\"\n      ]\n    },\n    {\n      \"id\": \"drug:levetiracetam\",\n      \"name\": \"levetiracetam\",\n      \"classifications\": [\n        \"anticonvulsant\"\n      ],\n      \"atc_codes\": [],\n      \"claims\": [\n        \"claim:levetiracetam-safety\"\n      ]\n    },\n    {\n      \"id\": \"drug:opioids\",\n      \"name\": \"opioids\",\n      \"classifications\": [\n        \"opioid analgesic\"\n      ],\n      \"atc_codes\": [],\n      \"claims\": [\n        \"claim:opioids-safety\"\n      ]\n    },\n    {\n      \"id\": \"drug:desflurane\",\n      \"name\": \"desflurane\",\n      \"classifications\": [\n        \"volatile anaesthetic\"\n      ],\n      \"atc_codes\": [],\n      \"claims\": [\n        \"claim:volatile-anaesthetics-nuanced\"\n      ]\n    },\n    {\n      \"id\": \"drug:halothane\",\n      \"name\": \"halothane\",\n      \"classifications\": [\n        \"volatile anaesthetic\"\n      ],\n      \"atc_codes\": [],\n      \"claims\": [\n        \"claim:volatile-anaesthetics-nuanced\"\n      ]\n    },\n    {\n      \"id\": \"drug:isoflurane\",\n      \"name\": \"isoflurane\",\n      \"classifications\": [\n        \"volatile anaesthetic\"\n      ],\n      \"atc_codes\": [],\n      \"claims\": [\n        \"claim:volatile-anaesthetics-nuanced\"\n      ]\n    },\n    {\n      \"id\": \"drug:sevoflurane\",\n      \"name\": \"sevoflurane\",\n      \"classifications\": [\n        \"volatile anaesthetic\"\n      ],\n      \"atc_codes\": [],\n      \"claims\": [\n        \"claim:volatile-anaesthetics-nuanced\"\n      ]\n    },\n    {\n      \"id\": \"drug:succinylcholine\",\n      \"name\": \"succinylcholine\",\n      \"classifications\": [\n        \"depolarising neuromuscular blocker\"\n      ],\n      \"atc_codes\": [],\n      \"claims\": [\n        \"claim:succinylcholine-malignant-hyperthermia\"\n      ]\n    },\n    {\n      \"id\": \"drug:opioid\",\n      \"name\": \"opioid\",\n      \"classifications\": [\n        \"opioid analgesic\"\n      ],\n      \"atc_codes\": [],\n      \"claims\": [\n        \"claim:opioids-safety\"\n      ]\n    }\n  ],\n  \"claims\": [\n    {\n      \"id\": \"claim:benzodiazepines-nuanced\",\n      \"type\": \"nuanced\",\n      \"summary\": \"Benzodiazepines (including midazolam) are described in several sources as commonly considered safe for use in patients with acute hepatic porphyrias, but other reviews and case discussions advise caution or list benzodiazepines among drugs to consider as potential triggers; the evidence across reports is mixed.\",\n      \"confidence\": \"medium\",\n      \"idiosyncratic_reaction\": {\n        \"flag\": false,\n        \"descriptors\": []\n      },\n      \"articles\": [\n        \"article:27052088\",\n        \"article:10504904\",\n        \"article:36575494\",\n        \"article:23993340\"\n      ],\n      \"drugs\": [\n        \"drug:benzodiazepines\",\n        \"drug:midazolam\"\n      ],\n      \"drug_classes\": [\n        \"benzodiazepine\"\n      ],\n      \"supporting_evidence\": [\n        {\n          \"snippet_id\": \"snippet:36\",\n          \"pmid\": \"27052088\",\n          \"article_title\": \"Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.\",\n          \"key_points\": [\n            \"Most (but not all) benzodiazepines commonly used for premedication like midazolam are considered safe.\",\n            \"Authors report safe use of midazolam in the presented case.\"\n          ],\n          \"notes\": \"\"\n        },\n        {\n          \"snippet_id\": \"snippet:38\",\n          \"pmid\": \"27052088\",\n          \"article_title\": \"Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.\",\n          \"key_points\": [\n            \"Reiterates that benzodiazepines such as midazolam are generally considered safe though further information may be needed.\"\n          ],\n          \"notes\": \"\"\n        },\n        {\n          \"snippet_id\": \"snippet:74\",\n          \"pmid\": \"10504904\",\n          \"article_title\": \"Anesthetic considerations in hepatic porphyrias.\",\n          \"key_points\": [\n            \"Review advises avoiding triggering drugs; states barbiturates, and perhaps benzodiazepines and ketamines, should be considered with caution.\"\n          ],\n          \"notes\": \"\"\n        },\n        {\n          \"snippet_id\": \"snippet:45\",\n          \"pmid\": \"36575494\",\n          \"article_title\": \"Porphyria: a case report.\",\n          \"key_points\": [\n            \"Lists benzodiazepines among first-line treatment options for seizures but notes many antiepileptic drugs are porphyrinogenic; warns that treating seizures with porphyrinogenic medications can trigger acute attacks.\"\n          ],\n          \"notes\": \"\"\n        },\n        {\n          \"snippet_id\": \"snippet:93\",\n          \"pmid\": \"23993340\",\n          \"article_title\": \"[State of dementia due to intermittent acute porphyria: a case report].\",\n          \"key_points\": [\n            \"Patient had been treated with benzodiazepines and neuroleptics for years; clinical improvement followed stopping implicated medications after porphyria diagnosis.\"\n          ],\n          \"notes\": \"\"\n        }\n      ]\n    },\n    {\n      \"id\": \"claim:propofol-nuanced\",\n      \"type\": \"nuanced\",\n      \"summary\": \"Propofol has been used as induction and maintenance anaesthesia in multiple case reports and a prospective series in porphyria patients without clinical porphyric crises, and some reviews state it appears safe; however, at least one report documented increased urinary porphyrin excretion after propofol exposure (without clinical manifestations), so biochemical effects have been observed and overall safety is not conclusively established.\",\n      \"confidence\": \"medium\",\n      \"idiosyncratic_reaction\": {\n        \"flag\": false,\n        \"descriptors\": []\n      },\n      \"articles\": [\n        \"article:1997060\",\n        \"article:2697245\",\n        \"article:8342401\",\n        \"article:25137868\"\n      ],\n      \"drugs\": [\n        \"drug:propofol\"\n      ],\n      \"drug_classes\": [\n        \"intravenous anaesthetic\"\n      ],\n      \"supporting_evidence\": [\n        {\n          \"snippet_id\": \"snippet:83\",\n          \"pmid\": \"1997060\",\n          \"article_title\": \"Propofol as an i.v. anaesthetic induction agent in variegate porphyria.\",\n          \"key_points\": [\n            \"Prospective trial in 13 variegate porphyria subjects showed no significant change in porphyrin or porphyrin precursor output after propofol induction.\",\n            \"No clinical manifestations of a porphyric attack reported in that series.\"\n          ],\n          \"notes\": \"\"\n        },\n        {\n          \"snippet_id\": \"snippet:58\",\n          \"pmid\": \"2697245\",\n          \"article_title\": \"The pharmacology of propofol.\",\n          \"key_points\": [\n            \"Review states propofol appears safe for use in patients with acute intermittent porphyria.\"\n          ],\n          \"notes\": \"\"\n        },\n        {\n          \"snippet_id\": \"snippet:71\",\n          \"pmid\": \"8342401\",\n          \"article_title\": \"Total intravenous anesthesia in South-African genetic porphyria (variegate porphyria).\",\n          \"key_points\": [\n            \"Case report showed a significant rise in urinary porphyrin excretion after propofol without associated clinical manifestations; authors conclude innocuity cannot be established without further studies.\"\n          ],\n          \"notes\": \"\"\n        },\n        {\n          \"snippet_id\": \"snippet:92\",\n          \"pmid\": \"25137868\",\n          \"article_title\": \"Ultrasound-guided regional anesthesia in a pediatric patient with acute intermittent porphyria: literature review and case report.\",\n          \"key_points\": [\n            \"Pediatric case with propofol induction proceeded without complications and the patient did not demonstrate signs of an AIP crisis.\"\n          ],\n          \"notes\": \"\"\n        }\n      ]\n    },\n    {\n      \"id\": \"claim:atracurium-safety\",\n      \"type\": \"safety\",\n      \"summary\": \"Atracurium has been used uneventfully in reported anaesthetic plans for patients with acute intermittent porphyria, including combination with propofol, midazolam, and fentanyl.\",\n      \"confidence\": \"medium\",\n      \"idiosyncratic_reaction\": {\n        \"flag\": false,\n        \"descriptors\": []\n      },\n      \"articles\": [\n        \"article:27052088\",\n        \"article:15021955\"\n      ],\n      \"drugs\": [\n        \"drug:atracurium\"\n      ],\n      \"drug_classes\": [\n        \"neuromuscular blocker (benzylisoquinolinium)\"\n      ],\n      \"supporting_evidence\": [\n        {\n          \"snippet_id\": \"snippet:37\",\n          \"pmid\": \"27052088\",\n          \"article_title\": \"Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.\",\n          \"key_points\": [\n            \"Case report: atracurium used uneventfully in combination with fentanyl, propofol, and midazolam; no complications reported.\"\n          ],\n          \"notes\": \"\"\n        },\n        {\n          \"snippet_id\": \"snippet:80\",\n          \"pmid\": \"15021955\",\n          \"article_title\": \"[Desflurane in acute intermittent porphyria].\",\n          \"key_points\": [\n            \"Desflurane-based balanced anaesthesia in one patient included atracurium and continuous monitoring of porphyrin precursors; no clinical porphyric attack occurred postoperatively.\"\n          ],\n          \"notes\": \"\"\n        }\n      ]\n    },\n    {\n      \"id\": \"claim:opioids-safety\",\n      \"type\": \"safety\",\n      \"summary\": \"Opioids, including fentanyl, are described in management guidance and case reports as part of recommended treatment for pain in acute hepatic porphyrias and have been used without precipitating attacks in reported perioperative cases.\",\n      \"confidence\": \"medium\",\n      \"idiosyncratic_reaction\": {\n        \"flag\": false,\n        \"descriptors\": []\n      },\n      \"articles\": [\n        \"article:39313028\",\n        \"article:27052088\",\n        \"article:15021955\"\n      ],\n      \"drugs\": [\n        \"drug:fentanyl\",\n        \"drug:opioids\",\n        \"drug:opioid\"\n      ],\n      \"drug_classes\": [\n        \"opioid analgesic\"\n      ],\n      \"supporting_evidence\": [\n        {\n          \"snippet_id\": \"snippet:62\",\n          \"pmid\": \"39313028\",\n          \"article_title\": \"Therapeutic approach to acute crises of hepatic porphyrias.\",\n          \"key_points\": [\n            \"Management of acute hepatic porphyria includes intravenous opioids for pain control as part of urgent treatment.\"\n          ],\n          \"notes\": \"\"\n        },\n        {\n          \"snippet_id\": \"snippet:39\",\n          \"pmid\": \"27052088\",\n          \"article_title\": \"Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.\",\n          \"key_points\": [\n            \"Case report: fentanyl used successfully in combination with propofol, midazolam, and atracurium with no disadvantage; patient discharged without complication.\"\n          ],\n          \"notes\": \"\"\n        },\n        {\n          \"snippet_id\": \"snippet:80\",\n          \"pmid\": \"15021955\",\n          \"article_title\": \"[Desflurane in acute intermittent porphyria].\",\n          \"key_points\": [\n            \"Postoperative epidural analgesia included fentanyl; perioperative monitoring showed no clinical symptoms of a porphyric attack.\"\n          ],\n          \"notes\": \"\"\n        }\n      ]\n    },\n    {\n      \"id\": \"claim:levetiracetam-safety\",\n      \"type\": \"safety\",\n      \"summary\": \"Levetiracetam is recommended in reviews and clinical guidance as a safer antiepileptic for patients with acute intermittent porphyria and hepatic dysfunction, and has been started as an alternative to porphyrinogenic agents in case reports.\",\n      \"confidence\": \"high\",\n      \"idiosyncratic_reaction\": {\n        \"flag\": false,\n        \"descriptors\": []\n      },\n      \"articles\": [\n        \"article:29097018\",\n        \"article:17190918\",\n        \"article:35164799\"\n      ],\n      \"drugs\": [\n        \"drug:levetiracetam\"\n      ],\n      \"drug_classes\": [\n        \"anticonvulsant\"\n      ],\n      \"supporting_evidence\": [\n        {\n          \"snippet_id\": \"snippet:48\",\n          \"pmid\": \"29097018\",\n          \"article_title\": \"Antiepileptic Drugs and Liver Disease.\",\n          \"key_points\": [\n            \"Review: newer antiepileptic drugs with minimal hepatic metabolism such as levetiracetam should be used as first-line in patients at risk; in AIP, levetiracetam, gabapentin, and vigabatrin are cited as safe choices.\"\n          ],\n          \"notes\": \"\"\n        },\n        {\n          \"snippet_id\": \"snippet:67\",\n          \"pmid\": \"17190918\",\n          \"article_title\": \"Optimizing therapy of seizures in patients with renal or hepatic dysfunction.\",\n          \"key_points\": [\n            \"Levetiracetam is preferred in hepatic dysfunction and may benefit porphyria sufferers; it is listed among preferred AEDs in these conditions.\"\n          ],\n          \"notes\": \"\"\n        },\n        {\n          \"snippet_id\": \"snippet:44\",\n          \"pmid\": \"35164799\",\n          \"article_title\": \"A boy with blistering of sun-exposed skin and finger shortening: the first case of Variegate Porphyria with a novel mutation in protoporphyrinogen oxidase (PPOX) gene in Iran: a case report and literature review.\",\n          \"key_points\": [\n            \"Case report: after tapering phenobarbital due to porphyria concerns, treatment with levetiracetam was started for seizure control.\"\n          ],\n          \"notes\": \"\"\n        }\n      ]\n    },\n    {\n      \"id\": \"claim:volatile-anaesthetics-nuanced\",\n      \"type\": \"nuanced\",\n      \"summary\": \"Volatile anaesthetics (desflurane, halothane, isoflurane, sevoflurane) have been reported used safely in individual cases and small series of patients with acute porphyrias, but volatile agents carry known idiosyncratic severe risks (malignant hyperpyrexia/malignant hyperthermia and halothane-associated hepatitis) that are unrelated to porphyria-specific biochemical induction.\",\n      \"confidence\": \"medium\",\n      \"idiosyncratic_reaction\": {\n        \"flag\": true,\n        \"descriptors\": [\n          \"malignant hyperpyrexia\",\n          \"halothane hepatitis\"\n        ]\n      },\n      \"articles\": [\n        \"article:15021955\",\n        \"article:17037005\",\n        \"article:1418699\"\n      ],\n      \"drugs\": [\n        \"drug:desflurane\",\n        \"drug:halothane\",\n        \"drug:isoflurane\",\n        \"drug:sevoflurane\"\n      ],\n      \"drug_classes\": [\n        \"volatile anaesthetic\"\n      ],\n      \"supporting_evidence\": [\n        {\n          \"snippet_id\": \"snippet:76\",\n          \"pmid\": \"15021955\",\n          \"article_title\": \"[Desflurane in acute intermittent porphyria].\",\n          \"key_points\": [\n            \"Report of desflurane used in an AIP patient for hemihepatectomy with perioperative monitoring of porphyrin precursors and no clinical porphyric attack.\",\n            \"Authors note halothane and isoflurane seem to be safe and discuss minimal P450 induction by desflurane.\"\n          ],\n          \"notes\": \"\"\n        },\n        {\n          \"snippet_id\": \"snippet:89\",\n          \"pmid\": \"17037005\",\n          \"article_title\": \"The use of rocuronium and sevoflurane in acute intermittent porphyria--a case report.\",\n          \"key_points\": [\n            \"Case report: safe use of sevoflurane and rocuronium for prolonged exposure in a patient with AIP.\"\n          ],\n          \"notes\": \"\"\n        },\n        {\n          \"snippet_id\": \"snippet:55\",\n          \"pmid\": \"1418699\",\n          \"article_title\": \"Adverse effects of general anaesthetics.\",\n          \"key_points\": [\n            \"Review: volatile agents can cause idiosyncratic reactions such as malignant hyperpyrexia (classically triggered by halothane with succinylcholine) and halothane hepatitis.\",\n            \"Notes these idiosyncratic reactions are important considerations in anaesthetic practice.\"\n          ],\n          \"notes\": \"\"\n        }\n      ]\n    },\n    {\n      \"id\": \"claim:succinylcholine-malignant-hyperthermia\",\n      \"type\": \"risk\",\n      \"summary\": \"Succinylcholine (suxamethonium) is a known trigger of malignant hyperthermia in susceptible individuals, particularly when used with volatile anaesthetic agents; this represents an idiosyncratic pharmacogenetic risk rather than a porphyria-specific drug-provoked biochemical crisis.\",\n      \"confidence\": \"high\",\n      \"idiosyncratic_reaction\": {\n        \"flag\": true,\n        \"descriptors\": [\n          \"malignant hyperpyrexia\",\n          \"malignant hyperthermia\"\n        ]\n      },\n      \"articles\": [\n        \"article:16296947\",\n        \"article:1418699\"\n      ],\n      \"drugs\": [\n        \"drug:succinylcholine\"\n      ],\n      \"drug_classes\": [\n        \"depolarising neuromuscular blocker\"\n      ],\n      \"supporting_evidence\": [\n        {\n          \"snippet_id\": \"snippet:52\",\n          \"pmid\": \"16296947\",\n          \"article_title\": \"Pharmacogenetics and anesthesiologists.\",\n          \"key_points\": [\n            \"Discusses historical pharmacogenetic insights from anesthesiology including prolonged apnea after succinylcholine and malignant hyperthermia investigations.\"\n          ],\n          \"notes\": \"\"\n        },\n        {\n          \"snippet_id\": \"snippet:55\",\n          \"pmid\": \"1418699\",\n          \"article_title\": \"Adverse effects of general anaesthetics.\",\n          \"key_points\": [\n            \"States malignant hyperpyrexia is triggered most often by halothane together with suxamethonium and has significant mortality; highlights this as an important idiosyncratic reaction to volatile agents and succinylcholine.\"\n          ],\n          \"notes\": \"\"\n        }\n      ]\n    }\n  ]\n}",
      "parsed": {
        "condition": "porphyria",
        "drugs": [
          {
            "id": "drug:midazolam",
            "name": "midazolam",
            "classifications": [
              "benzodiazepine"
            ],
            "atc_codes": [],
            "claims": [
              "claim:benzodiazepines-nuanced"
            ]
          },
          {
            "id": "drug:benzodiazepines",
            "name": "benzodiazepines",
            "classifications": [
              "benzodiazepine"
            ],
            "atc_codes": [],
            "claims": [
              "claim:benzodiazepines-nuanced"
            ]
          },
          {
            "id": "drug:atracurium",
            "name": "atracurium",
            "classifications": [
              "neuromuscular blocker (benzylisoquinolinium)"
            ],
            "atc_codes": [],
            "claims": [
              "claim:atracurium-safety"
            ]
          },
          {
            "id": "drug:propofol",
            "name": "propofol",
            "classifications": [
              "intravenous anaesthetic"
            ],
            "atc_codes": [],
            "claims": [
              "claim:propofol-nuanced"
            ]
          },
          {
            "id": "drug:fentanyl",
            "name": "fentanyl",
            "classifications": [
              "opioid analgesic"
            ],
            "atc_codes": [],
            "claims": [
              "claim:opioids-safety"
            ]
          },
          {
            "id": "drug:levetiracetam",
            "name": "levetiracetam",
            "classifications": [
              "anticonvulsant"
            ],
            "atc_codes": [],
            "claims": [
              "claim:levetiracetam-safety"
            ]
          },
          {
            "id": "drug:opioids",
            "name": "opioids",
            "classifications": [
              "opioid analgesic"
            ],
            "atc_codes": [],
            "claims": [
              "claim:opioids-safety"
            ]
          },
          {
            "id": "drug:desflurane",
            "name": "desflurane",
            "classifications": [
              "volatile anaesthetic"
            ],
            "atc_codes": [],
            "claims": [
              "claim:volatile-anaesthetics-nuanced"
            ]
          },
          {
            "id": "drug:halothane",
            "name": "halothane",
            "classifications": [
              "volatile anaesthetic"
            ],
            "atc_codes": [],
            "claims": [
              "claim:volatile-anaesthetics-nuanced"
            ]
          },
          {
            "id": "drug:isoflurane",
            "name": "isoflurane",
            "classifications": [
              "volatile anaesthetic"
            ],
            "atc_codes": [],
            "claims": [
              "claim:volatile-anaesthetics-nuanced"
            ]
          },
          {
            "id": "drug:sevoflurane",
            "name": "sevoflurane",
            "classifications": [
              "volatile anaesthetic"
            ],
            "atc_codes": [],
            "claims": [
              "claim:volatile-anaesthetics-nuanced"
            ]
          },
          {
            "id": "drug:succinylcholine",
            "name": "succinylcholine",
            "classifications": [
              "depolarising neuromuscular blocker"
            ],
            "atc_codes": [],
            "claims": [
              "claim:succinylcholine-malignant-hyperthermia"
            ]
          },
          {
            "id": "drug:opioid",
            "name": "opioid",
            "classifications": [
              "opioid analgesic"
            ],
            "atc_codes": [],
            "claims": [
              "claim:opioids-safety"
            ]
          }
        ],
        "claims": [
          {
            "id": "claim:benzodiazepines-nuanced",
            "type": "nuanced",
            "summary": "Benzodiazepines (including midazolam) are described in several sources as commonly considered safe for use in patients with acute hepatic porphyrias, but other reviews and case discussions advise caution or list benzodiazepines among drugs to consider as potential triggers; the evidence across reports is mixed.",
            "confidence": "medium",
            "idiosyncratic_reaction": {
              "flag": false,
              "descriptors": []
            },
            "articles": [
              "article:27052088",
              "article:10504904",
              "article:36575494",
              "article:23993340"
            ],
            "drugs": [
              "drug:benzodiazepines",
              "drug:midazolam"
            ],
            "drug_classes": [
              "benzodiazepine"
            ],
            "supporting_evidence": [
              {
                "snippet_id": "snippet:36",
                "pmid": "27052088",
                "article_title": "Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.",
                "key_points": [
                  "Most (but not all) benzodiazepines commonly used for premedication like midazolam are considered safe.",
                  "Authors report safe use of midazolam in the presented case."
                ],
                "notes": ""
              },
              {
                "snippet_id": "snippet:38",
                "pmid": "27052088",
                "article_title": "Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.",
                "key_points": [
                  "Reiterates that benzodiazepines such as midazolam are generally considered safe though further information may be needed."
                ],
                "notes": ""
              },
              {
                "snippet_id": "snippet:74",
                "pmid": "10504904",
                "article_title": "Anesthetic considerations in hepatic porphyrias.",
                "key_points": [
                  "Review advises avoiding triggering drugs; states barbiturates, and perhaps benzodiazepines and ketamines, should be considered with caution."
                ],
                "notes": ""
              },
              {
                "snippet_id": "snippet:45",
                "pmid": "36575494",
                "article_title": "Porphyria: a case report.",
                "key_points": [
                  "Lists benzodiazepines among first-line treatment options for seizures but notes many antiepileptic drugs are porphyrinogenic; warns that treating seizures with porphyrinogenic medications can trigger acute attacks."
                ],
                "notes": ""
              },
              {
                "snippet_id": "snippet:93",
                "pmid": "23993340",
                "article_title": "[State of dementia due to intermittent acute porphyria: a case report].",
                "key_points": [
                  "Patient had been treated with benzodiazepines and neuroleptics for years; clinical improvement followed stopping implicated medications after porphyria diagnosis."
                ],
                "notes": ""
              }
            ]
          },
          {
            "id": "claim:propofol-nuanced",
            "type": "nuanced",
            "summary": "Propofol has been used as induction and maintenance anaesthesia in multiple case reports and a prospective series in porphyria patients without clinical porphyric crises, and some reviews state it appears safe; however, at least one report documented increased urinary porphyrin excretion after propofol exposure (without clinical manifestations), so biochemical effects have been observed and overall safety is not conclusively established.",
            "confidence": "medium",
            "idiosyncratic_reaction": {
              "flag": false,
              "descriptors": []
            },
            "articles": [
              "article:1997060",
              "article:2697245",
              "article:8342401",
              "article:25137868"
            ],
            "drugs": [
              "drug:propofol"
            ],
            "drug_classes": [
              "intravenous anaesthetic"
            ],
            "supporting_evidence": [
              {
                "snippet_id": "snippet:83",
                "pmid": "1997060",
                "article_title": "Propofol as an i.v. anaesthetic induction agent in variegate porphyria.",
                "key_points": [
                  "Prospective trial in 13 variegate porphyria subjects showed no significant change in porphyrin or porphyrin precursor output after propofol induction.",
                  "No clinical manifestations of a porphyric attack reported in that series."
                ],
                "notes": ""
              },
              {
                "snippet_id": "snippet:58",
                "pmid": "2697245",
                "article_title": "The pharmacology of propofol.",
                "key_points": [
                  "Review states propofol appears safe for use in patients with acute intermittent porphyria."
                ],
                "notes": ""
              },
              {
                "snippet_id": "snippet:71",
                "pmid": "8342401",
                "article_title": "Total intravenous anesthesia in South-African genetic porphyria (variegate porphyria).",
                "key_points": [
                  "Case report showed a significant rise in urinary porphyrin excretion after propofol without associated clinical manifestations; authors conclude innocuity cannot be established without further studies."
                ],
                "notes": ""
              },
              {
                "snippet_id": "snippet:92",
                "pmid": "25137868",
                "article_title": "Ultrasound-guided regional anesthesia in a pediatric patient with acute intermittent porphyria: literature review and case report.",
                "key_points": [
                  "Pediatric case with propofol induction proceeded without complications and the patient did not demonstrate signs of an AIP crisis."
                ],
                "notes": ""
              }
            ]
          },
          {
            "id": "claim:atracurium-safety",
            "type": "safety",
            "summary": "Atracurium has been used uneventfully in reported anaesthetic plans for patients with acute intermittent porphyria, including combination with propofol, midazolam, and fentanyl.",
            "confidence": "medium",
            "idiosyncratic_reaction": {
              "flag": false,
              "descriptors": []
            },
            "articles": [
              "article:27052088",
              "article:15021955"
            ],
            "drugs": [
              "drug:atracurium"
            ],
            "drug_classes": [
              "neuromuscular blocker (benzylisoquinolinium)"
            ],
            "supporting_evidence": [
              {
                "snippet_id": "snippet:37",
                "pmid": "27052088",
                "article_title": "Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.",
                "key_points": [
                  "Case report: atracurium used uneventfully in combination with fentanyl, propofol, and midazolam; no complications reported."
                ],
                "notes": ""
              },
              {
                "snippet_id": "snippet:80",
                "pmid": "15021955",
                "article_title": "[Desflurane in acute intermittent porphyria].",
                "key_points": [
                  "Desflurane-based balanced anaesthesia in one patient included atracurium and continuous monitoring of porphyrin precursors; no clinical porphyric attack occurred postoperatively."
                ],
                "notes": ""
              }
            ]
          },
          {
            "id": "claim:opioids-safety",
            "type": "safety",
            "summary": "Opioids, including fentanyl, are described in management guidance and case reports as part of recommended treatment for pain in acute hepatic porphyrias and have been used without precipitating attacks in reported perioperative cases.",
            "confidence": "medium",
            "idiosyncratic_reaction": {
              "flag": false,
              "descriptors": []
            },
            "articles": [
              "article:39313028",
              "article:27052088",
              "article:15021955"
            ],
            "drugs": [
              "drug:fentanyl",
              "drug:opioids",
              "drug:opioid"
            ],
            "drug_classes": [
              "opioid analgesic"
            ],
            "supporting_evidence": [
              {
                "snippet_id": "snippet:62",
                "pmid": "39313028",
                "article_title": "Therapeutic approach to acute crises of hepatic porphyrias.",
                "key_points": [
                  "Management of acute hepatic porphyria includes intravenous opioids for pain control as part of urgent treatment."
                ],
                "notes": ""
              },
              {
                "snippet_id": "snippet:39",
                "pmid": "27052088",
                "article_title": "Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.",
                "key_points": [
                  "Case report: fentanyl used successfully in combination with propofol, midazolam, and atracurium with no disadvantage; patient discharged without complication."
                ],
                "notes": ""
              },
              {
                "snippet_id": "snippet:80",
                "pmid": "15021955",
                "article_title": "[Desflurane in acute intermittent porphyria].",
                "key_points": [
                  "Postoperative epidural analgesia included fentanyl; perioperative monitoring showed no clinical symptoms of a porphyric attack."
                ],
                "notes": ""
              }
            ]
          },
          {
            "id": "claim:levetiracetam-safety",
            "type": "safety",
            "summary": "Levetiracetam is recommended in reviews and clinical guidance as a safer antiepileptic for patients with acute intermittent porphyria and hepatic dysfunction, and has been started as an alternative to porphyrinogenic agents in case reports.",
            "confidence": "high",
            "idiosyncratic_reaction": {
              "flag": false,
              "descriptors": []
            },
            "articles": [
              "article:29097018",
              "article:17190918",
              "article:35164799"
            ],
            "drugs": [
              "drug:levetiracetam"
            ],
            "drug_classes": [
              "anticonvulsant"
            ],
            "supporting_evidence": [
              {
                "snippet_id": "snippet:48",
                "pmid": "29097018",
                "article_title": "Antiepileptic Drugs and Liver Disease.",
                "key_points": [
                  "Review: newer antiepileptic drugs with minimal hepatic metabolism such as levetiracetam should be used as first-line in patients at risk; in AIP, levetiracetam, gabapentin, and vigabatrin are cited as safe choices."
                ],
                "notes": ""
              },
              {
                "snippet_id": "snippet:67",
                "pmid": "17190918",
                "article_title": "Optimizing therapy of seizures in patients with renal or hepatic dysfunction.",
                "key_points": [
                  "Levetiracetam is preferred in hepatic dysfunction and may benefit porphyria sufferers; it is listed among preferred AEDs in these conditions."
                ],
                "notes": ""
              },
              {
                "snippet_id": "snippet:44",
                "pmid": "35164799",
                "article_title": "A boy with blistering of sun-exposed skin and finger shortening: the first case of Variegate Porphyria with a novel mutation in protoporphyrinogen oxidase (PPOX) gene in Iran: a case report and literature review.",
                "key_points": [
                  "Case report: after tapering phenobarbital due to porphyria concerns, treatment with levetiracetam was started for seizure control."
                ],
                "notes": ""
              }
            ]
          },
          {
            "id": "claim:volatile-anaesthetics-nuanced",
            "type": "nuanced",
            "summary": "Volatile anaesthetics (desflurane, halothane, isoflurane, sevoflurane) have been reported used safely in individual cases and small series of patients with acute porphyrias, but volatile agents carry known idiosyncratic severe risks (malignant hyperpyrexia/malignant hyperthermia and halothane-associated hepatitis) that are unrelated to porphyria-specific biochemical induction.",
            "confidence": "medium",
            "idiosyncratic_reaction": {
              "flag": true,
              "descriptors": [
                "malignant hyperpyrexia",
                "halothane hepatitis"
              ]
            },
            "articles": [
              "article:15021955",
              "article:17037005",
              "article:1418699"
            ],
            "drugs": [
              "drug:desflurane",
              "drug:halothane",
              "drug:isoflurane",
              "drug:sevoflurane"
            ],
            "drug_classes": [
              "volatile anaesthetic"
            ],
            "supporting_evidence": [
              {
                "snippet_id": "snippet:76",
                "pmid": "15021955",
                "article_title": "[Desflurane in acute intermittent porphyria].",
                "key_points": [
                  "Report of desflurane used in an AIP patient for hemihepatectomy with perioperative monitoring of porphyrin precursors and no clinical porphyric attack.",
                  "Authors note halothane and isoflurane seem to be safe and discuss minimal P450 induction by desflurane."
                ],
                "notes": ""
              },
              {
                "snippet_id": "snippet:89",
                "pmid": "17037005",
                "article_title": "The use of rocuronium and sevoflurane in acute intermittent porphyria--a case report.",
                "key_points": [
                  "Case report: safe use of sevoflurane and rocuronium for prolonged exposure in a patient with AIP."
                ],
                "notes": ""
              },
              {
                "snippet_id": "snippet:55",
                "pmid": "1418699",
                "article_title": "Adverse effects of general anaesthetics.",
                "key_points": [
                  "Review: volatile agents can cause idiosyncratic reactions such as malignant hyperpyrexia (classically triggered by halothane with succinylcholine) and halothane hepatitis.",
                  "Notes these idiosyncratic reactions are important considerations in anaesthetic practice."
                ],
                "notes": ""
              }
            ]
          },
          {
            "id": "claim:succinylcholine-malignant-hyperthermia",
            "type": "risk",
            "summary": "Succinylcholine (suxamethonium) is a known trigger of malignant hyperthermia in susceptible individuals, particularly when used with volatile anaesthetic agents; this represents an idiosyncratic pharmacogenetic risk rather than a porphyria-specific drug-provoked biochemical crisis.",
            "confidence": "high",
            "idiosyncratic_reaction": {
              "flag": true,
              "descriptors": [
                "malignant hyperpyrexia",
                "malignant hyperthermia"
              ]
            },
            "articles": [
              "article:16296947",
              "article:1418699"
            ],
            "drugs": [
              "drug:succinylcholine"
            ],
            "drug_classes": [
              "depolarising neuromuscular blocker"
            ],
            "supporting_evidence": [
              {
                "snippet_id": "snippet:52",
                "pmid": "16296947",
                "article_title": "Pharmacogenetics and anesthesiologists.",
                "key_points": [
                  "Discusses historical pharmacogenetic insights from anesthesiology including prolonged apnea after succinylcholine and malignant hyperthermia investigations."
                ],
                "notes": ""
              },
              {
                "snippet_id": "snippet:55",
                "pmid": "1418699",
                "article_title": "Adverse effects of general anaesthetics.",
                "key_points": [
                  "States malignant hyperpyrexia is triggered most often by halothane together with suxamethonium and has significant mortality; highlights this as an important idiosyncratic reaction to volatile agents and succinylcholine."
                ],
                "notes": ""
              }
            ]
          }
        ]
      },
      "usage": {
        "prompt_tokens": 10653,
        "completion_tokens": 9393,
        "total_tokens": 20046
      }
    }
  ],
  "processed_claims": [
    {
      "claim_id": "claim:opioids-safety",
      "classification": "safety",
      "summary": "Opioid analgesics (including morphine, fentanyl, remifentanil and other commonly used opioids) are reported as safe options for pain management in acute hepatic porphyria and are commonly used/indicated during acute attacks and chronic symptomatic periods.",
      "confidence": "high",
      "drugs": [
        "fentanyl",
        "morphine",
        "remifentanil",
        "opioids",
        "opioid"
      ],
      "drug_classes": [
        "opioid anesthetic",
        "opioid",
        "analgesic class",
        "analgesic class (singular)",
        "opioids",
        "opioid analgesics"
      ],
      "source_claim_ids": [
        "claim:opioids-safety"
      ],
      "supporting_evidence": [
        {
          "snippet_id": "snippet:5",
          "pmid": "34661997",
          "article_title": "Acute porphyrias - A neurological perspective.",
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/34661997/",
          "key_points": [
            "Table of 'safe medications' lists Morphine and hydromorphone among safe painkillers; opioids included in recommended options."
          ],
          "notes": null
        },
        {
          "snippet_id": "snippet:15",
          "pmid": "34661997",
          "article_title": "Acute porphyrias - A neurological perspective.",
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/34661997/",
          "key_points": [
            "Treatment guidance: opioids are usually indicated for adequate pain management during acute attacks; hemin indicated for severe cases."
          ],
          "notes": null
        },
        {
          "snippet_id": "snippet:22",
          "pmid": "36028858",
          "article_title": "Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION study.",
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/36028858/",
          "key_points": [
            "ENVISION trial baseline data show frequent opioid use among patients; fentanyl listed as an opioid anaesthetic used in the population."
          ],
          "notes": null
        },
        {
          "snippet_id": "snippet:54",
          "pmid": "29383964",
          "article_title": "Acute intermittent porphyria: general aspects with focus on pain.",
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/29383964/",
          "key_points": [
            "Review states that an important arsenal of reportedly safe opioid and non-opioid analgesics is available for AIP patients; opioids discussed as part of pain management."
          ],
          "notes": null
        },
        {
          "snippet_id": "article:34661997",
          "pmid": "34661997",
          "article_title": null,
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/34661997/",
          "key_points": [],
          "notes": null
        },
        {
          "snippet_id": "article:36028858",
          "pmid": "36028858",
          "article_title": null,
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/36028858/",
          "key_points": [],
          "notes": null
        },
        {
          "snippet_id": "article:27052088",
          "pmid": "27052088",
          "article_title": null,
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/27052088/",
          "key_points": [],
          "notes": null
        },
        {
          "snippet_id": "article:29383964",
          "pmid": "29383964",
          "article_title": null,
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/29383964/",
          "key_points": [],
          "notes": null
        }
      ],
      "drug_links": [
        {
          "term": "fentanyl",
          "term_kind": "drug"
        },
        {
          "term": "morphine",
          "term_kind": "drug"
        },
        {
          "term": "remifentanil",
          "term_kind": "drug"
        },
        {
          "term": "opioids",
          "term_kind": "drug"
        },
        {
          "term": "opioid",
          "term_kind": "drug"
        },
        {
          "term": "opioid anesthetic",
          "term_kind": "drug_class"
        },
        {
          "term": "opioid",
          "term_kind": "drug_class"
        },
        {
          "term": "analgesic class",
          "term_kind": "drug_class"
        },
        {
          "term": "analgesic class (singular)",
          "term_kind": "drug_class"
        },
        {
          "term": "opioids",
          "term_kind": "drug_class"
        },
        {
          "term": "opioid analgesics",
          "term_kind": "drug_class"
        }
      ]
    },
    {
      "claim_id": "claim:benzodiazepines-safety",
      "classification": "safety",
      "summary": "Benzodiazepines (examples lorazepam, midazolam, diazepam) are cited as safe options for seizure control and as sedative/anxiolytic agents in acute hepatic porphyria.",
      "confidence": "high",
      "drugs": [
        "lorazepam",
        "midazolam",
        "diazepam",
        "benzodiazepines"
      ],
      "drug_classes": [
        "benzodiazepines",
        "sedative/anxiolytic class"
      ],
      "source_claim_ids": [
        "claim:benzodiazepines-safety"
      ],
      "supporting_evidence": [
        {
          "snippet_id": "snippet:5",
          "pmid": "34661997",
          "article_title": "Acute porphyrias - A neurological perspective.",
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/34661997/",
          "key_points": [
            "Table of 'safe medications' lists Lorazepam and Midazolam among antiepileptic/sedative options considered safe."
          ],
          "notes": null
        },
        {
          "snippet_id": "snippet:16",
          "pmid": "36642627",
          "article_title": "AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review.",
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/36642627/",
          "key_points": [
            "Guidance states benzodiazepines appear to be safe options for management of seizures in AHP."
          ],
          "notes": null
        },
        {
          "snippet_id": "snippet:64",
          "pmid": "2660638",
          "article_title": "[Anesthesia and hepatic porphyria].",
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/2660638/",
          "key_points": [
            "Review discussion includes benzodiazepines among drugs with conflicting evidence but provides recommendations and experimental/clinical data used for guidance."
          ],
          "notes": null
        },
        {
          "snippet_id": "article:34661997",
          "pmid": "34661997",
          "article_title": null,
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/34661997/",
          "key_points": [],
          "notes": null
        },
        {
          "snippet_id": "article:36642627",
          "pmid": "36642627",
          "article_title": null,
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/36642627/",
          "key_points": [],
          "notes": null
        },
        {
          "snippet_id": "article:2660638",
          "pmid": "2660638",
          "article_title": null,
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/2660638/",
          "key_points": [],
          "notes": null
        }
      ],
      "drug_links": [
        {
          "term": "lorazepam",
          "term_kind": "drug"
        },
        {
          "term": "midazolam",
          "term_kind": "drug"
        },
        {
          "term": "diazepam",
          "term_kind": "drug"
        },
        {
          "term": "benzodiazepines",
          "term_kind": "drug"
        },
        {
          "term": "benzodiazepines",
          "term_kind": "drug_class"
        },
        {
          "term": "sedative/anxiolytic class",
          "term_kind": "drug_class"
        }
      ]
    },
    {
      "claim_id": "claim:levetiracetam-safety",
      "classification": "safety",
      "summary": "Levetiracetam is reported as a safe anticonvulsant option for patients with acute hepatic porphyria.",
      "confidence": "high",
      "drugs": [
        "levetiracetam"
      ],
      "drug_classes": [
        "anticonvulsant",
        "anticonvulsants"
      ],
      "source_claim_ids": [
        "claim:levetiracetam-safety"
      ],
      "supporting_evidence": [
        {
          "snippet_id": "snippet:5",
          "pmid": "34661997",
          "article_title": "Acute porphyrias - A neurological perspective.",
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/34661997/",
          "key_points": [
            "Levetiracetam listed among antiepileptic therapies that can be used in AHP."
          ],
          "notes": null
        },
        {
          "snippet_id": "snippet:17",
          "pmid": "36642627",
          "article_title": "AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review.",
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/36642627/",
          "key_points": [
            "Best practice advice: levetiracetam appears to be a safe option for seizures in AHP."
          ],
          "notes": null
        },
        {
          "snippet_id": "snippet:14",
          "pmid": "34661997",
          "article_title": "Acute porphyrias - A neurological perspective.",
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/34661997/",
          "key_points": [
            "Case context: levetiracetam was used to prevent seizures in a suspected porphyria patient being managed with steroids and other measures."
          ],
          "notes": null
        },
        {
          "snippet_id": "article:34661997",
          "pmid": "34661997",
          "article_title": null,
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/34661997/",
          "key_points": [],
          "notes": null
        },
        {
          "snippet_id": "article:36642627",
          "pmid": "36642627",
          "article_title": null,
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/36642627/",
          "key_points": [],
          "notes": null
        },
        {
          "snippet_id": "article:27052088",
          "pmid": "27052088",
          "article_title": null,
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/27052088/",
          "key_points": [],
          "notes": null
        }
      ],
      "drug_links": [
        {
          "term": "levetiracetam",
          "term_kind": "drug"
        },
        {
          "term": "anticonvulsant",
          "term_kind": "drug_class"
        },
        {
          "term": "anticonvulsants",
          "term_kind": "drug_class"
        }
      ]
    },
    {
      "claim_id": "claim:propofol-safety",
      "classification": "safety",
      "summary": "Propofol is repeatedly reported as a safe intravenous hypnotic/anaesthetic agent for induction and maintenance in patients with acute hepatic porphyria; case reports and reviews support its use.",
      "confidence": "high",
      "drugs": [
        "propofol"
      ],
      "drug_classes": [
        "intravenous anaesthetic"
      ],
      "source_claim_ids": [
        "claim:propofol-safety"
      ],
      "supporting_evidence": [
        {
          "snippet_id": "snippet:17",
          "pmid": "27052088",
          "article_title": "Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.",
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/27052088/",
          "key_points": [
            "Propofol described as considered safe for induction and maintenance of anesthesia in patients with acute intermittent porphyria."
          ],
          "notes": null
        },
        {
          "snippet_id": "snippet:59",
          "pmid": "2697245",
          "article_title": "The pharmacology of propofol.",
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/2697245/",
          "key_points": [
            "Pharmacology review states propofol appears safe for use in patients with acute intermittent porphyria and susceptibility to malignant hyperpyrexia."
          ],
          "notes": null
        },
        {
          "snippet_id": "snippet:22",
          "pmid": "27871506",
          "article_title": "Elective cholecystectomy performed on patient with variegate porphyria-Propofol-based total intravenous anesthesia with target-controlled infusion.",
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/27871506/",
          "key_points": [
            "Case report: propofol-based TIVA was used safely in a patient with variegate porphyria; clinical symptoms were unchanged and approach considered safe."
          ],
          "notes": null
        },
        {
          "snippet_id": "article:27052088",
          "pmid": "27052088",
          "article_title": null,
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/27052088/",
          "key_points": [],
          "notes": null
        },
        {
          "snippet_id": "article:2697245",
          "pmid": "2697245",
          "article_title": null,
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/2697245/",
          "key_points": [],
          "notes": null
        },
        {
          "snippet_id": "article:27871506",
          "pmid": "27871506",
          "article_title": null,
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/27871506/",
          "key_points": [],
          "notes": null
        }
      ],
      "drug_links": [
        {
          "term": "propofol",
          "term_kind": "drug"
        },
        {
          "term": "intravenous anaesthetic",
          "term_kind": "drug_class"
        }
      ]
    },
    {
      "claim_id": "claim:ketamine-nuanced",
      "classification": "nuanced",
      "summary": "Ketamine has conflicting reports: some case reports suggest it may trigger acute porphyric crises, while it has also been used safely in quiescent disease; safety may depend on context (quiescent vs active disease) and exposure.",
      "confidence": "medium",
      "drugs": [
        "ketamine"
      ],
      "drug_classes": [
        "NMDA antagonist / anaesthetic"
      ],
      "source_claim_ids": [
        "claim:ketamine-nuanced"
      ],
      "supporting_evidence": [
        {
          "snippet_id": "snippet:28",
          "pmid": "27052088",
          "article_title": "Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.",
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/27052088/",
          "key_points": [
            "Some reports suggest ketamine can trigger AIP crisis, but ketamine has also been used safely in quiescent AIP; authors state ketamine might be safe in selected situations."
          ],
          "notes": null
        },
        {
          "snippet_id": "snippet:11",
          "pmid": "34661997",
          "article_title": "Acute porphyrias - A neurological perspective.",
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/34661997/",
          "key_points": [
            "Discussion of anaesthetic agents notes conflicting evidence for several agents including ketamine; addition of magnesium and propofol has been successful in seizure management."
          ],
          "notes": null
        },
        {
          "snippet_id": "snippet:66",
          "pmid": "2660638",
          "article_title": "[Anesthesia and hepatic porphyria].",
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/2660638/",
          "key_points": [
            "Review highlights drugs with conflicting evidence regarding safe use in porphyric patients, listing ketamine among them."
          ],
          "notes": null
        },
        {
          "snippet_id": "article:27052088",
          "pmid": "27052088",
          "article_title": null,
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/27052088/",
          "key_points": [],
          "notes": null
        },
        {
          "snippet_id": "article:34661997",
          "pmid": "34661997",
          "article_title": null,
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/34661997/",
          "key_points": [],
          "notes": null
        },
        {
          "snippet_id": "article:2660638",
          "pmid": "2660638",
          "article_title": null,
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/2660638/",
          "key_points": [],
          "notes": null
        }
      ],
      "drug_links": [
        {
          "term": "ketamine",
          "term_kind": "drug"
        },
        {
          "term": "NMDA antagonist / anaesthetic",
          "term_kind": "drug_class"
        }
      ]
    },
    {
      "claim_id": "claim:volatile-anaesthetics-nuanced",
      "classification": "nuanced",
      "summary": "Modern inhalational (volatile) anaesthetics (sevoflurane, isoflurane, desflurane) are generally considered safe in porphyria by clinical reports and case series, but some older reports (notably halothane) have been associated with adverse events; duration/dose and perioperative factors may influence risk. Volatile agents also carry well-described idiosyncratic adverse reactions (e.g., malignant hyperpyrexia, halothane hepatitis) unrelated to porphyria susceptibility.",
      "confidence": "medium",
      "drugs": [
        "desflurane",
        "halothane",
        "isoflurane",
        "sevoflurane",
        "volatile agents",
        "volatile anaesthetics"
      ],
      "drug_classes": [
        "volatile anaesthetic",
        "inhalational anesthetic class",
        "inhalational anesthetic"
      ],
      "source_claim_ids": [
        "claim:volatile-anaesthetics-nuanced"
      ],
      "supporting_evidence": [
        {
          "snippet_id": "snippet:17",
          "pmid": "27052088",
          "article_title": "Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.",
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/27052088/",
          "key_points": [
            "Authors state modern inhalation agents are generally considered safe (sevoflurane, isoflurane) though reports about halothane are contradictory; exposure duration and dose may matter."
          ],
          "notes": null
        },
        {
          "snippet_id": "snippet:82",
          "pmid": "15021955",
          "article_title": "[Desflurane in acute intermittent porphyria].",
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/15021955/",
          "key_points": [
            "Case report of desflurane use without porphyric complications; authors note favourable pharmacokinetics and minimal cytochrome P450 induction as rationale for safety."
          ],
          "notes": null
        },
        {
          "snippet_id": "snippet:56",
          "pmid": "1418699",
          "article_title": "Adverse effects of general anaesthetics.",
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/1418699/",
          "key_points": [
            "Review describes important idiosyncratic reactions to volatile agents, notably malignant hyperpyrexia and halothane hepatitis, with incidence and clinical significance."
          ],
          "notes": null
        },
        {
          "snippet_id": "article:27052088",
          "pmid": "27052088",
          "article_title": null,
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/27052088/",
          "key_points": [],
          "notes": null
        },
        {
          "snippet_id": "article:15021955",
          "pmid": "15021955",
          "article_title": null,
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/15021955/",
          "key_points": [],
          "notes": null
        },
        {
          "snippet_id": "article:1418699",
          "pmid": "1418699",
          "article_title": null,
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/1418699/",
          "key_points": [],
          "notes": null
        }
      ],
      "drug_links": [
        {
          "term": "desflurane",
          "term_kind": "drug"
        },
        {
          "term": "halothane",
          "term_kind": "drug"
        },
        {
          "term": "isoflurane",
          "term_kind": "drug"
        },
        {
          "term": "sevoflurane",
          "term_kind": "drug"
        },
        {
          "term": "volatile agents",
          "term_kind": "drug"
        },
        {
          "term": "volatile anaesthetics",
          "term_kind": "drug"
        },
        {
          "term": "volatile anaesthetic",
          "term_kind": "drug_class"
        },
        {
          "term": "inhalational anesthetic class",
          "term_kind": "drug_class"
        },
        {
          "term": "inhalational anesthetic",
          "term_kind": "drug_class"
        }
      ]
    },
    {
      "claim_id": "claim:succinylcholine-safety",
      "classification": "safety",
      "summary": "Succinylcholine (suxamethonium) has been used widely and reported as safe in patients with acute intermittent porphyria in clinical series and perioperative reports.",
      "confidence": "medium",
      "drugs": [
        "succinylcholine"
      ],
      "drug_classes": [
        "depolarising neuromuscular blocker"
      ],
      "source_claim_ids": [
        "claim:succinylcholine-safety"
      ],
      "supporting_evidence": [
        {
          "snippet_id": "snippet:28",
          "pmid": "27052088",
          "article_title": "Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.",
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/27052088/",
          "key_points": [
            "Authors report that succinylcholine has been used for many years and has been proven to be safe in porphyric patients."
          ],
          "notes": null
        },
        {
          "snippet_id": "article:27052088",
          "pmid": "27052088",
          "article_title": null,
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/27052088/",
          "key_points": [],
          "notes": null
        }
      ],
      "drug_links": [
        {
          "term": "succinylcholine",
          "term_kind": "drug"
        },
        {
          "term": "depolarising neuromuscular blocker",
          "term_kind": "drug_class"
        }
      ]
    },
    {
      "claim_id": "claim:atracurium-safety",
      "classification": "safety",
      "summary": "Atracurium has been used safely in small numbers of porphyria patients and was used without complications in reported perioperative cases.",
      "confidence": "medium",
      "drugs": [
        "atracurium"
      ],
      "drug_classes": [
        "neuromuscular blocker (benzylisoquinolinium)"
      ],
      "source_claim_ids": [
        "claim:atracurium-safety"
      ],
      "supporting_evidence": [
        {
          "snippet_id": "snippet:29",
          "pmid": "27052088",
          "article_title": "Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.",
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/27052088/",
          "key_points": [
            "Atracurium and vecuronium have been used safely in small numbers of patients despite some experimental evidence for porphyrinogenicity; authors report safe use of atracurium in their case."
          ],
          "notes": null
        },
        {
          "snippet_id": "snippet:81",
          "pmid": "15021955",
          "article_title": "[Desflurane in acute intermittent porphyria].",
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/15021955/",
          "key_points": [
            "Balanced anaesthesia case used desflurane, sufentanil and atracurium without postoperative porphyric symptoms; monitored porphyrin precursor excretion returned to normal."
          ],
          "notes": null
        },
        {
          "snippet_id": "article:27052088",
          "pmid": "27052088",
          "article_title": null,
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/27052088/",
          "key_points": [],
          "notes": null
        },
        {
          "snippet_id": "article:15021955",
          "pmid": "15021955",
          "article_title": null,
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/15021955/",
          "key_points": [],
          "notes": null
        },
        {
          "snippet_id": "snippet:37",
          "pmid": "27052088",
          "article_title": "Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.",
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/27052088/",
          "key_points": [
            "Case report: atracurium used uneventfully in combination with fentanyl, propofol, and midazolam; no complications reported."
          ],
          "notes": null
        },
        {
          "snippet_id": "snippet:80",
          "pmid": "15021955",
          "article_title": "[Desflurane in acute intermittent porphyria].",
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/15021955/",
          "key_points": [
            "Desflurane-based balanced anaesthesia in one patient included atracurium and continuous monitoring of porphyrin precursors; no clinical porphyric attack occurred postoperatively."
          ],
          "notes": null
        }
      ],
      "drug_links": [
        {
          "term": "atracurium",
          "term_kind": "drug"
        },
        {
          "term": "neuromuscular blocker (benzylisoquinolinium)",
          "term_kind": "drug_class"
        }
      ]
    },
    {
      "claim_id": "claim:rocuronium-safety",
      "classification": "safety",
      "summary": "Rocuronium has been reported used safely in at least one case report with sevoflurane exposure for prolonged anesthesia in a patient with acute intermittent porphyria.",
      "confidence": "medium",
      "drugs": [
        "rocuronium"
      ],
      "drug_classes": [
        "neuromuscular blocker (aminosteroid)"
      ],
      "source_claim_ids": [
        "claim:rocuronium-safety"
      ],
      "supporting_evidence": [
        {
          "snippet_id": "snippet:88",
          "pmid": "17037005",
          "article_title": "The use of rocuronium and sevoflurane in acute intermittent porphyria--a case report.",
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/17037005/",
          "key_points": [
            "Case report describes safe use of rocuronium with sevoflurane for long exposure in an AIP patient."
          ],
          "notes": null
        },
        {
          "snippet_id": "snippet:35",
          "pmid": "27052088",
          "article_title": "Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.",
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/27052088/",
          "key_points": [
            "Authors note various neuromuscular blockers have mixed evidence; some (pancuronium/alcuronium) flagged unsafe by some authors but used without harm by others."
          ],
          "notes": null
        },
        {
          "snippet_id": "article:17037005",
          "pmid": "17037005",
          "article_title": null,
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/17037005/",
          "key_points": [],
          "notes": null
        },
        {
          "snippet_id": "article:27052088",
          "pmid": "27052088",
          "article_title": null,
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/27052088/",
          "key_points": [],
          "notes": null
        }
      ],
      "drug_links": [
        {
          "term": "rocuronium",
          "term_kind": "drug"
        },
        {
          "term": "neuromuscular blocker (aminosteroid)",
          "term_kind": "drug_class"
        }
      ]
    },
    {
      "claim_id": "claim:metoclopramide-risk",
      "classification": "risk",
      "summary": "Metoclopramide has been implicated in at least one case report as an exposure associated with triggering a porphyric crisis in a patient who subsequently developed hyponatremia, seizures and neurologic deterioration.",
      "confidence": "medium",
      "drugs": [
        "metoclopramide"
      ],
      "drug_classes": [
        "antiemetic / prokinetic"
      ],
      "source_claim_ids": [
        "claim:metoclopramide-risk"
      ],
      "supporting_evidence": [
        {
          "snippet_id": "snippet:86",
          "pmid": "21146060",
          "article_title": "Neuropathic pain in a patient with porphyria. Case report.",
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/21146060/",
          "key_points": [
            "Patient was exposed to drugs that can trigger porphyria, including metoclopramide; after exposure the patient developed severe porphyric features (hyponatremia, seizures, neurological decline)."
          ],
          "notes": null
        },
        {
          "snippet_id": "article:21146060",
          "pmid": "21146060",
          "article_title": null,
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/21146060/",
          "key_points": [],
          "notes": null
        }
      ],
      "drug_links": [
        {
          "term": "metoclopramide",
          "term_kind": "drug"
        },
        {
          "term": "antiemetic / prokinetic",
          "term_kind": "drug_class"
        }
      ]
    },
    {
      "claim_id": "claim:nitrous-oxide-safety",
      "classification": "safety",
      "summary": "Nitrous oxide has been used intraoperatively in at least one reported case of a patient with acute intermittent porphyria without precipitating an acute porphyric attack.",
      "confidence": "low",
      "drugs": [
        "nitrous oxide"
      ],
      "drug_classes": [
        "inhalational anesthetic / analgesic"
      ],
      "source_claim_ids": [
        "claim:nitrous-oxide-safety"
      ],
      "supporting_evidence": [
        {
          "snippet_id": "snippet:90",
          "pmid": "3986654",
          "article_title": "Induction of anaesthesia with etomidate in a patient with acute intermittent porphyria.",
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/3986654/",
          "key_points": [
            "Case report: anaesthesia induction with etomidate used nitrous oxide and intermittent fentanyl without subsequent porphyric attack; postoperative period uneventful."
          ],
          "notes": null
        },
        {
          "snippet_id": "snippet:56",
          "pmid": "1418699",
          "article_title": "Adverse effects of general anaesthetics.",
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/1418699/",
          "key_points": [
            "Review notes prolonged nitrous oxide exposure has other risks (bone marrow depression, pressure effects) but does not provide strong porphyria-specific contraindication."
          ],
          "notes": null
        },
        {
          "snippet_id": "article:3986654",
          "pmid": "3986654",
          "article_title": null,
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/3986654/",
          "key_points": [],
          "notes": null
        },
        {
          "snippet_id": "article:1418699",
          "pmid": "1418699",
          "article_title": null,
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/1418699/",
          "key_points": [],
          "notes": null
        }
      ],
      "drug_links": [
        {
          "term": "nitrous oxide",
          "term_kind": "drug"
        },
        {
          "term": "inhalational anesthetic / analgesic",
          "term_kind": "drug_class"
        }
      ]
    },
    {
      "claim_id": "claim:bupivacaine-safety",
      "classification": "safety",
      "summary": "Bupivacaine has been used for neuraxial/regional anesthesia in porphyria patients (e.g., obstetrical anesthesia) and is described as an acceptable option in selected situations.",
      "confidence": "medium",
      "drugs": [
        "bupivacaine"
      ],
      "drug_classes": [
        "local anaesthetic"
      ],
      "source_claim_ids": [
        "claim:bupivacaine-safety"
      ],
      "supporting_evidence": [
        {
          "snippet_id": "snippet:85",
          "pmid": "15826795",
          "article_title": "[Obstetrical anaesthesia and porphyrias].",
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/15826795/",
          "key_points": [
            "Authors describe locoregional anesthesia with bupivacaine as a technique of choice for asymptomatic or long-remission porphyria patients for labour analgesia and cesarean section."
          ],
          "notes": null
        },
        {
          "snippet_id": "article:15826795",
          "pmid": "15826795",
          "article_title": null,
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/15826795/",
          "key_points": [],
          "notes": null
        }
      ],
      "drug_links": [
        {
          "term": "bupivacaine",
          "term_kind": "drug"
        },
        {
          "term": "local anaesthetic",
          "term_kind": "drug_class"
        }
      ]
    },
    {
      "claim_id": "claim:glucagon-risk",
      "classification": "risk",
      "summary": "Experimental data indicate glucagon increases intracellular cAMP and can enhance drug-induced porphyrin biosynthesis in chick embryo liver cells, suggesting glucagon may promote porphyrin accumulation and thus could increase porphyrinogenic risk under some conditions.",
      "confidence": "medium",
      "drugs": [
        "glucagon"
      ],
      "drug_classes": [
        "hormone"
      ],
      "source_claim_ids": [
        "claim:glucagon-risk"
      ],
      "supporting_evidence": [
        {
          "snippet_id": "snippet:72",
          "pmid": "88665",
          "article_title": "Hormonal effects on the regulation of hepatic heme biosynthesis.",
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/88665/",
          "key_points": [
            "Study in chick embryo liver cells found agents that increase cAMP (including glucagon) enhanced drug-induced porphyrin biosynthesis; insulin:glucagon ratio affects porphyrin accumulation, providing mechanistic rationale for glucose therapy."
          ],
          "notes": null
        },
        {
          "snippet_id": "article:88665",
          "pmid": "88665",
          "article_title": null,
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/88665/",
          "key_points": [],
          "notes": null
        }
      ],
      "drug_links": [
        {
          "term": "glucagon",
          "term_kind": "drug"
        },
        {
          "term": "hormone",
          "term_kind": "drug_class"
        }
      ]
    },
    {
      "claim_id": "claim:ondansetron-safety",
      "classification": "safety",
      "summary": "Ondansetron (a 5-HT3 antagonist) appears in clinical summaries and trial medication lists as a commonly used antiemetic in patients with acute hepatic porphyria, without specific signals of porphyrinogenic risk in the provided texts.",
      "confidence": "medium",
      "drugs": [
        "ondansetron"
      ],
      "drug_classes": [
        "antiemetic (5HT3 antagonist)"
      ],
      "source_claim_ids": [
        "claim:ondansetron-safety"
      ],
      "supporting_evidence": [
        {
          "snippet_id": "snippet:5",
          "pmid": "34661997",
          "article_title": "Acute porphyrias - A neurological perspective.",
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/34661997/",
          "key_points": [
            "Ondansetron appears in the table of 'safe medications' under antiemetics."
          ],
          "notes": null
        },
        {
          "snippet_id": "snippet:22",
          "pmid": "36028858",
          "article_title": "Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION study.",
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/36028858/",
          "key_points": [
            "ENVISION trial baseline medication lists include 5HT3 antagonists among antiemetics used by participants."
          ],
          "notes": null
        },
        {
          "snippet_id": "article:34661997",
          "pmid": "34661997",
          "article_title": null,
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/34661997/",
          "key_points": [],
          "notes": null
        },
        {
          "snippet_id": "article:36028858",
          "pmid": "36028858",
          "article_title": null,
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/36028858/",
          "key_points": [],
          "notes": null
        }
      ],
      "drug_links": [
        {
          "term": "ondansetron",
          "term_kind": "drug"
        },
        {
          "term": "antiemetic (5HT3 antagonist)",
          "term_kind": "drug_class"
        }
      ]
    },
    {
      "claim_id": "claim:dexamethasone-safety",
      "classification": "safety",
      "summary": "Dexamethasone is listed among steroid preparations in medication tables in reviews of acute porphyrias; in the provided text it appears within lists of medications considered for use and not singled out as a routinely porphyrinogenic agent.",
      "confidence": "low",
      "drugs": [
        "dexamethasone"
      ],
      "drug_classes": [
        "steroids"
      ],
      "source_claim_ids": [
        "claim:dexamethasone-safety"
      ],
      "supporting_evidence": [
        {
          "snippet_id": "snippet:2",
          "pmid": "34661997",
          "article_title": "Acute porphyrias - A neurological perspective.",
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/34661997/",
          "key_points": [
            "Steroids (including dexamethasone) appear in tabulated medication lists in the review; authors advise consulting porphyria drug databases for up-to-date classifications."
          ],
          "notes": null
        },
        {
          "snippet_id": "article:34661997",
          "pmid": "34661997",
          "article_title": null,
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/34661997/",
          "key_points": [],
          "notes": null
        }
      ],
      "drug_links": [
        {
          "term": "dexamethasone",
          "term_kind": "drug"
        },
        {
          "term": "steroids",
          "term_kind": "drug_class"
        }
      ]
    },
    {
      "claim_id": "claim:atropine-safety",
      "classification": "safety",
      "summary": "Atropine is listed among 'other' agents in medication tables in porphyria reviews and is not highlighted as a known porphyrinogenic trigger in the provided excerpts.",
      "confidence": "low",
      "drugs": [
        "atropine"
      ],
      "drug_classes": [
        "anticholinergic"
      ],
      "source_claim_ids": [
        "claim:atropine-safety"
      ],
      "supporting_evidence": [
        {
          "snippet_id": "snippet:1",
          "pmid": "34661997",
          "article_title": "Acute porphyrias - A neurological perspective.",
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/34661997/",
          "key_points": [
            "Atropine appears in the medication listing under 'Others' alongside hormones and catecholamines; authors recommend checking specialized drug databases for current classifications."
          ],
          "notes": null
        },
        {
          "snippet_id": "article:34661997",
          "pmid": "34661997",
          "article_title": null,
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/34661997/",
          "key_points": [],
          "notes": null
        }
      ],
      "drug_links": [
        {
          "term": "atropine",
          "term_kind": "drug"
        },
        {
          "term": "anticholinergic",
          "term_kind": "drug_class"
        }
      ]
    },
    {
      "claim_id": "claim:benzodiazepines-nuanced",
      "classification": "nuanced",
      "summary": "Benzodiazepines (including midazolam) are described in several sources as commonly considered safe for use in patients with acute hepatic porphyrias, but other reviews and case discussions advise caution or list benzodiazepines among drugs to consider as potential triggers; the evidence across reports is mixed.",
      "confidence": "medium",
      "drugs": [
        "benzodiazepines",
        "midazolam"
      ],
      "drug_classes": [
        "benzodiazepine"
      ],
      "source_claim_ids": [
        "claim:benzodiazepines-nuanced"
      ],
      "supporting_evidence": [
        {
          "snippet_id": "snippet:36",
          "pmid": "27052088",
          "article_title": "Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.",
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/27052088/",
          "key_points": [
            "Most (but not all) benzodiazepines commonly used for premedication like midazolam are considered safe.",
            "Authors report safe use of midazolam in the presented case."
          ],
          "notes": null
        },
        {
          "snippet_id": "snippet:38",
          "pmid": "27052088",
          "article_title": "Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.",
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/27052088/",
          "key_points": [
            "Reiterates that benzodiazepines such as midazolam are generally considered safe though further information may be needed."
          ],
          "notes": null
        },
        {
          "snippet_id": "snippet:74",
          "pmid": "10504904",
          "article_title": "Anesthetic considerations in hepatic porphyrias.",
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/10504904/",
          "key_points": [
            "Review advises avoiding triggering drugs; states barbiturates, and perhaps benzodiazepines and ketamines, should be considered with caution."
          ],
          "notes": null
        },
        {
          "snippet_id": "snippet:45",
          "pmid": "36575494",
          "article_title": "Porphyria: a case report.",
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/36575494/",
          "key_points": [
            "Lists benzodiazepines among first-line treatment options for seizures but notes many antiepileptic drugs are porphyrinogenic; warns that treating seizures with porphyrinogenic medications can trigger acute attacks."
          ],
          "notes": null
        },
        {
          "snippet_id": "snippet:93",
          "pmid": "23993340",
          "article_title": "[State of dementia due to intermittent acute porphyria: a case report].",
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/23993340/",
          "key_points": [
            "Patient had been treated with benzodiazepines and neuroleptics for years; clinical improvement followed stopping implicated medications after porphyria diagnosis."
          ],
          "notes": null
        },
        {
          "snippet_id": "article:27052088",
          "pmid": "27052088",
          "article_title": null,
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/27052088/",
          "key_points": [],
          "notes": null
        },
        {
          "snippet_id": "article:10504904",
          "pmid": "10504904",
          "article_title": null,
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/10504904/",
          "key_points": [],
          "notes": null
        },
        {
          "snippet_id": "article:36575494",
          "pmid": "36575494",
          "article_title": null,
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/36575494/",
          "key_points": [],
          "notes": null
        },
        {
          "snippet_id": "article:23993340",
          "pmid": "23993340",
          "article_title": null,
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/23993340/",
          "key_points": [],
          "notes": null
        }
      ],
      "drug_links": [
        {
          "term": "benzodiazepines",
          "term_kind": "drug"
        },
        {
          "term": "midazolam",
          "term_kind": "drug"
        },
        {
          "term": "benzodiazepine",
          "term_kind": "drug_class"
        }
      ]
    },
    {
      "claim_id": "claim:propofol-nuanced",
      "classification": "nuanced",
      "summary": "Propofol has been used as induction and maintenance anaesthesia in multiple case reports and a prospective series in porphyria patients without clinical porphyric crises, and some reviews state it appears safe; however, at least one report documented increased urinary porphyrin excretion after propofol exposure (without clinical manifestations), so biochemical effects have been observed and overall safety is not conclusively established.",
      "confidence": "medium",
      "drugs": [
        "propofol"
      ],
      "drug_classes": [
        "intravenous anaesthetic"
      ],
      "source_claim_ids": [
        "claim:propofol-nuanced"
      ],
      "supporting_evidence": [
        {
          "snippet_id": "snippet:83",
          "pmid": "1997060",
          "article_title": "Propofol as an i.v. anaesthetic induction agent in variegate porphyria.",
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/1997060/",
          "key_points": [
            "Prospective trial in 13 variegate porphyria subjects showed no significant change in porphyrin or porphyrin precursor output after propofol induction.",
            "No clinical manifestations of a porphyric attack reported in that series."
          ],
          "notes": null
        },
        {
          "snippet_id": "snippet:58",
          "pmid": "2697245",
          "article_title": "The pharmacology of propofol.",
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/2697245/",
          "key_points": [
            "Review states propofol appears safe for use in patients with acute intermittent porphyria."
          ],
          "notes": null
        },
        {
          "snippet_id": "snippet:71",
          "pmid": "8342401",
          "article_title": "Total intravenous anesthesia in South-African genetic porphyria (variegate porphyria).",
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/8342401/",
          "key_points": [
            "Case report showed a significant rise in urinary porphyrin excretion after propofol without associated clinical manifestations; authors conclude innocuity cannot be established without further studies."
          ],
          "notes": null
        },
        {
          "snippet_id": "snippet:92",
          "pmid": "25137868",
          "article_title": "Ultrasound-guided regional anesthesia in a pediatric patient with acute intermittent porphyria: literature review and case report.",
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/25137868/",
          "key_points": [
            "Pediatric case with propofol induction proceeded without complications and the patient did not demonstrate signs of an AIP crisis."
          ],
          "notes": null
        },
        {
          "snippet_id": "article:1997060",
          "pmid": "1997060",
          "article_title": null,
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/1997060/",
          "key_points": [],
          "notes": null
        },
        {
          "snippet_id": "article:2697245",
          "pmid": "2697245",
          "article_title": null,
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/2697245/",
          "key_points": [],
          "notes": null
        },
        {
          "snippet_id": "article:8342401",
          "pmid": "8342401",
          "article_title": null,
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/8342401/",
          "key_points": [],
          "notes": null
        },
        {
          "snippet_id": "article:25137868",
          "pmid": "25137868",
          "article_title": null,
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/25137868/",
          "key_points": [],
          "notes": null
        }
      ],
      "drug_links": [
        {
          "term": "propofol",
          "term_kind": "drug"
        },
        {
          "term": "intravenous anaesthetic",
          "term_kind": "drug_class"
        }
      ]
    },
    {
      "claim_id": "claim:opioids-safety",
      "classification": "safety",
      "summary": "Opioids, including fentanyl, are described in management guidance and case reports as part of recommended treatment for pain in acute hepatic porphyrias and have been used without precipitating attacks in reported perioperative cases.",
      "confidence": "medium",
      "drugs": [
        "fentanyl",
        "opioids",
        "opioid"
      ],
      "drug_classes": [
        "opioid analgesic"
      ],
      "source_claim_ids": [
        "claim:opioids-safety"
      ],
      "supporting_evidence": [
        {
          "snippet_id": "snippet:62",
          "pmid": "39313028",
          "article_title": "Therapeutic approach to acute crises of hepatic porphyrias.",
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/39313028/",
          "key_points": [
            "Management of acute hepatic porphyria includes intravenous opioids for pain control as part of urgent treatment."
          ],
          "notes": null
        },
        {
          "snippet_id": "snippet:39",
          "pmid": "27052088",
          "article_title": "Anesthetic implication of tricuspid valve replacement in a patient with acute intermittent porphyria.",
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/27052088/",
          "key_points": [
            "Case report: fentanyl used successfully in combination with propofol, midazolam, and atracurium with no disadvantage; patient discharged without complication."
          ],
          "notes": null
        },
        {
          "snippet_id": "snippet:80",
          "pmid": "15021955",
          "article_title": "[Desflurane in acute intermittent porphyria].",
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/15021955/",
          "key_points": [
            "Postoperative epidural analgesia included fentanyl; perioperative monitoring showed no clinical symptoms of a porphyric attack."
          ],
          "notes": null
        },
        {
          "snippet_id": "article:39313028",
          "pmid": "39313028",
          "article_title": null,
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/39313028/",
          "key_points": [],
          "notes": null
        },
        {
          "snippet_id": "article:27052088",
          "pmid": "27052088",
          "article_title": null,
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/27052088/",
          "key_points": [],
          "notes": null
        },
        {
          "snippet_id": "article:15021955",
          "pmid": "15021955",
          "article_title": null,
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/15021955/",
          "key_points": [],
          "notes": null
        }
      ],
      "drug_links": [
        {
          "term": "fentanyl",
          "term_kind": "drug"
        },
        {
          "term": "opioids",
          "term_kind": "drug"
        },
        {
          "term": "opioid",
          "term_kind": "drug"
        },
        {
          "term": "opioid analgesic",
          "term_kind": "drug_class"
        }
      ]
    },
    {
      "claim_id": "claim:levetiracetam-safety",
      "classification": "safety",
      "summary": "Levetiracetam is recommended in reviews and clinical guidance as a safer antiepileptic for patients with acute intermittent porphyria and hepatic dysfunction, and has been started as an alternative to porphyrinogenic agents in case reports.",
      "confidence": "high",
      "drugs": [
        "levetiracetam"
      ],
      "drug_classes": [
        "anticonvulsant"
      ],
      "source_claim_ids": [
        "claim:levetiracetam-safety"
      ],
      "supporting_evidence": [
        {
          "snippet_id": "snippet:48",
          "pmid": "29097018",
          "article_title": "Antiepileptic Drugs and Liver Disease.",
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/29097018/",
          "key_points": [
            "Review: newer antiepileptic drugs with minimal hepatic metabolism such as levetiracetam should be used as first-line in patients at risk; in AIP, levetiracetam, gabapentin, and vigabatrin are cited as safe choices."
          ],
          "notes": null
        },
        {
          "snippet_id": "snippet:67",
          "pmid": "17190918",
          "article_title": "Optimizing therapy of seizures in patients with renal or hepatic dysfunction.",
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/17190918/",
          "key_points": [
            "Levetiracetam is preferred in hepatic dysfunction and may benefit porphyria sufferers; it is listed among preferred AEDs in these conditions."
          ],
          "notes": null
        },
        {
          "snippet_id": "snippet:44",
          "pmid": "35164799",
          "article_title": "A boy with blistering of sun-exposed skin and finger shortening: the first case of Variegate Porphyria with a novel mutation in protoporphyrinogen oxidase (PPOX) gene in Iran: a case report and literature review.",
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/35164799/",
          "key_points": [
            "Case report: after tapering phenobarbital due to porphyria concerns, treatment with levetiracetam was started for seizure control."
          ],
          "notes": null
        },
        {
          "snippet_id": "article:29097018",
          "pmid": "29097018",
          "article_title": null,
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/29097018/",
          "key_points": [],
          "notes": null
        },
        {
          "snippet_id": "article:17190918",
          "pmid": "17190918",
          "article_title": null,
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/17190918/",
          "key_points": [],
          "notes": null
        },
        {
          "snippet_id": "article:35164799",
          "pmid": "35164799",
          "article_title": null,
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/35164799/",
          "key_points": [],
          "notes": null
        }
      ],
      "drug_links": [
        {
          "term": "levetiracetam",
          "term_kind": "drug"
        },
        {
          "term": "anticonvulsant",
          "term_kind": "drug_class"
        }
      ]
    },
    {
      "claim_id": "claim:volatile-anaesthetics-nuanced",
      "classification": "nuanced",
      "summary": "Volatile anaesthetics (desflurane, halothane, isoflurane, sevoflurane) have been reported used safely in individual cases and small series of patients with acute porphyrias, but volatile agents carry known idiosyncratic severe risks (malignant hyperpyrexia/malignant hyperthermia and halothane-associated hepatitis) that are unrelated to porphyria-specific biochemical induction.",
      "confidence": "medium",
      "drugs": [
        "desflurane",
        "halothane",
        "isoflurane",
        "sevoflurane"
      ],
      "drug_classes": [
        "volatile anaesthetic"
      ],
      "source_claim_ids": [
        "claim:volatile-anaesthetics-nuanced"
      ],
      "supporting_evidence": [
        {
          "snippet_id": "snippet:76",
          "pmid": "15021955",
          "article_title": "[Desflurane in acute intermittent porphyria].",
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/15021955/",
          "key_points": [
            "Report of desflurane used in an AIP patient for hemihepatectomy with perioperative monitoring of porphyrin precursors and no clinical porphyric attack.",
            "Authors note halothane and isoflurane seem to be safe and discuss minimal P450 induction by desflurane."
          ],
          "notes": null
        },
        {
          "snippet_id": "snippet:89",
          "pmid": "17037005",
          "article_title": "The use of rocuronium and sevoflurane in acute intermittent porphyria--a case report.",
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/17037005/",
          "key_points": [
            "Case report: safe use of sevoflurane and rocuronium for prolonged exposure in a patient with AIP."
          ],
          "notes": null
        },
        {
          "snippet_id": "snippet:55",
          "pmid": "1418699",
          "article_title": "Adverse effects of general anaesthetics.",
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/1418699/",
          "key_points": [
            "Review: volatile agents can cause idiosyncratic reactions such as malignant hyperpyrexia (classically triggered by halothane with succinylcholine) and halothane hepatitis.",
            "Notes these idiosyncratic reactions are important considerations in anaesthetic practice."
          ],
          "notes": null
        },
        {
          "snippet_id": "article:15021955",
          "pmid": "15021955",
          "article_title": null,
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/15021955/",
          "key_points": [],
          "notes": null
        },
        {
          "snippet_id": "article:17037005",
          "pmid": "17037005",
          "article_title": null,
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/17037005/",
          "key_points": [],
          "notes": null
        },
        {
          "snippet_id": "article:1418699",
          "pmid": "1418699",
          "article_title": null,
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/1418699/",
          "key_points": [],
          "notes": null
        }
      ],
      "drug_links": [
        {
          "term": "desflurane",
          "term_kind": "drug"
        },
        {
          "term": "halothane",
          "term_kind": "drug"
        },
        {
          "term": "isoflurane",
          "term_kind": "drug"
        },
        {
          "term": "sevoflurane",
          "term_kind": "drug"
        },
        {
          "term": "volatile anaesthetic",
          "term_kind": "drug_class"
        }
      ]
    },
    {
      "claim_id": "claim:succinylcholine-malignant-hyperthermia",
      "classification": "risk",
      "summary": "Succinylcholine (suxamethonium) is a known trigger of malignant hyperthermia in susceptible individuals, particularly when used with volatile anaesthetic agents; this represents an idiosyncratic pharmacogenetic risk rather than a porphyria-specific drug-provoked biochemical crisis.",
      "confidence": "high",
      "drugs": [
        "succinylcholine"
      ],
      "drug_classes": [
        "depolarising neuromuscular blocker"
      ],
      "source_claim_ids": [
        "claim:succinylcholine-malignant-hyperthermia"
      ],
      "supporting_evidence": [
        {
          "snippet_id": "snippet:52",
          "pmid": "16296947",
          "article_title": "Pharmacogenetics and anesthesiologists.",
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/16296947/",
          "key_points": [
            "Discusses historical pharmacogenetic insights from anesthesiology including prolonged apnea after succinylcholine and malignant hyperthermia investigations."
          ],
          "notes": null
        },
        {
          "snippet_id": "snippet:55",
          "pmid": "1418699",
          "article_title": "Adverse effects of general anaesthetics.",
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/1418699/",
          "key_points": [
            "States malignant hyperpyrexia is triggered most often by halothane together with suxamethonium and has significant mortality; highlights this as an important idiosyncratic reaction to volatile agents and succinylcholine."
          ],
          "notes": null
        },
        {
          "snippet_id": "article:16296947",
          "pmid": "16296947",
          "article_title": null,
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/16296947/",
          "key_points": [],
          "notes": null
        },
        {
          "snippet_id": "article:1418699",
          "pmid": "1418699",
          "article_title": null,
          "citation_url": "https://pubmed.ncbi.nlm.nih.gov/1418699/",
          "key_points": [],
          "notes": null
        }
      ],
      "drug_links": [
        {
          "term": "succinylcholine",
          "term_kind": "drug"
        },
        {
          "term": "depolarising neuromuscular blocker",
          "term_kind": "drug_class"
        }
      ]
    }
  ]
}